{"companyName": "MyoKardia, Inc.", "reportNo1": {"reportType": "Form 4", "url": ["https://www.sec.gov/Archives/edgar/data/1413822/000089924318015319/xslF345X03/doc4.xml", "2018-06-06"], "content": {"nameOfOwner": "GIANAKAKOS ANASTASIOS", "position": "President and CEO", "dateOfReport": "2018-06-04", "transaction1": {"classOfStock": "Common Stock", "transactionDate": "2018-06-04", "amount": "3000", "price": "1.5068", "buyOrSell": "A", "ownershipAfterTransaction": "77949"}, "transaction2": {"classOfStock": "Common Stock", "transactionDate": "2018-06-04", "amount": "2400", "price": "46.7454", "buyOrSell": "D", "ownershipAfterTransaction": "75549"}, "transaction3": {"classOfStock": "Common Stock", "transactionDate": "2018-06-04", "amount": "500", "price": "47.63", "buyOrSell": "D", "ownershipAfterTransaction": "75049"}, "transaction4": {"classOfStock": "Common Stock", "transactionDate": "2018-06-04", "amount": "100", "price": "48.60", "buyOrSell": "D", "ownershipAfterTransaction": "74949"}, "transaction5": {"classOfStock": "Stock Option (Right to Buy)", "transactionDate": "2018-06-04", "amount": "3000", "price": "0.00", "buyOrSell": "D", "ownershipAfterTransaction": "120254"}}, "dateOfReport": "2018-06-04", "htmlOfReport": " <!DOCTYPE html PUBLIC \"-//W3C//DTD HTML 4.01 Transitional//EN\" \"http://www.w3.org/TR/html4/loose.dtd\">\n\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<title>SEC FORM \n            4</title>\n<style type=\"text/css\">\n              .FormData {color: blue; background-color: white; font-size: small; font-family: Times, serif;}\n              .FormDataC {color: blue; background-color: white; font-size: small; font-family: Times, serif; text-align: center;}\n              .FormDataR {color: blue; background-color: white; font-size: small; font-family: Times, serif; text-align: right;}\n              .SmallFormData {color: blue; background-color: white; font-size: x-small; font-family: Times, serif;}\n              .FootnoteData {color: green; background-color: white; font-size: x-small; font-family: Times, serif;}\n              .FormNumText {font-size: small; font-weight: bold; font-family: arial, helvetica, sans-serif;}\n              .FormAttention {font-size: medium; font-weight: bold; font-family: helvetica;}\n              .FormText {font-size: small; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: left;}\n              .FormTextR {font-size: small; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: right;}\n              .FormTextC {font-size: small; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: center;}\n              .FormEMText {font-size: medium; font-style: italic; font-weight: normal; font-family: arial, helvetica, sans-serif;}\n              .FormULText {font-size: medium; text-decoration: underline; font-weight: normal; font-family: arial, helvetica, sans-serif;}\n              .SmallFormText {font-size: xx-small; font-family: arial, helvetica, sans-serif; text-align: left;}\n              .SmallFormTextR {font-size: xx-small; font-family: arial, helvetica, sans-serif; text-align: right;}\n              .SmallFormTextC {font-size: xx-small; font-family: arial, helvetica, sans-serif; text-align: center;}\n              .MedSmallFormText {font-size: x-small; font-family: arial, helvetica, sans-serif; text-align: left;}\n              .FormTitle {font-size: medium; font-family: arial, helvetica, sans-serif; font-weight: bold;}\n              .FormTitle1 {font-size: small; font-family: arial, helvetica, sans-serif; font-weight: bold; border-top: black thick solid;}\n              .FormTitle2 {font-size: small; font-family: arial, helvetica, sans-serif; font-weight: bold;}\n              .FormTitle3 {font-size: small; font-family: arial, helvetica, sans-serif; font-weight: bold; padding-top: 2em; padding-bottom: 1em;}\n              .SectionTitle {font-size: small; text-align: left; font-family: arial, helvetica, sans-serif; \n              \t\tfont-weight: bold; border-top: gray thin solid; border-bottom: gray thin solid;}\n              .FormName {font-size: large; font-family: arial, helvetica, sans-serif; font-weight: bold;}\n              .CheckBox {text-align: center; width: 5px; cell-spacing: 0; padding: 0 3 0 3; border-width: thin; border-style: solid;  border-color: black:}\n              body {background: white;}\n      </style>\n</head>\n<body>SEC Form 4 \n   <table border=\"0\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<tr>\n<td align=\"center\" class=\"FormName\" colspan=\"2\" valign=\"top\" width=\"20%\">FORM 4</td>\n<td align=\"center\" rowspan=\"2\" valign=\"middle\" width=\"60%\">\n<span class=\"FormTitle\">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span><br/><span class=\"MedSmallFormText\">Washington, D.C. 20549</span><br/><br/><span class=\"FormTitle\">STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP</span><br/><br/><span class=\"MedSmallFormText\">Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934</span><br/><span class=\"MedSmallFormText\">or Section 30(h) of the Investment Company Act of 1940</span>\n</td>\n<td align=\"center\" rowspan=\"2\" valign=\"top\" width=\"20%\"><table border=\"1\" summary=\"OMB Approval Status Box\" width=\"100%\">\n<tr><td class=\"FormTextC\">OMB APPROVAL</td></tr>\n<tr><td><table border=\"0\" summary=\"OMB Interior Box\" width=\"100%\">\n<tr>\n<td class=\"SmallFormText\" colspan=\"3\">OMB Number:</td>\n<td class=\"SmallFormTextR\">3235-0287</td>\n</tr>\n<tr><td class=\"SmallFormText\" colspan=\"4\">Estimated average burden</td></tr>\n<tr>\n<td class=\"SmallFormText\" colspan=\"3\">hours per response:</td>\n<td class=\"SmallFormTextR\">0.5</td>\n</tr>\n</table></td></tr>\n</table></td>\n</tr>\n<tr valign=\"middle\">\n<td><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\"><tr><td>\u00a0\u00a0</td></tr></table></td>\n<td class=\"SmallFormText\">Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. \n         <i>See</i>\n\n         Instruction 1(b).</td>\n</tr>\n</table>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<tr>\n<td rowspan=\"3\" valign=\"top\" width=\"35%\">\n<span class=\"MedSmallFormText\">1. Name and Address of Reporting Person<sup>*</sup></span><table border=\"0\" width=\"100%\"><tr><td><a ANASTASIOS</a></td></tr></table>\n<hr width=\"98%\"/>\n<table border=\"0\" width=\"100%\"><tr>\n<td class=\"MedSmallFormText\" width=\"33%\">(Last)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(First)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(Middle)</td>\n</tr></table>\n<table border=\"0\" width=\"100%\">\n<tr><td><span class=\"FormData\">C/O MYOKARDIA, INC.</span></td></tr>\n<tr><td><span class=\"FormData\">333 ALLERTON AVENUE</span></td></tr>\n</table>\n<hr width=\"98%\"/>\n<span class=\"MedSmallFormText\">(Street)</span><table border=\"0\" width=\"100%\"><tr>\n<td width=\"33%\"><span class=\"FormData\">SOUTH SAN FRANCISCO</span></td>\n<td width=\"33%\"><span class=\"FormData\">CA</span></td>\n<td width=\"33%\"><span class=\"FormData\">94080</span></td>\n</tr></table>\n<hr width=\"98%\"/>\n<table border=\"0\" width=\"100%\"><tr>\n<td class=\"MedSmallFormText\" width=\"33%\">(City)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(State)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(Zip)</td>\n</tr></table>\n</td>\n<td valign=\"top\" width=\"35%\">\n<span class=\"MedSmallFormText\">2. Issuer Name <b>and</b> Ticker or Trading Symbol\n      </span><br/><a Inc</a>\n     [ <span class=\"FormData\">MYOK</span> ]\n   </td>\n<td rowspan=\"2\" valign=\"top\">\n<span class=\"MedSmallFormText\">5. Relationship of Reporting Person(s) to Issuer\n      </span><br/><span class=\"MedSmallFormText\">(Check all applicable)</span><table border=\"0\" width=\"100%\">\n<tr>\n<td align=\"center\" width=\"15%\"><span class=\"FormData\">X</span></td>\n<td class=\"MedSmallFormText\" width=\"35%\">Director</td>\n<td align=\"center\" width=\"15%\"></td>\n<td class=\"MedSmallFormText\" width=\"35%\">10% Owner</td>\n</tr>\n<tr>\n<td align=\"center\"><span class=\"FormData\">X</span></td>\n<td class=\"MedSmallFormText\">Officer (give title below)</td>\n<td align=\"center\"></td>\n<td class=\"MedSmallFormText\">Other (specify below)</td>\n</tr>\n<tr><td align=\"center\" colspan=\"4\"><span class=\"FormData\">President and CEO</span></td></tr>\n</table>\n</td>\n</tr>\n<tr><td valign=\"top\">\n<span class=\"MedSmallFormText\">3. Date of Earliest Transaction\n         (Month/Day/Year)</span><br/><span class=\"FormData\">06/04/2018</span>\n</td></tr>\n<tr>\n<td valign=\"top\">\n<span class=\"MedSmallFormText\">4. If Amendment, Date of Original Filed\n         (Month/Day/Year)</span><br/>\n</td>\n<td valign=\"top\">\n<span class=\"MedSmallFormText\">6. Individual or Joint/Group Filing (Check Applicable Line)\n      </span><table border=\"0\" width=\"100%\">\n<tr>\n<td align=\"center\" width=\"15%\"><span class=\"FormData\">X</span></td>\n<td class=\"MedSmallFormText\" width=\"85%\">Form filed by One Reporting Person</td>\n</tr>\n<tr>\n<td align=\"center\" width=\"15%\"></td>\n<td class=\"MedSmallFormText\" width=\"85%\">Form filed by More than One Reporting Person</td>\n</tr>\n</table>\n</td>\n</tr>\n</table>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<thead>\n<tr><th align=\"center\" class=\"FormTextC\" colspan=\"11\" valign=\"top\" width=\"100%\"><b>Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned</b></th></tr>\n<tr>\n<th align=\"left\" class=\"MedSmallFormText\" rowspan=\"2\" valign=\"top\" width=\"36%\">1. Title of Security (Instr. \n      3)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">2. Transaction Date\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">2A. Deemed Execution Date, if any\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"7%\">3. Transaction Code (Instr. \n      8)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"3\" valign=\"top\" width=\"19%\">4. Securities Acquired (A) or Disposed Of (D) (Instr. \n      3, 4 and 5)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"11%\">5. \n      Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. \n      3 and 4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"9%\">6. Ownership Form: Direct (D) or Indirect (I) (Instr. \n      4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"8%\">7. Nature of Indirect Beneficial Ownership (Instr. \n      4)\n   </th>\n</tr>\n<tr>\n<th align=\"center\" class=\"SmallFormText\" width=\"4%\">Code</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"3%\">V</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"8%\">Amount</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"5%\">(A) or (D)</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"6%\">Price</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"><span class=\"FormData\">06/04/2018</span></td>\n<td align=\"center\"><span class=\"FormData\"></span></td>\n<td align=\"center\">\n<span class=\"SmallFormData\">M</span><span class=\"FootnoteData\"><sup>(1)</sup></span>\n</td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"FormData\">3,000</span></td>\n<td align=\"center\"><span class=\"FormData\">A</span></td>\n<td align=\"center\">\n<span class=\"FormText\">$</span><span class=\"FormData\">1.5068</span><span class=\"FootnoteData\"><sup>(1)</sup></span>\n</td>\n<td align=\"center\"><span class=\"FormData\">77,949</span></td>\n<td align=\"center\"><span class=\"FormData\">D</span></td>\n<td align=\"left\"></td>\n</tr>\n<tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"><span class=\"FormData\">06/04/2018</span></td>\n<td align=\"center\"><span class=\"FormData\"></span></td>\n<td align=\"center\">\n<span class=\"SmallFormData\">S</span><span class=\"FootnoteData\"><sup>(1)</sup></span>\n</td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"FormData\">2,400</span></td>\n<td align=\"center\"><span class=\"FormData\">D</span></td>\n<td align=\"center\">\n<span class=\"FormText\">$</span><span class=\"FormData\">46.7454</span><span class=\"FootnoteData\"><sup>(2)</sup></span>\n</td>\n<td align=\"center\"><span class=\"FormData\">75,549</span></td>\n<td align=\"center\"><span class=\"FormData\">D</span></td>\n<td align=\"left\"></td>\n</tr>\n<tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"><span class=\"FormData\">06/04/2018</span></td>\n<td align=\"center\"><span class=\"FormData\"></span></td>\n<td align=\"center\">\n<span class=\"SmallFormData\">S</span><span class=\"FootnoteData\"><sup>(1)</sup></span>\n</td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"FormData\">500</span></td>\n<td align=\"center\"><span class=\"FormData\">D</span></td>\n<td align=\"center\">\n<span class=\"FormText\">$</span><span class=\"FormData\">47.63</span><span class=\"FootnoteData\"><sup>(3)</sup></span>\n</td>\n<td align=\"center\"><span class=\"FormData\">75,049</span></td>\n<td align=\"center\"><span class=\"FormData\">D</span></td>\n<td align=\"left\"></td>\n</tr>\n<tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"><span class=\"FormData\">06/04/2018</span></td>\n<td align=\"center\"><span class=\"FormData\"></span></td>\n<td align=\"center\">\n<span class=\"SmallFormData\">S</span><span class=\"FootnoteData\"><sup>(1)</sup></span>\n</td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"FormData\">100</span></td>\n<td align=\"center\"><span class=\"FormData\">D</span></td>\n<td align=\"center\">\n<span class=\"FormText\">$</span><span class=\"FormData\">48.6</span>\n</td>\n<td align=\"center\"><span class=\"FormData\">74,949</span></td>\n<td align=\"center\"><span class=\"FormData\">D</span></td>\n<td align=\"left\"></td>\n</tr>\n<tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"FormData\">85,973</span></td>\n<td align=\"center\"><span class=\"FormData\">I</span></td>\n<td align=\"left\"><span class=\"FormData\">By Reporting Person's Trust 2</span></td>\n</tr>\n<tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"FormData\">500,000</span></td>\n<td align=\"center\"><span class=\"FormData\">I</span></td>\n<td align=\"left\"><span class=\"FormData\">By Reporting Person's Trust 3</span></td>\n</tr>\n<tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"FormData\">12,200</span></td>\n<td align=\"center\"><span class=\"FormData\">I</span></td>\n<td align=\"left\"><span class=\"FormData\">By Trust 1</span></td>\n</tr>\n<tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"FormData\">12,200</span></td>\n<td align=\"center\"><span class=\"FormData\">I</span></td>\n<td align=\"left\"><span class=\"FormData\">By Trust 2</span></td>\n</tr>\n<tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"FormData\">12,200</span></td>\n<td align=\"center\"><span class=\"FormData\">I</span></td>\n<td align=\"left\"><span class=\"FormData\">By Trust 3</span></td>\n</tr>\n</tbody>\n</table>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<thead>\n<tr><th align=\"center\" class=\"FormTextC\" colspan=\"16\" valign=\"top\" width=\"100%\">\n<b>Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned</b><br/><b>(e.g., puts, calls, warrants, options, convertible securities)</b>\n</th></tr>\n<tr>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"13%\">1. Title of Derivative Security (Instr. \n      3)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">2. Conversion or Exercise Price of Derivative Security\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">3. Transaction Date\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">3A. Deemed Execution Date, if any\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"9%\">4. Transaction Code (Instr. \n      8)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"10%\">5. \n      Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. \n      3, 4 and 5)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"9%\">6. Date Exercisable and Expiration Date \n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"17%\">7. Title and Amount of Securities Underlying Derivative Security (Instr. \n      3 and 4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">8. Price of Derivative Security (Instr. \n      5)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">9. \n      Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. \n      4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">10. Ownership Form: Direct (D) or Indirect (I) (Instr. \n      4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"7%\">11. Nature of Indirect Beneficial Ownership (Instr. \n      4)\n   </th>\n</tr>\n<tr>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"4%\">Code</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"4%\">V</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"5%\">(A)</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"5%\">(D)</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"5%\">Date Exercisable</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"4%\">Expiration Date</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"10%\">Title</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"7%\">Amount or Number of Shares</th>\n</tr>\n</thead>\n<tbody><tr>\n<td align=\"left\"><span class=\"SmallFormData\">Stock Option (Right to Buy)</span></td>\n<td align=\"center\">\n<span class=\"SmallFormText\">$</span><span class=\"SmallFormData\">1.5068</span>\n</td>\n<td align=\"center\"><span class=\"SmallFormData\">06/04/2018</span></td>\n<td align=\"center\"><span class=\"SmallFormData\"></span></td>\n<td align=\"center\">\n<span class=\"SmallFormData\">M</span><span class=\"FootnoteData\"><sup>(1)</sup></span>\n</td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"SmallFormData\">3,000</span></td>\n<td align=\"center\">\n<span class=\"SmallFormData\">\n</span><span class=\"FootnoteData\"><sup>(4)</sup></span>\n</td>\n<td align=\"center\"><span class=\"SmallFormData\">06/03/2025</span></td>\n<td align=\"center\"><span class=\"SmallFormData\">Common Stock</span></td>\n<td align=\"center\"><span class=\"FormData\">3,000</span></td>\n<td align=\"center\">\n<span class=\"SmallFormText\">$</span><span class=\"SmallFormData\">0.00</span>\n</td>\n<td align=\"center\"><span class=\"SmallFormData\">120,254</span></td>\n<td align=\"center\"><span class=\"SmallFormData\">D</span></td>\n<td align=\"left\"></td>\n</tr></tbody>\n</table>\n<table border=\"0\" width=\"100%\">\n<tr><td class=\"MedSmallFormText\"><b>Explanation of Responses:</b></td></tr>\n<tr><td class=\"FootnoteData\">1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.</td></tr>\n<tr><td class=\"FootnoteData\">2. Represents the weighted average sale price of the shares sold ranging from $46.20 to $47.00 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.</td></tr>\n<tr><td class=\"FootnoteData\">3. Represents the weighted average sale price of the shares sold ranging from $47.25 to $47.95 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.</td></tr>\n<tr><td class=\"FootnoteData\">4. 25% of the shares subject to the option vested and became exercisable on June 4, 2016, and the remaining shares subject to this option vest and become exercisable in monthly installments through June 4, 2019, subject to the Reporting Person's continuous service to the Issuer.</td></tr>\n<tr><td class=\"FormText\"><b>Remarks:</b></td></tr>\n<tr><td class=\"FootnoteData\">Exhibit List: Exhibit 24.1 - Power of Attorney</td></tr>\n</table>\n<table border=\"0\" width=\"100%\">\n<tr>\n<td width=\"60%\"></td>\n<td width=\"20%\"><u><span class=\"FormData\">/s/Anastasios Gianakakos</span></u></td>\n<td width=\"20%\"><u><span class=\"FormData\">06/06/2018</span></u></td>\n</tr>\n<tr>\n<td></td>\n<td class=\"MedSmallFormText\">** Signature of Reporting Person</td>\n<td class=\"MedSmallFormText\">Date</td>\n</tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">* If the form is filed by more than one reporting person, \n                  <i>see</i>\n\n                  Instruction \n                  4\n\n                  (b)(v).</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">** Intentional misstatements or omissions of facts constitute Federal Criminal Violations \n                  <i>See</i>\n\n                  18 U.S.C. 1001 and 15 U.S.C. 78ff(a).</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, \n                  <i>see</i>\n\n                  Instruction 6 for procedure.</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\"><b>Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.</b></td></tr>\n</table>\n</body>\n</html>\n"}, "reportNo2": {"reportType": "Form 4", "url": ["https://www.sec.gov/Archives/edgar/data/1552451/000089924318014679/xslF345X03/doc4.xml", "2018-06-01"], "content": {"nameOfOwner": "Lee June", "position": "See Remarks", "dateOfReport": "2018-04-30", "transaction1": {"classOfStock": "Common Stock", "transactionDate": "2018-04-30", "amount": "426", "price": "33.15", "buyOrSell": "A", "ownershipAfterTransaction": "426"}}, "dateOfReport": "2018-04-30", "htmlOfReport": " <!DOCTYPE html PUBLIC \"-//W3C//DTD HTML 4.01 Transitional//EN\" \"http://www.w3.org/TR/html4/loose.dtd\">\n\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<title>SEC FORM \n            4</title>\n<style type=\"text/css\">\n              .FormData {color: blue; background-color: white; font-size: small; font-family: Times, serif;}\n              .FormDataC {color: blue; background-color: white; font-size: small; font-family: Times, serif; text-align: center;}\n              .FormDataR {color: blue; background-color: white; font-size: small; font-family: Times, serif; text-align: right;}\n              .SmallFormData {color: blue; background-color: white; font-size: x-small; font-family: Times, serif;}\n              .FootnoteData {color: green; background-color: white; font-size: x-small; font-family: Times, serif;}\n              .FormNumText {font-size: small; font-weight: bold; font-family: arial, helvetica, sans-serif;}\n              .FormAttention {font-size: medium; font-weight: bold; font-family: helvetica;}\n              .FormText {font-size: small; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: left;}\n              .FormTextR {font-size: small; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: right;}\n              .FormTextC {font-size: small; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: center;}\n              .FormEMText {font-size: medium; font-style: italic; font-weight: normal; font-family: arial, helvetica, sans-serif;}\n              .FormULText {font-size: medium; text-decoration: underline; font-weight: normal; font-family: arial, helvetica, sans-serif;}\n              .SmallFormText {font-size: xx-small; font-family: arial, helvetica, sans-serif; text-align: left;}\n              .SmallFormTextR {font-size: xx-small; font-family: arial, helvetica, sans-serif; text-align: right;}\n              .SmallFormTextC {font-size: xx-small; font-family: arial, helvetica, sans-serif; text-align: center;}\n              .MedSmallFormText {font-size: x-small; font-family: arial, helvetica, sans-serif; text-align: left;}\n              .FormTitle {font-size: medium; font-family: arial, helvetica, sans-serif; font-weight: bold;}\n              .FormTitle1 {font-size: small; font-family: arial, helvetica, sans-serif; font-weight: bold; border-top: black thick solid;}\n              .FormTitle2 {font-size: small; font-family: arial, helvetica, sans-serif; font-weight: bold;}\n              .FormTitle3 {font-size: small; font-family: arial, helvetica, sans-serif; font-weight: bold; padding-top: 2em; padding-bottom: 1em;}\n              .SectionTitle {font-size: small; text-align: left; font-family: arial, helvetica, sans-serif; \n              \t\tfont-weight: bold; border-top: gray thin solid; border-bottom: gray thin solid;}\n              .FormName {font-size: large; font-family: arial, helvetica, sans-serif; font-weight: bold;}\n              .CheckBox {text-align: center; width: 5px; cell-spacing: 0; padding: 0 3 0 3; border-width: thin; border-style: solid;  border-color: black:}\n              body {background: white;}\n      </style>\n</head>\n<body>SEC Form 4 \n   <table border=\"0\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<tr>\n<td align=\"center\" class=\"FormName\" colspan=\"2\" valign=\"top\" width=\"20%\">FORM 4</td>\n<td align=\"center\" rowspan=\"2\" valign=\"middle\" width=\"60%\">\n<span class=\"FormTitle\">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span><br/><span class=\"MedSmallFormText\">Washington, D.C. 20549</span><br/><br/><span class=\"FormTitle\">STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP</span><br/><br/><span class=\"MedSmallFormText\">Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934</span><br/><span class=\"MedSmallFormText\">or Section 30(h) of the Investment Company Act of 1940</span>\n</td>\n<td align=\"center\" rowspan=\"2\" valign=\"top\" width=\"20%\"><table border=\"1\" summary=\"OMB Approval Status Box\" width=\"100%\">\n<tr><td class=\"FormTextC\">OMB APPROVAL</td></tr>\n<tr><td><table border=\"0\" summary=\"OMB Interior Box\" width=\"100%\">\n<tr>\n<td class=\"SmallFormText\" colspan=\"3\">OMB Number:</td>\n<td class=\"SmallFormTextR\">3235-0287</td>\n</tr>\n<tr><td class=\"SmallFormText\" colspan=\"4\">Estimated average burden</td></tr>\n<tr>\n<td class=\"SmallFormText\" colspan=\"3\">hours per response:</td>\n<td class=\"SmallFormTextR\">0.5</td>\n</tr>\n</table></td></tr>\n</table></td>\n</tr>\n<tr valign=\"middle\">\n<td><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\"><tr><td>\u00a0\u00a0</td></tr></table></td>\n<td class=\"SmallFormText\">Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. \n         <i>See</i>\n\n         Instruction 1(b).</td>\n</tr>\n</table>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<tr>\n<td rowspan=\"3\" valign=\"top\" width=\"35%\">\n<span class=\"MedSmallFormText\">1. Name and Address of Reporting Person<sup>*</sup></span><table border=\"0\" width=\"100%\"><tr><td><a June</a></td></tr></table>\n<hr width=\"98%\"/>\n<table border=\"0\" width=\"100%\"><tr>\n<td class=\"MedSmallFormText\" width=\"33%\">(Last)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(First)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(Middle)</td>\n</tr></table>\n<table border=\"0\" width=\"100%\">\n<tr><td><span class=\"FormData\">C/O MYOKARDIA, INC.</span></td></tr>\n<tr><td><span class=\"FormData\">333 ALLERTON AVENUE</span></td></tr>\n</table>\n<hr width=\"98%\"/>\n<span class=\"MedSmallFormText\">(Street)</span><table border=\"0\" width=\"100%\"><tr>\n<td width=\"33%\"><span class=\"FormData\">SOUTH SAN FRANCISCO</span></td>\n<td width=\"33%\"><span class=\"FormData\">CA</span></td>\n<td width=\"33%\"><span class=\"FormData\">94080</span></td>\n</tr></table>\n<hr width=\"98%\"/>\n<table border=\"0\" width=\"100%\"><tr>\n<td class=\"MedSmallFormText\" width=\"33%\">(City)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(State)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(Zip)</td>\n</tr></table>\n</td>\n<td valign=\"top\" width=\"35%\">\n<span class=\"MedSmallFormText\">2. Issuer Name <b>and</b> Ticker or Trading Symbol\n      </span><br/><a Inc</a>\n     [ <span class=\"FormData\">MYOK</span> ]\n   </td>\n<td rowspan=\"2\" valign=\"top\">\n<span class=\"MedSmallFormText\">5. Relationship of Reporting Person(s) to Issuer\n      </span><br/><span class=\"MedSmallFormText\">(Check all applicable)</span><table border=\"0\" width=\"100%\">\n<tr>\n<td align=\"center\" width=\"15%\"></td>\n<td class=\"MedSmallFormText\" width=\"35%\">Director</td>\n<td align=\"center\" width=\"15%\"></td>\n<td class=\"MedSmallFormText\" width=\"35%\">10% Owner</td>\n</tr>\n<tr>\n<td align=\"center\"><span class=\"FormData\">X</span></td>\n<td class=\"MedSmallFormText\">Officer (give title below)</td>\n<td align=\"center\"></td>\n<td class=\"MedSmallFormText\">Other (specify below)</td>\n</tr>\n<tr><td align=\"center\" colspan=\"4\"><span class=\"FormData\">See Remarks</span></td></tr>\n</table>\n</td>\n</tr>\n<tr><td valign=\"top\">\n<span class=\"MedSmallFormText\">3. Date of Earliest Transaction\n         (Month/Day/Year)</span><br/><span class=\"FormData\">04/30/2018</span>\n</td></tr>\n<tr>\n<td valign=\"top\">\n<span class=\"MedSmallFormText\">4. If Amendment, Date of Original Filed\n         (Month/Day/Year)</span><br/>\n</td>\n<td valign=\"top\">\n<span class=\"MedSmallFormText\">6. Individual or Joint/Group Filing (Check Applicable Line)\n      </span><table border=\"0\" width=\"100%\">\n<tr>\n<td align=\"center\" width=\"15%\"><span class=\"FormData\">X</span></td>\n<td class=\"MedSmallFormText\" width=\"85%\">Form filed by One Reporting Person</td>\n</tr>\n<tr>\n<td align=\"center\" width=\"15%\"></td>\n<td class=\"MedSmallFormText\" width=\"85%\">Form filed by More than One Reporting Person</td>\n</tr>\n</table>\n</td>\n</tr>\n</table>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<thead>\n<tr><th align=\"center\" class=\"FormTextC\" colspan=\"11\" valign=\"top\" width=\"100%\"><b>Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned</b></th></tr>\n<tr>\n<th align=\"left\" class=\"MedSmallFormText\" rowspan=\"2\" valign=\"top\" width=\"36%\">1. Title of Security (Instr. \n      3)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">2. Transaction Date\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">2A. Deemed Execution Date, if any\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"7%\">3. Transaction Code (Instr. \n      8)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"3\" valign=\"top\" width=\"19%\">4. Securities Acquired (A) or Disposed Of (D) (Instr. \n      3, 4 and 5)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"11%\">5. \n      Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. \n      3 and 4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"9%\">6. Ownership Form: Direct (D) or Indirect (I) (Instr. \n      4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"8%\">7. Nature of Indirect Beneficial Ownership (Instr. \n      4)\n   </th>\n</tr>\n<tr>\n<th align=\"center\" class=\"SmallFormText\" width=\"4%\">Code</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"3%\">V</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"8%\">Amount</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"5%\">(A) or (D)</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"6%\">Price</th>\n</tr>\n</thead>\n<tbody><tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"><span class=\"FormData\">04/30/2018</span></td>\n<td align=\"center\"><span class=\"FormData\"></span></td>\n<td align=\"center\"><span class=\"SmallFormData\">A</span></td>\n<td align=\"center\"><span class=\"SmallFormData\">V</span></td>\n<td align=\"center\">\n<span class=\"FormData\">426</span><span class=\"FootnoteData\"><sup>(1)</sup></span>\n</td>\n<td align=\"center\"><span class=\"FormData\">A</span></td>\n<td align=\"center\">\n<span class=\"FormText\">$</span><span class=\"FormData\">33.15</span>\n</td>\n<td align=\"center\"><span class=\"FormData\">426</span></td>\n<td align=\"center\"><span class=\"FormData\">D</span></td>\n<td align=\"left\"></td>\n</tr></tbody>\n</table>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\"><thead>\n<tr><th align=\"center\" class=\"FormTextC\" colspan=\"16\" valign=\"top\" width=\"100%\">\n<b>Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned</b><br/><b>(e.g., puts, calls, warrants, options, convertible securities)</b>\n</th></tr>\n<tr>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"13%\">1. Title of Derivative Security (Instr. \n      3)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">2. Conversion or Exercise Price of Derivative Security\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">3. Transaction Date\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">3A. Deemed Execution Date, if any\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"9%\">4. Transaction Code (Instr. \n      8)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"10%\">5. \n      Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. \n      3, 4 and 5)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"9%\">6. Date Exercisable and Expiration Date \n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"17%\">7. Title and Amount of Securities Underlying Derivative Security (Instr. \n      3 and 4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">8. Price of Derivative Security (Instr. \n      5)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">9. \n      Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. \n      4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">10. Ownership Form: Direct (D) or Indirect (I) (Instr. \n      4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"7%\">11. Nature of Indirect Beneficial Ownership (Instr. \n      4)\n   </th>\n</tr>\n<tr>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"4%\">Code</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"4%\">V</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"5%\">(A)</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"5%\">(D)</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"5%\">Date Exercisable</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"4%\">Expiration Date</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"10%\">Title</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"7%\">Amount or Number of Shares</th>\n</tr>\n</thead></table>\n<table border=\"0\" width=\"100%\">\n<tr><td class=\"MedSmallFormText\"><b>Explanation of Responses:</b></td></tr>\n<tr><td class=\"FootnoteData\">1. Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan.</td></tr>\n<tr><td class=\"FormText\"><b>Remarks:</b></td></tr>\n<tr><td class=\"FootnoteData\">Chief Development Officer and Chief Operating Officer</td></tr>\n</table>\n<table border=\"0\" width=\"100%\">\n<tr>\n<td width=\"60%\"></td>\n<td width=\"20%\"><u><span class=\"FormData\">/s/Jake Bauer, Attorney-in-Fact</span></u></td>\n<td width=\"20%\"><u><span class=\"FormData\">06/01/2018</span></u></td>\n</tr>\n<tr>\n<td></td>\n<td class=\"MedSmallFormText\">** Signature of Reporting Person</td>\n<td class=\"MedSmallFormText\">Date</td>\n</tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">* If the form is filed by more than one reporting person, \n                  <i>see</i>\n\n                  Instruction \n                  4\n\n                  (b)(v).</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">** Intentional misstatements or omissions of facts constitute Federal Criminal Violations \n                  <i>See</i>\n\n                  18 U.S.C. 1001 and 15 U.S.C. 78ff(a).</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, \n                  <i>see</i>\n\n                  Instruction 6 for procedure.</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\"><b>Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.</b></td></tr>\n</table>\n</body>\n</html>\n"}, "reportNo3": {"reportType": "Form 4", "url": ["https://www.sec.gov/Archives/edgar/data/1552451/000089924318014678/xslF345X03/doc4.xml", "2018-06-01"], "content": {"nameOfOwner": "Lambing Joseph", "position": "See Remarks", "dateOfReport": "2018-04-30", "transaction1": {"classOfStock": "Common Stock", "transactionDate": "2018-04-30", "amount": "368", "price": "33.15", "buyOrSell": "A", "ownershipAfterTransaction": "93914"}}, "dateOfReport": "2018-04-30", "htmlOfReport": " <!DOCTYPE html PUBLIC \"-//W3C//DTD HTML 4.01 Transitional//EN\" \"http://www.w3.org/TR/html4/loose.dtd\">\n\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<title>SEC FORM \n            4</title>\n<style type=\"text/css\">\n              .FormData {color: blue; background-color: white; font-size: small; font-family: Times, serif;}\n              .FormDataC {color: blue; background-color: white; font-size: small; font-family: Times, serif; text-align: center;}\n              .FormDataR {color: blue; background-color: white; font-size: small; font-family: Times, serif; text-align: right;}\n              .SmallFormData {color: blue; background-color: white; font-size: x-small; font-family: Times, serif;}\n              .FootnoteData {color: green; background-color: white; font-size: x-small; font-family: Times, serif;}\n              .FormNumText {font-size: small; font-weight: bold; font-family: arial, helvetica, sans-serif;}\n              .FormAttention {font-size: medium; font-weight: bold; font-family: helvetica;}\n              .FormText {font-size: small; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: left;}\n              .FormTextR {font-size: small; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: right;}\n              .FormTextC {font-size: small; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: center;}\n              .FormEMText {font-size: medium; font-style: italic; font-weight: normal; font-family: arial, helvetica, sans-serif;}\n              .FormULText {font-size: medium; text-decoration: underline; font-weight: normal; font-family: arial, helvetica, sans-serif;}\n              .SmallFormText {font-size: xx-small; font-family: arial, helvetica, sans-serif; text-align: left;}\n              .SmallFormTextR {font-size: xx-small; font-family: arial, helvetica, sans-serif; text-align: right;}\n              .SmallFormTextC {font-size: xx-small; font-family: arial, helvetica, sans-serif; text-align: center;}\n              .MedSmallFormText {font-size: x-small; font-family: arial, helvetica, sans-serif; text-align: left;}\n              .FormTitle {font-size: medium; font-family: arial, helvetica, sans-serif; font-weight: bold;}\n              .FormTitle1 {font-size: small; font-family: arial, helvetica, sans-serif; font-weight: bold; border-top: black thick solid;}\n              .FormTitle2 {font-size: small; font-family: arial, helvetica, sans-serif; font-weight: bold;}\n              .FormTitle3 {font-size: small; font-family: arial, helvetica, sans-serif; font-weight: bold; padding-top: 2em; padding-bottom: 1em;}\n              .SectionTitle {font-size: small; text-align: left; font-family: arial, helvetica, sans-serif; \n              \t\tfont-weight: bold; border-top: gray thin solid; border-bottom: gray thin solid;}\n              .FormName {font-size: large; font-family: arial, helvetica, sans-serif; font-weight: bold;}\n              .CheckBox {text-align: center; width: 5px; cell-spacing: 0; padding: 0 3 0 3; border-width: thin; border-style: solid;  border-color: black:}\n              body {background: white;}\n      </style>\n</head>\n<body>SEC Form 4 \n   <table border=\"0\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<tr>\n<td align=\"center\" class=\"FormName\" colspan=\"2\" valign=\"top\" width=\"20%\">FORM 4</td>\n<td align=\"center\" rowspan=\"2\" valign=\"middle\" width=\"60%\">\n<span class=\"FormTitle\">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span><br/><span class=\"MedSmallFormText\">Washington, D.C. 20549</span><br/><br/><span class=\"FormTitle\">STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP</span><br/><br/><span class=\"MedSmallFormText\">Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934</span><br/><span class=\"MedSmallFormText\">or Section 30(h) of the Investment Company Act of 1940</span>\n</td>\n<td align=\"center\" rowspan=\"2\" valign=\"top\" width=\"20%\"><table border=\"1\" summary=\"OMB Approval Status Box\" width=\"100%\">\n<tr><td class=\"FormTextC\">OMB APPROVAL</td></tr>\n<tr><td><table border=\"0\" summary=\"OMB Interior Box\" width=\"100%\">\n<tr>\n<td class=\"SmallFormText\" colspan=\"3\">OMB Number:</td>\n<td class=\"SmallFormTextR\">3235-0287</td>\n</tr>\n<tr><td class=\"SmallFormText\" colspan=\"4\">Estimated average burden</td></tr>\n<tr>\n<td class=\"SmallFormText\" colspan=\"3\">hours per response:</td>\n<td class=\"SmallFormTextR\">0.5</td>\n</tr>\n</table></td></tr>\n</table></td>\n</tr>\n<tr valign=\"middle\">\n<td><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\"><tr><td>\u00a0\u00a0</td></tr></table></td>\n<td class=\"SmallFormText\">Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. \n         <i>See</i>\n\n         Instruction 1(b).</td>\n</tr>\n</table>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<tr>\n<td rowspan=\"3\" valign=\"top\" width=\"35%\">\n<span class=\"MedSmallFormText\">1. Name and Address of Reporting Person<sup>*</sup></span><table border=\"0\" width=\"100%\"><tr><td><a Joseph</a></td></tr></table>\n<hr width=\"98%\"/>\n<table border=\"0\" width=\"100%\"><tr>\n<td class=\"MedSmallFormText\" width=\"33%\">(Last)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(First)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(Middle)</td>\n</tr></table>\n<table border=\"0\" width=\"100%\">\n<tr><td><span class=\"FormData\">C/O MYOKARDIA, INC.</span></td></tr>\n<tr><td><span class=\"FormData\">333 ALLERTON AVENUE</span></td></tr>\n</table>\n<hr width=\"98%\"/>\n<span class=\"MedSmallFormText\">(Street)</span><table border=\"0\" width=\"100%\"><tr>\n<td width=\"33%\"><span class=\"FormData\">SOUTH SAN FRANCISCO</span></td>\n<td width=\"33%\"><span class=\"FormData\">CA</span></td>\n<td width=\"33%\"><span class=\"FormData\">94080</span></td>\n</tr></table>\n<hr width=\"98%\"/>\n<table border=\"0\" width=\"100%\"><tr>\n<td class=\"MedSmallFormText\" width=\"33%\">(City)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(State)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(Zip)</td>\n</tr></table>\n</td>\n<td valign=\"top\" width=\"35%\">\n<span class=\"MedSmallFormText\">2. Issuer Name <b>and</b> Ticker or Trading Symbol\n      </span><br/><a Inc</a>\n     [ <span class=\"FormData\">MYOK</span> ]\n   </td>\n<td rowspan=\"2\" valign=\"top\">\n<span class=\"MedSmallFormText\">5. Relationship of Reporting Person(s) to Issuer\n      </span><br/><span class=\"MedSmallFormText\">(Check all applicable)</span><table border=\"0\" width=\"100%\">\n<tr>\n<td align=\"center\" width=\"15%\"></td>\n<td class=\"MedSmallFormText\" width=\"35%\">Director</td>\n<td align=\"center\" width=\"15%\"></td>\n<td class=\"MedSmallFormText\" width=\"35%\">10% Owner</td>\n</tr>\n<tr>\n<td align=\"center\"><span class=\"FormData\">X</span></td>\n<td class=\"MedSmallFormText\">Officer (give title below)</td>\n<td align=\"center\"></td>\n<td class=\"MedSmallFormText\">Other (specify below)</td>\n</tr>\n<tr><td align=\"center\" colspan=\"4\"><span class=\"FormData\">See Remarks</span></td></tr>\n</table>\n</td>\n</tr>\n<tr><td valign=\"top\">\n<span class=\"MedSmallFormText\">3. Date of Earliest Transaction\n         (Month/Day/Year)</span><br/><span class=\"FormData\">04/30/2018</span>\n</td></tr>\n<tr>\n<td valign=\"top\">\n<span class=\"MedSmallFormText\">4. If Amendment, Date of Original Filed\n         (Month/Day/Year)</span><br/>\n</td>\n<td valign=\"top\">\n<span class=\"MedSmallFormText\">6. Individual or Joint/Group Filing (Check Applicable Line)\n      </span><table border=\"0\" width=\"100%\">\n<tr>\n<td align=\"center\" width=\"15%\"><span class=\"FormData\">X</span></td>\n<td class=\"MedSmallFormText\" width=\"85%\">Form filed by One Reporting Person</td>\n</tr>\n<tr>\n<td align=\"center\" width=\"15%\"></td>\n<td class=\"MedSmallFormText\" width=\"85%\">Form filed by More than One Reporting Person</td>\n</tr>\n</table>\n</td>\n</tr>\n</table>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<thead>\n<tr><th align=\"center\" class=\"FormTextC\" colspan=\"11\" valign=\"top\" width=\"100%\"><b>Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned</b></th></tr>\n<tr>\n<th align=\"left\" class=\"MedSmallFormText\" rowspan=\"2\" valign=\"top\" width=\"36%\">1. Title of Security (Instr. \n      3)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">2. Transaction Date\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">2A. Deemed Execution Date, if any\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"7%\">3. Transaction Code (Instr. \n      8)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"3\" valign=\"top\" width=\"19%\">4. Securities Acquired (A) or Disposed Of (D) (Instr. \n      3, 4 and 5)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"11%\">5. \n      Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. \n      3 and 4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"9%\">6. Ownership Form: Direct (D) or Indirect (I) (Instr. \n      4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"8%\">7. Nature of Indirect Beneficial Ownership (Instr. \n      4)\n   </th>\n</tr>\n<tr>\n<th align=\"center\" class=\"SmallFormText\" width=\"4%\">Code</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"3%\">V</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"8%\">Amount</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"5%\">(A) or (D)</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"6%\">Price</th>\n</tr>\n</thead>\n<tbody><tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"><span class=\"FormData\">04/30/2018</span></td>\n<td align=\"center\"><span class=\"FormData\"></span></td>\n<td align=\"center\"><span class=\"SmallFormData\">A</span></td>\n<td align=\"center\"><span class=\"SmallFormData\">V</span></td>\n<td align=\"center\">\n<span class=\"FormData\">368</span><span class=\"FootnoteData\"><sup>(1)</sup></span>\n</td>\n<td align=\"center\"><span class=\"FormData\">A</span></td>\n<td align=\"center\">\n<span class=\"FormText\">$</span><span class=\"FormData\">33.15</span>\n</td>\n<td align=\"center\"><span class=\"FormData\">93,914</span></td>\n<td align=\"center\"><span class=\"FormData\">D</span></td>\n<td align=\"left\"></td>\n</tr></tbody>\n</table>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\"><thead>\n<tr><th align=\"center\" class=\"FormTextC\" colspan=\"16\" valign=\"top\" width=\"100%\">\n<b>Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned</b><br/><b>(e.g., puts, calls, warrants, options, convertible securities)</b>\n</th></tr>\n<tr>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"13%\">1. Title of Derivative Security (Instr. \n      3)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">2. Conversion or Exercise Price of Derivative Security\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">3. Transaction Date\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">3A. Deemed Execution Date, if any\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"9%\">4. Transaction Code (Instr. \n      8)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"10%\">5. \n      Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. \n      3, 4 and 5)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"9%\">6. Date Exercisable and Expiration Date \n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"17%\">7. Title and Amount of Securities Underlying Derivative Security (Instr. \n      3 and 4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">8. Price of Derivative Security (Instr. \n      5)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">9. \n      Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. \n      4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">10. Ownership Form: Direct (D) or Indirect (I) (Instr. \n      4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"7%\">11. Nature of Indirect Beneficial Ownership (Instr. \n      4)\n   </th>\n</tr>\n<tr>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"4%\">Code</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"4%\">V</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"5%\">(A)</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"5%\">(D)</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"5%\">Date Exercisable</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"4%\">Expiration Date</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"10%\">Title</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"7%\">Amount or Number of Shares</th>\n</tr>\n</thead></table>\n<table border=\"0\" width=\"100%\">\n<tr><td class=\"MedSmallFormText\"><b>Explanation of Responses:</b></td></tr>\n<tr><td class=\"FootnoteData\">1. Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan.</td></tr>\n<tr><td class=\"FormText\"><b>Remarks:</b></td></tr>\n<tr><td class=\"FootnoteData\">Senior Vice President, Non-Clinical and  Pharmaceutical Development</td></tr>\n</table>\n<table border=\"0\" width=\"100%\">\n<tr>\n<td width=\"60%\"></td>\n<td width=\"20%\"><u><span class=\"FormData\">/s/Jake Bauer, Attorney-in-Fact</span></u></td>\n<td width=\"20%\"><u><span class=\"FormData\">06/01/2018</span></u></td>\n</tr>\n<tr>\n<td></td>\n<td class=\"MedSmallFormText\">** Signature of Reporting Person</td>\n<td class=\"MedSmallFormText\">Date</td>\n</tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">* If the form is filed by more than one reporting person, \n                  <i>see</i>\n\n                  Instruction \n                  4\n\n                  (b)(v).</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">** Intentional misstatements or omissions of facts constitute Federal Criminal Violations \n                  <i>See</i>\n\n                  18 U.S.C. 1001 and 15 U.S.C. 78ff(a).</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, \n                  <i>see</i>\n\n                  Instruction 6 for procedure.</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\"><b>Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.</b></td></tr>\n</table>\n</body>\n</html>\n"}, "reportNo4": {"reportType": "Form 4", "url": ["https://www.sec.gov/Archives/edgar/data/1121404/000089924318014266/xslF345X03/doc4.xml", "2018-05-29"], "content": {"nameOfOwner": "Sanofi", "position": false, "dateOfReport": "2018-05-25", "transaction1": {"classOfStock": "Common stock Par value per share $ 0.0001", "transactionDate": "2018-05-25", "amount": "150000", "price": "49.00", "buyOrSell": "A", "ownershipAfterTransaction": "4168899"}}, "dateOfReport": "2018-05-25", "htmlOfReport": " <!DOCTYPE html PUBLIC \"-//W3C//DTD HTML 4.01 Transitional//EN\" \"http://www.w3.org/TR/html4/loose.dtd\">\n\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<title>SEC FORM \n            4</title>\n<style type=\"text/css\">\n              .FormData {color: blue; background-color: white; font-size: small; font-family: Times, serif;}\n              .FormDataC {color: blue; background-color: white; font-size: small; font-family: Times, serif; text-align: center;}\n              .FormDataR {color: blue; background-color: white; font-size: small; font-family: Times, serif; text-align: right;}\n              .SmallFormData {color: blue; background-color: white; font-size: x-small; font-family: Times, serif;}\n              .FootnoteData {color: green; background-color: white; font-size: x-small; font-family: Times, serif;}\n              .FormNumText {font-size: small; font-weight: bold; font-family: arial, helvetica, sans-serif;}\n              .FormAttention {font-size: medium; font-weight: bold; font-family: helvetica;}\n              .FormText {font-size: small; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: left;}\n              .FormTextR {font-size: small; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: right;}\n              .FormTextC {font-size: small; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: center;}\n              .FormEMText {font-size: medium; font-style: italic; font-weight: normal; font-family: arial, helvetica, sans-serif;}\n              .FormULText {font-size: medium; text-decoration: underline; font-weight: normal; font-family: arial, helvetica, sans-serif;}\n              .SmallFormText {font-size: xx-small; font-family: arial, helvetica, sans-serif; text-align: left;}\n              .SmallFormTextR {font-size: xx-small; font-family: arial, helvetica, sans-serif; text-align: right;}\n              .SmallFormTextC {font-size: xx-small; font-family: arial, helvetica, sans-serif; text-align: center;}\n              .MedSmallFormText {font-size: x-small; font-family: arial, helvetica, sans-serif; text-align: left;}\n              .FormTitle {font-size: medium; font-family: arial, helvetica, sans-serif; font-weight: bold;}\n              .FormTitle1 {font-size: small; font-family: arial, helvetica, sans-serif; font-weight: bold; border-top: black thick solid;}\n              .FormTitle2 {font-size: small; font-family: arial, helvetica, sans-serif; font-weight: bold;}\n              .FormTitle3 {font-size: small; font-family: arial, helvetica, sans-serif; font-weight: bold; padding-top: 2em; padding-bottom: 1em;}\n              .SectionTitle {font-size: small; text-align: left; font-family: arial, helvetica, sans-serif; \n              \t\tfont-weight: bold; border-top: gray thin solid; border-bottom: gray thin solid;}\n              .FormName {font-size: large; font-family: arial, helvetica, sans-serif; font-weight: bold;}\n              .CheckBox {text-align: center; width: 5px; cell-spacing: 0; padding: 0 3 0 3; border-width: thin; border-style: solid;  border-color: black:}\n              body {background: white;}\n      </style>\n</head>\n<body>SEC Form 4 \n   <table border=\"0\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<tr>\n<td align=\"center\" class=\"FormName\" colspan=\"2\" valign=\"top\" width=\"20%\">FORM 4</td>\n<td align=\"center\" rowspan=\"2\" valign=\"middle\" width=\"60%\">\n<span class=\"FormTitle\">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span><br/><span class=\"MedSmallFormText\">Washington, D.C. 20549</span><br/><br/><span class=\"FormTitle\">STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP</span><br/><br/><span class=\"MedSmallFormText\">Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934</span><br/><span class=\"MedSmallFormText\">or Section 30(h) of the Investment Company Act of 1940</span>\n</td>\n<td align=\"center\" rowspan=\"2\" valign=\"top\" width=\"20%\"><table border=\"1\" summary=\"OMB Approval Status Box\" width=\"100%\">\n<tr><td class=\"FormTextC\">OMB APPROVAL</td></tr>\n<tr><td><table border=\"0\" summary=\"OMB Interior Box\" width=\"100%\">\n<tr>\n<td class=\"SmallFormText\" colspan=\"3\">OMB Number:</td>\n<td class=\"SmallFormTextR\">3235-0287</td>\n</tr>\n<tr><td class=\"SmallFormText\" colspan=\"4\">Estimated average burden</td></tr>\n<tr>\n<td class=\"SmallFormText\" colspan=\"3\">hours per response:</td>\n<td class=\"SmallFormTextR\">0.5</td>\n</tr>\n</table></td></tr>\n</table></td>\n</tr>\n<tr valign=\"middle\">\n<td><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\"><tr><td>\u00a0\u00a0</td></tr></table></td>\n<td class=\"SmallFormText\">Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. \n         <i>See</i>\n\n         Instruction 1(b).</td>\n</tr>\n</table>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<tr>\n<td rowspan=\"3\" valign=\"top\" width=\"35%\">\n<span class=\"MedSmallFormText\">1. Name and Address of Reporting Person<sup>*</sup></span><table border=\"0\" width=\"100%\"><tr><td><a width=\"98%\"/>\n<table border=\"0\" width=\"100%\"><tr>\n<td class=\"MedSmallFormText\" width=\"33%\">(Last)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(First)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(Middle)</td>\n</tr></table>\n<table border=\"0\" width=\"100%\">\n<tr><td><span class=\"FormData\">54 RUE LA BOETIE</span></td></tr>\n<tr><td><span class=\"FormData\"></span></td></tr>\n</table>\n<hr width=\"98%\"/>\n<span class=\"MedSmallFormText\">(Street)</span><table border=\"0\" width=\"100%\"><tr>\n<td width=\"33%\"><span class=\"FormData\">PARIS</span></td>\n<td width=\"33%\"><span class=\"FormData\">I0</span></td>\n<td width=\"33%\"><span class=\"FormData\">75008</span></td>\n</tr></table>\n<hr width=\"98%\"/>\n<table border=\"0\" width=\"100%\"><tr>\n<td class=\"MedSmallFormText\" width=\"33%\">(City)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(State)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(Zip)</td>\n</tr></table>\n</td>\n<td valign=\"top\" width=\"35%\">\n<span class=\"MedSmallFormText\">2. Issuer Name <b>and</b> Ticker or Trading Symbol\n      </span><br/><a Inc</a>\n     [ <span class=\"FormData\">MYOK</span> ]\n   </td>\n<td rowspan=\"2\" valign=\"top\">\n<span class=\"MedSmallFormText\">5. Relationship of Reporting Person(s) to Issuer\n      </span><br/><span class=\"MedSmallFormText\">(Check all applicable)</span><table border=\"0\" width=\"100%\">\n<tr>\n<td align=\"center\" width=\"15%\"></td>\n<td class=\"MedSmallFormText\" width=\"35%\">Director</td>\n<td align=\"center\" width=\"15%\"><span class=\"FormData\">X</span></td>\n<td class=\"MedSmallFormText\" width=\"35%\">10% Owner</td>\n</tr>\n<tr>\n<td align=\"center\"></td>\n<td class=\"MedSmallFormText\">Officer (give title below)</td>\n<td align=\"center\"></td>\n<td class=\"MedSmallFormText\">Other (specify below)</td>\n</tr>\n<tr><td align=\"center\" colspan=\"4\"></td></tr>\n</table>\n</td>\n</tr>\n<tr><td valign=\"top\">\n<span class=\"MedSmallFormText\">3. Date of Earliest Transaction\n         (Month/Day/Year)</span><br/><span class=\"FormData\">05/25/2018</span>\n</td></tr>\n<tr>\n<td valign=\"top\">\n<span class=\"MedSmallFormText\">4. If Amendment, Date of Original Filed\n         (Month/Day/Year)</span><br/>\n</td>\n<td valign=\"top\">\n<span class=\"MedSmallFormText\">6. Individual or Joint/Group Filing (Check Applicable Line)\n      </span><table border=\"0\" width=\"100%\">\n<tr>\n<td align=\"center\" width=\"15%\"><span class=\"FormData\">X</span></td>\n<td class=\"MedSmallFormText\" width=\"85%\">Form filed by One Reporting Person</td>\n</tr>\n<tr>\n<td align=\"center\" width=\"15%\"></td>\n<td class=\"MedSmallFormText\" width=\"85%\">Form filed by More than One Reporting Person</td>\n</tr>\n</table>\n</td>\n</tr>\n</table>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<thead>\n<tr><th align=\"center\" class=\"FormTextC\" colspan=\"11\" valign=\"top\" width=\"100%\"><b>Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned</b></th></tr>\n<tr>\n<th align=\"left\" class=\"MedSmallFormText\" rowspan=\"2\" valign=\"top\" width=\"36%\">1. Title of Security (Instr. \n      3)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">2. Transaction Date\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">2A. Deemed Execution Date, if any\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"7%\">3. Transaction Code (Instr. \n      8)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"3\" valign=\"top\" width=\"19%\">4. Securities Acquired (A) or Disposed Of (D) (Instr. \n      3, 4 and 5)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"11%\">5. \n      Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. \n      3 and 4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"9%\">6. Ownership Form: Direct (D) or Indirect (I) (Instr. \n      4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"8%\">7. Nature of Indirect Beneficial Ownership (Instr. \n      4)\n   </th>\n</tr>\n<tr>\n<th align=\"center\" class=\"SmallFormText\" width=\"4%\">Code</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"3%\">V</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"8%\">Amount</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"5%\">(A) or (D)</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"6%\">Price</th>\n</tr>\n</thead>\n<tbody><tr>\n<td align=\"left\"><span class=\"FormData\">Common stock Par value per share $ 0.0001</span></td>\n<td align=\"center\"><span class=\"FormData\">05/25/2018</span></td>\n<td align=\"center\"><span class=\"FormData\"></span></td>\n<td align=\"center\"><span class=\"SmallFormData\">P</span></td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"FormData\">150,000</span></td>\n<td align=\"center\"><span class=\"FormData\">A</span></td>\n<td align=\"center\">\n<span class=\"FormText\">$</span><span class=\"FormData\">49</span>\n</td>\n<td align=\"center\"><span class=\"FormData\">4,168,899</span></td>\n<td align=\"center\"><span class=\"FormData\">I</span></td>\n<td align=\"left\"><span class=\"FormData\">Via wholly owned subsidiary Aventis Inc.</span></td>\n</tr></tbody>\n</table>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\"><thead>\n<tr><th align=\"center\" class=\"FormTextC\" colspan=\"16\" valign=\"top\" width=\"100%\">\n<b>Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned</b><br/><b>(e.g., puts, calls, warrants, options, convertible securities)</b>\n</th></tr>\n<tr>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"13%\">1. Title of Derivative Security (Instr. \n      3)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">2. Conversion or Exercise Price of Derivative Security\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">3. Transaction Date\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">3A. Deemed Execution Date, if any\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"9%\">4. Transaction Code (Instr. \n      8)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"10%\">5. \n      Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. \n      3, 4 and 5)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"9%\">6. Date Exercisable and Expiration Date \n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"17%\">7. Title and Amount of Securities Underlying Derivative Security (Instr. \n      3 and 4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">8. Price of Derivative Security (Instr. \n      5)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">9. \n      Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. \n      4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">10. Ownership Form: Direct (D) or Indirect (I) (Instr. \n      4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"7%\">11. Nature of Indirect Beneficial Ownership (Instr. \n      4)\n   </th>\n</tr>\n<tr>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"4%\">Code</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"4%\">V</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"5%\">(A)</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"5%\">(D)</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"5%\">Date Exercisable</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"4%\">Expiration Date</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"10%\">Title</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"7%\">Amount or Number of Shares</th>\n</tr>\n</thead></table>\n<table border=\"0\" width=\"100%\">\n<tr><td class=\"MedSmallFormText\"><b>Explanation of Responses:</b></td></tr>\n<tr><td class=\"FormText\"><b>Remarks:</b></td></tr>\n<tr><td class=\"FootnoteData\"></td></tr>\n</table>\n<table border=\"0\" width=\"100%\">\n<tr>\n<td width=\"60%\"></td>\n<td width=\"20%\"><u><span class=\"FormData\">/s/ Alexandra Roger, Head of Securities Law and Capital Markets</span></u></td>\n<td width=\"20%\"><u><span class=\"FormData\">05/29/2018</span></u></td>\n</tr>\n<tr>\n<td></td>\n<td class=\"MedSmallFormText\">** Signature of Reporting Person</td>\n<td class=\"MedSmallFormText\">Date</td>\n</tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">* If the form is filed by more than one reporting person, \n                  <i>see</i>\n\n                  Instruction \n                  4\n\n                  (b)(v).</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">** Intentional misstatements or omissions of facts constitute Federal Criminal Violations \n                  <i>See</i>\n\n                  18 U.S.C. 1001 and 15 U.S.C. 78ff(a).</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, \n                  <i>see</i>\n\n                  Instruction 6 for procedure.</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\"><b>Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.</b></td></tr>\n</table>\n</body>\n</html>\n"}, "reportNo5": {"reportType": "8-K", "url": "https://www.sec.gov/Archives/edgar/data/1552451/000119312518172163/d586211d8k.htm", "dateOfReport": "2018-05-23", "content": "On May22, 2018, MyoKardia, Inc. (the \u0093Company\u0094) entered into an underwriting agreement (the \u0093Underwriting Agreement\u0094) with J.P.\nMorgan Securities LLC, Merrill Lynch, Pierce, Fenner& Smith Incorporated, Credit Suisse Securities (USA) LLC and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein (collectively, the\n\u0093Underwriters\u0094), relating to the issuance and sale of 3,750,000 shares of the Company\u0092s common stock, par value $0.0001 per share (the \u0093Common Stock\u0094). The price to the public in this offering is $49.00 per share. The\nUnderwriters have agreed to purchase the shares from the Company pursuant to the Underwriting Agreement at a price of $46.06 per share. The net proceeds to the Company from the offering are expected to be approximately $172.1million, after\ndeducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The offering is expected to close on or about May25, 2018, subject to customary closing conditions. In addition, under the terms of the\nUnderwriting Agreement, the Company has granted the Underwriters a 30-day option to purchase up to 562,500 additional shares of Common Stock. The offering is being made pursuant to the Company\u0092s effective registration statement on Form S-3 (Registration\nStatement No.333- 223526), which was previously filed with the Securities and Exchange Commission (the \u0093SEC\u0094) on March8, 2018 and was automatically effective upon filing, and a related prospectus supplement and accompanying\nprospectus filed with the SEC on May23, 2018 pursuant to Rule 424 under the Securities Act of 1933, as amended (the \u0093Securities Act\u0094). The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification\nobligations of the Company and the Underwriters, including for liabilities under the Securities Act, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement\nwere made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement and may be subject to limitations agreed upon by the contracting parties. The foregoing description of the Underwriting Agreement is not complete and is qualified in its entirety by reference to the full text of the Underwriting\nAgreement, a copy of which is filed as Exhibit 1.1 to this report and is incorporated by reference herein. A copy of the opinion of Goodwin Procter LLP relating to the legality of the issuance and sale of Common Stock in the offering is attached as\nExhibit 5.1 to this report. On May21, 2018, the Company issued a press release announcing the proposed offering, and on May22, 2018, the\nCompany issued a press release announcing the pricing of the offering. Copies of the press releases are attached hereto as Exhibits 99.1 and 99.2, respectively, to this report. Forward-Looking Statements This report contains\nforward-looking statements as that term is defined in Section27A of the Securities Act and Section21E of the Securities Exchange Act of 1934, as amended. Statements in this report that are not purely historical are forward-looking\nstatements. Such forward-looking statements include, among other things, references to the completion of the offering and the expected net proceeds therefrom. Actual results could differ from those projected in any forward-looking statements due to\nnumerous factors. Such factors include, among others, the risk and uncertainties associated with market conditions and the satisfaction of customary closing conditions relating to the offering, as well as risks and uncertainties in the\nCompany\u0092s business, including those risks described in the Company\u0092s periodic reports it files with the SEC. These forward-looking statements are made as of the date hereof, andthe Companyassumes no obligation to update the\nforward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Investors should consult all of the information set forth herein and should also refer to the risk factor\ndisclosure set forth under the section \u0093Risk Factors\u0094 in the preliminary prospectus supplement filed by the Company with the SEC on May21, 2018, including the documents incorporated by reference therein, and in the reports and other\ndocuments the Company files with theSEC available at www.sec.gov, including without limitation the Company\u0092s Annual Report on Form 10-K for the year endedDecember 31, 2017and\nsubsequent Quarterly Reports on Form 10-Q. \n\n", "htmlOfReport": " <document>\n<type>8-K\n<sequence>1\n<filename>d586211d8k.htm\n<description>FORM 8-K\n<text>\n<html><head>\n<title>Form 8-K</title>\n</head>\n<body bgcolor=\"WHITE\">\n<p style=\"line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000\">\u00a0</p>\n<p style=\"line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000\">\u00a0</p> <p align=\"center\" style=\"margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman\"><b>UNITED STATES </b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman\"><b>SECURITIES AND EXCHANGE COMMISSION </b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman\"><b>Washington, D.C. 20549 </b></p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p><center>\n<p style=\"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%\">\u00a0</p></center> <p align=\"center\" style=\"margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman\"><b><font style=\"white-space:nowrap\">FORM\u00a08-K</font> </b></p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p><center>\n<p style=\"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%\">\u00a0</p></center> <p align=\"center\" style=\"margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman\"><b>CURRENT REPORT\n</b></p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman\"><b>Pursuant to Section\u00a013 or 15(d) </b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman\"><b>of the Securities Exchange Act of 1934 </b></p>\n<p align=\"center\" style=\"margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman\"><b>Date of Report (Date of earliest event reported): May\u00a022, 2018 </b></p>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p><center> <p style=\"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%\">\u00a0</p></center>\n<p align=\"center\" style=\"margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman\"><b>MYOKARDIA,\u00a0INC. </b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>(Exact name of registrant as specified in its charter) </b></p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p><center>\n<p style=\"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%\">\u00a0</p></center> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt\" width=\"100%\">\n<tr>\n<td width=\"34%\"></td>\n<td valign=\"bottom\"></td>\n<td width=\"32%\"></td>\n<td valign=\"bottom\" width=\"1%\"></td>\n<td width=\"32%\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td align=\"center\" valign=\"top\"><b>Delaware</b></td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"center\" valign=\"top\"><b><font style=\"white-space:nowrap\">001-37609</font></b></td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"center\" valign=\"top\"><b><font style=\"white-space:nowrap\">44-5500552</font></b></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\">\n<td align=\"center\" valign=\"top\"> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>(State or other jurisdiction</b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman\"><b>of incorporation)</b></p></td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"center\" valign=\"top\"> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>(Commission</b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman\"><b>File Number)</b></p></td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"center\" valign=\"top\"> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>(I.R.S. Employer</b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman\"><b>Identification No.)</b></p></td></tr>\n</table> <p align=\"center\" style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>333 Allerton Ave. </b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>South San Francisco, CA 94080 </b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>(Address of principal executive offices, including zip code) </b></p>\n<p align=\"center\" style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>(650) <font style=\"white-space:nowrap\">741-0900</font> </b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>(Registrant\u0092s telephone number, including area code) </b></p>\n<p align=\"center\" style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>Not Applicable </b></p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>(Former\nName or Former Address, if Changed Since Last Report) </b></p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p><center>\n<p style=\"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%\">\u00a0</p></center> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Check the appropriate box below\nif the <font style=\"white-space:nowrap\">Form\u00a08-K</font> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </p>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"4%\">\u2610</td>\n<td align=\"left\" valign=\"top\">Written communications pursuant to Rule\u00a0425 under the Securities Act (17 CFR 230.425) </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"4%\">\u2610</td>\n<td align=\"left\" valign=\"top\">Soliciting material pursuant to <font style=\"white-space:nowrap\">Rule\u00a014a-12</font> under the Exchange Act (17 CFR <font style=\"white-space:nowrap\">240.14a-12)</font> </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"4%\">\u2610</td>\n<td align=\"left\" valign=\"top\"><font style=\"white-space:nowrap\">Pre-commencement</font> communications pursuant to <font style=\"white-space:nowrap\">Rule\u00a014d-2(b)\u00a0under</font> the Exchange Act (17 CFR\n<font style=\"white-space:nowrap\">240.14d-2(b))</font> </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"4%\">\u2610</td>\n<td align=\"left\" valign=\"top\"><font style=\"white-space:nowrap\">Pre-commencement</font> communications pursuant to <font style=\"white-space:nowrap\">Rule\u00a013e-4(c)\u00a0under</font> the Exchange Act (17 CFR\n<font style=\"white-space:nowrap\">240.13e-4(c))</font> </td></tr></table> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Indicate by check mark whether the registrant is an emerging growth company as defined\nin Rule 405 of the Securities Act of 1933 (\u00a7\u00a0230.405 of this chapter) or Rule <font style=\"white-space:nowrap\">12b-2</font> of the Securities Exchange Act of 1934 <font style=\"white-space:nowrap\">(\u00a7\u00a0240.12b-2</font> of this\nchapter). </p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Emerging growth company\u00a0\u00a0\u2612 </p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">If an\nemerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section\u00a013(a) of the Exchange\nAct.\u00a0\u00a0\u2612 </p> <p style=\"font-size:10pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p> <p style=\"line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000\">\u00a0</p>\n<p style=\"line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000\">\u00a0</p>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>Item\u00a08.01 Other Events </b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">On May\u00a022, 2018, MyoKardia, Inc. (the \u0093Company\u0094) entered into an underwriting agreement (the \u0093Underwriting Agreement\u0094) with J.P.\nMorgan Securities LLC, Merrill Lynch, Pierce, Fenner\u00a0&amp; Smith Incorporated, Credit Suisse Securities (USA) LLC and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein (collectively, the\n\u0093Underwriters\u0094), relating to the issuance and sale of 3,750,000 shares of the Company\u0092s common stock, par value $0.0001 per share (the \u0093Common Stock\u0094). The price to the public in this offering is $49.00 per share. The\nUnderwriters have agreed to purchase the shares from the Company pursuant to the Underwriting Agreement at a price of $46.06 per share. The net proceeds to the Company from the offering are expected to be approximately $172.1\u00a0million, after\ndeducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The offering is expected to close on or about May\u00a025, 2018, subject to customary closing conditions. In addition, under the terms of the\nUnderwriting Agreement, the Company has granted the Underwriters a <font style=\"white-space:nowrap\">30-day</font> option to purchase up to 562,500 additional shares of Common Stock. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The offering is being made pursuant to the Company\u0092s effective registration statement on Form <font style=\"white-space:nowrap\">S-3</font> (Registration\nStatement No.\u00a0333- 223526), which was previously filed with the Securities and Exchange Commission (the \u0093SEC\u0094) on March\u00a08, 2018 and was automatically effective upon filing, and a related prospectus supplement and accompanying\nprospectus filed with the SEC on May\u00a023, 2018 pursuant to Rule 424 under the Securities Act of 1933, as amended (the \u0093Securities Act\u0094). </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification\nobligations of the Company and the Underwriters, including for liabilities under the Securities Act, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement\nwere made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement and may be subject to limitations agreed upon by the contracting parties. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The foregoing description of the Underwriting Agreement is not complete and is qualified in its entirety by reference to the full text of the Underwriting\nAgreement, a copy of which is filed as Exhibit 1.1 to this report and is incorporated by reference herein. A copy of the opinion of Goodwin Procter LLP relating to the legality of the issuance and sale of Common Stock in the offering is attached as\nExhibit 5.1 to this report. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">On May\u00a021, 2018, the Company issued a press release announcing the proposed offering, and on May\u00a022, 2018, the\nCompany issued a press release announcing the pricing of the offering. Copies of the press releases are attached hereto as Exhibits 99.1 and 99.2, respectively, to this report. </p>\n<p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>Forward-Looking Statements </b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">This report contains\nforward-looking statements as that term is defined in Section\u00a027A of the Securities Act and Section\u00a021E of the Securities Exchange Act of 1934, as amended. Statements in this report that are not purely historical are forward-looking\nstatements. Such forward-looking statements include, among other things, references to the completion of the offering and the expected net proceeds therefrom. Actual results could differ from those projected in any forward-looking statements due to\nnumerous factors. Such factors include, among others, the risk and uncertainties associated with market conditions and the satisfaction of customary closing conditions relating to the offering, as well as risks and uncertainties in the\nCompany\u0092s business, including those risks described in the Company\u0092s periodic reports it files with the SEC. These forward-looking statements are made as of the date hereof, and\u00a0the Company\u00a0assumes no obligation to update the\nforward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Investors should consult all of the information set forth herein and should also refer to the risk factor\ndisclosure set forth under the section \u0093Risk Factors\u0094 in the preliminary prospectus supplement filed by the Company with the SEC on May\u00a021, 2018, including the documents incorporated by reference therein, and in the reports and other\ndocuments the Company files with the\u00a0SEC available at <u>www.sec.gov</u>, including without limitation the Company\u0092s Annual Report on Form <font style=\"white-space:nowrap\">10-K</font> for the year ended\u00a0December 31, 2017\u00a0and\nsubsequent Quarterly Reports on Form <font style=\"white-space:nowrap\">10-Q.</font> </p>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>Item\u00a09.01 Financial Statements and Exhibits </b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">(d)<u>\u00a0Exhibits</u>. </p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr>\n<td></td>\n<td valign=\"bottom\" width=\"5%\"></td>\n<td width=\"92%\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\">\n<td align=\"center\" nowrap=\"\" valign=\"bottom\"> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\">Exhibit</p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:23.50pt; display:inline; font-size:8pt; font-family:Times New Roman; \">No.</p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td align=\"center\" nowrap=\"\" valign=\"bottom\"> <p align=\"center\" style=\" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; display:inline; font-size:8pt; font-family:Times New Roman; \">Description</p></td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"8\"></td>\n<td colspan=\"2\" height=\"8\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td nowrap=\"\" valign=\"top\">\u00a0\u00a01.1</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">Underwriting Agreement, dated May\u00a022, 2018, by and among MyoKardia, Inc. and J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner\u00a0&amp; Smith Incorporated, Credit Suisse Securities (USA) LLC and Wells Fargo\nSecurities, LLC, as representatives of the several underwriters named therein</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"8\"></td>\n<td colspan=\"2\" height=\"8\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td nowrap=\"\" valign=\"top\">\u00a0\u00a05.1</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">Opinion of Goodwin Procter LLP</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"8\"></td>\n<td colspan=\"2\" height=\"8\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td nowrap=\"\" valign=\"top\">23.1</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">Consent of Goodwin Procter LLP (included in Exhibit 5.1)</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"8\"></td>\n<td colspan=\"2\" height=\"8\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td nowrap=\"\" valign=\"top\">99.1</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">Press Release, dated May\u00a021, 2018</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"8\"></td>\n<td colspan=\"2\" height=\"8\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td nowrap=\"\" valign=\"top\">99.2</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">Press Release, dated May\u00a022, 2018</td></tr>\n</table>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>EXHIBIT INDEX </b></p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr>\n<td></td>\n<td valign=\"bottom\" width=\"5%\"></td>\n<td width=\"92%\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\">\n<td align=\"center\" nowrap=\"\" valign=\"bottom\"> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\">Exhibit</p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:23.50pt; display:inline; font-size:8pt; font-family:Times New Roman; \">No.</p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td align=\"center\" nowrap=\"\" valign=\"bottom\"> <p align=\"center\" style=\" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; display:inline; font-size:8pt; font-family:Times New Roman; \">Description</p></td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"8\"></td>\n<td colspan=\"2\" height=\"8\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td nowrap=\"\" valign=\"top\">\u00a0\u00a01.1</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\"><a Agreement, dated May\u00a022, 2018, by and among MyoKardia, Inc. and J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner\u00a0\n&amp; Smith Incorporated, Credit Suisse Securities (USA) LLC and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein</a></td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"8\"></td>\n<td colspan=\"2\" height=\"8\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td nowrap=\"\" valign=\"top\">\u00a0\u00a05.1</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\"><a of Goodwin Procter LLP</a></td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"8\"></td>\n<td colspan=\"2\" height=\"8\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td nowrap=\"\" valign=\"top\">23.1</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\"><a of Goodwin Procter LLP (included in Exhibit 5.1) </a></td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"8\"></td>\n<td colspan=\"2\" height=\"8\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td nowrap=\"\" valign=\"top\">99.1</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\"><a Release, dated May\u00a021, 2018</a></td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"8\"></td>\n<td colspan=\"2\" height=\"8\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td nowrap=\"\" valign=\"top\">99.2</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\"><a Release, dated May\u00a022, 2018 </a></td></tr>\n</table>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>SIGNATURES </b></p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned\nhereunto duly authorized. </p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr>\n<td width=\"46%\"></td>\n<td valign=\"bottom\" width=\"1%\"></td>\n<td width=\"4%\"></td>\n<td valign=\"bottom\"></td>\n<td width=\"2%\"></td>\n<td valign=\"bottom\" width=\"1%\"></td>\n<td width=\"45%\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\">Date: May\u00a023, 2018</td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td colspan=\"3\" valign=\"top\"><b>MyoKardia, Inc.</b></td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"16\"></td>\n<td colspan=\"2\" height=\"16\"></td>\n<td colspan=\"2\" height=\"16\"></td>\n<td colspan=\"2\" height=\"16\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\">By:</p></td>\n<td style=\" BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\">/s/ Taylor Harris</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\">Taylor Harris</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">Chief Financial Officer</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\"><b>(principal\u00a0financial and accounting officer)</b></td></tr>\n</table>\n</p></p></p></p></body></html>\n</text>\n</description></filename></sequence></type></document>\n"}, "reportNo6": {"reportType": "424B5", "url": "https://www.sec.gov/Archives/edgar/data/1552451/000119312518172138/d579741d424b5.htm", "dateOfReport": "2018-05-23", "content": {"logoAddress": "https://www.sec.gov/Archives/edgar/data/1552451/000119312518172138/g579741g95t12.jpg", "sharesOffered": "['3,750,000 shares ']", "tableCode": "<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr>\n<td width=\"76%\"></td>\n<td valign=\"bottom\" width=\"4%\"></td>\n<td></td>\n<td></td>\n<td></td>\n<td valign=\"bottom\" width=\"4%\"></td>\n<td></td>\n<td></td>\n<td></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:9pt\">\n<td style=\"BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td colspan=\"2\" style=\"BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\"><b>Per\u00a0share</b></td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td colspan=\"2\" style=\"BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\"><b>Total</b></td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"10\"></td>\n<td colspan=\"4\" height=\"10\"></td>\n<td colspan=\"4\" height=\"10\"></td></tr>\n<tr bgcolor=\"#cceeff\" style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Public offering price</p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">$</td>\n<td align=\"right\" valign=\"top\">49.00</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">$</td>\n<td align=\"right\" valign=\"top\">183,750,000</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"10\"></td>\n<td colspan=\"4\" height=\"10\"></td>\n<td colspan=\"4\" height=\"10\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Underwriting discounts and commissions(1)</p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">$</td>\n<td align=\"right\" valign=\"top\">2.94</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">$</td>\n<td align=\"right\" valign=\"top\">11,025,000</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"10\"></td>\n<td colspan=\"4\" height=\"10\"></td>\n<td colspan=\"4\" height=\"10\"></td></tr>\n<tr bgcolor=\"#cceeff\" style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Proceeds to MyoKardia, Inc. before expenses</p></td>\n<td style=\" BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\">$</td>\n<td align=\"right\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\">46.06</td>\n<td nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\">\u00a0</td>\n<td style=\" BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\">$</td>\n<td align=\"right\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\">172,725,000</td>\n<td nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\">\u00a0</td></tr>\n</table>", "html": "<div align=\"left\" style=\"width:8.5in\">\n<p align=\"right\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>Filed Pursuant to Rule 424(b)(5) <br/>Registration No. 333-223526 </b></p>\n<p align=\"center\" style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>CALCULATION OF REGISTRATION FEE </b></p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt\" width=\"100%\">\n<tr>\n<td width=\"44%\"></td>\n<td valign=\"bottom\" width=\"1%\"></td>\n<td width=\"13%\"></td>\n<td valign=\"bottom\" width=\"1%\"></td>\n<td width=\"13%\"></td>\n<td valign=\"bottom\" width=\"1%\"></td>\n<td width=\"13%\"></td>\n<td valign=\"bottom\" width=\"1%\"></td>\n<td width=\"13%\"></td></tr>\n<tr style=\"font-size:1px; \">\n<td colspan=\"9\" valign=\"bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\">\n<td align=\"center\" style=\"BORDER-TOP:1px solid #000000\" valign=\"bottom\"> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>Title of each class of</b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman\"><b>securities to be registered</b></p></td>\n<td style=\" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td align=\"center\" nowrap=\"\" style=\"BORDER-TOP:1px solid #000000\" valign=\"bottom\"> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>Amount</b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>to\u00a0be</b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman\"><b>registered(1)</b></p></td>\n<td style=\" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td align=\"center\" nowrap=\"\" style=\"BORDER-TOP:1px solid #000000\" valign=\"bottom\"> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>Maximum</b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman\"><b>offering<br/>price per share</b></p></td>\n<td style=\" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td align=\"center\" nowrap=\"\" style=\"BORDER-TOP:1px solid #000000\" valign=\"bottom\"> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>Maximum</b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>aggregate</b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman\"><b>offering\u00a0price</b></p></td>\n<td style=\" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td align=\"center\" nowrap=\"\" style=\"BORDER-TOP:1px solid #000000\" valign=\"bottom\"> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>Amount\u00a0of</b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>registration</b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman\"><b>fee(2)</b></p></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td style=\"BORDER-TOP:1px solid #000000\" valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\">Common stock, par value $0.0001 per share</p></td>\n<td style=\" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td align=\"center\" nowrap=\"\" style=\"BORDER-TOP:1px solid #000000\" valign=\"bottom\">4,312,500 shares</td>\n<td style=\" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td align=\"center\" nowrap=\"\" style=\"BORDER-TOP:1px solid #000000\" valign=\"bottom\">$49.00</td>\n<td style=\" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td align=\"center\" nowrap=\"\" style=\"BORDER-TOP:1px solid #000000\" valign=\"bottom\">$211,312,500.00</td>\n<td style=\" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td align=\"center\" nowrap=\"\" style=\"BORDER-TOP:1px solid #000000\" valign=\"bottom\">$26,308.41</td></tr>\n<tr style=\"font-size:1px; \">\n<td colspan=\"9\" valign=\"bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td></tr>\n<tr style=\"font-size:1px; \">\n<td colspan=\"9\" valign=\"bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td></tr>\n</table>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"4%\">(1)</td>\n<td align=\"left\" valign=\"top\">Includes 562,500\u00a0shares of common stock issuable upon exercise of the underwriters\u0092 option to purchase additional shares of common stock. </td></tr></table>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"4%\">(2)</td>\n<td align=\"left\" valign=\"top\">This filing fee is calculated and being paid pursuant to Rule\u00a0457(r) of the Securities Act of 1933, as amended, and relates to our Registration Statement on Form\u00a0S-3ASR (File No.\u00a0333-223526).\n</td></tr></table>\n</div>"}, "htmlOfReport": " <document>\n<type>424B5\n<sequence>1\n<filename>d579741d424b5.htm\n<description>424B5\n<text>\n<html><head>\n<title>424B5</title>\n</head>\n<body bgcolor=\"WHITE\">\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p align=\"right\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>Filed Pursuant to Rule 424(b)(5) <br/>Registration No. 333-223526 </b></p>\n<p align=\"center\" style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>CALCULATION OF REGISTRATION FEE </b></p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt\" width=\"100%\">\n<tr>\n<td width=\"44%\"></td>\n<td valign=\"bottom\" width=\"1%\"></td>\n<td width=\"13%\"></td>\n<td valign=\"bottom\" width=\"1%\"></td>\n<td width=\"13%\"></td>\n<td valign=\"bottom\" width=\"1%\"></td>\n<td width=\"13%\"></td>\n<td valign=\"bottom\" width=\"1%\"></td>\n<td width=\"13%\"></td></tr>\n<tr style=\"font-size:1px; \">\n<td colspan=\"9\" valign=\"bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\">\n<td align=\"center\" style=\"BORDER-TOP:1px solid #000000\" valign=\"bottom\"> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>Title of each class of</b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman\"><b>securities to be registered</b></p></td>\n<td style=\" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td align=\"center\" nowrap=\"\" style=\"BORDER-TOP:1px solid #000000\" valign=\"bottom\"> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>Amount</b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>to\u00a0be</b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman\"><b>registered(1)</b></p></td>\n<td style=\" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td align=\"center\" nowrap=\"\" style=\"BORDER-TOP:1px solid #000000\" valign=\"bottom\"> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>Maximum</b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman\"><b>offering<br/>price per share</b></p></td>\n<td style=\" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td align=\"center\" nowrap=\"\" style=\"BORDER-TOP:1px solid #000000\" valign=\"bottom\"> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>Maximum</b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>aggregate</b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman\"><b>offering\u00a0price</b></p></td>\n<td style=\" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td align=\"center\" nowrap=\"\" style=\"BORDER-TOP:1px solid #000000\" valign=\"bottom\"> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>Amount\u00a0of</b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>registration</b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman\"><b>fee(2)</b></p></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td style=\"BORDER-TOP:1px solid #000000\" valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\">Common stock, par value $0.0001 per share</p></td>\n<td style=\" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td align=\"center\" nowrap=\"\" style=\"BORDER-TOP:1px solid #000000\" valign=\"bottom\">4,312,500 shares</td>\n<td style=\" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td align=\"center\" nowrap=\"\" style=\"BORDER-TOP:1px solid #000000\" valign=\"bottom\">$49.00</td>\n<td style=\" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td align=\"center\" nowrap=\"\" style=\"BORDER-TOP:1px solid #000000\" valign=\"bottom\">$211,312,500.00</td>\n<td style=\" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td align=\"center\" nowrap=\"\" style=\"BORDER-TOP:1px solid #000000\" valign=\"bottom\">$26,308.41</td></tr>\n<tr style=\"font-size:1px; \">\n<td colspan=\"9\" valign=\"bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td></tr>\n<tr style=\"font-size:1px; \">\n<td colspan=\"9\" valign=\"bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td></tr>\n</table>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"4%\">(1)</td>\n<td align=\"left\" valign=\"top\">Includes 562,500\u00a0shares of common stock issuable upon exercise of the underwriters\u0092 option to purchase additional shares of common stock. </td></tr></table>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"4%\">(2)</td>\n<td align=\"left\" valign=\"top\">This filing fee is calculated and being paid pursuant to Rule\u00a0457(r) of the Securities Act of 1933, as amended, and relates to our Registration Statement on Form\u00a0S-3ASR (File No.\u00a0333-223526).\n</td></tr></table>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial\"><b>Prospectus supplement </b></p>\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial\"><b>(To prospectus dated March\u00a08, 2018) </b></p> <p style=\"margin-top:14pt; margin-bottom:0pt; font-size:18pt; font-family:arial\"><b><i>3,750,000 shares </i></b></p>\n<p style=\"font-size:14pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p> <p style=\"font-size:0pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p> <p style=\"margin-top:0pt;margin-bottom:0pt\">\n<img alt=\"LOGO\" src=\"g579741g95t12.jpg\"/>\n</p> <p style=\"margin-top:14pt; margin-bottom:0pt; font-size:18pt; font-family:arial\"><b><i>Common stock </i></b></p> <p style=\"margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We are offering\n3,750,000 shares of our common stock. </p> <p style=\"margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Our common stock is listed on the Nasdaq Global Select Market under the symbol \u0093MYOK\u0094. On May\u00a022, 2018, the\nlast reported sale price of our common stock on the Nasdaq Global Select Market was $50.35 per share. </p> <p style=\"font-size:14pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr>\n<td width=\"76%\"></td>\n<td valign=\"bottom\" width=\"4%\"></td>\n<td></td>\n<td></td>\n<td></td>\n<td valign=\"bottom\" width=\"4%\"></td>\n<td></td>\n<td></td>\n<td></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:9pt\">\n<td style=\"BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td colspan=\"2\" style=\"BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\"><b>Per\u00a0share</b></td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td colspan=\"2\" style=\"BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\"><b>Total</b></td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"10\"></td>\n<td colspan=\"4\" height=\"10\"></td>\n<td colspan=\"4\" height=\"10\"></td></tr>\n<tr bgcolor=\"#cceeff\" style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Public offering price</p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">$</td>\n<td align=\"right\" valign=\"top\">49.00</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">$</td>\n<td align=\"right\" valign=\"top\">183,750,000</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"10\"></td>\n<td colspan=\"4\" height=\"10\"></td>\n<td colspan=\"4\" height=\"10\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Underwriting discounts and commissions(1)</p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">$</td>\n<td align=\"right\" valign=\"top\">2.94</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">$</td>\n<td align=\"right\" valign=\"top\">11,025,000</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"10\"></td>\n<td colspan=\"4\" height=\"10\"></td>\n<td colspan=\"4\" height=\"10\"></td></tr>\n<tr bgcolor=\"#cceeff\" style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Proceeds to MyoKardia, Inc. before expenses</p></td>\n<td style=\" BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\">$</td>\n<td align=\"right\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\">46.06</td>\n<td nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\">\u00a0</td>\n<td style=\" BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\">$</td>\n<td align=\"right\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\">172,725,000</td>\n<td nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\">\u00a0</td></tr>\n</table> <p style=\"font-size:4pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"2%\">(1)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">See \u0093Underwriting\u0094 for a description of the compensation payable to the underwriters. </td></tr></table> <p style=\"margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We have granted the\nunderwriters an option for a period of 30 days to purchase up to an additional 562,500\u00a0shares of our common stock. </p> <p style=\"margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Sanofi S.A. (\u0093Sanofi\u0094), our\nstrategic collaboration partner and one of our existing stockholders (through its wholly owned subsidiary, Aventis Inc.), has agreed to purchase an aggregate of 150,000\u00a0shares of our common stock in this offering at the public offering price\nand on the same terms as the other purchasers in this offering. The underwriters will receive the same underwriting discount on any shares purchased by Sanofi as they will on any other shares sold to the public in this offering. </p>\n<p style=\"margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b>Investing in our common stock involves a high degree of risk. See \u0093<a factors</a>\u0094 beginning on page <font style=\"white-space:nowrap\">S-8</font> of this prospectus supplement. </b></p> <p style=\"margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b>Neither the Securities and Exchange Commission nor any state securities commission has\napproved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense. </b></p>\n<p style=\"margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The underwriters expect to deliver the shares of common stock to purchasers on or about May\u00a025, 2018. </p>\n<p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:15pt\" width=\"100%\">\n<tr>\n<td width=\"22%\"></td>\n<td valign=\"bottom\" width=\"2%\"></td>\n<td></td>\n<td valign=\"bottom\" width=\"2%\"></td>\n<td></td>\n<td valign=\"bottom\" width=\"2%\"></td>\n<td></td>\n<td></td>\n<td></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:15pt\">\n<td valign=\"bottom\"><b>J.P.\u00a0Morgan</b></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\"><b>BofA\u00a0Merrill\u00a0Lynch</b></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\"><b>Credit\u00a0Suisse</b></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\"><b>\u00a0</b></td>\n<td align=\"right\" valign=\"bottom\"><b>Wells\u00a0Fargo\u00a0Securities</b></td>\n<td nowrap=\"\" valign=\"bottom\"><b>\u00a0</b></td></tr>\n</table> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:arial\"><b>May\u00a022, 2018 </b></p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial\"><b><a name=\"toc\"></a>Table of contents </b></p> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr>\n<td width=\"94%\"></td>\n<td valign=\"bottom\" width=\"2%\"></td>\n<td></td>\n<td></td>\n<td></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:8pt\">\n<td valign=\"bottom\"><b>Prospectus supplement</b></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td align=\"right\" colspan=\"2\" valign=\"bottom\"><b>Page</b></td>\n<td valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a this prospectus supplement</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\"><font style=\"white-space:nowrap\">S-1</font></td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a supplement summary</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\"><font style=\"white-space:nowrap\">S-2</font></td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a offering</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\"><font style=\"white-space:nowrap\">S-6</font></td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a factors</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\"><font style=\"white-space:nowrap\">S-8</font></td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a note regarding forward-looking statements</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\"><font style=\"white-space:nowrap\">S-13</font></td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a of proceeds</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\"><font style=\"white-space:nowrap\">S-14</font></td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\"><font style=\"white-space:nowrap\">S-15</font></td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a U.S. federal income tax consequences to <font style=\"white-space:nowrap\">Non-U.S.\n</font> Holders</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\"><font style=\"white-space:nowrap\">S-16</font></td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\"><font style=\"white-space:nowrap\">S-20</font></td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a matters</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\"><font style=\"white-space:nowrap\">S-32</font></td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\"><font style=\"white-space:nowrap\">S-32</font></td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a you can find more information; incorporation by reference</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\"><font style=\"white-space:nowrap\">S-32</font></td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n</table> <p style=\"font-size:16pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr>\n<td width=\"95%\"></td>\n<td valign=\"bottom\" width=\"3%\"></td>\n<td></td>\n<td></td>\n<td></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:8pt\">\n<td valign=\"bottom\"><b>Prospectus</b></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td align=\"right\" colspan=\"2\" valign=\"bottom\"><b>Page</b></td>\n<td valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a this prospectus</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">1</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a factors</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">2</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a statement regarding forward-looking statements</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">3</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a Company</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">5</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a of earnings to fixed charges</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">6</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a of proceeds</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">6</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a we may offer</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">7</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a of capital stock</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">7</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a of debt securities</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">13</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a of warrants</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">20</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a of units</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">21</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a of distribution</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">24</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a matters</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">27</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">27</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a you can find more information</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">27</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a by reference</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">27</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n</table>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">i </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial\"><b><a name=\"supptoc579741_1\"></a>About this prospectus supplement </b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">This document is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offering of common stock and also adds to and\nupdates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. The second part is the accompanying prospectus dated March\u00a08, 2018,\nincluded in our registration statement on Form <font style=\"white-space:nowrap\">S-3</font> (File <font style=\"white-space:nowrap\">No.\u00a0333-223526)</font> that became effective automatically upon filing with the Securities and Exchange Commission\n(the \u0093SEC\u0094), along with the documents incorporated by reference, which provides more general information, some of which may not apply to this offering. Generally, when we refer to this prospectus, we are referring to both parts of this\ndocument combined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in any document incorporated by reference that was\nfiled with the SEC, before the date of this prospectus supplement, on the other hand, you should rely on the information contained in this prospectus supplement. If any statement in one of these documents is inconsistent with a statement in another\ndocument having a later date\u0097for example, a document incorporated by reference in the accompanying prospectus\u0097the statement in the document having the later date modifies or supersedes the earlier statement. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">This prospectus supplement and the accompanying prospectus are part of a registration statement that we filed with the SEC, utilizing a \u0093shelf\u0094 registration\nprocess as a \u0093well-known seasoned issuer\u0094 as defined in Rule 405 under the Securities Act of 1933, as amended (the \u0093Securities Act\u0094). Under this shelf registration process, we may offer from time to time various securities, of\nwhich this offering of shares of our common stock is a part. Such registration statement also includes exhibits that provide more detail on the matters discussed in this prospectus supplement and the accompanying prospectus. You should read this\nprospectus supplement, the accompanying prospectus, including the information incorporated by reference, the exhibits filed with the SEC, and any free writing prospectus that we have authorized for use in connection with this offering, in their\nentirety before making an investment decision. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">You should rely only on the information contained or incorporated by reference in this prospectus supplement and the\naccompanying prospectus, along with the information contained in any free writing prospectus that we have authorized for use in connection with this offering. We have not, and the underwriters have not, authorized anyone to provide you with\ndifferent or additional information. If anyone provides you with different or inconsistent information, you should not rely on it. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other\ninformation that others may give you. You should assume that the information appearing in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference in this prospectus supplement and the accompanying prospectus,\nand in any free writing prospectus that we have authorized for use in connection with this offering is accurate only as of the respective dates of those documents, unless we indicate otherwise. Our business, financial condition, results of\noperations and prospects may have changed since those dates. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We further note that the representations, warranties and covenants made by us in any agreement that is\nfiled as an exhibit to any document that is incorporated by reference in this prospectus supplement or the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of\nallocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties and covenants were accurate only as of the date when made; therefore, such\nrepresentations, warranties and covenants should not be relied on as accurate representations of the current state of our affairs. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">When we refer to\n\u0093MyoKardia,\u0094 \u0093we,\u0094 \u0093our,\u0094 \u0093us\u0094 and the \u0093Company\u0094 in this prospectus, we mean MyoKardia, Inc. and, where appropriate, our subsidiary, unless otherwise specified. When we refer to \u0093you,\u0094 we\nmean the holders of our common stock. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-1 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<div style=\"BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%\"><div style=\"width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial\"><b><a name=\"supptoc579741_2\"></a>Prospectus supplement summary </b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><i>This summary highlights certain information about us, this offering and selected information contained elsewhere in, or incorporated by reference into, this\nprospectus supplement and the accompanying prospectus. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in our common stock. For a more complete understanding of our\ncompany and this offering, we encourage you to read and consider carefully the more detailed information in this prospectus supplement and the accompanying prospectus, including our financial statements and related notes and the other information\nincorporated by reference into this prospectus supplement and the accompanying prospectus, and the information included in any free writing prospectus that we have authorized for use in connection with this offering, including the information\nreferred to under the heading \u0093Risk Factors\u0094 in this prospectus supplement beginning on page <font style=\"white-space:nowrap\">S-8</font> and in the documents incorporated herein by reference. </i></p>\n<p style=\"margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial\"><b>Company overview </b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We are a clinical stage biopharmaceutical company\npioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus is on the treatment of heritable cardiomyopathies, a group\nof rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. We have used our precision medicine platform to generate a robust pipeline of therapeutic programs for the chronic treatment of\nthe two most common forms of heritable cardiomyopathy\u0097hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Our mission is to change the world for patients with serious cardiovascular disease through bold and innovative science.\n</p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Our lead candidate, mavacamten is advancing into a pivotal Phase 3 clinical trial, known as <font style=\"white-space:nowrap\">EXPLORER-HCM</font> in patients with\nsymptomatic, obstructive HCM (oHCM). Mavacamten is intended to reduce cardiac muscle contractility by inhibiting the excessive myosin-actin crossbridge formation that underlies the excessive contractility, left ventricular hypertrophy and reduced\ncompliance characteristic of HCM. In 2016, mavacamten was granted Orphan Drug Designation by the U.S. Food and Drug Administration, or the FDA, for the treatment of symptomatic oHCM. We are also studying mavacamten for a second potential indication,\nsymptomatic, <font style=\"white-space:nowrap\">non-obstructive</font> HCM (nHCM), in a Phase 2 clinical trial, known as <font style=\"white-space:nowrap\">MAVERICK-HCM.</font> A second product candidate, <font style=\"white-space:nowrap\">MYK-491,</font>\nis a myosin activator designed to restore the inadequate output characteristic of a DCM heart by targeting the biomechanical defects underlying disease and improving cardiac contractility. <font style=\"white-space:nowrap\">MYK-491</font> has\ncompleted its <font style=\"white-space:nowrap\"><font style=\"white-space:nowrap\">first-in-human</font></font> Phase 1 clinical trial in healthy volunteers and we are currently enrolling patients in a Phase 1b clinical trial. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We have never been profitable and have incurred net losses in each year since inception. Our net loss for the years ended December\u00a031, 2017 and 2016, before\nrevisions due to the adoption of ASC 606 \u0093Revenue from Contracts with Customers\u0094, was $46.0\u00a0million and $13.2\u00a0million, respectively. As of March\u00a031, 2018, we had an accumulated deficit of $152.7\u00a0million. To date, we\nhave not generated any product revenue. We do not expect to receive any revenue from any product candidates that we develop until we obtain regulatory approval and commercialize our products or enter into additional collaborative agreements with\nthird parties. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. As of March\u00a031, 2018, we had\n$259.3\u00a0million of cash, cash equivalents, and investments (short-term and long-term). We expect our current cash, cash equivalents and investments, together with anticipated payments under our collaboration agreement with Sanofi, to fund our\nplanned operations into 2020. </p>\n</div></div>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-2 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<div style=\"BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%\"><div style=\"width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial\"><b>Recent developments </b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In May\n2018, we announced the design of our planned Phase 3 clinical trial, known as <font style=\"white-space:nowrap\">EXPLORER-HCM,</font> to evaluate mavacamten for the potential treatment of patients with symptomatic oHCM. We expect to dose the first\npatient in the <font style=\"white-space:nowrap\">EXPLORER-HCM</font> trial in the second quarter of 2018, and we anticipate that data from this trial will be available in the second half of 2020. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><font style=\"white-space:nowrap\">EXPLORER-HCM</font> is a multi-national randomized double-blind study designed to assess the effects of a\n<font style=\"white-space:nowrap\">30-week</font> treatment of mavacamten versus placebo with a primary endpoint of clinical response. The clinical response endpoint is intended to broadly capture the potential benefits of treatment with mavacamten on\nhow patients feel and function by utilizing both peak oxygen consumption (peak VO<sub style=\"font-size:85%; vertical-align:bottom\">2)</sub> and New York Heart Association (NYHA) functional classification. Clinical response can be achieved by meeting\neither of two definitions: 1) an improvement of at least 1.5 mL/kg/min in peak VO<sub style=\"font-size:85%; vertical-align:bottom\">2 </sub>accompanied by a reduction from baseline of at least one NYHA functional class, or 2) an improvement from\nbaseline of 3.0 mL/kg/min or greater in peak VO<sub style=\"font-size:85%; vertical-align:bottom\">2 </sub>without worsening in NYHA functional class. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Approximately\n220 patients will be enrolled and randomized on a 1:1 basis to receive either mavacamten or placebo. The <font style=\"white-space:nowrap\">EXPLORER-HCM</font> trial design includes two opportunities for individualized dose adjustment throughout the <font style=\"white-space:nowrap\">30-week</font> treatment period. Patients in the active treatment arm will start on a once-daily 5mg dose of mavacamten. At Weeks 8 and 14, daily doses may be increased to 10mg or 15mg, or remain unchanged, based on\nmeasurements of provoked left ventricular outflow tract (LVOT) gradient conducted at Weeks 6 and 12. A reduction in provoked LVOT gradient under 50 mmHg has been shown in PIONEER to correlate to improvements in several clinical measurements,\nincluding NYHA class and peak VO<sub style=\"font-size:85%; vertical-align:bottom\">2</sub>. All assessments and dose adjustments will be conducted in a blinded fashion. Patients will be allowed to maintain their\n<font style=\"white-space:nowrap\">HCM-related</font> background medications for the duration of the <font style=\"white-space:nowrap\">EXPLORER-HCM</font> Phase 3 trial, including beta blockers or calcium channel blockers. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Secondary endpoints in the Phase 3 <font style=\"white-space:nowrap\">EXPLORER-HCM</font> trial will include the average change from baseline in post-exercise peak LVOT\ngradient, NYHA functional class, peak VO<sub style=\"font-size:85%; vertical-align:bottom\">2, </sub>the proportion of patients achieving post-exercise peak LVOT gradient below 50 mmHg or 30 mmHg at Week 30 and patient-reported outcome measures.\nExploratory endpoints will include changes in echocardiographic indices of cardiac structure and function, <font style=\"white-space:nowrap\">N-terminal</font> pro <font style=\"white-space:nowrap\">b-type</font> natriuretic peptide <font style=\"white-space:nowrap\">(NT-proBNP)</font> concentrations, quality of life questionnaire scores and daily physical activity assessed using a wearable accelerometer. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Throughout the <font style=\"white-space:nowrap\">EXPLORER-HCM</font> study, patients will be monitored for adverse events and certain assessments will be performed. If at\nany time during the trial, a patient\u0092s plasma concentration is above an upper target range or LVEF falls below the normal range, doses of mavacamten may be decreased. Following the <font style=\"white-space:nowrap\">30-week</font> treatment\nperiod and eight-week post-treatment <font style=\"white-space:nowrap\">wash-out</font> period, patients will be able to participate in a long-term extension study of mavacamten. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In May 2018, we also announced the dosing of the first patient in the PIONEER open-label extension <font style=\"white-space:nowrap\">(PIONEER-OLE)</font> study of\nmavacamten for symptomatic oHCM. The <font style=\"white-space:nowrap\">PIONEER-OLE</font> study, which will enroll patients who previously completed the Phase 2 <font style=\"white-space:nowrap\">PIONEER-HCM</font> trial, is intended to provide data on\nlonger-term exposure to mavacamten. Patients will receive an individualized daily dose of 5mg, 10mg, or 15 mg of mavacamten, with a dose adjustment at week 6 based on pharmacodynamic and pharmacokinetic criteria, as well as the patient\u0092s past\nexperience with mavacamten. We anticipate reporting the first interim data update from the <font style=\"white-space:nowrap\">PIONEER-OLE</font> study in the first quarter of 2019. </p>\n</div></div>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-3 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<div style=\"BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%\"><div style=\"width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In April 2018, we announced that the first patient had been dosed in the Phase 2\n<font style=\"white-space:nowrap\">MAVERICK-HCM</font> clinical trial, which is the first clinical trial of mavacamten in nHCM. In nHCM, the heart contracts excessively, but no physical obstruction is present in the outflow tract of the left\nventricle. As a result of the hypercontractility, the left ventricle becomes abnormally thick and fibrotic, which prevents the heart from being able to relax and fill with blood normally. The Phase 2\n<font style=\"white-space:nowrap\">MAVERICK-HCM</font> trial is a double-blind, placebo-controlled study designed to assess the safety and tolerability of a <font style=\"white-space:nowrap\">16-week</font> treatment course of mavacamten. The trial is\nexpected to enroll approximately 60 patients with nHCM and preserved left ventricular ejection fraction. Patients will be randomized evenly into three groups to receive a once-daily dose of mavacamten targeting one of two plasma concentration levels\nof drug or placebo. Secondary endpoints from the trial will assess the effect of mavacamten on exercise capacity as measured by peak VO<sub style=\"font-size:85%; vertical-align:bottom\">2</sub>, changes in NYHA functional classification, diastolic\nand systolic function as measured by echocardiography, symptoms and quality of life measures, NT <font style=\"white-space:nowrap\">pro-BNP</font> levels and patient activity as measured by a wrist-worn accelerometer. In addition to the <font style=\"white-space:nowrap\">16-week</font> treatment period, patients will participate in a screening period of up to four weeks and will be monitored for an additional eight weeks after discontinuation of mavacamten. We expect to report topline data\nfrom the <font style=\"white-space:nowrap\">MAVERICK-HCM</font> trial in the second half of 2019. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In March 2018, data from both cohorts of the Phase 2 <font style=\"white-space:nowrap\">PIONEER-HCM</font> clinical trial were presented at the American College of Cardiology (ACC) 67th Annual Scientific Session. In the <font style=\"white-space:nowrap\">PIONEER-HCM</font> Phase 2 clinical trial of 21\nsymptomatic oHCM patients, mavacamten achieved the primary endpoint of reduction in post-exercise LVOT gradient from baseline to week 12 with statistical significance across both cohorts tested. Improvements in peak VO<sub style=\"font-size:85%; vertical-align:bottom\">2</sub>, NYHA classification and dyspnea rating scores were also observed. Mavacamten was generally well-tolerated. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In\nFebruary 2018, we initiated a single-ascending dose study of <font style=\"white-space:nowrap\">MYK-491</font> in symptomatic DCM patients with stable, moderate heart failure. The objectives of this randomized, double-blind, placebo-controlled Phase\n1b trial are to assess safety, tolerability, preliminary pharmacokinetics and pharmacodynamics of <font style=\"white-space:nowrap\">MYK-491</font> in DCM patients, including echocardiographic measures of effect on contractility. We anticipate\nreporting data from this trial in the second half of 2018. Data from the Phase 1 program of <font style=\"white-space:nowrap\">MYK-491</font> will inform a Phase 2 clinical study of <font style=\"white-space:nowrap\">MYK-491</font> in DCM patients,\nwhich is planned to begin dosing in the second half of 2018. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In addition, we are advancing a third program toward clinical development and anticipate filing an\nInvestigational New Drug application in the next 12-18 months. </p> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial\"><b>Corporate information </b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We were incorporated in Delaware in June 2012. Our principal executive offices are located at 333 Allerton Ave., South San Francisco, California 94080. Our telephone\nnumber is <font style=\"white-space:nowrap\">(650)\u00a0741-0900</font> and our <font style=\"white-space:nowrap\">e-mail</font> address is info@myokardia.com. Our Internet website address is <i>www.myokardia.com</i>. No portion of our website is\nincorporated by reference into this prospectus. We do not incorporate the information on or accessible through our website into this prospectus supplement or the underlying prospectus, and you should not consider any information on, or that can be\naccessed through, our website as part of this prospectus supplement or the underlying prospectus. Our common stock trades on the Nasdaq Global Select Market under the symbol \u0093MYOK\u0094. </p>\n</div></div>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-4 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<div style=\"BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%\"><div style=\"width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We qualify as an \u0093emerging growth company\u0094 as defined in the Jumpstart Our Business Startups Act of 2012, as\namended (the \u0093JOBS Act\u0094). As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. We would cease to be an emerging growth\ncompany on the date that is the earliest of: (i)\u00a0December\u00a031, 2020, (ii) the last day of the fiscal year in which we have total annual gross revenue of $1.07\u00a0billion or more, (iii)\u00a0the last day of the fiscal year in which we are\ndeemed to be a large accelerated filer, which means the market value of our common stock that is held by <font style=\"white-space:nowrap\">non-affiliates</font> exceeds $700.0\u00a0million as of the prior June 30th and (iv)\u00a0the date on which we\nhave issued more than $1.0\u00a0billion in <font style=\"white-space:nowrap\">non-convertible</font> debt during any three-year period before that time. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We use\nvarious trademarks and trade names in our business, including without limitation our corporate name and logo. All other trademarks or trade names referred to in this prospectus are the property of their respective owners. Solely for convenience, the\ntrademarks and trade names in this prospectus may be referred to without the <sup style=\"font-size:85%; vertical-align:top\">\u00ae</sup> and \u0099 symbols, but such references should not be construed as any indicator that their respective owners\nwill not assert, to the fullest extent under applicable law, their rights thereto. </p>\n</div></div>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-5 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<div style=\"BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%\"><div style=\"width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial\"><b><a name=\"supptoc579741_3\"></a>The offering </b></p>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr valign=\"TOP\">\n<td width=\"27%\"> <p style=\" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial\"><b>Common stock offered by us </b></p></td>\n<td>3,750,000 shares (or 4,312,500 shares if the underwriters exercise their option to purchase additional shares in full) </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr valign=\"TOP\">\n<td width=\"27%\"> <p style=\" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial\"><b>Common stock to be outstanding immediately after this offering </b></p></td>\n<td>39,672,982 shares (or 40,235,482 shares if the underwriters exercise their option to purchase additional shares in full) </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr valign=\"TOP\">\n<td width=\"27%\"> <p style=\" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial\"><b>Option to purchase additional shares </b></p></td>\n<td>We have granted the underwriters an option for a period of 30 days from the date of this prospectus supplement to purchase up to 562,500 additional shares of our common stock. </td></tr></table>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr valign=\"TOP\">\n<td width=\"27%\"> <p style=\" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial\"><b>Use of proceeds </b></p></td>\n<td>We intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and short-term and long-term investments, to fund research and development activities for our development programs, including, but not\nlimited to, our planned Phase 3 <font style=\"white-space:nowrap\">EXPLORER-HCM</font> clinical trial of mavacamten and our planned Phase 2 clinical trial of <font style=\"white-space:nowrap\">MYK-491,</font> as well as our other ongoing and planned\nclinical trials for mavacamten and <font style=\"white-space:nowrap\">MYK-491,</font> our ongoing preclinical, discovery and research programs and the expansion of our platform, and for working capital and other general corporate purposes. See also\nthe section entitled \u0093Use of proceeds\u0094 on page <font style=\"white-space:nowrap\">S-14</font> of this prospectus supplement. </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr valign=\"TOP\">\n<td width=\"27%\"> <p style=\" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial\"><b>Risk factors </b></p></td>\n<td>Investing in our common stock involves a high degree of risk. See \u0093Risk factors\u0094 beginning on page <font style=\"white-space:nowrap\">S-8</font> of this prospectus supplement, as well as those \u0093Risk factors\u0094 incorporated by\nreference into this prospectus supplement, for a discussion of factors you should consider carefully before deciding to purchase any shares of our common stock. </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr valign=\"TOP\">\n<td width=\"27%\"> <p style=\" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial\"><b>Nasdaq Global Select Market symbol </b></p></td>\n<td>MYOK </td></tr></table> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The number of shares of our common stock to be outstanding immediately after this offering is based on 35,922,982 shares of our common stock\noutstanding as of March\u00a031, 2018. The number of shares outstanding as of March\u00a031, 2018 excludes: </p> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">3,793,364 shares of common stock issuable upon the exercise of stock options and awards outstanding as of March\u00a031, 2018, at a weighted average exercise price of $22.15 per share; </td></tr></table>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">170,420 shares of common stock issuable upon the exercise of outstanding stock options and awards granted subsequent to March\u00a031, 2018, at a weighted average exercise price of $42.23 per share; and\n</td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">2,164,614 shares of common stock reserved for future issuance under our 2015 Stock Option and Incentive Plan and our 2015 Employee Stock Purchase Plan as of March\u00a031, 2018. </td></tr></table>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Except as otherwise indicated, all information in this prospectus supplement assumes no exercise by the underwriters of their option to purchase up to an additional\n562,500 shares of our common stock. </p>\n</div></div>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-6 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<div style=\"BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%\"><div style=\"width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial\"><b>Indications of interest </b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Sanofi, our strategic collaboration partner and one of our existing stockholders (through its wholly owned subsidiary Aventis Inc.), has agreed to purchase an aggregate\nof 150,000\u00a0shares of our common stock in this offering at the public offering price and on the same terms as the other purchasers in this offering. </p>\n</div></div>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-7 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial\"><b><a name=\"supptoc579741_4\"></a>Risk factors </b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><i>Investing in our common stock involves a high degree of risk. You should carefully consider the risk factors described below and the risk factors incorporated by\nreference to our most recent Quarterly Report on Form <font style=\"white-space:nowrap\">10-Q</font> and Annual Report on Form <font style=\"white-space:nowrap\">10-K,</font> and any subsequent Quarterly Reports on Form\n<font style=\"white-space:nowrap\">10-Q</font> or Current Reports on Form <font style=\"white-space:nowrap\">8-K</font> we file after the date of this prospectus supplement, and all other information contained or incorporated by reference into this\nprospectus supplement and the accompanying prospectus, including our financial statements and the related notes, as updated by our subsequent filings under the Securities Exchange Act of 1934, as amended (the \u0093Exchange Act\u0094) and in any\nfree writing prospectus that we have authorized for use in connection with this offering before acquiring any of our common stock. These risks could have a material and adverse impact on our business, results of operations, financial condition and\ngrowth prospects, which may cause the trading price of our common stock to decline and you could lose all or part of your investment. </i></p> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial\"><b>Risks related to our\nequity securities and this offering </b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>The market price of our common stock has been and may continue to be highly volatile. </i></b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The market price of our common stock has experienced volatility since our initial public offering in October 2015 and is likely to continue to be volatile. Our stock\nprice could be subject to wide fluctuations in response to a variety of factors, including the following: </p> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">adverse results or delays in preclinical studies or clinical trials; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">reports of adverse events in clinical trials of our product candidates or in other products for the treatment of cardiovascular diseases or clinical trials of such products; </td></tr></table>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">inability to obtain additional funding; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any delay in filing an IND or NDA for any of our product candidates and any adverse development or perceived adverse development with respect to the FDA\u0092s review of that IND or NDA; </td></tr></table>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">failure to develop successfully and commercialize our product candidates; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any adverse developments relating to our Collaboration Agreement with Sanofi, or any failure to maintain our existing strategic collaborations or enter into new collaborations; </td></tr></table>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">failure by us or our licensors and strategic collaborators to prosecute, maintain or enforce our intellectual property rights; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">changes in laws or regulations applicable to future products; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">inability to obtain adequate product supply for our product candidates or the inability to do so at acceptable prices; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">adverse regulatory decisions affecting our product candidates or development programs; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">introduction of new products, services or technologies by our competitors; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">failure to meet or exceed financial projections we may provide to the public or to the investment community; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us, our strategic collaboration partner or our competitors; </td></tr></table>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-8 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; </td></tr></table>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">additions or departures of key scientific or management personnel; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">significant lawsuits, including patent or stockholder litigation; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">changes in the market valuations of similar companies; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">sales of our common stock by us or our stockholders in the future; and </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">trading volume of our common stock. </td></tr></table> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In addition, companies trading in the stock market in general, and the Nasdaq Global\nSelect Market in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the\nmarket price of our common stock, regardless of our actual operating performance. In the past, following periods of volatility in the market, securities class-action litigation has often been instituted against companies. Such litigation, if\ninstituted against us, could result in substantial costs and diversion of management\u0092s attention and resources, which could materially and adversely affect our business, financial condition, results of operations and growth prospects. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>We will have broad discretion in the use of proceeds from this offering and may invest or spend the proceeds in ways with which you do not agree or in ways that\nultimately may not increase the value of your investment. </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We will have broad discretion over the use of proceeds from this offering. You may not agree with\nour decisions, and our use of the proceeds may not yield any return on your investment. We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to fund research and development activities for our\ndevelopment programs, including, but not limited to, our planned Phase 3 <font style=\"white-space:nowrap\">EXPLORER-HCM</font> clinical trial of mavacamten and our planned Phase 2 clinical trial of <font style=\"white-space:nowrap\">MYK-491,</font> as\nwell as our other ongoing and planned clinical trials for mavacamten and <font style=\"white-space:nowrap\">MYK-491,</font> our ongoing preclinical, discovery and research programs and the expansion of our platform, and for working capital and other\ngeneral corporate purposes. Our failure to apply the net proceeds from this offering effectively could compromise our ability to pursue our growth strategy and we might not be able to yield a significant return, if any, on our investment of these\nnet proceeds. In addition, the net proceeds from this offering may not be sufficient for our anticipated uses, and we may need additional resources to progress our product candidates to the stage we expect. You will not have the opportunity to\ninfluence our decisions on how to use our net proceeds from this offering. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>If you purchase our common stock in this offering, you will incur immediate and\nsubstantial dilution in the book value of your shares. </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Investors purchasing shares of common stock in this offering will pay a price per share that\nsubstantially exceeds the as adjusted book value per share of our tangible assets after subtracting our liabilities as of March\u00a031, 2018. As a result, investors purchasing shares of common stock in this offering will incur immediate dilution of\n$39.19 per share based on the public offering price of $49.00 per share. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Further, investors purchasing shares of common stock in this offering will contribute\napproximately\u00a028% of the total amount invested by stockholders since our inception (or 31% of the total amount invested by our stockholders since our inception if the underwriters\u0092 option to purchase additional shares is exercised in\nfull), but will own only approximately 9% of the shares of common stock outstanding (or 11% of the shares of common stock outstanding if the underwriters\u0092 option to purchase additional shares is exercised in full). For information on how the\nforegoing amounts were calculated, see \u0093Dilution.\u0094 </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-9 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">This dilution is due to the substantially lower price paid by our investors who purchased shares prior to this\noffering as compared to the price offered to investors in this offering, and the exercise price of stock options granted to our employees. The exercise of any of these options would result in additional dilution. As a result of the dilution to\ninvestors purchasing shares in this offering, investors may receive significantly less than the purchase price paid in this offering, if anything, in the event of our liquidation. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional\ndilution of the percentage ownership of our stockholders and could cause our stock price to fall. </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Additional capital will be needed in the future to\ncontinue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more\ntransactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may\nalso result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In addition, sales of a\nsubstantial number of shares of our outstanding common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce\nthe market price of our common stock. Significant portions of our outstanding shares of common stock are held by a relatively small number of stockholders. Sales by our stockholders of a substantial number of shares, or the expectation that such\nsales may occur, could significantly reduce the market price of our common stock. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We have also registered all shares of our common stock subject to options or other\nequity awards issued or reserved for future issuance under our equity incentive plans. As a result, these shares will be eligible for sale in the public market to the extent permitted by any applicable vesting requirements and the exercise of\noptions, and restrictions under applicable securities laws. In addition, our directors, executive officers and certain affiliates have established, or may in the future establish, programmed selling plans under Rule\n<font style=\"white-space:nowrap\">10b5-1</font> of the Exchange Act for the purpose of effecting sales of our common stock. If any of these events cause a large number of our shares to be sold in the public market, the sales could reduce the trading\nprice of our common stock and impede our ability to raise future capital. Moreover, certain holders of our common stock have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include\ntheir shares in registration statements that we may file for ourselves or other stockholders. In particular, we have filed a registration statement on Form <font style=\"white-space:nowrap\">S-3</font> registering for resale 9,184,352 shares of common\nstock held by entities affiliated with our major shareholder, Third Rock Ventures, which was declared effective by the SEC on July\u00a021, 2017. These shares, together with any additional shares that we may register for resale, can be freely sold\nin the public market. If these additional shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Pursuant to the 2015 Stock Option and Incentive Plan, we are authorized to grant stock options and other equity-based awards to our employees, directors and consultants.\nBeginning on January\u00a01, 2017, the number of shares available for future grant under the 2015 Stock Option and Incentive Plan automatically increases each year by up to 4% of all shares of our capital stock outstanding as of December\u00a031 of\nthe prior calendar year, subject to the ability of our board of directors to take action to reduce the size of the increase in any given year. In addition, pursuant to the 2015 Employee Stock Purchase Plan, we initially reserved 255,000 shares for\npurchase by eligible employees. Beginning on January\u00a01, 2017 and ending on January\u00a01, 2025, the number of shares available for future issuance under the 2015 Employee Stock Purchase Plan automatically increases each year by up to the\nlesser of 3,000,000 shares of common stock or 1% of all shares of our capital stock </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-10 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">\noutstanding as of December\u00a031 of the prior calendar year, subject to the ability of our board of directors to take action to reduce the size of the increase in any given year. Currently, we\nplan to register the increased number of shares available for issuance under the 2015 Stock Option and Incentive Plan and the 2015 Employee Stock Purchase Plan each year. If our board of directors elects to increase the number of shares available\nfor future grant under these plans by the maximum amount each year, our stockholders may experience additional dilution, which could cause our stock price to fall. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to\nstockholder approval. </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">As of March\u00a031, 2018, our executive officers, directors, five percent or greater stockholders and their affiliates beneficially\nown approximately 41.6% of our outstanding voting stock. In addition, Sanofi, our strategic collaboration partner and one of our existing stockholders (through its wholly owned subsidiary Aventis Inc.), has agreed to purchase an aggregate of\n150,000\u00a0shares of our common stock in this offering at the public offering price and on the same terms as the other purchasers in this offering. If Sanofi were to purchase 150,000 shares of our common stock, our executive officers, directors,\nfive percent or greater stockholders and their affiliates will beneficially own approximately 33.4% of our outstanding voting stock upon the closing of this offering (assuming no exercise of the underwriters\u0092 option to purchase additional\nshares and no exercise of outstanding options). These stockholders will have the ability to influence us through their ownership positions. These stockholders may be able to determine all matters requiring stockholder approval. For example, these\nstockholders, acting together, may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited\nacquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>If securities or industry\nanalysts do not publish research, or publish inaccurate or unfavorable research, about our business, our stock price and trading volume could decline. </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The\ntrading market for our common stock will depend, in part, on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts may not publish an adequate amount of research on our\ncompany, which may negatively impact the trading price for our stock. In addition, if one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely\ndecline. Further, if our operating results fail to meet the forecasts of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock\ncould decrease, which might cause our stock price and trading volume to decline. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Because we do not anticipate paying any cash dividends on our capital stock\nin the foreseeable future, capital appreciation, if any, will be your sole source of gain. </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We have never declared or paid cash dividends on our capital\nstock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital\nappreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>We could be subject to securities class action\nlitigation. </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its\nsecurities. This risk is especially relevant for us because biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a\ndiversion of management\u0092s attention and resources, which could harm our business. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-11 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Changes in tax law may adversely affect us or our investors. </i></b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the IRS and the\nU.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in\nthe future. It cannot be predicted whether, when, in what form, or with what effective dates, tax laws, regulations and rulings may be enacted, promulgated or issued, which could result in an increase in our or our shareholders\u0092 tax liability\nor require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-12 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial\"><b><a name=\"supptoc579741_5\"></a>Cautionary note regarding forward-looking statements </b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">This prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein, and any free writing prospectus that we have\nauthorized for use in connection with this offering, contain forward-looking statements. All statements other than statements of historical facts contained in this prospectus supplement, the accompanying prospectus and the documents incorporated by\nreference herein are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future\nresults, performance or achievements expressed or implied by the forward-looking statements. This prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein also contain estimates and other statistical data\nmade by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition,\nprojections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In some cases, you can identify forward-looking statements by terms such as \u0093may,\u0094 \u0093will,\u0094 \u0093should,\u0094 \u0093expect,\u0094 \u0093plan,\u0094\n\u0093anticipate,\u0094 \u0093could,\u0094 \u0093intend,\u0094 \u0093target,\u0094 \u0093project,\u0094 \u0093contemplates,\u0094 \u0093believes,\u0094 \u0093estimates,\u0094 \u0093predicts,\u0094 \u0093potential\u0094 or \u0093continue\u0094 or the\nnegative of these terms or other similar expressions. The forward-looking statements in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein, and any free writing prospectus that we\nhave authorized for use in connection with this offering, are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect\nour business, financial condition and results of operations. These forward-looking statements speak only as of the date of this prospectus supplement and are subject to a number of risks, uncertainties and assumptions, including those under the\nheading \u0093Risk factors\u0094 in this prospectus supplement and in the documents incorporated by reference herein, and elsewhere in this prospectus supplement. The events and circumstances reflected in our forward-looking statements may not be\nachieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not\npossible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained in this prospectus supplement, the accompanying\nprospectus or the documents incorporated by reference herein and therein, and any free writing prospectus that we have authorized for use in connection with this offering, whether as a result of any new information, future events, changed\ncircumstances or otherwise. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-13 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial\"><b><a name=\"supptoc579741_6\"></a>Use of proceeds </b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We estimate that we will receive net proceeds of approximately $172.1\u00a0million from the sale of 3,750,000\u00a0shares of our common stock offered in this offering,\nbased on the public offering price of $49.00 per share, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. If the underwriters exercise their option to purchase up to an additional 562,500\nshares in full, we estimate that the net proceeds of the shares we sell in this offering will be approximately $198.0\u00a0million. </p> <p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We intend to use the net\nproceeds from this offering, together with our existing cash, cash equivalents and short-term and long-term investments, to fund research and development activities for our development programs, including, but not limited to, our planned Phase 3 <font style=\"white-space:nowrap\">EXPLORER-HCM</font> clinical trial of mavacamten and our planned Phase 2 clinical trial of <font style=\"white-space:nowrap\">MYK-491,</font> as well as our other ongoing and planned clinical trials for mavacamten and <font style=\"white-space:nowrap\">MYK-491,</font> our ongoing preclinical, discovery and research programs and the expansion of our platform, and for working capital and other general corporate purposes. We expect our current cash, cash equivalents and\ninvestments, together with anticipated payments under our collaboration agreement with Sanofi and the anticipated net proceeds from this offering, to fund our planned operations into 2021. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We may also use a portion of the net proceeds to <font style=\"white-space:nowrap\">in-license,</font> acquire or invest in new businesses, technology or assets. Although\nwe have no specific agreements, commitments or understandings with respect to any <font style=\"white-space:nowrap\">in-license</font> or acquisition, we evaluate such opportunities and engage in related discussions with other business entities from\ntime to time. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The amounts and timing of our actual expenditures will depend on numerous factors, including the factors described under \u0093Risk factors\u0094 in\nthis prospectus supplement, the accompanying prospectus and in the documents incorporated by reference herein, as well as the amount of cash used in our operations. We may find it necessary or advisable to use the net proceeds for other purposes,\nand we will have broad discretion in the application of the net proceeds. Pending the uses described above, we plan to invest the net proceeds from this offering in short- and intermediate-term, interest-bearing obligations, investment-grade\ninstruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-14 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial\"><b><a name=\"supptoc579741_7\"></a>Dilution </b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">If you invest in our common stock in this offering, your ownership interest will be diluted to the extent of the difference between the public offering price per share\nof our common stock and the net tangible book value per share of our common stock immediately after this offering. The net tangible book value of our common stock as of March\u00a031, 2018 was approximately $217.2\u00a0million, or approximately\n$6.05\u00a0per share of common stock based upon 35,922,982\u00a0shares outstanding. Net tangible book value per share is equal to our total tangible assets, less our total liabilities, divided by the total number of shares of common stock\noutstanding as of March\u00a031, 2018. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Net tangible book value dilution per share to investors participating in this offering represents the difference between the\namount per share paid by purchasers of shares of common stock in this offering and the as adjusted net tangible book value per share of common stock immediately after completion of this offering. After giving effect to the issuance and sale by us of\n3,750,000\u00a0shares of our common stock at the public offering price of $49.00\u00a0per share, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted net tangible book value as of\nMarch\u00a031, 2018 would have been $389.2\u00a0million, or $9.81\u00a0per share of our common stock. This represents an immediate increase in net tangible book value of $3.76\u00a0per share to our existing stockholders and an immediate dilution in\nnet tangible book value of $39.19\u00a0per share to new investors in this offering. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The following table illustrates this calculation on a per share basis: </p>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr>\n<td width=\"85%\"></td>\n<td valign=\"bottom\" width=\"3%\"></td>\n<td></td>\n<td></td>\n<td></td>\n<td valign=\"bottom\" width=\"3%\"></td>\n<td></td>\n<td></td>\n<td></td></tr>\n<tr bgcolor=\"#cceeff\" style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td style=\"BORDER-TOP:2.00pt solid #000000\" valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Public offering price per share</p></td>\n<td style=\" BORDER-TOP:2.00pt solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td style=\"BORDER-TOP:2.00pt solid #000000\" valign=\"bottom\">\u00a0</td>\n<td style=\"BORDER-TOP:2.00pt solid #000000\" valign=\"bottom\">\u00a0</td>\n<td style=\"BORDER-TOP:2.00pt solid #000000\" valign=\"bottom\">\u00a0</td>\n<td style=\" BORDER-TOP:2.00pt solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td style=\"BORDER-TOP:2.00pt solid #000000\" valign=\"bottom\">$</td>\n<td align=\"right\" style=\"BORDER-TOP:2.00pt solid #000000\" valign=\"bottom\">49.00</td>\n<td nowrap=\"\" style=\"BORDER-TOP:2.00pt solid #000000\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Net tangible book value per share as of March\u00a031, 2018</p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">$</td>\n<td align=\"right\" valign=\"bottom\">6.05</td>\n<td nowrap=\"\" valign=\"bottom\"></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\"></td></tr>\n<tr bgcolor=\"#cceeff\" style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Increase in net tangible book value per share attributable to the offering</p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">3.76</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\"></td></tr>\n<tr style=\"font-size:1px; \">\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td>\n<td valign=\"bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td>\n<td>\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">As adjusted net tangible book value per share after giving effect to the offering</p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">$</td>\n<td align=\"right\" valign=\"bottom\">9.81</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"font-size:1px; \">\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td>\n<td valign=\"bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td>\n<td>\u00a0</td></tr>\n<tr bgcolor=\"#cceeff\" style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Dilution in net tangible book value per share to new investors in\nthis offering</p></td>\n<td style=\" BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td style=\" BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">$</td>\n<td align=\"right\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">39.19</td>\n<td nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0</td></tr>\n</table> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">If the underwriters exercise in full their option to purchase up to 562,500\u00a0additional shares of common stock at the public offering\nprice of $49.00\u00a0per share, the as adjusted net tangible book value after this offering would be $10.32\u00a0per share of our common stock, representing an increase of as adjusted net tangible book value of $4.27\u00a0per share to our existing\nstockholders and an immediate dilution of $0.51\u00a0per share to new investors purchasing shares in this offering. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The number of shares of our common stock to be\noutstanding immediately after this offering is based on 35,922,982 shares of our common stock outstanding as of March\u00a031, 2018. The number of shares outstanding as of March\u00a031, 2018 excludes: </p>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">3,793,364 shares of common stock issuable upon the exercise of stock options and awards outstanding as of March\u00a031, 2018, at a weighted average exercise price of $22.15 per share; </td></tr></table>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">170,420 shares of common stock issuable upon the exercise of outstanding stock options and awards granted subsequent to March\u00a031, 2018, at a weighted average exercise price of $42.23 per share; and\n</td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">2,164,614 shares of common stock reserved for future issuance under our 2015 Stock Option and Incentive Plan and our 2015 Employee Stock Purchase Plan as of March\u00a031, 2018. </td></tr></table>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Sanofi, our strategic collaboration partner and one of our existing stockholders (through its wholly owned subsidiary Aventis Inc.), has agreed to purchase an aggregate\nof 150,000\u00a0shares of our common stock in this offering at the public offering price and on the same terms as the other purchasers in this offering. The above discussion and tables do not reflect any potential purchases in this offering by\nSanofi. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-15 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial\"><b><a name=\"supptoc579741_8\"></a>Material U.S. federal income tax consequences to\n<font style=\"white-space:nowrap\">Non-U.S.</font> Holders </b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The following discussion is a summary of the material U.S. federal income tax consequences to <font style=\"white-space:nowrap\">Non-U.S.</font> Holders (as defined below) of the purchase, ownership and disposition of our common stock issued pursuant to this offering, but does not purport to be a complete analysis of all potential tax effects. The\neffects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or <font style=\"white-space:nowrap\">non-U.S.</font> tax laws are not discussed. This discussion is based on the U.S. Internal Revenue Code of\n1986, as amended (the \u0093Code\u0094), Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service (the \u0093IRS\u0094), in each case in effect as\nof the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a\n<font style=\"white-space:nowrap\">Non-U.S.</font> Holder of our common stock. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary\nposition to that discussed below regarding the tax consequences of the purchase, ownership and disposition of our common stock. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">This discussion is limited to <font style=\"white-space:nowrap\">Non-U.S.</font> Holders that hold our common stock as a \u0093capital asset\u0094 within the meaning of Section\u00a01221 of the Code (generally, property held for investment). This discussion does not address all U.S.\nfederal income tax consequences relevant to a <font style=\"white-space:nowrap\">Non-U.S.</font> Holder\u0092s particular circumstances, including the impact of the Medicare contribution tax on net investment income. In addition, it does not address\nconsequences relevant to <font style=\"white-space:nowrap\">Non-U.S.</font> Holders subject to special rules, including, without limitation: </p> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">U.S. expatriates and former citizens or long-term residents of the United States; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">persons subject to the alternative minimum tax; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">persons holding our common stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion transaction or other integrated investment; </td></tr></table>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">banks, insurance companies and other financial institutions; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">brokers, dealers or traders in securities; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">\u0093controlled foreign corporations,\u0094 \u0093passive foreign investment companies\u0094 and corporations that accumulate earnings to avoid U.S. federal income tax; </td></tr></table>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors therein); </td></tr></table>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\"><font style=\"white-space:nowrap\">tax-exempt</font> organizations or governmental organizations; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">persons deemed to sell our common stock under the constructive sale provisions of the Code; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as compensation; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\"><font style=\"white-space:nowrap\">tax-qualified\u00a0retirement\u00a0plans;\u00a0and</font> </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">\u0093qualified foreign pension funds\u0094 as defined in Section\u00a0897(l)(2) of the Code and entities all of the interests of which are held by qualified foreign pension funds. </td></tr></table>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">If an entity treated as a partnership for U.S. federal income tax purposes holds our common stock, the tax treatment of a partner in the partnership will depend on the\nstatus of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships holding our common stock and the partners in such partnerships should consult their tax advisors regarding the\nU.S. federal income tax consequences to them. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-16 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b>THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX\nADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT\nTAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR <font style=\"white-space:nowrap\">NON-U.S.</font> TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY. </b></p>\n<p style=\"margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial\"><b>Definition of a <font style=\"white-space:nowrap\">Non-U.S.</font> Holder </b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">For\npurposes of this discussion, a <font style=\"white-space:nowrap\">\u0093Non-U.S.</font> Holder\u0094 is any beneficial owner of our common stock that is neither a \u0093U.S. person\u0094 nor an entity treated as a partnership for U.S. federal income\ntax purposes. A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of the following: </p> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">an individual who is a citizen or resident of the United States; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">a corporation created or organized under the laws of the United States, any state thereof, or the District of Columbia; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">a trust that (1)\u00a0is subject to the primary supervision of a U.S. court and the control of one or more \u0093United States persons\u0094 (within the meaning of Section\u00a07701(a)(30) of the Code) or (2)\u00a0has a\nvalid election in effect to be treated as a United States person for U.S. federal income tax purposes. </td></tr></table> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial\"><b>Distributions </b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">If we make distributions of cash or property on our common stock, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid\nfrom our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of capital and first be applied against and\nreduce a <font style=\"white-space:nowrap\">Non-U.S.</font> Holder\u0092s adjusted tax basis in its common stock, but not below zero. Any excess will be treated as capital gain and will be treated as described below under \u0093\u0097Sale or other\ntaxable disposition.\u0094 </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Subject to the discussion below on effectively connected income, dividends paid to a <font style=\"white-space:nowrap\">Non-U.S.</font>\nHolder of our common stock will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty, provided the\n<font style=\"white-space:nowrap\">Non-U.S.</font> Holder furnishes a valid IRS Form <font style=\"white-space:nowrap\">W-8BEN</font> or <font style=\"white-space:nowrap\"><font style=\"white-space:nowrap\">W-8BEN-E</font></font> (or other applicable\ndocumentation) certifying qualification for the lower treaty rate). A <font style=\"white-space:nowrap\">Non-U.S.</font> Holder that does not timely furnish the required documentation, but that qualifies for a reduced treaty rate, may obtain a refund\nof any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. <font style=\"white-space:nowrap\">Non-U.S.</font> Holders should consult their tax advisors regarding their entitlement to benefits under any applicable\nincome tax treaty. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">If dividends paid to a <font style=\"white-space:nowrap\">Non-U.S.</font> Holder are effectively connected with the\n<font style=\"white-space:nowrap\">Non-U.S.</font> Holder\u0092s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the <font style=\"white-space:nowrap\">Non-U.S.</font> Holder maintains a\npermanent establishment in the United States to which such dividends are attributable), the <font style=\"white-space:nowrap\">Non-U.S.</font> Holder will be exempt from the U.S. federal withholding tax described above. To claim the exemption, the <font style=\"white-space:nowrap\">Non-U.S.</font> Holder must furnish to the applicable withholding agent a valid IRS Form <font style=\"white-space:nowrap\">W-8ECI,</font> certifying that the dividends are effectively connected with the <font style=\"white-space:nowrap\">Non-U.S.</font> Holder\u0092s conduct of a trade or business within the United States. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Any such effectively connected dividends will be\nsubject to U.S. federal income tax on a net income basis at the regular graduated rates. A <font style=\"white-space:nowrap\">Non-U.S.</font> Holder that is a corporation for U.S. federal income tax purposes also may\n</p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-17 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">\nbe subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected dividends, as adjusted for certain items.\nNon-U.S. Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules. </p> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial\"><b>Sale or other taxable disposition\n</b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Subject to the discussion below regarding backup withholding and FATCA, a <font style=\"white-space:nowrap\">Non-U.S.</font> Holder will not be subject to U.S.\nfederal income tax on any gain realized upon the sale or other taxable disposition of our common stock unless: </p> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the gain is effectively connected with the <font style=\"white-space:nowrap\">Non-U.S.</font> Holder\u0092s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the\n<font style=\"white-space:nowrap\">Non-U.S.</font> Holder maintains a permanent establishment in the United States to which such gain is attributable); </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the <font style=\"white-space:nowrap\">Non-U.S.</font> Holder is a nonresident alien individual present in the United States for 183 days or more during the taxable year of the disposition and certain other requirements\nare met; or </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">our common stock constitutes a U.S. real property interest (\u0093USRPI\u0094) by reason of our status as a U.S. real property holding corporation (\u0093USRPHC\u0094) for U.S. federal income tax purposes.\n</td></tr></table> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Gain described in the first bullet point above generally will be subject to U.S. federal income tax on a net income basis at the regular graduated\nrates. A <font style=\"white-space:nowrap\">Non-U.S.</font> Holder that is a corporation for U.S. federal income tax purposes also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax\ntreaty) on such effectively connected gain, as adjusted for certain items. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Gain described in the second bullet point above will be subject to U.S. federal income\ntax at a rate of 30% (or such lower rate specified by an applicable income tax treaty), which may be offset by certain U.S. source capital losses of the <font style=\"white-space:nowrap\">Non-U.S.</font> Holder (even though the individual is not\nconsidered a resident of the United States), provided the <font style=\"white-space:nowrap\">Non-U.S.</font> Holder has timely filed U.S. federal income tax returns with respect to such losses. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">With respect to the third bullet point above, we believe we currently are not, and do not anticipate becoming, a USRPHC. Because the determination of whether we are a\nUSRPHC depends, however, on the fair market value of our USRPIs relative to the fair market value of our <font style=\"white-space:nowrap\">non-U.S.</font> real property interests and our other business assets, there can be no assurance we currently\nare not a USRPHC or will not become one in the future. Even if we are or were to become a USRPHC, gain arising from the sale or other taxable disposition by a <font style=\"white-space:nowrap\">Non-U.S.</font> Holder of our common stock will not be\nsubject to U.S. federal income tax if our common stock is \u0093regularly traded,\u0094 as defined by applicable Treasury Regulations, on an established securities market, and such <font style=\"white-space:nowrap\">Non-U.S.</font> Holder owned,\nactually and constructively, 5% or less of our common stock throughout the shorter of the <font style=\"white-space:nowrap\">five-year</font> period ending on the date of the sale or other taxable disposition or the\n<font style=\"white-space:nowrap\">Non-U.S.</font> Holder\u0092s holding period. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><font style=\"white-space:nowrap\">Non-U.S.</font> Holders should consult their tax\nadvisors regarding any applicable tax treaties that may provide for different rules. </p> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial\"><b>Information reporting and backup withholding </b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Payments of dividends on our common stock will not be subject to backup withholding, provided the applicable withholding agent does not have actual knowledge or reason\nto know the holder is a United States person and the holder either certifies its <font style=\"white-space:nowrap\">non-U.S.</font> status, such as by furnishing a valid IRS Form <font style=\"white-space:nowrap\">W-8BEN,</font> <font style=\"white-space:nowrap\"><font style=\"white-space:nowrap\">W-8BEN-E</font></font> or <font style=\"white-space:nowrap\">W-8ECI,</font> or otherwise establishes an exemption. However, information returns are required to be filed with the IRS in\nconnection with any dividends on our common stock paid to the <font style=\"white-space:nowrap\">Non-U.S.</font> Holder, regardless of whether </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-18 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">\nany tax was actually withheld. In addition, proceeds of the sale or other taxable disposition of our common stock within the United States or conducted through certain U.S.-related brokers\ngenerally will not be subject to backup withholding or information reporting, if the applicable withholding agent receives the certification described above and does not have actual knowledge or reason to know that such holder is a United States\nperson, or the holder otherwise establishes an exemption. Proceeds of a disposition of our common stock conducted through a <font style=\"white-space:nowrap\">non-U.S.</font> office of a <font style=\"white-space:nowrap\">non-U.S.</font> broker that\ndoes not have certain enumerated relationships with the United States generally will not be subject to backup withholding or information reporting. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Copies of\ninformation returns that are filed with the IRS may also be made available under the provisions of an applicable treaty or agreement to the tax authorities of the country in which the <font style=\"white-space:nowrap\">Non-U.S.</font> Holder resides\nor is established. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit\nagainst a <font style=\"white-space:nowrap\">Non-U.S.</font> Holder\u0092s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. </p>\n<p style=\"margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial\"><b>Additional withholding tax on payments made to foreign accounts </b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Withholding\ntaxes may be imposed under Sections 1471 to 1474 of the Code (such Sections commonly referred to as the Foreign Account Tax Compliance Act (\u0093FATCA\u0094)) on certain types of payments made to <font style=\"white-space:nowrap\">non-U.S.</font>\nfinancial institutions and certain other <font style=\"white-space:nowrap\">non-U.S.</font> entities. Specifically, a 30% withholding tax may be imposed on dividends on, or gross proceeds from the sale or other disposition of, our common stock paid to\na \u0093foreign financial institution\u0094 or a <font style=\"white-space:nowrap\">\u0093non-financial</font> foreign entity\u0094 (each as defined in the Code), unless (1)\u00a0the foreign financial institution undertakes certain diligence and\nreporting obligations, (2)\u00a0the <font style=\"white-space:nowrap\">non-financial</font> foreign entity either certifies it does not have any \u0093substantial United States owners\u0094 (as defined in the Code) or furnishes identifying information\nregarding each substantial United States owner, or (3)\u00a0the foreign financial institution or <font style=\"white-space:nowrap\">non-financial</font> foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign\nfinancial institution and is subject to the diligence and reporting requirements in (1)\u00a0above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held\nby certain \u0093specified United States persons\u0094 or \u0093United States owned foreign entities\u0094 (each as defined in the Code), annually report certain information about such accounts, and withhold 30% on certain payments to <font style=\"white-space:nowrap\">non-compliant</font> foreign financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA\nmay be subject to different rules. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to payments of\ndividends on our common stock, and, beginning on January\u00a01, 2019, will apply to payments of gross proceeds from the sale or other disposition of such stock. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Prospective investors should consult their tax advisors regarding the potential application of withholding under FATCA to their investment in our common stock. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-19 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial\"><b><a name=\"supptoc579741_9\"></a>Underwriting </b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We are offering the shares of common stock described in this prospectus supplement through a number of underwriters. J.P. Morgan Securities LLC, Merrill Lynch, Pierce,\nFenner\u00a0&amp; Smith Incorporated, Credit Suisse Securities (USA) LLC and Wells Fargo Securities, LLC are acting as joint book-running managers of the offering and as representatives of the underwriters. We have entered into an underwriting\nagreement with the underwriters. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to the underwriters, and each underwriter has severally agreed to purchase, at the public offering price less the underwriting\ndiscounts and commissions set forth on the cover page of this prospectus supplement, the number of shares of common stock listed next to its name in the following table: </p> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr>\n<td width=\"89%\"></td>\n<td valign=\"bottom\" width=\"2%\"></td>\n<td></td>\n<td></td>\n<td></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:9pt\">\n<td style=\"BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\"><b>Name</b></td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td align=\"right\" colspan=\"2\" style=\"BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\"><b>Number\u00a0of<br/>shares</b></td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0</td></tr>\n<tr bgcolor=\"#cceeff\" style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">J.P. Morgan Securities LLC</p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">1,406,250</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Merrill Lynch, Pierce, Fenner &amp;\nSmith<br/>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Incorporated</p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">1,031,250</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr bgcolor=\"#cceeff\" style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Credit Suisse Securities (USA) LLC</p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">881,250</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Wells Fargo Securities, LLC</p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">431,250</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"font-size:1px; \">\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td>\n<td valign=\"bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td>\n<td>\u00a0</td></tr>\n<tr bgcolor=\"#cceeff\" style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Total</p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">3,750,000</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"font-size:1px; font-family:arial; font-size:10pt\">\n<td colspan=\"4\" valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000\">\u00a0</p></td>\n<td>\u00a0</td></tr>\n</table> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The underwriters are committed to purchase all the shares of common stock offered by us if they purchase any shares. The underwriting\nagreement also provides that if an underwriter defaults, the purchase commitments of <font style=\"white-space:nowrap\">non-defaulting</font> underwriters may also be increased or the offering may be terminated. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The underwriters propose to offer the shares of common stock directly to the public at the public offering price set forth on the cover page of this prospectus\nsupplement and to certain dealers at that price less a concession not in excess of $1.764 per share. Any such dealers may resell shares to certain other brokers or dealers at a discount of up to $0.588 per share from the public offering price. After\nthe public offering of the shares, the offering price and other selling terms may be changed by the underwriters. Sales of shares made outside of the United States may be made by affiliates of the underwriters. The offering of the shares by the\nunderwriters is subject to receipt and acceptance and subject to the underwriters\u0092 right to reject any order in whole or in part. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The underwriters have an\noption to buy up to 562,500 additional shares of common stock from us. The underwriters have 30 days from the date of this prospectus supplement to exercise this option to purchase the additional shares. If any shares are purchased with this option,\nthe underwriters will purchase shares in approximately the same proportion as shown in the table above. If any additional shares of common stock are purchased, the underwriters will offer the additional shares on the same terms as those on which the\nshares are being offered. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Sanofi, our strategic collaboration partner and one of our existing stockholders (through its wholly owned subsidiary Aventis Inc.), has\nagreed to purchase an aggregate of 150,000\u00a0shares of our common stock in this offering at the public offering price and on the same terms as the other purchasers in this offering. The underwriters will receive the same underwriting discount on\nany shares purchased by Sanofi as they will on any other shares sold to the public in this offering. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-20 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The underwriting fee is equal to the public offering price per share of common stock less the amount paid by the\nunderwriters to us per share of common stock. The underwriting fee is $2.94\u00a0per share. The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters assuming both no exercise and full\nexercise of the underwriters\u0092 option to purchase additional shares of common stock. </p> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt\" width=\"100%\">\n<tr>\n<td width=\"74%\"></td>\n<td valign=\"bottom\" width=\"3%\"></td>\n<td></td>\n<td></td>\n<td></td>\n<td valign=\"bottom\" width=\"3%\"></td>\n<td></td>\n<td></td>\n<td></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:9pt\">\n<td style=\"BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td align=\"right\" colspan=\"2\" style=\"BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\"> <p align=\"right\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial\"><b>Without</b></p>\n<p align=\"right\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial\"><b>option\u00a0to</b></p> <p align=\"right\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial\"><b>purchase</b></p>\n<p align=\"right\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial\"><b>additional</b></p> <p align=\"right\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial\"><b>shares</b></p>\n<p align=\"right\" style=\"margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial\"><b>exercise</b></p></td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td align=\"right\" colspan=\"2\" style=\"BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\"> <p align=\"right\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial\"><b>With\u00a0full</b></p>\n<p align=\"right\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial\"><b>option\u00a0to</b></p> <p align=\"right\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial\"><b>purchase</b></p>\n<p align=\"right\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial\"><b>additional</b></p> <p align=\"right\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial\"><b>shares</b></p>\n<p align=\"right\" style=\"margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial\"><b>exercise</b></p></td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0</td></tr>\n<tr bgcolor=\"#cceeff\" style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Per share</p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">$</td>\n<td align=\"right\" valign=\"bottom\">2.94</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">$</td>\n<td align=\"right\" valign=\"bottom\">2.94</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Total</p></td>\n<td style=\" BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">$</td>\n<td align=\"right\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">11,025,000</td>\n<td nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td style=\" BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">$</td>\n<td align=\"right\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">12,678,750</td>\n<td nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0</td></tr>\n</table> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We estimate that the total expenses of this offering, including registration, filing and listing fees, printing fees and legal and\naccounting expenses, but excluding the underwriting discounts and commissions, will be approximately $665,000. We have agreed to reimburse the underwriters for up to $25,000 for expenses relating to the clearance of this offering with the Financial\nIndustry Regulatory Authority, Inc. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">A prospectus in electronic format may be made available on the web sites maintained by one or more underwriters, or selling\ngroup members, if any, participating in the offering. The underwriters may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by\nthe representatives to underwriters and selling group members that may make Internet distributions on the same basis as other allocations. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We have agreed that we\nwill not offer, sell, issue, contract to sell, pledge or otherwise dispose of, directly or indirectly, or file with the SEC a registration statement under the Securities Act relating to, any shares of our common stock or securities convertible into\nor exchangeable or exercisable for any shares of our common stock, or publicly disclose the intention to make any offer, sale, pledge, disposition or filing, without the prior written consent of J.P. Morgan Securities LLC, Merrill Lynch, Pierce,\nFenner\u00a0&amp; Smith Incorporated, Credit Suisse Securities (USA) LLC and Wells Fargo Securities, LLC for a period of 90 days after the date of this prospectus supplement. The restrictions described in this paragraph do not apply to\n(a)\u00a0grants of employee stock options or other equity-based awards pursuant to the terms of our equity inventive plans, (b)\u00a0issuances of shares of our common stock or securities convertible into or exchangeable or exercisable for any shares\nof our common stock pursuant to the exercise of such options or other equity-based awards, (c)\u00a0issuances of shares of our common stock pursuant to the conversion or exchange of convertible or exchangeable securities or the exercise of options,\nin each case outstanding on the date hereof, (d)\u00a0the issuance of shares of our common stock in this offering, or (e)\u00a0the entry into any agreement providing for our issuance of common stock or securities exercisable or convertible into\ncommon stock in connection with (x)\u00a0our acquisition of the securities, business, intellectual property or other assets of any person or entity or pursuant to an employee benefit plan assumed by us in connection with any such acquisition, and\nthe issuance of any common stock or securities exercisable or convertible into common stock pursuant to any such agreement or (y)\u00a0the entry into any agreement relating to a joint venture, licensing transaction, collaboration or other strategic\ntransaction; provided, that the aggregate number of shares of common stock (and securities exercisable or convertible into common stock) that we may sell or issue or agree to sell or issue pursuant to this clause (e)\u00a0may not exceed 5.0% of the\ntotal outstanding shares of our capital stock following the completion of this offering; and provided in the case of clauses (b), (c) and (e), the recipients of such securities agree to be bound by a lockup letter in the form executed by our\ndirectors and officers. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Our officers and directors have agreed that they will not offer, sell, contract to sell, pledge or otherwise dispose of, directly or\nindirectly, any shares of our common stock or securities convertible into or exchangeable or </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-21 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">\nexercisable for any shares of our common stock, enter into a transaction that would have the same effect, or enter into any swap, hedge or other arrangement that transfers, in whole or in part,\nany of the economic consequences of ownership of our common stock, whether any of these transactions is to be settled by delivery of our common stock or other securities, in cash or otherwise, or publicly disclose the intention to make any offer,\nsale, pledge or disposition, or to enter into any transaction, swap, hedge or other arrangement, without, in each case, the prior written consent of J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner\u00a0&amp; Smith Incorporated, Credit\nSuisse Securities (USA) LLC and Wells Fargo Securities, LLC for a period of, in the case of our officers and directors, 90\u00a0days, or in the case of Sanofi, who has agreed to purchase an aggregate of 150,000\u00a0shares of our common stock in\nthis offering at the public offering price and on the same terms as the other purchasers in this offering, 45\u00a0days after the date of this prospectus supplement. If, prior to the expiration of such period, a request to release securities subject\nto a <font style=\"white-space:nowrap\">lock-up</font> agreement is received, J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner\u00a0&amp; Smith Incorporated, Credit Suisse Securities (USA) LLC and Wells Fargo Securities, LLC will consider,\namong other factors, such holder\u0092s reasons for requesting the release, the number of securities for which the release is being requested and market conditions at the time. The restrictions described in this paragraph do not apply to: </p>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">a)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any shares of our common stock acquired by the <font style=\"white-space:nowrap\">lock-up</font> signatory in the open market, or in the case of Sanofi, in the offering; </td></tr></table>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">b)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the exercise with cash of stock options or other similar awards granted pursuant to our equity incentive plans, provided that such restrictions shall apply to any of the <font style=\"white-space:nowrap\">lock-up</font>\nsignatory\u0092s shares of common stock issued upon such exercise or the cashless exercise of stock options (the term cashless exercise being intended to include the surrender of a portion of the option shares or previously owned shares to the\nCompany to cover payment of the exercise price) for the purposes of exercising such stock options solely in the case of termination of employment or board service following death, disability or other than for cause (including any such transfer in\nrespect of tax liabilities arising from such exercise) if such options would otherwise expire; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">c)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the establishment of any contract, instruction or plan (\u0093Plan\u0094), that satisfies all of the requirements of Rule <font style=\"white-space:nowrap\">10b5-1</font> under the Exchange Act for the transfer of shares\nof common stock, provided that no sales of the <font style=\"white-space:nowrap\">lock-up</font> signatory\u0092s shares of common stock shall be made pursuant to such a Plan prior to the expiration of the applicable period referred to above;\n</td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">d)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">transfers of our common stock or other securities as a bona fide gift or gifts not involving a disposition for value or for bona fide estate planning purposes, as a bona fide gift to a charity or educational\ninstitution, transfers to a member or members of the <font style=\"white-space:nowrap\">lock-up</font> signatory\u0092s family or to a trust, the direct or indirect beneficiaries of which are the <font style=\"white-space:nowrap\">lock-up</font>\nsignatory and/or a member or members of the <font style=\"white-space:nowrap\">lock-up</font> signatory\u0092s family, by testate succession or intestate distribution, if the undersigned is a trust, to any beneficiary of the undersigned or to the\nestate of any such beneficiary, distributions not involving a disposition for value of shares of our common stock or such other securities to members, partners or stockholders of, or owner of a similar equity interest in, the <font style=\"white-space:nowrap\">lock-up</font> signatory or to any corporation, partnership or other person or entity that is a direct or indirect affiliate of the <font style=\"white-space:nowrap\">lock-up</font> signatory, or transfers of our common\nstock or any security convertible into or exchangeable for shares of our common stock that occurs by operation of law pursuant to a qualified domestic order or in connection with a divorce settlement or other court order provided that each donee,\ndistributee or transferee, as the case may be, agrees to be subject to the same restrictions as the <font style=\"white-space:nowrap\">lock-up</font> signatory; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">e)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\"> <p align=\"left\" style=\" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt\">the transfer of the <font style=\"white-space:nowrap\">lock-up</font> signatory\u0092s shares of our common stock or any\nsecurity convertible into or exercisable or exchangeable for shares of our common stock to us pursuant to any contractual arrangement in effect on the date of the <font style=\"white-space:nowrap\">lock-up</font> agreement that provides for the\nrepurchase of the <font style=\"white-space:nowrap\">lock-up</font> </p></td></tr></table>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-22 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"4%\">\u00a0</td>\n<td align=\"left\" valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt\">\nsignatory\u0092s shares of common stock or such other securities by us or in connection with the termination of the <font style=\"white-space:nowrap\">lock-up</font> signatory\u0092s employment or\nother service relationship with us; and </p></td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">f)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the sale or transfer of the <font style=\"white-space:nowrap\">lock-up</font> signatory\u0092s shares of our common stock under a trading plan (a \u0093Trading Plan\u0094) pursuant to Rule\n<font style=\"white-space:nowrap\">10b5-1</font> promulgated under the Exchange Act that has been entered into prior to the date hereof which has been provided to J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner\u00a0&amp; Smith Incorporated,\nCredit Suisse Securities (USA) LLC and Wells Fargo Securities, LLC or their legal counsel. </td></tr></table> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In the case of a transfer or distribution pursuant to\nclause (a), no filing under the Exchange Act or other public announcement shall be required or voluntarily made by or on behalf of the transferee during the applicable period referred to above with respect to the subsequent sales of such shares of\ncommon stock acquired by the <font style=\"white-space:nowrap\">lock-up</font> signatory in the offering or in the open market. In the case of any transfer or distribution pursuant to clause (b)\u00a0or (c), no filing under the Exchange Act or other\npublic announcement shall be required or voluntarily made during the applicable period referred to above. In the case of a transfer or distribution pursuant to clause (d), no filing under the Exchange Act or other public announcement shall be\nrequired or voluntarily made by any party (other than a filing on Form 5 after the expiration of the applicable period referred to above). In the case of a sale or transfer pursuant to clause (f), to the extent a public announcement or filing under\nthe Exchange Act, if any, is required of, or voluntarily made by or on behalf of, the <font style=\"white-space:nowrap\">lock-up</font> signatory or us regarding such sale or transfer, such announcement or filing shall include a statement that such\ntransfer is in accordance with an established Trading Plan. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We have agreed to indemnify the several underwriters against liabilities under the Securities Act, or\ncontribute to payments that the underwriters may be required to make in that respect. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Our common stock is listed on the Nasdaq Global Select Market under the symbol\n\u0093MYOK.\u0094 </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In connection with this offering, the underwriters may engage in stabilizing transactions, which involve making bids for, purchasing and selling\nshares of common stock in the open market for the purpose of preventing or retarding a decline in the market price of the common stock while this offering is in progress. These stabilizing transactions may include making short sales of the common\nstock, which involve the sale by the underwriters of a greater number of shares of common stock than they are required to purchase in this offering, and purchasing shares of common stock on the open market to cover positions created by short sales.\nShort sales may be \u0093covered\u0094 shorts, which are short positions in an amount not greater than the underwriters\u0092 option to purchase additional shares referred to above, or may be \u0093naked\u0094 shorts, which are short positions in\nexcess of that amount. The underwriters may close out any covered short position either by exercising their option to purchase additional shares, in whole or in part, or by purchasing shares in the open market. In making this determination, the\nunderwriters will consider, among other things, the price of shares available for purchase in the open market compared to the price at which the underwriters may purchase shares through the option to purchase additional shares. A naked short\nposition is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market that could adversely affect investors who purchase in this offering. To the extent that\nthe underwriters create a naked short position, they will purchase shares in the open market to cover the position. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The underwriters have advised us that, pursuant\nto Regulation M of the Securities Act, they may also engage in other activities that stabilize, maintain or otherwise affect the price of the common stock, including the imposition of penalty bids. This means that if the representatives of the\nunderwriters purchase common stock in the open market in stabilizing transactions or to cover short sales, the representatives can require the underwriters that sold those shares as part of this offering to repay the underwriting discounts and\ncommissions received by them. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-23 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">These activities may have the effect of raising or maintaining the market price of the common stock or preventing or\nretarding a decline in the market price of the common stock, and, as a result, the price of the common stock may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities, they may\ndiscontinue them at any time. The underwriters may carry out these transactions on the Nasdaq Global Select Market, in the <font style=\"white-space:nowrap\"><font style=\"white-space:nowrap\">over-the-counter</font></font> market or otherwise. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In addition, in connection with this offering certain of the underwriters (and selling group members) may engage in passive market making transactions in our common\nstock on the Nasdaq Global Select Market prior to the pricing and completion of this offering. Passive market making consists of displaying bids on the Nasdaq Global Select Market no higher than the bid prices of independent market makers and making\npurchases at prices no higher than these independent bids and effected in response to order flow. Net purchases by a passive market maker on each day are generally limited to a specified percentage of the passive market maker\u0092s average daily\ntrading volume in the common stock during a specified period and must be discontinued when such limit is reached. Passive market making may cause the price of our common stock to be higher than the price that otherwise would exist in the open market\nin the absence of these transactions. If passive market making is commenced, it may be discontinued at any time. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Other than in the United States, no action has been\ntaken by us or the underwriters that would permit a public offering of the securities offered by this prospectus supplement in any jurisdiction where action for that purpose is required. The securities offered by this prospectus supplement may not\nbe offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under\ncircumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus supplement comes are advised to inform themselves about and to observe any restrictions\nrelating to the offering and the distribution of this prospectus supplement. This prospectus supplement does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which\nsuch an offer or a solicitation is unlawful. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Certain of the underwriters and their affiliates have provided in the past to us and our affiliates and may provide\nfrom time to time in the future certain commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received and may continue to receive\ncustomary fees and commissions. In addition, from time to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves or their customers, long or\nshort positions in our debt or equity securities or loans, and may do so in the future. </p> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial\"><b>Selling restrictions </b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors in the European Economic Area </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In\nrelation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a \u0093Relevant Member State\u0094), with effect from and including the date on which the Prospectus Directive is implemented in that\nRelevant Member State, no offer of shares of common stock may be made to the public in that Relevant Member State other than: </p> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">A.</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">B.</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), subject to obtaining the prior consent of the underwriters; or </td></tr></table>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">C.</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </td></tr></table>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-24 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">provided that no such offer of shares of common stock shall require the Company or any underwriter to publish a\nprospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive and each person who initially acquires any shares of common stock or to whom any offer is made will be deemed\nto have represented, acknowledged and agreed to and with each of the underwriters and the Company that it is a \u0093qualified investor\u0094 within the meaning of the law in that Relevant Member State implementing Article 2(1)(e) of the Prospectus\nDirective. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In the case of any shares of common stock being offered to a financial intermediary as that term is used in Article 3(2) of the Prospectus Directive,\neach such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares of common stock acquired by it in the offer have not been acquired on a <font style=\"white-space:nowrap\">non-discretionary</font> basis on\nbehalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares of common stock to the public other than their offer or resale in a Relevant Member State to\nqualified investors as so defined or in circumstances in which the prior consent of the representatives have been obtained to each such proposed offer or resale. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">For the purposes of this provision, the expression an \u0093offer of shares of common stock to the public\u0094 in relation to any shares of common stock in any Relevant\nMember State means the communication in any form and by means of sufficient information on the terms of the offer and the shares of common stock to be offered so as to enable an investor to decide to purchase shares of common stock, as the same may\nbe varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression \u0093Prospectus Directive\u0094 means Directive 2003/71/EC (as amended, including by Directive 2010/73/EU), and includes any\nrelevant implementing measure in the Relevant Member State. </p> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors in the United Kingdom </i></b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons\nwho are \u0093qualified investors\u0094 (as defined in the Prospectus Directive)\u00a0(i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial\nPromotion) Order 2005, as amended (the \u0093Order\u0094) and/or (ii)\u00a0who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d)\u00a0of the Order (all such persons\ntogether being referred to as \u0093relevant persons\u0094) or otherwise in circumstances which have not resulted and will not result in an offer to the public of the shares of common stock in the United Kingdom within the meaning of the Financial\nServices and Markets Act 2000. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Any person in the United Kingdom that is not a relevant person should not act or rely on the information included in this document or\nuse it as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons. </p>\n<p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors in Canada </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The shares of common stock\nmay be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument <font style=\"white-space:nowrap\">45-106</font> Prospectus Exemptions or subsection 73.3(1) of the\nSecurities Act (Ontario), and are permitted clients, as defined in National <font style=\"white-space:nowrap\">Instrument\u00a031-103</font> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares of common\nstock must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Securities\nlegislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation,\n</p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-25 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">\nprovided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser\u0092s province or territory.\nThe purchaser should refer to any applicable provisions of the securities legislation of the purchaser\u0092s province or territory for particulars of these rights or consult with a legal advisor. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Pursuant to section 3A.3 of National Instrument <font style=\"white-space:nowrap\">33-105</font> Underwriting Conflicts (NI\n<font style=\"white-space:nowrap\">33-105),</font> the underwriters are not required to comply with the disclosure requirements of NI <font style=\"white-space:nowrap\">33-105</font> regarding underwriter conflicts of interest in connection with this\noffering. </p> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors in Switzerland </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The\nshares of common stock may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (\u0093SIX\u0094) or on any other stock exchange or regulated trading facility in Switzerland. This document does not constitute a\nprospectus within the meaning of, and has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under\nart. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the shares of common stock or the\noffering may be publicly distributed or otherwise made publicly available in Switzerland. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Neither this document nor any other offering or marketing material\nrelating to the offering, the Company, the shares of common stock have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares of common stock will not be\nsupervised by, the Swiss Financial Market Supervisory Authority FINMA (FINMA), and the offer of shares of common stock has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (\u0093CISA\u0094). The\ninvestor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares of common stock. </p>\n<p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors in the Dubai International Financial Centre (\u0093DIFC\u0094) </i></b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">This document relates to an Exempt Offer in accordance with the Markets Rules 2012 of the Dubai Financial Services Authority (\u0093DFSA\u0094). This document is\nintended for distribution only to persons of a type specified in the Markets Rules 2012 of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any documents in\nconnection with Exempt Offers. The DFSA has not approved this prospectus supplement nor taken steps to verify the information set forth herein and has no responsibility for this document. The securities to which this document relates may be illiquid\nand/or subject to restrictions on their resale. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand the contents of this document you should consult an authorized\nfinancial advisor. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In relation to its use in the DIFC, this document is strictly private and confidential and is being distributed to a limited number of investors\nand must not be provided to any person other than the original recipient, and may not be reproduced or used for any other purpose. The interests in the securities may not be offered or sold directly or indirectly to the public in the DIFC. </p>\n<p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors in the United Arab Emirates </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The\nshares of common stock have not been, and are not being, publicly offered, sold, promoted or advertised in the United Arab Emirates (including the Dubai International Financial Centre) other than in compliance with the laws of the United Arab\nEmirates (and the Dubai International Financial Centre) governing the issue, offering </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-26 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">\nand sale of securities. Further, this prospectus does not constitute a public offer of securities in the United Arab Emirates (including the Dubai International Financial Centre) and is not\nintended to be a public offer. This prospectus has not been approved by or filed with the Central Bank of the United Arab Emirates, the Securities and Commodities Authority or the Dubai Financial Services Authority. </p>\n<p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors in Australia </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">This prospectus\nsupplement: </p> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">does not constitute a product disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001 (Cth) (the \u0093Corporations Act\u0094); </td></tr></table>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">has not been, and will not be, lodged with the Australian Securities and Investments Commission (\u0093ASIC\u0094), as a disclosure document for the purposes of the Corporations Act and does not purport to include the\ninformation required of a disclosure document under Chapter 6D.2 of the Corporations Act; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">does not constitute or involve a recommendation to acquire, an offer or\u00a0invitation for issue or sale, an offer or invitation to arrange the issue or sale, or an issue or sale, of interests to a \u0093retail\nclient\u0094 (as defined in section 761G of the Corporations Act and applicable regulations) in Australia; and </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">may only be provided in Australia to select investors who are able to demonstrate that they fall within one or more of the categories of investors (\u0093Exempt Investors\u0094) available under section 708 of the\nCorporations Act. </td></tr></table> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The shares of common stock may not be directly or indirectly offered for subscription or purchased or sold, and no invitations to\nsubscribe for or buy the shares of common stock may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to any shares of common stock may be distributed in Australia, except where disclosure\nto investors is not required under Chapter 6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the shares of common stock, you represent and warrant to us\nthat you are an Exempt Investor. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">As any offer of shares of common stock under this document will be made without disclosure in Australia under Chapter 6D.2 of the\nCorporations Act, the offer of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under Chapter 6D.2 if none of the exemptions in section 708 applies to that\nresale. By applying for the shares of common stock you undertake to us that you will not, for a period of 12 months from the date of issue of the shares of common stock, offer, transfer, assign or otherwise alienate those securities to investors in\nAustralia except in circumstances where disclosure to investors is not required under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC. </p>\n<p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors in Japan </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The shares of common stock\nhave not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Act. Accordingly, none of the shares of common stock nor any interest therein may be offered or sold, directly or indirectly, in\nJapan or to, or for the benefit of, any \u0093resident\u0094 of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for <font style=\"white-space:nowrap\">re-offering</font> or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the\nFinancial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant time. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-27 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors in Hong Kong </i></b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The shares of common stock have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)\u00a0to\n\u0093professional investors\u0094 as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b)\u00a0in other circumstances which do not result in the document being a\n\u0093prospectus\u0094 as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or\ndocument relating to the shares of common stock has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely\nto be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares of common stock which are or are intended to be disposed of only to persons outside Hong Kong\nor only to \u0093professional investors\u0094 as defined in the Securities and Futures Ordinance and any rules made under that Ordinance. </p> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Warning\n</i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer.\nIf you are in any doubt about any of the contents of this document, you should obtain independent professional advice.\u0094 </p> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors\nin Singapore </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other\ndocument or material in connection with the offer or sale, or invitation for subscription or purchase, of shares of common stock may not be circulated or distributed, nor may the shares of common stock be offered or sold, or be made the subject of\nan invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)\u00a0to an institutional investor under Section\u00a0274 of the Securities and Futures Act, Chapter 289 of Singapore (the\n\u0093SFA\u0094), (ii) to a relevant person pursuant to Section\u00a0275(1), or any person pursuant to Section\u00a0275(1A), and in accordance with the conditions specified in Section\u00a0275 of the SFA, or (iii)\u00a0otherwise pursuant to, and in\naccordance with the conditions of, any other applicable provision of the SFA. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Where the shares of common stock are subscribed or purchased under Section\u00a0275 of\nthe SFA by a relevant person which is: </p> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">a)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">a corporation (which is not an accredited investor (as defined in Section\u00a04A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals,\neach of whom is an accredited investor; or </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">b)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, </td></tr></table>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">securities (as defined in Section\u00a0239(1) of the SFA) of that corporation or the beneficiaries\u0092 rights and interest (howsoever described) in that trust shall\nnot be transferred within six months after that corporation or that trust has acquired the shares of common stock pursuant to an offer made under Section\u00a0275 of the SFA except: </p>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">a)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">to an institutional investor or to a relevant person defined in Section\u00a0275(2) of the SFA, or to any person arising from an offer referred to in Section\u00a0275(1A) or Section\u00a0276(4)(i)(B) of the SFA;\n</td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">b)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">where no consideration is or will be given for the transfer; </td></tr></table>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-28 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">c)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">where the transfer is by operation of law; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">d)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">as specified in Section\u00a0276(7) of the SFA; or </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">e)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore </td></tr></table>\n<p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors in Bermuda </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Shares of common stock may\nbe offered or sold in Bermuda only in compliance with the provisions of the Investment Business Act of 2003 of Bermuda which regulates the sale of securities in Bermuda. Additionally, <font style=\"white-space:nowrap\">non-Bermudian</font> persons\n(including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are permitted to do so under applicable Bermuda legislation. </p>\n<p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors in Saudi Arabia </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">This document may not\nbe distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Offers of Securities Regulations as issued by the board of the Saudi Arabian Capital Market Authority (\u0093CMA\u0094) pursuant to resolution number <font style=\"white-space:nowrap\"><font style=\"white-space:nowrap\">2-11-2004</font></font> dated 4\u00a0October 2004 as amended by resolution number <font style=\"white-space:nowrap\"><font style=\"white-space:nowrap\">1-28-2008,</font></font> as amended (the\n\u0093CMA Regulations\u0094). The CMA does not make any representation as to the accuracy or completeness of this document and expressly disclaims any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this\ndocument. Prospective purchasers of the securities offered hereby should conduct their own due diligence on the accuracy of the information relating to the securities. If you do not understand the contents of this document, you should consult an\nauthorised financial adviser. </p> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors in the British Virgin Islands </i></b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The shares of common stock are not being, and may not be offered to the public or to any person in the British Virgin Islands for purchase or subscription by or on\nbehalf of the Company. The shares of common stock may be offered to companies incorporated under the BVI Business Companies Act, 2004 (British Virgin Islands), \u0093BVI Companies\u0094), but only where the offer will be made to, and received by,\nthe relevant BVI Company entirely outside of the British Virgin Islands. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">This prospectus supplement has not been, and will not be, registered with the Financial\nServices Commission of the British Virgin Islands. No registered prospectus has been or will be prepared in respect of the shares of common stock for the purposes of the Securities and Investment Business Act, 2010 (\u0093SIBA\u0094) or the Public\nIssuers Code of the British Virgin Islands. </p> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors in China </i></b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">This prospectus supplement does not constitute a public offer of shares of common stock, whether by sale or subscription, in the People\u0092s Republic of China (the\n\u0093PRC\u0094). The shares of common stock are not being offered or sold directly or indirectly in the PRC to or for the benefit of, legal or natural persons of the PRC. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Further, no legal or natural persons of the PRC may directly or indirectly purchase any of the shares of common stock or any beneficial interest therein without\nobtaining all prior PRC\u0092s governmental approvals that are required, whether statutorily or otherwise. Persons who come into possession of this document are required by the issuer and its representatives to observe these restrictions. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-29 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors in Korea </i></b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The shares of common stock have not been and will not be registered under the Financial Investments Services and Capital Markets Act of Korea and the decrees and\nregulations thereunder (the \u0093FSCMA\u0094), and the shares of common stock have been and will be offered in Korea as a private placement under the FSCMA. None of the shares of common stock may be offered, sold or delivered directly or\nindirectly, or offered or sold to any person for <font style=\"white-space:nowrap\">re-offering</font> or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to the applicable laws and regulations of Korea, including\nthe FSCMA and the Foreign Exchange Transaction Law of Korea and the decrees and regulations thereunder (the \u0093FETL\u0094). Furthermore, the purchaser of the shares of common stock shall comply with all applicable regulatory requirements\n(including but not limited to requirements under the FETL) in connection with the purchase of the shares of common stock. By the purchase of the shares of common stock, the relevant holder thereof will be deemed to represent and warrant that if it\nis in Korea or is a resident of Korea, it purchased the shares of common stock pursuant to the applicable laws and regulations of Korea. </p> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to\nprospective investors in Malaysia </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">No prospectus or other offering material or document in connection with the offer and sale of the shares of common stock\nhas been or will be registered with the Securities Commission of Malaysia (\u0093Commission\u0094) for the Commission\u0092s approval pursuant to the Capital Markets and Services Act 2007. Accordingly, this prospectus supplement and any other\ndocument or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares of common stock may not be circulated or distributed, nor may the shares of common stock be offered or sold, or be made the subject\nof an invitation for subscription or purchase, whether directly or indirectly, to persons in Malaysia other than (i)\u00a0a closed end fund approved by the Commission; (ii)\u00a0a holder of a Capital Markets Services Licence; (iii)\u00a0a person who\nacquires the shares of common stock, as principal, if the offer is on terms that the shares of common stock may only be acquired at a consideration of not less than RM250,000 (or its equivalent in foreign currencies) for each transaction;\n(iv)\u00a0an individual whose total net personal assets or total net joint assets with his or her spouse exceeds RM3\u00a0million (or its equivalent in foreign currencies), excluding the value of the primary residence of the individual; (v)\u00a0an\nindividual who has a gross annual income exceeding RM300,000 (or its equivalent in foreign currencies) per annum in the preceding twelve months; (vi)\u00a0an individual who, jointly with his or her spouse, has a gross annual income of RM400,000 (or\nits equivalent in foreign currencies), per annum in the preceding twelve months; (vii)\u00a0a corporation with total net assets exceeding RM10\u00a0million (or its equivalent in a foreign currencies) based on the last audited accounts; (viii)\u00a0a\npartnership with total net assets exceeding RM10\u00a0million (or its equivalent in foreign currencies); (ix) a bank licensee or insurance licensee as defined in the Labuan Financial Services and Securities Act 2010; (x) an Islamic bank licensee or\ntakaful licensee as defined in the Labuan Financial Services and Securities Act 2010; and (xi)\u00a0any other person as may be specified by the Commission; provided that, in the each of the preceding categories (i)\u00a0to (xi), the distribution of\nthe shares of common stock is made by a holder of a Capital Markets Services Licence who carries on the business of dealing in securities. The distribution in Malaysia of this prospectus supplement is subject to Malaysian laws. This prospectus\nsupplement does not constitute and may not be used for the purpose of public offering or an issue, offer for subscription or purchase, invitation to subscribe for or purchase any securities requiring the registration of a prospectus with the\nCommission under the Capital Markets and Services Act 2007. </p> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors in Taiwan </i></b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The shares of common stock have not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities laws and\nregulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which constitutes an offer within the </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-30 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">\nmeaning of the Securities and Exchange Act of Taiwan that requires a registration or approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorised\nto offer, sell, give advice regarding or otherwise intermediate the offering and sale of the shares of common stock in Taiwan. </p> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective\ninvestors in South Africa </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Due to restrictions under the securities laws of South Africa, the shares of common stock are not offered, and the offer shall not\nbe transferred, sold, renounced or delivered, in South Africa or to a person with an address in South Africa, unless one or other of the following exemptions applies: </p> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">i</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the offer, transfer, sale, renunciation or delivery is to: </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"4%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"3%\">(a)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">persons whose ordinary business is to deal in securities, as principal or agent; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"4%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"3%\">(b)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the South African Public Investment Corporation; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"4%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"3%\">(c)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">persons or entities regulated by the Reserve Bank of South Africa; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"4%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"3%\">(d)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">authorised financial service providers under South African law; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"4%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"3%\">(e)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">financial institutions recognised as such under South African law; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"4%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"3%\">(f)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">a wholly-owned subsidiary of any person or entity contemplated in (c), (d) or (e), acting as agent in the capacity of an authorised portfolio manager for a pension fund or collective investment scheme (in each case duly\nregistered as such under South African law); or </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"4%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"3%\">(g)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any combination of the person in (a)\u00a0to (f); or </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">ii</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the total contemplated acquisition cost of the securities, for any single addressee acting as principal is equal to or greater than ZAR1,000,000. </td></tr></table>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">No \u0093offer to the public\u0094 (as such term is defined in the South African Companies Act, No.\u00a071 of 2008 (as amended or\n<font style=\"white-space:nowrap\">re-enacted)</font> (the \u0093South African Companies Act\u0094)) in South Africa is being made in connection with the issue of the shares of common stock. Accordingly, this document does not, nor is it intended to,\nconstitute a \u0093registered prospectus\u0094 (as that term is defined in the South African Companies Act) prepared and registered under the South African Companies Act and has not been approved by, and/or filed with, the South African Companies\nand Intellectual Property Commission or any other regulatory authority in South Africa. Any issue or offering of the shares of common stock in South Africa constitutes an offer of the shares of common stock in South Africa for subscription or sale\nin South Africa only to persons who fall within the exemption from \u0093offers to the public\u0094 set out in section 96(1)(a) of the South African Companies Act. Accordingly, this document must not be acted on or relied on by persons in South\nAfrica who do not fall within section 96(1)(a) of the South African Companies Act (such persons being referred to as \u0093SA Relevant Persons\u0094). Any investment or investment activity to which this document relates is available in South Africa\nonly to SA Relevant Persons and will be engaged in South Africa only with SA relevant persons. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">No South African residents or offshore subsidiary of a South African\nresident may subscribe for or purchase any of the shares of common stock or beneficially own or hold any of the shares of common stock unless specific approval has been obtained from the financial surveillance department of the South African Reserve\nBank (the \u0093SARB\u0094) by such persons or such subscription, purchase or beneficial holding or ownership is otherwise permitted under the South African Exchange Control Regulations or the rulings promulgated thereunder (including, without\nlimitation, the rulings issued by the SARB providing for foreign investment allowances applicable to persons who are residents of South Africa under the applicable exchange control laws of South Africa). </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-31 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial\"><b><a name=\"supptoc579741_10\"></a>Legal matters </b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Certain legal matters in connection with this offering will be passed upon for us by Goodwin Procter LLP, San Francisco, California. The underwriters are being\nrepresented in connection with this offering by Latham\u00a0&amp; Watkins LLP, Menlo Park, California. </p> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:16pt; font-family:arial\"><b><a name=\"supptoc579741_11\"></a>Experts </b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The financial statements incorporated in this Prospectus by reference to the Annual Report on Form <font style=\"white-space:nowrap\">10-K</font> for the year ended\nDecember\u00a031, 2017 have been so incorporated in reliance on the report of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </p>\n<p style=\"margin-top:16pt; margin-bottom:0pt; font-size:16pt; font-family:arial\"><b><a name=\"supptoc579741_12\"></a>Where you can find more information; incorporation by reference </b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial\"><b>Available information </b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We file annual, quarterly and current reports, proxy\nstatements and other information with the SEC. Information filed with the SEC by us can be inspected and copied at the Public Reference Room maintained by the SEC at 100 F Street, N.E., Washington, D.C. 20549. You may also obtain copies of this\ninformation by mail from the Public Reference Room of the SEC at prescribed rates. Further information on the operation of the SEC\u0092s Public Reference Room in Washington, D.C. can be obtained by calling the SEC at\n<font style=\"white-space:nowrap\"><font style=\"white-space:nowrap\"><font style=\"white-space:nowrap\">1-800-SEC-0330.</font></font></font> The SEC also maintains a web site that contains reports, proxy and information statements and other information\nabout issuers, such as us, who file electronically with the SEC. The address of that website is <i>http://www.sec.gov</i>. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Our web site address is\n<i>www.myokardia.com</i>. The information on our web site, however, is not, and should not be deemed to be, a part of this prospectus supplement or the accompanying prospectus. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">This prospectus supplement is part of an automatic registration statement on Form <font style=\"white-space:nowrap\">S-3</font> that we filed with the SEC and does not\ncontain all of the information in the registration statement. The full registration statement may be obtained from the SEC or us, as provided above. Forms of indenture and other documents establishing the terms of the offered securities are or may\nbe filed as exhibits to the registration statement. Statements in this prospectus supplement about these documents are summaries and each statement is qualified in all respects by reference to the document to which it refers. You should refer to the\nactual documents for a more complete description of the relevant matters. You may inspect a copy of the registration statement at the SEC\u0092s Public Reference Room in Washington, D.C. or through the SEC\u0092s website, as provided above. </p>\n<p style=\"margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial\"><b>Incorporation by reference </b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The SEC\u0092s rules allow us to incorporate by\nreference information into this prospectus supplement, which means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is deemed to be part\nof this prospectus supplement and the accompanying prospectus, and subsequent information that we file with the SEC will automatically update and supersede that information. Any statement contained in a previously filed document incorporated by\nreference will be deemed to be modified or superseded for purposes of this prospectus supplement to the extent that a statement contained in this prospectus supplement modifies or replaces that statement. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We incorporate by reference our documents listed below and any future filings made by us with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act,\nbetween the date of this prospectus supplement and the </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-32 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">\ntermination of the offering of the securities described in this prospectus supplement. We are not, however, incorporating by reference any documents or portions thereof, whether specifically\nlisted below or filed in the future, that are not deemed \u0093filed\u0094 with the SEC, including any information furnished pursuant to Items 2.02 or 7.01 of Form <font style=\"white-space:nowrap\">8-K</font> or related exhibits furnished pursuant to\nItem 9.01 of <font style=\"white-space:nowrap\">Form\u00a08-K.</font> </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">This prospectus supplement and the accompanying prospectus incorporate by reference the\ndocuments set forth below that have previously been filed with the SEC: </p> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">Annual Report on Form <font style=\"white-space:nowrap\">10-K</font> for the year ended December\u00a031, 2017, filed with the SEC on March\u00a08, 2018; </td></tr></table>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">Quarterly Report on Form <font style=\"white-space:nowrap\">10-Q</font> for the quarter ended March\u00a031, 2018, filed with the SEC on May\u00a08, 2018; </td></tr></table>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">The information specifically incorporated by reference into our Annual Report on Form <font style=\"white-space:nowrap\">10-K</font> for the year ended December\u00a031, 2017 from our definitive proxy statement on\nSchedule 14A (other than information furnished rather than filed), which was filed with the SEC on April\u00a017, 2018; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">Current Reports on Form <font style=\"white-space:nowrap\">8-K</font> filed with the SEC on March\u00a05, 2018, March\u00a08, 2018 <font style=\"white-space:nowrap\">(Acc-no:</font> <font style=\"white-space:nowrap\"><font style=\"white-space:nowrap\">0001193125-18-075156)</font></font> (as to Item 8.01 only),\u00a0April\u00a04, 2018 (as to Item 5.02 only), and May\u00a021, 2018; and </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">The description of our common stock contained in our registration statement on Form <font style=\"white-space:nowrap\">8-A</font> filed with the SEC on October\u00a027, 2015 under Section\u00a012(b) of the Exchange Act,\nincluding any amendments or reports filed for the purpose of updating such description. </td></tr></table> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Upon request, we will provide, without charge, to each person,\nincluding any beneficial owner, to whom a copy of this prospectus supplement is delivered, a copy of the documents incorporated by reference into this prospectus supplement and the accompanying prospectus but not delivered with the prospectus. You\nmay request a copy of these filings, and any exhibits we have specifically incorporated by reference as an exhibit in this prospectus supplement, at no cost by writing or telephoning us at the following address: 333 Allerton Ave., South San\nFrancisco, CA 94080; telephone: <font style=\"white-space:nowrap\">(650)\u00a0741-0900.</font> </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">You may also access these documents free of charge on the SEC\u0092s\nwebsite at <i>www.sec.gov</i> or on our website at <i>www.myokardia.com</i>. Information contained on our website is not incorporated by reference into this prospectus supplement or the accompanying prospectus, and you should not consider any\ninformation on, or that can be accessed from, our website as part of this prospectus supplement or the accompanying prospectus. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">This prospectus supplement and the\naccompanying prospectus are part of an automatic registration statement we filed with the SEC. We have incorporated exhibits into the registration statement. You should read the exhibits carefully for provisions that may be important to you. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">You should rely only on the information incorporated by reference or provided in this prospectus supplement and the accompanying prospectus. We have not authorized\nanyone to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus supplement, the accompanying prospectus or\nin the documents incorporated by reference is accurate as of any date other than the date on the front of this prospectus supplement or those documents. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-33 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>PROSPECTUS </b></p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<p align=\"center\" style=\"margin-top:0pt;margin-bottom:0pt\">\n<img alt=\"LOGO\" src=\"g579741g95t12.jpg\"/>\n</p> <p align=\"center\" style=\"margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman\"><b>Common Stock </b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman\"><b>Preferred Stock </b></p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman\"><b>Debt\nSecurities </b></p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman\"><b>Warrants </b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman\"><b>Units </b></p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p><center>\n<p style=\"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%\">\u00a0</p></center> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We may from time to time issue,\nin one or more series or classes, our common stock, preferred stock, debt securities, warrants and/or units. We may offer these securities separately or together in units. We will specify in the accompanying prospectus supplement the terms of the\nsecurities being offered. We may sell these securities to or through underwriters and also to other purchasers or through agents. We will set forth the names of any underwriters or agents, and any fees, conversions or discount arrangements, in the\naccompanying prospectus supplement. We may not sell any securities under this prospectus without delivery of the applicable prospectus supplement. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">You\nshould read this document and any prospectus supplement or amendment carefully before you invest in our securities. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Our common stock is listed on The\nNASDAQ Global Select Market under the symbol \u0093MYOK.\u0094 On March 6, 2018, the closing price for our common stock, as reported on The NASDAQ Global Select Market, was $57.95 per share. Our principal executive office is located at 333 Allerton\nAve., South San Francisco, California 94080. </p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p><center>\n<p style=\"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%\">\u00a0</p></center> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman\"><b>Investing in our securities\ninvolves a high degree of risk. You should review carefully the risks and uncertainties referenced under the heading \u0093<a Factors</a>\u0094 contained in this prospectus beginning on page 2\u00a0and any applicable\nprospectus supplement, and under similar headings in the other documents that are incorporated by reference into this prospectus. </b></p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman\"><b>This prospectus\nmay not be used to offer or sell securities unless accompanied by a prospectus supplement. </b></p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman\"><b>Neither the Securities and Exchange Commission nor any\nstate securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </b></p>\n<p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p><center> <p style=\"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%\">\u00a0</p></center>\n<p align=\"center\" style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>The date of this Prospectus is March 8, 2018. </b></p> <p style=\"font-size:50pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<p style=\"font-size:100pt; margin-top:0pt; margin-bottom:0pt\">\u00a0</p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>TABLE OF CONTENTS </b></p>\n<p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr>\n<td width=\"95%\"></td>\n<td valign=\"bottom\" width=\"3%\"></td>\n<td></td>\n<td></td>\n<td></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\">\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td align=\"center\" colspan=\"2\" style=\"border-bottom:1.00pt solid #000000\" valign=\"bottom\"><b>Page</b></td>\n<td valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a this Prospectus </a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">1</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a Factors</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">2</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a Statement Regarding Forward-Looking Statements</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">3</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a Company</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">5</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a of Earnings to Fixed Charges</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">6</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a of Proceeds</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">6</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a We May\u00a0Offer</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">7</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a of Capital Stock</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">7</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a of Debt Securities</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">13</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a of Warrants</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">20</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a of Units</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">21</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a of Distribution</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">24</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a Matters</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">27</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">27</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a You Can Find More Information</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">27</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a by Reference</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">27</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n</table>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">i </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_1\"></a>ABOUT THIS PROSPECTUS </b></p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">This prospectus is part of an automatic registration statement that we filed with the Securities and Exchange Commission, or the SEC, using a\n\u0093shelf\u0094 registration process as a \u0093well-known seasoned issuer\u0094 as defined in Rule 405 under the Securities Act of 1933, as amended, or the Securities Act. Under this shelf registration process, we may from time to time sell any\ncombination of the securities described in this prospectus in one or more offerings. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">This prospectus provides you with a general description of the\nsecurities we may offer. Each time we sell securities, we will provide one or more prospectus supplements that will contain specific information about the terms of the offering. The prospectus supplement may also add, update or change information\ncontained in this prospectus. You should read both this prospectus and the accompanying prospectus supplement together with the additional information described under the heading \u0093Where You Can Find More Information\u0094 beginning on\npage\u00a027 of this prospectus. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">You should rely only on the information contained in or incorporated by reference in this prospectus, any accompanying\nprospectus supplement or in any related free writing prospectus filed by us with the SEC. We have not authorized anyone to provide you with different information. This prospectus and the accompanying prospectus supplement do not constitute an offer\nto sell or the solicitation of an offer to buy any securities other than the securities described in the accompanying prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such\noffer or solicitation is unlawful. You should assume that the information appearing in this prospectus, any prospectus supplement, the documents incorporated by reference and any related free writing prospectus is accurate only as of their\nrespective dates. Our business, financial condition, results of operations and prospects may have changed materially since those dates. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><i>Unless the\ncontext suggests otherwise, all references to \u0093us,\u0094 \u0093our,\u0094 \u0093MyoKardia,\u0094 \u0093we,\u0094 the \u0093Company\u0094 and similar designations refer to MyoKardia, Inc. and, where appropriate, our subsidiary. </i></p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">1 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_2\"></a>RISK FACTORS </b></p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Investing in our securities involves a high degree of risk. You should carefully consider the risks referenced below and described in the documents\nincorporated by reference in this prospectus and any prospectus supplement, as well as other information we include or incorporate by reference into this prospectus and any applicable prospectus supplement, before making an investment decision. Our\nbusiness, financial condition or results of operations could be materially adversely affected by the materialization of any of these risks. The trading price of our securities could decline due to the materialization of any of these risks, and you\nmay lose all or part of your investment. This prospectus and the documents incorporated herein by reference also contain forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those anticipated\nin these forward-looking statements as a result of certain factors, including the risks referenced below and described in the documents incorporated herein by reference, including (i)\u00a0our annual report on\n<font style=\"white-space:nowrap\">Form\u00a010-K</font> for the fiscal year ended December\u00a031, 2017, which is on file with the SEC and is incorporated herein by reference, and (ii)\u00a0other documents we file with the SEC that are deemed\nincorporated by reference into this prospectus. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">2 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_3\"></a>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </b></p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">This prospectus, including the documents that we incorporate by reference, contains forward-looking statements within the meaning of Section\u00a027A of the\nSecurities Act of 1933, as amended, or the Securities Act, and Section\u00a021E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Any statements about our expectations, beliefs, plans, objectives, assumptions or future events\nor performance are not historical facts and may be forward-looking. These statements are often, but are not always, made through the use of words or phrases such as \u0093may,\u0094 \u0093will,\u0094 \u0093could,\u0094 \u0093should,\u0094\n\u0093expects,\u0094 \u0093intends,\u0094 \u0093plans,\u0094 \u0093anticipates,\u0094 \u0093believes,\u0094 \u0093estimates,\u0094 \u0093predicts,\u0094 \u0093projects,\u0094 \u0093potential,\u0094 \u0093continue,\u0094 and similar expressions, or\nthe negative of these terms, or similar expressions. Accordingly, these statements involve estimates, assumptions, risks and uncertainties which could cause actual results to differ materially from those expressed in them. Any forward-looking\nstatements are qualified in their entirety by reference to the factors discussed throughout this prospectus and any accompanying prospectus supplement or the documents incorporated by reference herein, and in particular those factors referenced in\nthe section \u0093Risk Factors.\u0094 </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">This prospectus contains forward-looking statements that are based on our management\u0092s belief and assumptions\nand on information currently available to our management. These statements relate to future events or our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of\nactivity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not\nlimited to, statements about: </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the timing and success of, and our ability to generate positive data from, our planned pivotal Phase 3 clinical trial, EXPLORER\u0096HCM, of mavacamten (formerly known as <font style=\"white-space:nowrap\">MYK-461)</font>\nin symptomatic, obstructive HCM (oHCM) patients, our planned Phase 2 clinical trial, MAVERICK\u0096HCM, of mavacamten in symptomatic <font style=\"white-space:nowrap\">non-obstructive</font> HCM (nHCM) patients, our Phase 2 clinical trial,\nPIONEER\u0096HCM, of mavacamten in symptomatic, obstructive HCM patients, our Phase 1 clinical trials of <font style=\"white-space:nowrap\">MYK-491</font> in healthy volunteers and our Phase 1b clinical trial of\n<font style=\"white-space:nowrap\">MYK-491</font> in DCM patients; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">our ability to enroll patients in our clinical trials at the pace that we project; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">our ability to execute our clinical development plans and obtain regulatory approval for any of our product candidates without the need for large, outcome-based studies; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">our ability to identify and advance through clinical development any additional product candidates from our precision medicine platform, including from our <font style=\"white-space:nowrap\">HCM-2,</font> <font style=\"white-space:nowrap\">DCM-2</font> and <font style=\"white-space:nowrap\">LUS-1</font> programs; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">our ability to successfully maintain our strategic collaboration with Sanofi; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">our ability to obtain and maintain intellectual property protection for our precision medicine platform and our product candidates; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">our ability to successfully build a specialty sales force and commercial infrastructure to market mavacamten and any other product candidates from our programs, if approved, in the United States and any product\ncandidates from our other programs worldwide; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">our ability to compete with companies currently producing or engaged in the clinical development of treatments for the disease indications that we pursue; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">our reliance on third parties to conduct our clinical trials and to manufacture drug substance for use in our clinical trials; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">our ability to retain and recruit key personnel; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">our expectations regarding government and third-party payor coverage and reimbursement; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">our estimates of our expenses, ongoing losses, capital requirements, future revenue and our needs for or ability to obtain additional financing; </td></tr></table>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">3 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">our expectations regarding the time during which we will be an emerging growth company under the JOBS Act; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">our financial performance; and </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">developments and projections relating to our competitors or our industry. </td></tr></table> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">These forward-looking statements\nare neither promises nor guarantees of future performance due to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those indicated by these forward-looking\nstatements, including, without limitation the risk factors and cautionary statements described in other documents that we file from time to time with the SEC, specifically under \u0093Item 1A: Risk Factors\u0094 and elsewhere in our most recent\nAnnual Report on Form <font style=\"white-space:nowrap\">10-K</font> for the period ended December\u00a031, 2017, and our Current Reports on Form <font style=\"white-space:nowrap\">8-K</font> to the extent incorporated by reference in this prospectus,\nand the section of any accompanying prospectus supplement entitled \u0093Risk Factors.\u0094 </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The forward-looking statements in this prospectus and the\ndocuments incorporated by reference represent our views as of their respective dates. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at\nsome point in the future, we assume no obligation to update or revise any forward-looking statements except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of\nany date subsequent to the dates on which they were made. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">This prospectus and the documents incorporated by reference also contain estimates, projections\nand other information concerning our industry, our business, and the markets for certain diseases, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is\nbased on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless\notherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications,\ngovernment data and similar sources. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">4 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_4\"></a>THE COMPANY </b></p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We are a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the\ntreatment of serious and neglected rare cardiovascular diseases. Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle\ncontraction. We have used our precision medicine platform to generate a robust pipeline of therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy\u0097hypertrophic cardiomyopathy, or HCM, and dilated\ncardiomyopathy, or DCM. Our lead candidate, mavacamten, is initially being developed for the treatment of symptomatic oHCM. In a Phase 2 clinical trial, known as <font style=\"white-space:nowrap\">PIONEER-HCM,</font> mavacamten achieved statistically\nsignificant changes in the primary endpoint of post-exercise left ventricular outflow tract (LVOT) gradient from baseline and demonstrated improvements across key secondary endpoints including New York Heart Association classification, exercise\ncapacity as measured by peak oxygen consumption, or peak VO2, and change in dyspnea scores. In the first half of 2018, we plan to initiate three additional studies of mavacamten\u0097a pivotal Phase 3 clinical trial of oHCM patients known as <font style=\"white-space:nowrap\">EXPLORER-HCM;</font> a long-term extension trial of oHCM patients from our Phase 2 trial; and a Phase 2 clinical trial in a second potential indication for mavacamten, symptomatic,\n<font style=\"white-space:nowrap\">non-obstructive</font> HCM known as <font style=\"white-space:nowrap\">MAVERICK-HCM.</font> In 2016, mavacamten was granted Orphan Drug Designation by the U.S. Food and Drug Administration, or the FDA, for the\ntreatment of symptomatic oHCM. A second product candidate, <font style=\"white-space:nowrap\">MYK-491,</font> for the treatment of DCM, has completed its <font style=\"white-space:nowrap\"><font style=\"white-space:nowrap\">first-in-human</font></font>\nPhase 1 in healthy volunteers and we are currently enrolling patients in a Phase 1b clinical trial. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We have never been profitable and have incurred net\nlosses in each year since inception.\u00a0Our net loss for the years ended December\u00a031, 2017 and 2016 was $46.0\u00a0million and $13.2\u00a0million, respectively. As of December\u00a031, 2017, we had an accumulated deficit of\n$123.8\u00a0million. To date, we have not generated any product revenue. We do not expect to receive any revenue from any product candidates that we develop until we obtain regulatory approval and commercialize our products or enter into\ncollaborative agreements with third parties. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. As\nof December\u00a031, 2017, we had $276.4\u00a0million of cash and cash equivalents. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We qualify as an \u0093emerging growth company\u0094 as defined in\nthe Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. We\nwould cease to be an emerging growth company on the date that is the earliest of: (i)\u00a0the last day of the fiscal year in which we have total annual gross revenues of $1.07\u00a0billion or more; (ii)\u00a0December\u00a031, 2020; (iii)\u00a0the\ndate on which we have issued more than $1\u00a0billion in nonconvertible debt during the previous three years; or (iv)\u00a0the date on which we are deemed to be a large accelerated filer under the rules of the SEC. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We were incorporated in Delaware in June 2012. Our principal executive offices are located at 333 Allerton Ave., South San Francisco, California 94080. Our\ntelephone number is <font style=\"white-space:nowrap\">(650)\u00a0741-0900</font> and our <font style=\"white-space:nowrap\">e-mail</font> address is info@myokardia.com. Our Internet website address is <i>www.myokardia.com</i>. No portion of our website\nis incorporated by reference into this prospectus. We do not incorporate the information on or accessible through our website into this prospectus, and you should not consider any information on, or that can be accessed through, our website as part\nof this prospectus. Our common stock trades on The NASDAQ Global Select Market under the symbol \u0093MYOK\u0094. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We use various trademarks and trade\nnames in our business, including without limitation our corporate name and logo. All other trademarks or trade names referred to in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names\nin this prospectus may be referred to without the <sup style=\"font-size:85%; vertical-align:top\">\u00ae</sup> and \u0099 symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the\nfullest extent under applicable law, their rights thereto. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">5 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_5\"></a>RATIO OF EARNINGS TO FIXED CHARGES </b></p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The following table sets forth our ratio of earnings to fixed charges for the periods shown. You should read this table in conjunction with the financial\nstatements and notes incorporated by reference in this prospectus. We paid no dividends on preferred shares during the periods indicated. Therefore, the ratios of earnings to combined fixed charges and preferred dividends are the same as the ratios\nof earnings to fixed charges presented below. </p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt\" width=\"100%\">\n<tr>\n<td width=\"80%\"></td>\n<td valign=\"bottom\" width=\"3%\"></td>\n<td></td>\n<td></td>\n<td></td>\n<td valign=\"bottom\" width=\"3%\"></td>\n<td></td>\n<td></td>\n<td></td>\n<td valign=\"bottom\" width=\"3%\"></td>\n<td></td>\n<td></td>\n<td></td>\n<td valign=\"bottom\" width=\"3%\"></td>\n<td></td>\n<td></td>\n<td></td>\n<td valign=\"bottom\" width=\"3%\"></td>\n<td></td>\n<td></td>\n<td></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\">\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td align=\"center\" colspan=\"18\" style=\"border-bottom:1.00pt solid #000000\" valign=\"bottom\"><b>Years\u00a0Ended\u00a0December\u00a031,</b></td>\n<td valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\">\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td align=\"center\" colspan=\"2\" style=\"border-bottom:1.00pt solid #000000\" valign=\"bottom\"><b>2017</b></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td align=\"center\" colspan=\"2\" style=\"border-bottom:1.00pt solid #000000\" valign=\"bottom\"><b>2016</b></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td align=\"center\" colspan=\"2\" style=\"border-bottom:1.00pt solid #000000\" valign=\"bottom\"><b>2015</b></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td align=\"center\" colspan=\"2\" style=\"border-bottom:1.00pt solid #000000\" valign=\"bottom\"><b>2014</b></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td align=\"center\" colspan=\"2\" style=\"border-bottom:1.00pt solid #000000\" valign=\"bottom\"><b>2013</b></td>\n<td valign=\"bottom\">\u00a0</td></tr>\n<tr bgcolor=\"#cceeff\" style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><b>Ratio of Earnings to Fixed Charges</b></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">N/A</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">N/A</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">N/A</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">N/A</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">N/A</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n</table> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">For purposes of calculating the ratios in the table above, earnings consist of net loss before income taxes. Fixed charges\ninclude any interest expense on indebtedness and an estimate of the interest expense within rental expense. We had no indebtedness for any of the periods presented. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Due to our net losses for the years ended December\u00a031, 2017, 2016, 2015, 2014 and 2013, earnings were insufficient to cover fixed charges for such\nperiods and we are unable to disclose a ratio of earnings to fixed charges for such periods. The dollar amount of the deficiency in earnings available for fixed charges for the years ended December\u00a031, 2017, 2016, 2015, 2014 and 2013 was\napproximately $46.0 million, $13.2 million, 22.9\u00a0million, $16.8\u00a0million, and $12.7\u00a0\nmillion, respectively. </p> <p align=\"center\" style=\"margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_6\"></a>USE OF PROCEEDS </b></p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We intend to use the net proceeds from the sale of any securities offered under this prospectus for general corporate purposes unless otherwise indicated in\nthe applicable prospectus supplement. General corporate purposes may include research and development and clinical development costs to support the advancement of our product candidates and the expansion of our product candidate pipeline; working\ncapital; capital expenditures; office expansion; and other general corporate purposes. We may temporarily invest the net proceeds in a variety of capital preservation instruments, including short-term, investment-grade, interest-bearing instruments\nand U.S. government securities, or may hold such proceeds as cash, until they are used for their stated purpose. We have not determined the amount of net proceeds to be used specifically for such purposes.\u00a0As a result, management will retain\nbroad discretion over the allocation of net proceeds. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">6 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_7\"></a>SECURITIES WE MAY\u00a0OFFER </b></p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><i>This prospectus contains summary descriptions of the securities we may offer from time to time. These summary descriptions are not meant to be complete\ndescriptions of each security. The particular terms of any security will be described in the applicable prospectus supplement. </i></p> <p align=\"center\" style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_8\">\n</a>DESCRIPTION OF CAPITAL STOCK </b></p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><i>The following description of our common stock and preferred stock, together with the additional information we\ninclude in any applicable prospectus supplements, summarizes the material terms and provisions of the common stock and preferred stock that we may offer under this prospectus. The following description of our capital stock does not purport to be\ncomplete and is subject to, and qualified in its entirety by, our certificate of incorporation and bylaws, which are exhibits to the registration statement of which this prospectus forms a part, and by applicable law. The terms of our common stock\nand preferred stock may also be affected by Delaware law. </i></p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>Authorized Capital Stock </b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Our authorized capital stock consists of 150,000,000 shares of common stock, par value $0.0001 per share, and 5,000,000 shares of preferred stock, par value\n$0.0001 per share, all of which are undesignated preferred stock. As of March\u00a01, 2018, we had 35,923,637 shares of common stock outstanding and no shares of preferred stock outstanding. </p>\n<p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>Common Stock </b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The holders of our common stock are\nentitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends\ndeclared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other subscription\nrights or redemption or sinking fund provisions. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled\nto share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock. All outstanding shares are fully paid and nonassessable. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">When we issue shares of common stock under this prospectus, the shares will fully be paid and nonassessable and will not have, or be subject to, any\npreemptive or similar rights. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>Undesignated Preferred Stock </b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Our board of directors is authorized to issue up to 5,000,000 shares of undesignated preferred stock in one or more series without stockholder approval. Our\nboard of directors may determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The purpose of authorizing our board of directors to issue preferred stock in one or more series and determine the number of shares in the series and its\nrights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. Examples of rights and preferences that the Board may fix are: </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">dividend rights; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">conversion rights; </td></tr></table>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">7 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">voting rights; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">terms of redemption; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">liquidation preferences; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">sinking fund terms; and </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. </td></tr></table>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The existence of authorized but unissued shares of undesignated preferred stock may enable our board of directors to render more difficult or to discourage an\nattempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best\ninterests of us or our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the\nproposed acquirer, stockholder or stockholder group.\u00a0The rights of holders of our common stock described above, will be subject to, and may be adversely affected by, the rights of any preferred stock that we may designate and issue in the\nfuture. The issuance of shares of undesignated preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including\nvoting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We will incorporate by reference\nas an exhibit to the registration statement, which includes this prospectus, the form of any certificate of designation that describes the terms of the series of preferred stock we are offering. This description and the applicable prospectus\nsupplement will include: </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the title and stated value; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the number of shares authorized; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the liquidation preference per share; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the purchase price; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the dividend rate, period and payment date, and method of calculation for dividends; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">whether dividends will be cumulative or <font style=\"white-space:nowrap\">non-cumulative</font> and, if cumulative, the date from which dividends will accumulate; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the procedures for any auction and remarketing, if any; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the provisions for a sinking fund, if any; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase rights; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any listing of the preferred stock on any securities exchange or market; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">whether the preferred stock will be convertible into our common stock, and, if applicable, the conversion price, or how it will be calculated, and the conversion period; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price, or how it will be calculated, and the exchange period; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">voting rights, if any, of the preferred stock; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">preemptive rights, if any; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">restrictions on transfer, sale or other assignment, if any; </td></tr></table>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">8 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">whether interests in the preferred stock will be represented by depositary shares; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">a discussion of any material United States federal income tax considerations applicable to the preferred stock; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any limitations on issuance of any class or series of preferred stock ranking senior to or on a parity with the series of preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our\naffairs; and </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any other specific terms, preferences, rights or limitations of, or restrictions on, the preferred stock. </td></tr></table>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">When we issue shares of preferred stock under this prospectus, the shares will fully be paid and nonassessable and will not be subject to any preemptive or\nsimilar rights. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>Registration Rights </b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman\">The holders of certain shares of our common stock, or their permitted transferees, which we refer to as our registrable securities, are\nentitled to rights with respect to the registration of these securities under the Securities Act. These rights are provided under the terms of the investor rights agreement. The investor rights agreement includes demand registration rights,\nshort-form registration rights and piggyback registration rights. All fees, costs and expenses incurred in connection with registrations under the investor rights agreement will be borne by us, and all selling expenses, including underwriting\ndiscounts and selling commissions, will be borne by the holders of the shares being registered. The investor rights agreement does not provide for any penalties for delays in registering our registrable securities. We have filed a registration\nstatement on Form <font style=\"white-space:nowrap\">S-3</font> (File <font style=\"white-space:nowrap\">No.\u00a0333-219220)</font> registering for resale the remaining registrable securities under the investor rights agreement. The registration\nstatement was declared effective on July\u00a021, 2017. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Demand Registration Rights </i></b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman\">The holders of our registrable securities are entitled to demand registration rights. Under the terms of the investor rights agreement, we will\nbe required, upon the request of holders of at least 25% of our outstanding registrable securities, to file a registration statement with an anticipated offering amount of at least $3.0\u00a0million and use commercially reasonable efforts to effect\nthe registration of these shares for public resale. We are required to effect up to two registrations pursuant to this provision of the investor rights agreement. </p>\n<p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Short Form Registration Rights </i></b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman\">The holders of our registrable securities are also entitled to short form registration rights. Pursuant to the investor rights agreement, if we\nare eligible to file a registration statement on Form <font style=\"white-space:nowrap\">S-3,</font> upon the request of holders of at least 25% of our outstanding registrable securities to sell registrable securities with an anticipated aggregate\noffering amount of at least $1.0\u00a0million net of certain expenses related to the offering, we will be required to use our commercially reasonable efforts to effect a registration of such shares. We are required to effect up to two registrations\nin any twelve month period pursuant to this provision of the investor rights agreement. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Piggyback Registration Rights </i></b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman\">The holders of our registrable securities are entitled to piggyback registration rights. If we register any of our securities either for our\nown account or for the account of other security holders, the holders of our outstanding registrable securities are entitled to include their shares in the registration. Subject to certain exceptions contained in the investor rights agreement, we\nand the underwriters may limit the number of shares included in the underwritten offering if the underwriters determine that marketing factors require a limitation of the number of shares to be underwritten. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">9 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Indemnification </i></b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman\">Our investor rights agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of\nregistrable securities in the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them. </p>\n<p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Expenses of Registration </i></b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman\">We will\npay the registration expenses, subject to certain limited exceptions contained in the investor rights agreement, of the holders of the shares registered pursuant to the demand, short form and piggyback registration rights described above, including\nthe expenses of one counsel for the selling holders. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Expiration of Registration Rights </i></b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman\">The registration rights granted under the investor rights agreement will terminate upon the earlier of (i)\u00a0certain events constituting a\nsale of the company, (ii)\u00a0the consummation of a transaction or series of transactions in which a person, or a group of persons, acquires from our stockholders, shares representing more than 50% of our outstanding voting stock, (iii)\u00a0at\nsuch time when all registrable securities could be sold under Rule 144 of the Securities Act or a similar exemption without limitation during a three-month period without registration or (iv)\u00a0the third anniversary of our IPO. </p>\n<p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>Antitakeover Effects of Delaware Law and Provisions of our Restated Certificate of Incorporation and Amended and Restated Bylaws </b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Certain provisions of the Delaware General Corporation Law and of our restated certificate of incorporation and amended and restated bylaws could have the\neffect of delaying, deferring or discouraging another party from acquiring control of us. These provisions, which are summarized below, are expected to discourage certain types of coercive takeover practices and inadequate takeover bids and, as a\nconsequence, they might also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions are also designed in part to encourage anyone seeking to acquire\ncontrol of us to first negotiate with our board of directors. These provisions might also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that\nstockholders might otherwise deem to be in their best interests. However, we believe that the advantages gained by protecting our ability to negotiate with any unsolicited and potentially unfriendly acquirer outweigh the disadvantages of\ndiscouraging such proposals, including those priced above the then-current market value of our common stock, because, among other reasons, the negotiation of such proposals could improve their terms. </p>\n<p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><i>Delaware Takeover Statute </i></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We are subject to the\nprovisions of Section\u00a0203 of the Delaware General Corporation Law. In general, Section\u00a0203 prohibits a publicly held Delaware corporation from engaging in a \u0093business combination\u0094 with an \u0093interested stockholder\u0094 for a\nthree-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section\u00a0203, a business combination between a corporation and an interested\nstockholder is prohibited unless it satisfies one of the following conditions: </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">before the stockholder became interested, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\"> <p align=\"left\" style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt\">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the\ninterested stockholder owned at least 85% of the voting stock of the corporation </p></td></tr></table>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">10 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"8%\">\u00a0</td>\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt\">\noutstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee\nstock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or </p></td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">at or after the time the stockholder became interested, the business combination was approved by our board of directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at\nleast <font style=\"white-space:nowrap\">two-thirds</font> of the outstanding voting stock which is not owned by the interested stockholder. </td></tr></table>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Section\u00a0203 defines a business combination to include: </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any merger or consolidation involving the corporation and the interested stockholder; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any sale, transfer, lease, pledge, exchange, mortgage or other disposition involving the interested stockholder of 10% or more of the assets of the corporation; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested\nstockholder; or </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. </td></tr></table>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">In general, Section\u00a0203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the\ncorporation and any entity or person affiliated with or controlling or controlled by the entity or person. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><i>Provisions of our Restated Certificate of\nIncorporation and Amended and Restated Bylaws </i></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Our restated certificate of incorporation and amended and restated bylaws include a number of provisions\nthat may have the effect of delaying, deferring or discouraging another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors\nrather than pursue <font style=\"white-space:nowrap\">non-negotiated</font> takeover attempts. These provisions include the items described below. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><i>Board\ncomposition and filling vacancies</i>. In accordance with our restated certificate of incorporation, our board is divided into three classes serving staggered three-year terms, with one class being elected each year. Our\u00a0restated certificate of\nincorporation also provides that directors may be removed only for cause and then only by the affirmative vote of the holders of 75% or more of the shares then entitled to vote at an election of directors. Furthermore, any vacancy on our board of\ndirectors, however occurring, including a vacancy resulting from an increase in the size of our board, may only be filled by the affirmative vote of a majority of our directors then in office even if less than a quorum. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><i>No written consent of stockholders</i>. Our restated certificate of incorporation provides that all stockholder actions are required to be taken by a vote\nof the stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the\namendment of our bylaws or removal of directors by our stockholder without holding a meeting of stockholders. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><i>Meetings of stockholders</i>. Our bylaws\nprovide that only a majority of the members of our board of directors then in office may call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting\nof stockholders. Our bylaws limit the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">11 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><i>Advance notice requirements</i>. Our bylaws establish advance notice procedures with regard to\nstockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing\nto our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90 days or more than 120 days prior to the first anniversary date\nof the annual meeting for the preceding year. The notice must contain certain information specified in our bylaws. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><i>Amendment to certificate of\nincorporation and bylaws</i>. As required by the Delaware General Corporation Law, any amendment of our restated certificate of incorporation must first be approved by a majority of our board of directors, and if required by law or our restated\ncertificate of incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment, and a majority of the outstanding shares of<i> </i>each class entitled to vote thereon as a class, except that the\namendment of the provisions relating to stockholder action, directors, limitation of liability and the amendment of our restated certificate of incorporation must be approved by not less than 75% of the outstanding shares entitled to vote on the\namendment, and not less than 75% of the outstanding shares of each class entitled to vote thereon as a class. Our bylaws may be amended by the affirmative vote of a majority vote of the directors then in office, subject to any limitations set forth\nin the\u00a0bylaws; and may also be amended by the affirmative vote of at least 75% of the outstanding shares entitled to vote on the amendment, or, if the board of directors recommends that the stockholders approve the amendment, by the affirmative\nvote of the majority of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><i>Undesignated\npreferred stock</i>. Our restated certificate of incorporation provides for authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board of directors to render more difficult or to\ndiscourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not\nin the best interests of us or our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other\nrights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our restated certificate of incorporation grants our board of directors broad power to establish the rights and preferences of authorized and unissued\nshares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights\u00a0and powers,\nincluding voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">12 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_9\"></a>DESCRIPTION OF DEBT SECURITIES </b></p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">This section describes the general terms and provisions of our debt securities that we may issue from time to time. We may issue debt securities, in one or\nmore series, as either senior or subordinated debt or as senior or subordinated convertible debt. While the terms we have summarized below will apply generally to any future debt securities we may offer under this prospectus, the applicable\nprospectus supplement or free writing prospectus will describe the specific terms of any debt securities offered through that prospectus supplement or free writing prospectus. The terms of any debt securities we offer under a prospectus supplement\nor free writing prospectus may differ from the terms we describe below. Unless the context requires otherwise, whenever we refer to the \u0093indentures,\u0094 we also are referring to any supplemental indentures that specify the terms of a\nparticular series of debt securities. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We will issue any senior debt securities under the senior indenture that we will enter into with the trustee named\nin the senior indenture. We will issue any subordinated debt securities under the subordinated indenture that we will enter into with the trustee named in the subordinated indenture. We have filed forms of these documents as exhibits to the\nregistration statement, of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this\nprospectus is a part or will be incorporated by reference from reports that we file with the SEC. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The indentures will be qualified under the Trust\nIndenture Act of 1939, as amended, or the Trust Indenture Act. We use the term \u0093trustee\u0094 to refer to either the trustee under the senior indenture or the trustee under the subordinated indenture, as applicable. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The following summaries of material provisions of the senior debt securities, the subordinated debt securities and the indentures are subject to, and\nqualified in their entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplement or free writing prospectus and any related free\nwriting prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete applicable indenture that contains the terms of the debt securities. Except as we may otherwise indicate, the terms of the senior\nindenture and the subordinated indenture are identical. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>General </i></b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We will describe in the applicable prospectus supplement or free writing prospectus the terms of the series of debt securities being offered, including: </p>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the title; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the principal amount being offered, and if a series, the total amount authorized and the total amount outstanding; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any limit on the amount that may be issued; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">whether or not we will issue the series of debt securities in global form, and, if so, the terms and who the depository will be; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the maturity date; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">whether and under what circumstances, if any, we will pay additional amounts on any debt securities held by a person who is not a United States person for tax purposes, and whether we can redeem the debt securities if\nwe have to pay such additional amounts; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the annual interest rate, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest\npayment dates or the method for determining such dates; </td></tr></table>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">13 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the terms of the subordination of any series of subordinated debt; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the place where payments will be payable; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">restrictions on transfer, sale or other assignment, if any; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">our right, if any, to defer payment of interest and the maximum length of any such deferral period; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the date, if any, after which, the conditions upon which, and the price at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms\nof those redemption provisions; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the date, if any, on which, and the price at which we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder\u0092s option, to purchase, the series\nof debt securities and the currency or currency unit in which the debt securities are payable; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">whether the indenture will restrict our ability or the ability of our subsidiaries to: </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">incur additional indebtedness; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">issue additional securities; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">create liens; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">pay dividends or make distributions in respect of our capital stock or the capital stock of our subsidiaries; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">redeem capital stock; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">place restrictions on our subsidiaries\u0092 ability to pay dividends, make distributions or transfer assets; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">make investments or other restricted payments; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">sell or otherwise dispose of assets; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">enter into sale-leaseback transactions; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">engage in transactions with stockholders or affiliates; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">issue or sell stock of our subsidiaries; or </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">effect a consolidation or merger; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">whether the indenture will require us to maintain any interest coverage, fixed charge, cash flow-based, asset-based or other financial ratios; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">a discussion of certain material or special United States federal income tax considerations applicable to the debt securities; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">information describing any book-entry features; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">provisions for a sinking fund purchase or other analogous fund, if any; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the applicability of the provisions in the indenture on discharge; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">whether the debt securities are to be offered at a price such that they will be deemed to be offered at an \u0093original issue discount\u0094 as defined in paragraph\u00a0(a) of Section\u00a01273 of the Internal\nRevenue Code of 1986, as amended; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S. dollars; and </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, including any additional events of default or covenants provided with respect to the debt securities, and any\nterms that may be required by us or advisable under applicable laws or regulations or advisable in connection with the marketing of the debt securities. </td></tr></table>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">14 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Conversion or Exchange Rights </i></b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We will set forth in the applicable prospectus supplement or free writing prospectus the terms on which a series of debt securities may be convertible into or\nexchangeable for our common stock, our preferred stock or other securities (including securities of a third-party). We will include provisions as to whether conversion or exchange is mandatory, at the option of the holder or at our option. We may\ninclude provisions pursuant to which the number of shares of our common stock, our preferred stock or other securities (including securities of a third-party) that the holders of the series of debt securities receive would be subject to adjustment.\n</p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Consolidation, Merger or Sale </i></b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Unless we\nprovide otherwise in the prospectus supplement or free writing prospectus applicable to a particular series of debt securities, the indentures will not contain any covenant that restricts our ability to merge or consolidate, or sell, convey,\ntransfer or otherwise dispose of all or substantially all of our assets. However, any successor to or acquirer of such assets must assume all of our obligations under the indentures or the debt securities, as appropriate. If the debt securities are\nconvertible into or exchangeable for other securities of ours or securities of other entities, the person with whom we consolidate or merge or to whom we sell all of our property must make provisions for the conversion of the debt securities into\nsecurities that the holders of the debt securities would have received if they had converted the debt securities before the consolidation, merger or sale. </p>\n<p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Events of Default Under the Indenture </i></b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Unless we\nprovide otherwise in the prospectus supplement or free writing prospectus applicable to a particular series of debt securities, the following are events of default under the indentures with respect to any series of debt securities that we may issue:\n</p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">if we fail to pay interest when due and payable and our failure continues for 90\u00a0days and the time for payment has not been extended; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">if we fail to pay the principal, premium or sinking fund payment, if any, when due and payable at maturity, upon redemption or repurchase or otherwise, and the time for payment has not been extended; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">if we fail to observe or perform any other covenant contained in the debt securities or the indentures, other than a covenant specifically relating to another series of debt securities, and our failure continues for\n90\u00a0days after we receive notice from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">if specified events of bankruptcy, insolvency or reorganization occur. </td></tr></table> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We will describe in each applicable\nprospectus supplement or free writing prospectus any additional events of default relating to the relevant series of debt securities. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">If an event of\ndefault with respect to debt securities of any series occurs and is continuing, other than an event of default specified in the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt\nsecurities of that series, by notice to us in writing, and to the trustee if notice is given by such holders, may declare the unpaid principal, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default\nspecified in the last bullet point above occurs with respect to us, the unpaid principal, premium, if any, and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on\nthe part of the trustee or any holder. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive\nany default or event of default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance\nwith the indenture. Any waiver shall cure the default or event of default. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">15 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Subject to the terms of the indentures, if an event of default under an indenture shall occur and be\ncontinuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the\ntrustee reasonable indemnity or security satisfactory to it against any loss, liability or expense. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and\nplace of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that: </p>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the direction so given by the holder is not in conflict with any law or the applicable indenture; and </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding.\n</td></tr></table> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">A holder of the debt securities of any series will have the right to institute a proceeding under the indentures or to appoint a receiver\nor trustee, or to seek other remedies if: </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the holder has given written notice to the trustee of a continuing event of default with respect to that series; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written request, and such holders have offered reasonable indemnity to the trustee or security\nsatisfactory to it against any loss, liability or expense or to be incurred in compliance with instituting the proceeding as trustee; and </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting directions within\n90\u00a0days after the notice, request and offer. </td></tr></table> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">These limitations do not apply to a suit instituted by a holder of debt securities if we\ndefault in the payment of the principal, premium, if any, or interest on, the debt securities, or other defaults that may be specified in the applicable prospectus supplement or free writing prospectus. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We will periodically file statements with the trustee regarding our compliance with specified covenants in the indentures. </p>\n<p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Modification of Indenture; Waiver </i></b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Subject to the\nterms of the indenture for any series of debt securities that we may issue, we and the trustee may change an indenture without the consent of any holders with respect to the following specific matters: </p>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">to fix any ambiguity, defect or inconsistency in the indenture; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">to comply with the provisions described above under \u0093Description of Our Debt Securities\u0097Consolidation, Merger or Sale;\u0094 </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture;\n</td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">to provide for the issuance of and establish the form and terms and conditions of the debt securities of any series as provided under \u0093Description of Our Debt Securities\u0097General,\u0094 to establish the form of\nany certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series of debt securities; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">to evidence and provide for the acceptance of appointment hereunder by a successor trustee; </td></tr></table>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">16 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">to provide for uncertificated debt securities and to make all appropriate changes for such purpose; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">to add to our covenants such new covenants, restrictions, conditions or provisions for the benefit of the holders, to make the occurrence, or the occurrence and the continuance, of a default in any such additional\ncovenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred to us in the indenture; or </td></tr></table> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">to change anything that does not materially adversely affect the interests of any holder of debt securities of any series. </td></tr></table>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">In addition, under the indentures, the rights of holders of a series of debt securities may be changed by us and the trustee with the written consent of the\nholders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, subject to the terms of the indenture for any series of debt securities that we may issue or as otherwise\nprovided in the prospectus supplement or free writing prospectus applicable to a particular series of debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities\naffected: </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">extending the stated maturity of the series of debt securities; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption or repurchase of any debt securities; or </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">reducing the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or waiver. </td></tr></table>\n<p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Discharge </i></b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Each indenture provides that, subject\nto the terms of the indenture and any limitation otherwise provided in the prospectus supplement or free writing prospectus applicable to a particular series of debt securities, we can elect to be discharged from our obligations with respect to one\nor more series of debt securities, except for specified obligations, including obligations to: </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">register the transfer or exchange of debt securities of the series; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">replace stolen, lost or mutilated debt securities of the series; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">maintain paying agencies; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">hold monies for payment in trust; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">recover excess money held by the trustee; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">compensate and indemnify the trustee; and </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">appoint any successor trustee. </td></tr></table> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">In order to exercise our rights to be discharged, we must deposit with the\ntrustee money or government obligations sufficient to pay all the principal of, any premium and interest on, the debt securities of the series on the dates payments are due. </p>\n<p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Form, Exchange and Transfer </i></b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We will issue the\ndebt securities of each series only in fully registered form without coupons and, unless we otherwise specify in the applicable prospectus supplement or free writing prospectus, in denominations of $1,000 and any integral multiple thereof. The\nindentures provide that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company or another depository named by us and\nidentified in a prospectus supplement or free writing prospectus with respect to that series. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">17 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">At the option of the holder, subject to the terms of the indentures and the limitations applicable to global\nsecurities described in the applicable prospectus supplement or free writing prospectus, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination\nand of like tenor and aggregate principal amount. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Subject to the terms of the indentures and the limitations applicable to global securities set forth in\nthe applicable prospectus supplement or free writing prospectus, holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed\nif so required by us or the security registrar, at the office of the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer\nor exchange, we will make no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We will name in the applicable prospectus supplement or free writing prospectus the security registrar, and any transfer agent in addition to the security\nregistrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except\nthat we will be required to maintain a transfer agent in each place of payment for the debt securities of each series. If we elect to redeem the debt securities of any series, we will not be required to: </p>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business 15\u00a0days before the day of mailing of a notice of redemption of any debt\nsecurities that may be selected for redemption and ending at the close of business on the day of the mailing; or </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part. </td></tr></table>\n<p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Information Concerning the Trustee </i></b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The trustee,\nother than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the trustee\nmust use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Subject to this provision, the\ntrustee is under no obligation to exercise any of the powers given it by the indentures at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might\nincur. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Payment and Paying Agents </i></b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Unless we\notherwise indicate in the applicable prospectus supplement or free writing prospectus, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities, or one or more\npredecessor securities, are registered at the close of business on the regular record date for the interest. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We will pay principal of and any premium and\ninterest on the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise indicate in the applicable prospectus supplement or free writing prospectus, we will make interest payments\nby check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable prospectus supplement or free writing prospectus, we will designate the corporate trust office of the trustee as our sole\npaying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement or free writing prospectus any other paying agents that we initially designate for the debt securities of a particular\nseries. We will maintain a paying agent in each place of payment for the debt securities of a particular series. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">18 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or\ninterest on any debt securities that remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment\nthereof. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Governing Law </i></b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The indentures and\nthe debt securities will be governed by and construed in accordance with the laws of the State of New York, except to the extent that the Trust Indenture Act is applicable. </p>\n<p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Ranking of Debt Securities </i></b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The subordinated debt\nsecurities will be subordinate and junior in priority of payment to certain of our other indebtedness to the extent described in a prospectus supplement or free writing prospectus. The subordinated indenture does not limit the amount of subordinated\ndebt securities that we may issue. It also does not limit us from issuing any other secured or unsecured debt. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The senior debt securities will rank\nequally in right of payment to all our other senior unsecured debt. The senior indenture does not limit the amount of senior debt securities that we may issue. It also does not limit us from issuing any other secured or unsecured debt. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">19 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_10\"></a>DESCRIPTION OF WARRANTS </b></p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The following description, together with the additional information we may include in any applicable prospectus supplements, summarizes the material terms and\nprovisions of the warrants that we may offer under this prospectus and the related warrant agreements and warrant certificates. While the terms summarized below will apply generally to any warrants that we may offer, we will describe the particular\nterms of any series of warrants in more detail in the applicable prospectus supplement. If we indicate in the prospectus supplement, the terms of any warrants offered under that prospectus supplement may differ from the terms described below.\nSpecific warrant agreements will contain additional important terms and provisions and will be incorporated by reference as an exhibit to the registration statement, which includes this prospectus. </p>\n<p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>General </b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We may issue warrants for the purchase of common\nstock, preferred stock and/or debt securities in one or more series. We may issue warrants independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from these securities.\n</p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We will evidence each series of warrants by warrant certificates that we will issue under a separate warrant agreement. We will enter into the warrant\nagreement with a warrant agent. We will indicate the name and address of the warrant agent in the applicable prospectus supplement relating to a particular series of warrants. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We will describe in the applicable prospectus supplement the terms of the series of warrants, including: </p>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the offering price and aggregate number of warrants offered; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the currency for which the warrants may be purchased; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">if applicable, the date on and after which the warrants and the related securities will be separately transferable; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may\nbe purchased upon such exercise; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these\nshares may be purchased upon such exercise; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreement and the warrants; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the terms of any rights to redeem or call the warrants; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the periods during which, and places at which, the warrants are exercisable; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the manner of exercise; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the dates on which the right to exercise the warrants will commence and expire; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the manner in which the warrant agreement and warrants may be modified; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">federal income tax consequences of holding or exercising the warrants; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the terms of the securities issuable upon exercise of the warrants; and </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any other specific terms, preferences, rights or limitations of or restrictions on the warrants. </td></tr></table>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">20 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_11\"></a>DESCRIPTION OF UNITS </b></p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We may issue units comprised of shares of common stock, shares of preferred stock, debt securities and warrants in any combination. We may issue units in such\namounts and in as many distinct series as we wish. This section outlines certain provisions of the units that we may issue. If we issue units, they will be issued under one or more unit agreements to be entered into between us and a bank or other\nfinancial institution, as unit agent. The information described in this section may not be complete in all respects and is qualified entirely by reference to the unit agreement with respect to the units of any particular series. The specific terms\nof any series of units offered will be described in the applicable prospectus supplement. If so described in a particular supplement, the specific terms of any series of units may differ from the general description of terms presented below. We urge\nyou to read any prospectus supplement related to any series of units we may offer, as well as the complete unit agreement and unit certificate that contain the terms of the units. If we issue units, forms of unit agreements and unit certificates\nrelating to such units will be incorporated by reference as exhibits to the registration statement, which includes this prospectus. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Each unit that we may\nissue will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a\nunit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date. The applicable prospectus supplement may describe: </p>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any provisions of the governing unit agreement; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the price or prices at which such units will be issued; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the applicable United States federal income tax considerations relating to the units; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units; and </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any other terms of the units and of the securities comprising the units. </td></tr></table> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The provisions described in this\nsection, as well as those described under \u0093Description of Capital Stock,\u0094 \u0093Description of Debt Securities\u0094 and \u0093Description of Warrants\u0094 will apply to the securities included in each unit, to the extent relevant and as\nmay be updated in any prospectus supplements. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>Issuance in Series </b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We may issue units in such amounts and in as many distinct series as we wish. This section summarizes terms of the units that apply generally to all series.\nMost of the financial and other specific terms of a particular series of units will be described in the applicable prospectus supplement. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>Unit\nAgreements </b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We will issue the units under one or more unit agreements to be entered into between us and a bank or other financial institution, as unit\nagent. We may add, replace or terminate unit agents from time to time. We will identify the unit agreement under which each series of units will be issued and the unit agent under that agreement in the applicable prospectus supplement. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">21 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The following provisions will generally apply to all unit agreements unless otherwise stated in the\napplicable prospectus supplement: </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Modification without Consent </i></b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We and the applicable unit agent may amend any unit or unit agreement without the consent of any holder: </p>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">to cure any ambiguity; any provisions of the governing unit agreement that differ from those described below; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">to correct or supplement any defective or inconsistent provision; or </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">to make any other change that we believe is necessary or desirable and will not adversely affect the interests of the affected holders in any material respect. </td></tr></table>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We do not need any approval to make changes that affect only units to be issued after the changes take effect. We may also make changes that do not adversely\naffect a particular unit in any material respect, even if they adversely affect other units in a material respect. In those cases, we do not need to obtain the approval of the holder of the unaffected unit; we need only obtain any required approvals\nfrom the holders of the affected units. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Modification with Consent </i></b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We may not amend any particular unit or a unit agreement with respect to any particular unit unless we obtain the consent of the holder of that unit, if the\namendment would: </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">impair any right of the holder to exercise or enforce any right under a security included in the unit if the terms of that security require the consent of the holder to any changes that would impair the exercise or\nenforcement of that right; or </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">reduce the percentage of outstanding units or any series or class the consent of whose holders is required to amend that series or class, or the applicable unit agreement with respect to that series or class, as\ndescribed below. </td></tr></table> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Any other change to a particular unit agreement and the units issued under that agreement would require the following\napproval: </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">If the change affects only the units of a particular series issued under that agreement, the change must be approved by the holders of a majority of the outstanding units of that series; or </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">If the change affects the units of more than one series issued under that agreement, it must be approved by the holders of a majority of all outstanding units of all series affected by the change, with the units of all\nthe affected series voting together as one class for this purpose. </td></tr></table> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">These provisions regarding changes with majority approval also apply to\nchanges affecting any securities issued under a unit agreement, as the governing document. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">In each case, the required approval must be given by written\nconsent. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Unit Agreements Will Not Be Qualified under Trust Indenture Act </i></b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">No unit agreement will be qualified as an indenture, and no unit agent will be required to qualify as a trustee, under the Trust Indenture Act. Therefore,\nholders of units issued under unit agreements will not have the protections of the Trust Indenture Act with respect to their units. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Mergers and\nSimilar Transactions Permitted; No Restrictive Covenants or Events of Default </i></b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The unit agreements will not restrict our ability to merge or\nconsolidate with, or sell our assets to, another corporation or other entity or to engage in any other transactions. If at any time we merge or consolidate with, or </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">22 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">\nsell our assets substantially as an entirety to, another corporation or other entity, the successor entity will succeed to and assume our obligations under the unit agreements. We will then be\nrelieved of any further obligation under these agreements. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The unit agreements will not include any restrictions on our ability to put liens on our\nassets, nor will they restrict our ability to sell our assets. The unit agreements also will not provide for any events of default or remedies upon the occurrence of any events of default. </p>\n<p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Governing Law </i></b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The unit agreements and the units\nwill be governed by Delaware law. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Form, Exchange and Transfer </i></b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We will issue each unit in global\u0097i.e., book-entry\u0097form only. Units in book-entry form will be represented by a global security registered in the\nname of a depositary, which will be the holder of all the units represented by the global security. Those who own beneficial interests in a unit will do so through participants in the depositary\u0092s system, and the rights of these indirect owners\nwill be governed solely by the applicable procedures of the depositary and its participants. We will describe book-entry securities, and other terms regarding the issuance and registration of the units in the applicable prospectus supplement. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Each unit and all securities comprising the unit will be issued in the same form. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">If we issue any units in registered, <font style=\"white-space:nowrap\">non-global</font> form, the following will apply to them. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The units will be issued in the denominations stated in the applicable prospectus supplement. Holders may exchange their units for units of smaller\ndenominations or combined into fewer units of larger denominations, as long as the total amount is not changed. </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">Holders may exchange or transfer their units at the office of the unit agent. Holders may also replace lost, stolen, destroyed or mutilated units at that office. We may appoint another entity to perform these functions\nor perform them ourselves. </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">Holders will not be required to pay a service charge to transfer or exchange their units, but they may be required to pay for any tax or other governmental charge associated with the transfer or exchange. The transfer\nor exchange, and any replacement, will be made only if our transfer agent is satisfied with the holder\u0092s proof of legal ownership. The transfer agent may also require an indemnity before replacing any units. </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">If we have the right to redeem, accelerate or settle any units before their maturity, and we exercise our right as to less than all those units or other securities, we may block the exchange or transfer of those units\nduring the period beginning 15\u00a0days before the day we mail the notice of exercise and ending on the day of that mailing, in order to freeze the list of holders to prepare the mailing. We may also refuse to register transfers of or exchange any\nunit selected for early settlement, except that we will continue to permit transfers and exchanges of the unsettled portion of any unit being partially settled. We may also block the transfer or exchange of any unit in this manner if the unit\nincludes securities that are or may be selected for early settlement. </td></tr></table> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Only the depositary will be entitled to transfer or exchange a unit\nin global form, since it will be the sole holder of the unit. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Payments and Notices </i></b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">In making payments and giving notices with respect to our units, we will follow the procedures as described in the applicable prospectus supplement. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">23 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_12\"></a>PLAN OF DISTRIBUTION </b></p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We may sell securities: </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">through underwriters; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">through dealers; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">through agents; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">directly to purchasers; or </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">through a combination of any of these methods or any other method permitted by law. </td></tr></table> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">In addition, we may issue\nthe securities as a dividend or distribution or in a subscription rights offering to our existing security holders. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We may directly solicit offers to\npurchase securities, or agents may be designated to solicit such offers. In the prospectus supplement relating to such offering, we will name any agent that could be viewed as an underwriter under the Securities Act and describe any commissions that\nwe must pay to any such agent. Any such agent will be acting on a best efforts basis for the period of its appointment or, if indicated in the applicable prospectus supplement, on a firm commitment basis. This prospectus may be used in connection\nwith any offering of our securities through any of these methods or other methods described in the applicable prospectus supplement. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The distribution of\nthe securities may be effected from time to time in one or more transactions: </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">at a fixed price, or prices, which may be changed from time to time; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">at market prices prevailing at the time of sale; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">at prices related to such prevailing market prices; or </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">at negotiated prices. </td></tr></table> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Each prospectus supplement will describe the method of distribution of the securities\nand any applicable restrictions. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The prospectus supplement with respect to the securities of a particular series will describe the terms of the offering\nof the securities, including the following: </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the name of the agent or any underwriters; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the public offering or purchase price; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any discounts and commissions to be allowed or paid to the agent or underwriters; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">all other items constituting underwriting compensation; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any discounts and commissions to be allowed or paid to dealers; and </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any exchanges on which the securities will be listed. </td></tr></table> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">If any underwriters or agents are used in the sale of\nthe securities in respect of which this prospectus is delivered, we will enter into an underwriting agreement, sales agreement or other agreement with them at the time of sale to them, and we will set forth in the prospectus supplement relating to\nsuch offering the names of the underwriters or agents and the terms of the related agreement with them. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">In connection with the offering of securities, we\nmay grant to the underwriters an option to purchase additional securities with an additional underwriting commission, as may be set forth in the accompanying prospectus supplement. If we grant any such option, the terms of such option will be set\nforth in the prospectus supplement for such securities. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">24 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">If a dealer is used in the sale of the securities in respect of which the prospectus is delivered, we will\nsell such securities to the dealer, as principal. The dealer, who may be deemed to be an \u0093underwriter\u0094 as that term is defined in the Securities Act, may then resell such securities to the public at varying prices to be determined by such\ndealer at the time of resale. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">If we offer securities in a subscription rights offering to our existing security holders, we may enter into a standby\nunderwriting agreement with dealers, acting as standby underwriters. We may pay the standby underwriters a commitment fee for the securities they commit to purchase on a standby basis. If we do not enter into a standby underwriting arrangement, we\nmay retain a dealer-manager to manage a subscription rights offering for us. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Agents, underwriters, dealers and other persons may be entitled under\nagreements which they may enter into with us to indemnification by us against certain civil liabilities, including liabilities under the Securities Act, and may be customers of, engage in transactions with or perform services for us in the ordinary\ncourse of business. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">If so indicated in the applicable prospectus supplement, we will authorize underwriters or other persons acting as our agents to\nsolicit offers by certain institutions to purchase securities from us pursuant to delayed delivery contracts providing for payment and delivery on the date stated in the prospectus supplement. Each contract will be for an amount not less than, and\nthe aggregate amount of securities sold pursuant to such contracts shall not be less nor more than, the respective amounts stated in the prospectus supplement. Institutions with whom the contracts, when authorized, may be made include commercial and\nsavings banks, insurance companies, pension funds, investment companies, educational and charitable institutions and other institutions, but shall in all cases be subject to our approval. Delayed delivery contracts will not be subject to any\nconditions except that: </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the purchase by an institution of the securities covered under that contract shall not at the time of delivery be prohibited under the laws of the jurisdiction to which that institution is subject; and\n</td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">if the securities are also being sold to underwriters acting as principals for their own account, the underwriters shall have purchased such securities not sold for delayed delivery. The underwriters and other persons\nacting as our agents will not have any responsibility in respect of the validity or performance of delayed delivery contracts. </td></tr></table> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Offered\nsecurities may also be offered and sold, if so indicated in the prospectus supplement, in connection with a remarketing upon their purchase, in accordance with a redemption or repayment pursuant to their terms, or otherwise, by one or more\nremarketing firms, acting as principals for their own accounts or as agents for us. Any remarketing firm will be identified and the terms of its agreement, if any, with us and its compensation will be described in the applicable prospectus\nsupplement. Remarketing firms may be deemed to be underwriters in connection with their remarketing of offered securities. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Certain agents, underwriters\nand dealers, and their associates and affiliates, may be customers of, have borrowing relationships with, engage in other transactions with, or perform services, including investment banking services, for us or one or more of our respective\naffiliates in the ordinary course of business. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">In order to facilitate the offering of the securities, any underwriters may engage in transactions that\nstabilize, maintain or otherwise affect the price of the securities or any other securities the prices of which may be used to determine payments on such securities. Specifically, any underwriters may overallot in connection with the offering,\ncreating a short position for their own accounts. In addition, to cover overallotments or to stabilize the price of the securities or of any such other securities, the underwriters may bid for, and purchase, the securities or any such other\nsecurities in the open market. Finally, in any offering of the securities through a syndicate of underwriters, the underwriting syndicate may reclaim selling concessions allowed to an underwriter or a dealer for distributing the securities in the\noffering if the syndicate repurchases previously distributed securities in transactions to cover syndicate short positions, in stabilization transactions or otherwise. Any of these activities may stabilize or maintain the market price of the\nsecurities above independent market levels. Any such underwriters are not required to engage in these activities and may end any of these activities at any time. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">25 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We may engage in at the market offerings into an existing trading market in accordance with Rule 415(a)(4)\nunder the Securities Act. In addition, we may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement so\nindicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party may use securities pledged by us\nor borrowed from us or others to settle those sales or to close out any related open borrowings of stock, and may use securities received from us in settlement of those derivatives to close out any related open borrowings of stock. The third party\nin such sale transactions will be an underwriter and, if not identified in this prospectus, will be named in the applicable prospectus supplement (or a post-effective amendment). In addition, we may otherwise loan or pledge securities to a financial\ninstitution or other third party that in turn may sell the securities short using this prospectus and an applicable prospectus supplement. Such financial institution or other third party may transfer its economic short position to investors in our\nsecurities or in connection with a concurrent offering of other securities. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Under <font style=\"white-space:nowrap\">Rule\u00a015c6-1</font> of the\nExchange Act, trades in the secondary market generally are required to settle in three business days, unless the parties to any such trade expressly agree otherwise. The applicable prospectus supplement may provide that the original issue date for\nyour securities may be more than three scheduled business days after the trade date for your securities. Accordingly, in such a case, if you wish to trade securities on any date prior to the third business day before the original issue date for your\nsecurities, you will be required, by virtue of the fact that your securities initially are expected to settle in more than three scheduled business days after the trade date for your securities, to make alternative settlement arrangements to prevent\na failed settlement. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The securities may be new issues of securities and may have no established trading market. The securities may or may not be listed\non a national securities exchange. We can make no assurance as to the liquidity of or the existence of trading markets for any of the securities. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The\nspecific terms of any <font style=\"white-space:nowrap\">lock-up</font> provisions in respect of any given offering will be described in the applicable prospectus supplement. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The underwriters, dealers and agents may engage in transactions with us, or perform services for us, in the ordinary course of business for which they receive\ncompensation. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The anticipated date of delivery of offered securities will be set forth in the applicable prospectus supplement relating to each offer.\n</p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">26 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_13\"></a>LEGAL MATTERS </b></p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Certain legal matters in connection with this offering will be passed upon for us by Goodwin Procter LLP, San\u00a0Francisco, California. Any underwriters\nwill also be advised about the validity of the securities and other legal matters by their own counsel, which will be named in the prospectus supplement. </p>\n<p align=\"center\" style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_14\"></a>EXPERTS </b></p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The\nfinancial statements incorporated in this Prospectus by reference to the Annual Report on Form <font style=\"white-space:nowrap\">10-K</font> for the year ended December\u00a031, 2017 have been so incorporated in reliance on the report of\nPricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </p>\n<p align=\"center\" style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_15\"></a>WHERE YOU CAN FIND MORE INFORMATION </b></p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">This prospectus is part of a registration statement that we have filed with the SEC. Certain information in the registration statement has been omitted from\nthis prospectus in accordance with the rules of the SEC. We are subject to the information requirements of the Exchange Act and, in accordance therewith, file annual, quarterly and special reports, proxy statements and other information with the\nSEC. You may read and copy any document we file at the SEC\u0092s Public Reference Room\u00a0at 100 F Street, N.E., Washington, D.C. 20549. You may call the SEC at <font style=\"white-space:nowrap\"><font style=\"white-space:nowrap\"><font style=\"white-space:nowrap\">1-800-SEC-0330</font></font></font> for further information on the operation of the Public Reference Room. These documents also may be accessed through the SEC\u0092s electronic data gathering, analysis and retrieval\nsystem, or EDGAR, via electronic means, including the SEC\u0092s home page\u00a0on the Internet <i>(www.sec.gov</i>). </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We have the authority to designate\nand issue more than one class or series of stock having various preferences, conversion and other rights, voting powers, restrictions, limitations as to dividends, qualifications, and terms and conditions of redemption. See \u0093Description of\nCapital Stock.\u0094 We will furnish a full statement of the relative rights and preferences of each class or series of our stock which has been so designated and any restrictions on the ownership or transfer of our stock to any stockholder upon\nrequest and without charge. Written requests for such copies should be directed to Investor Relations, MyoKardia, Inc., 333 Allerton Ave., South San Francisco,\u00a0CA 94080; telephone: <font style=\"white-space:nowrap\">(650)\u00a0741-0900.</font>\nInformation contained on our website is not incorporated by reference into this prospectus and, therefore, is not part of this prospectus or any accompanying prospectus supplement. </p>\n<p align=\"center\" style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_16\"></a>INCORPORATION BY REFERENCE </b></p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The SEC allows us to incorporate by reference the information and reports we file with it, which means that we can disclose important information to you by\nreferring you to these documents. The information incorporated by reference is an important part of this prospectus, and information that we file later with the SEC will automatically update and supersede the information already incorporated by\nreference. We are incorporating by reference the documents listed below, which we have already filed with the SEC (SEC File <font style=\"white-space:nowrap\">No.\u00a0001-37609),</font> and any future filings we make with the SEC under Sections\n13(a), 13(c), 14 or 15(d) of the Exchange Act, including all filings made after the date of the filing of this registration statement and prior to the effectiveness of this registration statement, except as to any portion of any future report or\ndocument that is not deemed filed under such provisions, after the date of this prospectus and prior to the termination of this offering: </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">Annual Report on Form <font style=\"white-space:nowrap\">10-K</font> for the year ended December\u00a031, 2017, filed with the SEC on March\u00a08, 2018; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">Current Reports on Form <font style=\"white-space:nowrap\">8-K</font> filed with the SEC on March 5, 2018 and March 8, 2018 (as to Item 8.01 only); and </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">The description of our common stock contained in our registration statement on Form <font style=\"white-space:nowrap\">8-A</font> filed with the SEC on October\u00a027, 2015 under Section\u00a012(b) of the Exchange Act,\nincluding any amendments or reports filed for the purpose of updating such description. </td></tr></table>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">27 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Upon request, we will provide, without charge, to each person, including any beneficial owner, to whom a\ncopy of this prospectus is delivered, a copy of the documents incorporated by reference into this prospectus but not delivered with the prospectus. You may request a copy of these filings, and any exhibits we have specifically incorporated by\nreference as an exhibit in this prospectus, at no cost by writing or telephoning us at the following address: 333 Allerton Ave., South San Francisco, CA 94080; telephone: <font style=\"white-space:nowrap\">(650)\u00a0741-0900.</font> </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">You may also access these documents, free of charge on the SEC\u0092s website at <i>www.sec.gov</i> or on our website at <i>www.myokardia.com</i>. Information\ncontained on our website is not incorporated by reference into this prospectus, and you should not consider any information on, or that can be accessed from, our website as part of this prospectus or any accompanying prospectus supplement. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">This prospectus is part of a registration statement we filed with the SEC. We have incorporated exhibits into this registration statement. You should read the\nexhibits carefully for provisions that may be important to you. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">You should rely only on the information incorporated by reference or provided in this\nprospectus or any prospectus supplement. We have not authorized anyone to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the\ninformation in this prospectus or in the documents incorporated by reference is accurate as of any date other than the date on the front of this prospectus or those documents. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">28 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"font-size:48pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:36pt; margin-bottom:0pt; font-size:18pt; font-family:arial\"><b><i>3,750,000 shares\n</i></b></p> <p style=\"font-size:24pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p> <p style=\"font-size:96pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p> <p style=\"font-size:36pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<p style=\"font-size:0pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt;margin-bottom:0pt\">\n<img alt=\"LOGO\" src=\"g579741g95t12.jpg\"/>\n</p> <p align=\"center\" style=\"margin-top:24pt; margin-bottom:0pt; font-size:18pt; font-family:arial\"><b><i>Common stock </i></b></p>\n<p align=\"center\" style=\"margin-top:60pt; margin-bottom:0pt; font-size:24pt; font-family:arial\"><b>Prospectus supplement </b></p> <p style=\"font-size:60pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:15pt\" width=\"100%\">\n<tr>\n<td width=\"18%\"></td>\n<td valign=\"bottom\"></td>\n<td width=\"28%\"></td>\n<td valign=\"bottom\" width=\"1%\"></td>\n<td width=\"20%\"></td>\n<td valign=\"bottom\" width=\"1%\"></td>\n<td width=\"31%\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:15pt\">\n<td valign=\"top\"><b>J.P.\u00a0Morgan</b></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\"><b>BofA\u00a0Merrill\u00a0Lynch</b></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\"><b>Credit\u00a0Suisse</b></td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"top\"><b>Wells\u00a0Fargo\u00a0Securities</b></td></tr>\n</table> <p style=\"font-size:60pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p> <p style=\"margin-top:36pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial\">May\u00a022, 2018 </p>\n</div></center>\n</p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></body></html>\n</text>\n</description></filename></sequence></type></document>\n"}, "reportNo7": {"reportType": "424B5", "url": "https://www.sec.gov/Archives/edgar/data/1552451/000119312518169736/d579741d424b5.htm", "dateOfReport": "2018-05-21", "content": {"logoAddress": "https://www.sec.gov/Archives/edgar/data/1552451/000119312518169736/g579741g95t12.jpg", "sharesOffered": "['3,750,000 shares ']", "tableCode": "<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr>\n<td width=\"82%\"></td>\n<td valign=\"bottom\" width=\"3%\"></td>\n<td></td>\n<td></td>\n<td></td>\n<td valign=\"bottom\" width=\"3%\"></td>\n<td></td>\n<td></td>\n<td></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:9pt\">\n<td style=\"BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td colspan=\"2\" style=\"BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\"><b>Per\u00a0share</b></td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td colspan=\"2\" style=\"BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\"><b>Total</b></td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"10\"></td>\n<td colspan=\"4\" height=\"10\"></td>\n<td colspan=\"4\" height=\"10\"></td></tr>\n<tr bgcolor=\"#cceeff\" style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Public offering price</p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td nowrap=\"\" valign=\"top\">$</td>\n<td align=\"right\" nowrap=\"\" valign=\"top\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td nowrap=\"\" valign=\"top\">$</td>\n<td align=\"right\" nowrap=\"\" valign=\"top\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"10\"></td>\n<td colspan=\"4\" height=\"10\"></td>\n<td colspan=\"4\" height=\"10\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Underwriting discounts and commissions(1)</p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td nowrap=\"\" valign=\"top\">$</td>\n<td align=\"right\" nowrap=\"\" valign=\"top\"></td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td nowrap=\"\" valign=\"top\">$</td>\n<td align=\"right\" nowrap=\"\" valign=\"top\"></td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"10\"></td>\n<td colspan=\"4\" height=\"10\"></td>\n<td colspan=\"4\" height=\"10\"></td></tr>\n<tr bgcolor=\"#cceeff\" style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Proceeds to MyoKardia, Inc. before expenses</p></td>\n<td style=\" BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\">$</td>\n<td align=\"right\" nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\"></td>\n<td nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\">\u00a0</td>\n<td style=\" BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\">$</td>\n<td align=\"right\" nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\"></td>\n<td nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\">\u00a0</td></tr>\n</table>", "html": "<div align=\"left\" style=\"width:8.5in\">\n<p align=\"right\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Filed Pursuant to Rule 424(b)(5)<br/> Registration No. 333-223526 </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><font color=\"#8b3f4e\"><b>This prospectus supplement relates to an effective registration statement\nunder the Securities Act of 1933, but is not complete and may be changed. Neither this prospectus supplement nor the accompanying prospectus is an offer to sell these securities, and we are not soliciting an offer to buy these securities, in any\njurisdiction where the offer or sale is not permitted. </b></font></p> <p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p>\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial\"><font color=\"#8b3f4e\"><b>Subject to completion, dated May\u00a021, 2018 </b></font></p>\n<p style=\"margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:arial\"><b>Prospectus supplement </b></p> <p style=\"margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial\"><b>(To prospectus dated March\u00a08, 2018) </b></p>\n<p style=\"margin-top:14pt; margin-bottom:0pt; font-size:18pt; font-family:arial\"><b><i>3,750,000 shares </i></b></p> <p style=\"font-size:14pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<p style=\"font-size:0pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p> <p style=\"margin-top:0pt;margin-bottom:0pt\">\n<img alt=\"LOGO\" src=\"g579741g95t12.jpg\"/>\n</p> <p style=\"margin-top:14pt; margin-bottom:0pt; font-size:18pt; font-family:arial\"><b><i>Common stock </i></b></p> <p style=\"margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We are offering\n3,750,000 shares of our common stock. </p> <p style=\"margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Our common stock is listed on the Nasdaq Global Select Market under the symbol \u0093MYOK\u0094. On May\u00a018, 2018, the\nlast reported sale price of our common stock on the Nasdaq Global Select Market was $51.75 per share. </p> <p style=\"font-size:14pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr>\n<td width=\"82%\"></td>\n<td valign=\"bottom\" width=\"3%\"></td>\n<td></td>\n<td></td>\n<td></td>\n<td valign=\"bottom\" width=\"3%\"></td>\n<td></td>\n<td></td>\n<td></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:9pt\">\n<td style=\"BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td colspan=\"2\" style=\"BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\"><b>Per\u00a0share</b></td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td colspan=\"2\" style=\"BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\"><b>Total</b></td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"10\"></td>\n<td colspan=\"4\" height=\"10\"></td>\n<td colspan=\"4\" height=\"10\"></td></tr>\n<tr bgcolor=\"#cceeff\" style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Public offering price</p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td nowrap=\"\" valign=\"top\">$</td>\n<td align=\"right\" nowrap=\"\" valign=\"top\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td nowrap=\"\" valign=\"top\">$</td>\n<td align=\"right\" nowrap=\"\" valign=\"top\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"10\"></td>\n<td colspan=\"4\" height=\"10\"></td>\n<td colspan=\"4\" height=\"10\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Underwriting discounts and commissions(1)</p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td nowrap=\"\" valign=\"top\">$</td>\n<td align=\"right\" nowrap=\"\" valign=\"top\"></td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td nowrap=\"\" valign=\"top\">$</td>\n<td align=\"right\" nowrap=\"\" valign=\"top\"></td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"10\"></td>\n<td colspan=\"4\" height=\"10\"></td>\n<td colspan=\"4\" height=\"10\"></td></tr>\n<tr bgcolor=\"#cceeff\" style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Proceeds to MyoKardia, Inc. before expenses</p></td>\n<td style=\" BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\">$</td>\n<td align=\"right\" nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\"></td>\n<td nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\">\u00a0</td>\n<td style=\" BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\">$</td>\n<td align=\"right\" nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\"></td>\n<td nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\">\u00a0</td></tr>\n</table> <p style=\"font-size:4pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"2%\">(1)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">See \u0093Underwriting\u0094 for a description of the compensation payable to the underwriters. </td></tr></table> <p style=\"margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We have granted the\nunderwriters an option for a period of 30 days to purchase up to an additional 562,500 shares of our common stock. </p> <p style=\"margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Sanofi S.A. (\u0093Sanofi\u0094), our strategic\ncollaboration partner and one of our existing stockholders (through its wholly owned subsidiary, Aventis Inc.), has indicated an interest in purchasing up to an aggregate of approximately 200,000\u00a0shares of our common stock in this offering at\nthe public offering price and on the same terms as the other purchasers in this offering. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters could determine to sell fewer shares to Sanofi\nthan it indicated an interest in purchasing or sell no shares to Sanofi, and Sanofi could determine to purchase fewer shares than it indicated an interest in purchasing or purchase no shares in this offering. The underwriters will receive the same\nunderwriting discount on any shares purchased by Sanofi as they will on any other shares sold to the public in this offering. </p> <p style=\"margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b>Investing in our common stock\ninvolves a high degree of risk. See \u0093<a href=\"#supptoc579741_4\">Risk factors</a>\u0094 beginning on page <font style=\"white-space:nowrap\">S-8</font> of this prospectus supplement. </b></p>\n<p style=\"margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or\naccuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense. </b></p> <p style=\"margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The underwriters expect to\ndeliver the shares of common stock to purchasers on or about May\u00a0\u00a0\u00a0\u00a0\u00a0, 2018. </p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:15pt\" width=\"100%\">\n<tr>\n<td width=\"22%\"></td>\n<td valign=\"bottom\" width=\"2%\"></td>\n<td></td>\n<td valign=\"bottom\" width=\"2%\"></td>\n<td></td>\n<td valign=\"bottom\" width=\"2%\"></td>\n<td></td>\n<td></td>\n<td></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:15pt\">\n<td valign=\"bottom\"><b>J.P.\u00a0Morgan</b></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\"><b>BofA\u00a0Merrill\u00a0Lynch</b></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\"><b>Credit\u00a0Suisse</b></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\"><b>\u00a0</b></td>\n<td align=\"right\" valign=\"bottom\"><b>Wells\u00a0Fargo\u00a0Securities</b></td>\n<td nowrap=\"\" valign=\"bottom\"><b>\u00a0</b></td></tr>\n</table> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:arial\"><b>May\u00a0\u00a0\u00a0\u00a0\u00a0, 2018 </b></p>\n</div>"}, "htmlOfReport": " <document>\n<type>424B5\n<sequence>1\n<filename>d579741d424b5.htm\n<description>424B5\n<text>\n<html><head>\n<title>424B5</title>\n</head>\n<body bgcolor=\"WHITE\">\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p align=\"right\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Filed Pursuant to Rule 424(b)(5)<br/> Registration No. 333-223526 </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><font color=\"#8b3f4e\"><b>This prospectus supplement relates to an effective registration statement\nunder the Securities Act of 1933, but is not complete and may be changed. Neither this prospectus supplement nor the accompanying prospectus is an offer to sell these securities, and we are not soliciting an offer to buy these securities, in any\njurisdiction where the offer or sale is not permitted. </b></font></p> <p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p>\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial\"><font color=\"#8b3f4e\"><b>Subject to completion, dated May\u00a021, 2018 </b></font></p>\n<p style=\"margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:arial\"><b>Prospectus supplement </b></p> <p style=\"margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial\"><b>(To prospectus dated March\u00a08, 2018) </b></p>\n<p style=\"margin-top:14pt; margin-bottom:0pt; font-size:18pt; font-family:arial\"><b><i>3,750,000 shares </i></b></p> <p style=\"font-size:14pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<p style=\"font-size:0pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p> <p style=\"margin-top:0pt;margin-bottom:0pt\">\n<img alt=\"LOGO\" src=\"g579741g95t12.jpg\"/>\n</p> <p style=\"margin-top:14pt; margin-bottom:0pt; font-size:18pt; font-family:arial\"><b><i>Common stock </i></b></p> <p style=\"margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We are offering\n3,750,000 shares of our common stock. </p> <p style=\"margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Our common stock is listed on the Nasdaq Global Select Market under the symbol \u0093MYOK\u0094. On May\u00a018, 2018, the\nlast reported sale price of our common stock on the Nasdaq Global Select Market was $51.75 per share. </p> <p style=\"font-size:14pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr>\n<td width=\"82%\"></td>\n<td valign=\"bottom\" width=\"3%\"></td>\n<td></td>\n<td></td>\n<td></td>\n<td valign=\"bottom\" width=\"3%\"></td>\n<td></td>\n<td></td>\n<td></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:9pt\">\n<td style=\"BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td colspan=\"2\" style=\"BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\"><b>Per\u00a0share</b></td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td colspan=\"2\" style=\"BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\"><b>Total</b></td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"10\"></td>\n<td colspan=\"4\" height=\"10\"></td>\n<td colspan=\"4\" height=\"10\"></td></tr>\n<tr bgcolor=\"#cceeff\" style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Public offering price</p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td nowrap=\"\" valign=\"top\">$</td>\n<td align=\"right\" nowrap=\"\" valign=\"top\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td nowrap=\"\" valign=\"top\">$</td>\n<td align=\"right\" nowrap=\"\" valign=\"top\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"10\"></td>\n<td colspan=\"4\" height=\"10\"></td>\n<td colspan=\"4\" height=\"10\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Underwriting discounts and commissions(1)</p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td nowrap=\"\" valign=\"top\">$</td>\n<td align=\"right\" nowrap=\"\" valign=\"top\"></td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td nowrap=\"\" valign=\"top\">$</td>\n<td align=\"right\" nowrap=\"\" valign=\"top\"></td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"10\"></td>\n<td colspan=\"4\" height=\"10\"></td>\n<td colspan=\"4\" height=\"10\"></td></tr>\n<tr bgcolor=\"#cceeff\" style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Proceeds to MyoKardia, Inc. before expenses</p></td>\n<td style=\" BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\">$</td>\n<td align=\"right\" nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\"></td>\n<td nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\">\u00a0</td>\n<td style=\" BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\">$</td>\n<td align=\"right\" nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\"></td>\n<td nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\">\u00a0</td></tr>\n</table> <p style=\"font-size:4pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"2%\">(1)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">See \u0093Underwriting\u0094 for a description of the compensation payable to the underwriters. </td></tr></table> <p style=\"margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We have granted the\nunderwriters an option for a period of 30 days to purchase up to an additional 562,500 shares of our common stock. </p> <p style=\"margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Sanofi S.A. (\u0093Sanofi\u0094), our strategic\ncollaboration partner and one of our existing stockholders (through its wholly owned subsidiary, Aventis Inc.), has indicated an interest in purchasing up to an aggregate of approximately 200,000\u00a0shares of our common stock in this offering at\nthe public offering price and on the same terms as the other purchasers in this offering. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters could determine to sell fewer shares to Sanofi\nthan it indicated an interest in purchasing or sell no shares to Sanofi, and Sanofi could determine to purchase fewer shares than it indicated an interest in purchasing or purchase no shares in this offering. The underwriters will receive the same\nunderwriting discount on any shares purchased by Sanofi as they will on any other shares sold to the public in this offering. </p> <p style=\"margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b>Investing in our common stock\ninvolves a high degree of risk. See \u0093<a factors</a>\u0094 beginning on page <font style=\"white-space:nowrap\">S-8</font> of this prospectus supplement. </b></p>\n<p style=\"margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or\naccuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense. </b></p> <p style=\"margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The underwriters expect to\ndeliver the shares of common stock to purchasers on or about May\u00a0\u00a0\u00a0\u00a0\u00a0, 2018. </p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:15pt\" width=\"100%\">\n<tr>\n<td width=\"22%\"></td>\n<td valign=\"bottom\" width=\"2%\"></td>\n<td></td>\n<td valign=\"bottom\" width=\"2%\"></td>\n<td></td>\n<td valign=\"bottom\" width=\"2%\"></td>\n<td></td>\n<td></td>\n<td></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:15pt\">\n<td valign=\"bottom\"><b>J.P.\u00a0Morgan</b></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\"><b>BofA\u00a0Merrill\u00a0Lynch</b></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\"><b>Credit\u00a0Suisse</b></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\"><b>\u00a0</b></td>\n<td align=\"right\" valign=\"bottom\"><b>Wells\u00a0Fargo\u00a0Securities</b></td>\n<td nowrap=\"\" valign=\"bottom\"><b>\u00a0</b></td></tr>\n</table> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:arial\"><b>May\u00a0\u00a0\u00a0\u00a0\u00a0, 2018 </b></p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial\"><b><a name=\"toc\"></a>Table of contents </b></p> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr>\n<td width=\"94%\"></td>\n<td valign=\"bottom\" width=\"2%\"></td>\n<td></td>\n<td></td>\n<td></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:8pt\">\n<td valign=\"bottom\"><b>Prospectus supplement</b></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td align=\"right\" colspan=\"2\" valign=\"bottom\"><b>Page</b></td>\n<td valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a this prospectus supplement</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\"><font style=\"white-space:nowrap\">S-1</font></td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a supplement summary</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\"><font style=\"white-space:nowrap\">S-2</font></td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a offering</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\"><font style=\"white-space:nowrap\">S-6</font></td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a factors</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\"><font style=\"white-space:nowrap\">S-8</font></td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a note regarding forward-looking statements</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\"><font style=\"white-space:nowrap\">S-13</font></td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a of proceeds</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\"><font style=\"white-space:nowrap\">S-14</font></td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\"><font style=\"white-space:nowrap\">S-15</font></td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a U.S. federal income tax consequences to <font style=\"white-space:nowrap\">Non-U.S.\n</font> Holders</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\"><font style=\"white-space:nowrap\">S-17</font></td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\"><font style=\"white-space:nowrap\">S-21</font></td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a matters</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\"><font style=\"white-space:nowrap\">S-33</font></td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\"><font style=\"white-space:nowrap\">S-33</font></td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a you can find more information; incorporation by reference</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\"><font style=\"white-space:nowrap\">S-33</font></td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n</table> <p style=\"font-size:16pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr>\n<td width=\"95%\"></td>\n<td valign=\"bottom\" width=\"3%\"></td>\n<td></td>\n<td></td>\n<td></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:8pt\">\n<td valign=\"bottom\"><b>Prospectus</b></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td align=\"right\" colspan=\"2\" valign=\"bottom\"><b>Page</b></td>\n<td valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a this prospectus</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">1</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a factors</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">2</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a statement regarding forward-looking statements</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">3</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a Company</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">5</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a of earnings to fixed charges</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">6</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a of proceeds</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">6</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a we may offer</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">7</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a of capital stock</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">7</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a of debt securities</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">13</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a of warrants</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">20</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a of units</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">21</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a of distribution</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">24</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a matters</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">27</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">27</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a you can find more information</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">27</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"5\"></td>\n<td colspan=\"4\" height=\"5\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\"><a by reference</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\">\u00a0</td>\n<td align=\"right\" valign=\"top\">27</td>\n<td nowrap=\"\" valign=\"top\">\u00a0</td></tr>\n</table>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">i </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial\"><b><a name=\"supptoc579741_1\"></a>About this prospectus supplement </b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">This document is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offering of common stock and also adds to and\nupdates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. The second part is the accompanying prospectus dated March\u00a08, 2018,\nincluded in our registration statement on Form <font style=\"white-space:nowrap\">S-3</font> (File <font style=\"white-space:nowrap\">No.\u00a0333-223526)</font> that became effective automatically upon filing with the Securities and Exchange Commission\n(the \u0093SEC\u0094), along with the documents incorporated by reference, which provides more general information, some of which may not apply to this offering. Generally, when we refer to this prospectus, we are referring to both parts of this\ndocument combined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in any document incorporated by reference that was\nfiled with the SEC, before the date of this prospectus supplement, on the other hand, you should rely on the information contained in this prospectus supplement. If any statement in one of these documents is inconsistent with a statement in another\ndocument having a later date\u0097for example, a document incorporated by reference in the accompanying prospectus\u0097the statement in the document having the later date modifies or supersedes the earlier statement. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">This prospectus supplement and the accompanying prospectus are part of a registration statement that we filed with the SEC, utilizing a \u0093shelf\u0094 registration\nprocess as a \u0093well-known seasoned issuer\u0094 as defined in Rule 405 under the Securities Act of 1933, as amended (the \u0093Securities Act\u0094). Under this shelf registration process, we may offer from time to time various securities, of\nwhich this offering of shares of our common stock is a part. Such registration statement also includes exhibits that provide more detail on the matters discussed in this prospectus supplement and the accompanying prospectus. You should read this\nprospectus supplement, the accompanying prospectus, including the information incorporated by reference, the exhibits filed with the SEC, and any free writing prospectus that we have authorized for use in connection with this offering, in their\nentirety before making an investment decision. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">You should rely only on the information contained or incorporated by reference in this prospectus supplement and the\naccompanying prospectus, along with the information contained in any free writing prospectus that we have authorized for use in connection with this offering. We have not, and the underwriters have not, authorized anyone to provide you with\ndifferent or additional information. If anyone provides you with different or inconsistent information, you should not rely on it. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other\ninformation that others may give you. You should assume that the information appearing in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference in this prospectus supplement and the accompanying prospectus,\nand in any free writing prospectus that we have authorized for use in connection with this offering is accurate only as of the respective dates of those documents, unless we indicate otherwise. Our business, financial condition, results of\noperations and prospects may have changed since those dates. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We further note that the representations, warranties and covenants made by us in any agreement that is\nfiled as an exhibit to any document that is incorporated by reference in this prospectus supplement or the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of\nallocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties and covenants were accurate only as of the date when made; therefore, such\nrepresentations, warranties and covenants should not be relied on as accurate representations of the current state of our affairs. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">When we refer to\n\u0093MyoKardia,\u0094 \u0093we,\u0094 \u0093our,\u0094 \u0093us\u0094 and the \u0093Company\u0094 in this prospectus, we mean MyoKardia, Inc. and, where appropriate, our subsidiary, unless otherwise specified. When we refer to \u0093you,\u0094 we\nmean the holders of our common stock. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-1 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<div style=\"BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%\"><div style=\"width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial\"><b><a name=\"supptoc579741_2\"></a>Prospectus supplement summary </b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><i>This summary highlights certain information about us, this offering and selected information contained elsewhere in, or incorporated by reference into, this\nprospectus supplement and the accompanying prospectus. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in our common stock. For a more complete understanding of our\ncompany and this offering, we encourage you to read and consider carefully the more detailed information in this prospectus supplement and the accompanying prospectus, including our financial statements and related notes and the other information\nincorporated by reference into this prospectus supplement and the accompanying prospectus, and the information included in any free writing prospectus that we have authorized for use in connection with this offering, including the information\nreferred to under the heading \u0093Risk Factors\u0094 in this prospectus supplement beginning on page <font style=\"white-space:nowrap\">S-8</font> and in the documents incorporated herein by reference. </i></p>\n<p style=\"margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial\"><b>Company overview </b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We are a clinical stage biopharmaceutical company\npioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus is on the treatment of heritable cardiomyopathies, a group\nof rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. We have used our precision medicine platform to generate a robust pipeline of therapeutic programs for the chronic treatment of\nthe two most common forms of heritable cardiomyopathy\u0097hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Our mission is to change the world for patients with serious cardiovascular disease through bold and innovative science.\n</p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Our lead candidate, mavacamten is advancing into a pivotal Phase 3 clinical trial, known as <font style=\"white-space:nowrap\">EXPLORER-HCM</font> in patients with\nsymptomatic, obstructive HCM (oHCM). Mavacamten is intended to reduce cardiac muscle contractility by inhibiting the excessive myosin-actin crossbridge formation that underlies the excessive contractility, left ventricular hypertrophy and reduced\ncompliance characteristic of HCM. In 2016, mavacamten was granted Orphan Drug Designation by the U.S. Food and Drug Administration, or the FDA, for the treatment of symptomatic oHCM. We are also studying mavacamten for a second potential indication,\nsymptomatic, <font style=\"white-space:nowrap\">non-obstructive</font> HCM (nHCM), in a Phase 2 clinical trial, known as <font style=\"white-space:nowrap\">MAVERICK-HCM.</font> A second product candidate, <font style=\"white-space:nowrap\">MYK-491,</font>\nis a myosin activator designed to restore the inadequate output characteristic of a DCM heart by targeting the biomechanical defects underlying disease and improving cardiac contractility. <font style=\"white-space:nowrap\">MYK-491</font> has\ncompleted its <font style=\"white-space:nowrap\"><font style=\"white-space:nowrap\">first-in-human</font></font> Phase 1 clinical trial in healthy volunteers and we are currently enrolling patients in a Phase 1b clinical trial. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We have never been profitable and have incurred net losses in each year since inception. Our net loss for the years ended December\u00a031, 2017 and 2016, before\nrevisions due to the adoption of ASC 606 \u0093Revenue from Contracts with Customers\u0094, was $46.0\u00a0million and $13.2\u00a0million, respectively. As of March\u00a031, 2018, we had an accumulated deficit of $152.7\u00a0million. To date, we\nhave not generated any product revenue. We do not expect to receive any revenue from any product candidates that we develop until we obtain regulatory approval and commercialize our products or enter into additional collaborative agreements with\nthird parties. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. As of March\u00a031, 2018, we had\n$259.3\u00a0million of cash, cash equivalents, and investments (short-term and long-term). We expect our current cash, cash equivalents and investments, together with anticipated payments under our collaboration agreement with Sanofi, to fund our\nplanned operations into 2020. </p>\n</div></div>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-2 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<div style=\"BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%\"><div style=\"width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial\"><b>Recent developments </b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In May\n2018, we announced the design of our planned Phase 3 clinical trial, known as <font style=\"white-space:nowrap\">EXPLORER-HCM,</font> to evaluate mavacamten for the potential treatment of patients with symptomatic oHCM. We expect to dose the first\npatient in the <font style=\"white-space:nowrap\">EXPLORER-HCM</font> trial in the second quarter of 2018, and we anticipate that data from this trial will be available in the second half of 2020. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><font style=\"white-space:nowrap\">EXPLORER-HCM</font> is a multi-national randomized double-blind study designed to assess the effects of a\n<font style=\"white-space:nowrap\">30-week</font> treatment of mavacamten versus placebo with a primary endpoint of clinical response. The clinical response endpoint is intended to broadly capture the potential benefits of treatment with mavacamten on\nhow patients feel and function by utilizing both peak oxygen consumption (peak VO<sub style=\"font-size:85%; vertical-align:bottom\">2)</sub> and New York Heart Association (NYHA) functional classification. Clinical response can be achieved by meeting\neither of two definitions: 1) an improvement of at least 1.5 mL/kg/min in peak VO<sub style=\"font-size:85%; vertical-align:bottom\">2 </sub>accompanied by a reduction from baseline of at least one NYHA functional class, or 2) an improvement from\nbaseline of 3.0 mL/kg/min or greater in peak VO<sub style=\"font-size:85%; vertical-align:bottom\">2 </sub>without worsening in NYHA functional class. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Approximately\n220 patients will be enrolled and randomized on a 1:1 basis to receive either mavacamten or placebo. The <font style=\"white-space:nowrap\">EXPLORER-HCM</font> trial design includes two opportunities for individualized dose adjustment throughout the <font style=\"white-space:nowrap\">30-week</font> treatment period. Patients in the active treatment arm will start on a once-daily 5mg dose of mavacamten. At Weeks 8 and 14, daily doses may be increased to 10mg or 15mg, or remain unchanged, based on\nmeasurements of provoked left ventricular outflow tract (LVOT) gradient conducted at Weeks 6 and 12. A reduction in provoked LVOT gradient under 50 mmHg has been shown in PIONEER to correlate to improvements in several clinical measurements,\nincluding NYHA class and peak VO<sub style=\"font-size:85%; vertical-align:bottom\">2</sub>. All assessments and dose adjustments will be conducted in a blinded fashion. Patients will be allowed to maintain their\n<font style=\"white-space:nowrap\">HCM-related</font> background medications for the duration of the <font style=\"white-space:nowrap\">EXPLORER-HCM</font> Phase 3 trial, including beta blockers or calcium channel blockers. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Secondary endpoints in the Phase 3 <font style=\"white-space:nowrap\">EXPLORER-HCM</font> trial will include the average change from baseline in post-exercise peak LVOT\ngradient, NYHA functional class, peak VO<sub style=\"font-size:85%; vertical-align:bottom\">2, </sub>the proportion of patients achieving post-exercise peak LVOT gradient below 50 mmHg or 30 mmHg at Week 30 and patient-reported outcome measures.\nExploratory endpoints will include changes in echocardiographic indices of cardiac structure and function, <font style=\"white-space:nowrap\">N-terminal</font> pro <font style=\"white-space:nowrap\">b-type</font> natriuretic peptide <font style=\"white-space:nowrap\">(NT-proBNP)</font> concentrations, quality of life questionnaire scores and daily physical activity assessed using a wearable accelerometer. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Throughout the <font style=\"white-space:nowrap\">EXPLORER-HCM</font> study, patients will be monitored for adverse events and certain assessments will be performed. If at\nany time during the trial, a patient\u0092s plasma concentration is above an upper target range or LVEF falls below the normal range, doses of mavacamten may be decreased. Following the <font style=\"white-space:nowrap\">30-week</font> treatment\nperiod and eight-week post-treatment <font style=\"white-space:nowrap\">wash-out</font> period, patients will be able to participate in a long-term extension study of mavacamten. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In May 2018, we also announced the dosing of the first patient in the PIONEER open-label extension <font style=\"white-space:nowrap\">(PIONEER-OLE)</font> study of\nmavacamten for symptomatic oHCM. The <font style=\"white-space:nowrap\">PIONEER-OLE</font> study, which will enroll patients who previously completed the Phase 2 <font style=\"white-space:nowrap\">PIONEER-HCM</font> trial, is intended to provide data on\nlonger-term exposure to mavacamten. Patients will receive an individualized daily dose of 5mg, 10mg, or 15 mg of mavacamten, with a dose adjustment at week 6 based on pharmacodynamic and pharmacokinetic criteria, as well as the patient\u0092s past\nexperience with mavacamten. We anticipate reporting the first interim data update from the <font style=\"white-space:nowrap\">PIONEER-OLE</font> study in the first quarter of 2019. </p>\n</div></div>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-3 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<div style=\"BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%\"><div style=\"width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In April 2018, we announced that the first patient had been dosed in the Phase 2\n<font style=\"white-space:nowrap\">MAVERICK-HCM</font> clinical trial, which is the first clinical trial of mavacamten in nHCM. In nHCM, the heart contracts excessively, but no physical obstruction is present in the outflow tract of the left\nventricle. As a result of the hypercontractility, the left ventricle becomes abnormally thick and fibrotic, which prevents the heart from being able to relax and fill with blood normally. The Phase 2\n<font style=\"white-space:nowrap\">MAVERICK-HCM</font> trial is a double-blind, placebo-controlled study designed to assess the safety and tolerability of a <font style=\"white-space:nowrap\">16-week</font> treatment course of mavacamten. The trial is\nexpected to enroll approximately 60 patients with nHCM and preserved left ventricular ejection fraction. Patients will be randomized evenly into three groups to receive a once-daily dose of mavacamten targeting one of two plasma concentration levels\nof drug or placebo. Secondary endpoints from the trial will assess the effect of mavacamten on exercise capacity as measured by peak VO<sub style=\"font-size:85%; vertical-align:bottom\">2</sub>, changes in NYHA functional classification, diastolic\nand systolic function as measured by echocardiography, symptoms and quality of life measures, NT <font style=\"white-space:nowrap\">pro-BNP</font> levels and patient activity as measured by a wrist-worn accelerometer. In addition to the <font style=\"white-space:nowrap\">16-week</font> treatment period, patients will participate in a screening period of up to four weeks and will be monitored for an additional eight weeks after discontinuation of mavacamten. We expect to report topline data\nfrom the <font style=\"white-space:nowrap\">MAVERICK-HCM</font> trial in the second half of 2019. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In March 2018, data from both cohorts of the Phase 2 <font style=\"white-space:nowrap\">PIONEER-HCM</font> clinical trial were presented at the American College of Cardiology (ACC) 67th Annual Scientific Session. In the <font style=\"white-space:nowrap\">PIONEER-HCM</font> Phase 2 clinical trial of 21\nsymptomatic oHCM patients, mavacamten achieved the primary endpoint of reduction in post-exercise LVOT gradient from baseline to week 12 with statistical significance across both cohorts tested. Improvements in peak VO<sub style=\"font-size:85%; vertical-align:bottom\">2</sub>, NYHA classification and dyspnea rating scores were also observed. Mavacamten was generally well-tolerated. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In\nFebruary 2018, we initiated a single-ascending dose study of <font style=\"white-space:nowrap\">MYK-491</font> in symptomatic DCM patients with stable, moderate heart failure. The objectives of this randomized, double-blind, placebo-controlled Phase\n1b trial are to assess safety, tolerability, preliminary pharmacokinetics and pharmacodynamics of <font style=\"white-space:nowrap\">MYK-491</font> in DCM patients, including echocardiographic measures of effect on contractility. We anticipate\nreporting data from this trial in the second half of 2018. Data from the Phase 1 program of <font style=\"white-space:nowrap\">MYK-491</font> will inform a Phase 2 clinical study of <font style=\"white-space:nowrap\">MYK-491</font> in DCM patients,\nwhich is planned to begin dosing in the second half of 2018. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In addition, we are advancing a third program toward clinical development and anticipate filing an\nInvestigational New Drug application in the next 12-18 months. </p> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial\"><b>Corporate information </b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We were incorporated in Delaware in June 2012. Our principal executive offices are located at 333 Allerton Ave., South San Francisco, California 94080. Our telephone\nnumber is <font style=\"white-space:nowrap\">(650)\u00a0741-0900</font> and our <font style=\"white-space:nowrap\">e-mail</font> address is info@myokardia.com. Our Internet website address is <i>www.myokardia.com</i>. No portion of our website is\nincorporated by reference into this prospectus. We do not incorporate the information on or accessible through our website into this prospectus supplement or the underlying prospectus, and you should not consider any information on, or that can be\naccessed through, our website as part of this prospectus supplement or the underlying prospectus. Our common stock trades on the Nasdaq Global Select Market under the symbol \u0093MYOK\u0094. </p>\n</div></div>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-4 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<div style=\"BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%\"><div style=\"width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We qualify as an \u0093emerging growth company\u0094 as defined in the Jumpstart Our Business Startups Act of 2012, as\namended (the \u0093JOBS Act\u0094). As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. We would cease to be an emerging growth\ncompany on the date that is the earliest of: (i)\u00a0December\u00a031, 2020, (ii) the last day of the fiscal year in which we have total annual gross revenue of $1.07\u00a0billion or more, (iii)\u00a0the last day of the fiscal year in which we are\ndeemed to be a large accelerated filer, which means the market value of our common stock that is held by <font style=\"white-space:nowrap\">non-affiliates</font> exceeds $700.0\u00a0million as of the prior June 30th and (iv)\u00a0the date on which we\nhave issued more than $1.0\u00a0billion in <font style=\"white-space:nowrap\">non-convertible</font> debt during any three-year period before that time. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We use\nvarious trademarks and trade names in our business, including without limitation our corporate name and logo. All other trademarks or trade names referred to in this prospectus are the property of their respective owners. Solely for convenience, the\ntrademarks and trade names in this prospectus may be referred to without the <sup style=\"font-size:85%; vertical-align:top\">\u00ae</sup> and \u0099 symbols, but such references should not be construed as any indicator that their respective owners\nwill not assert, to the fullest extent under applicable law, their rights thereto. </p>\n</div></div>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-5 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<div style=\"BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%\"><div style=\"width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial\"><b><a name=\"supptoc579741_3\"></a>The offering </b></p>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr valign=\"TOP\">\n<td width=\"27%\"> <p style=\" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial\"><b>Common stock offered by us </b></p></td>\n<td>3,750,000 shares (or 4,312,500 shares if the underwriters exercise their option to purchase additional shares in full) </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr valign=\"TOP\">\n<td width=\"27%\"> <p style=\" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial\"><b>Common stock to be outstanding immediately after this offering </b></p></td>\n<td>39,672,982 shares (or 40,235,482 shares if the underwriters exercise their option to purchase additional shares in full) </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr valign=\"TOP\">\n<td width=\"27%\"> <p style=\" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial\"><b>Option to purchase additional shares </b></p></td>\n<td>We have granted the underwriters an option for a period of 30 days from the date of this prospectus supplement to purchase up to 562,500 additional shares of our common stock. </td></tr></table>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr valign=\"TOP\">\n<td width=\"27%\"> <p style=\" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial\"><b>Use of proceeds </b></p></td>\n<td>We intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and short-term and long-term investments, to fund research and development activities for our development programs, including, but not\nlimited to, our planned Phase 3 <font style=\"white-space:nowrap\">EXPLORER-HCM</font> clinical trial of mavacamten and our planned Phase 2 clinical trial of <font style=\"white-space:nowrap\">MYK-491,</font> as well as our other ongoing and planned\nclinical trials for mavacamten and <font style=\"white-space:nowrap\">MYK-491,</font> our ongoing preclinical, discovery and research programs and the expansion of our platform, and for working capital and other general corporate purposes. See also\nthe section entitled \u0093Use of proceeds\u0094 on page <font style=\"white-space:nowrap\">S-14</font> of this prospectus supplement. </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr valign=\"TOP\">\n<td width=\"27%\"> <p style=\" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial\"><b>Risk factors </b></p></td>\n<td>Investing in our common stock involves a high degree of risk. See \u0093Risk factors\u0094 beginning on page <font style=\"white-space:nowrap\">S-8</font> of this prospectus supplement, as well as those \u0093Risk factors\u0094 incorporated by\nreference into this prospectus supplement, for a discussion of factors you should consider carefully before deciding to purchase any shares of our common stock. </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr valign=\"TOP\">\n<td width=\"27%\"> <p style=\" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial\"><b>Nasdaq Global Select Market symbol </b></p></td>\n<td>MYOK </td></tr></table> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The number of shares of our common stock to be outstanding immediately after this offering is based on 35,922,982 shares of our common stock\noutstanding as of March\u00a031, 2018. The number of shares outstanding as of March\u00a031, 2018 excludes: </p> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">3,793,364 shares of common stock issuable upon the exercise of stock options and awards outstanding as of March\u00a031, 2018, at a weighted average exercise price of $22.15 per share; </td></tr></table>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">170,420 shares of common stock issuable upon the exercise of outstanding stock options and awards granted subsequent to March\u00a031, 2018, at a weighted average exercise price of $42.23 per share; and\n</td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">2,164,614 shares of common stock reserved for future issuance under our 2015 Stock Option and Incentive Plan and our 2015 Employee Stock Purchase Plan as of March\u00a031, 2018. </td></tr></table>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Except as otherwise indicated, all information in this prospectus supplement assumes no exercise by the underwriters of their option to purchase up to an additional\n562,500 shares of our common stock. </p>\n</div></div>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-6 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<div style=\"BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%\"><div style=\"width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial\"><b>Indications of interest </b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Sanofi, our strategic collaboration partner and one of our existing stockholders (through its wholly owned subsidiary Aventis Inc.), has indicated an interest in\npurchasing up to an aggregate of approximately 200,000 shares of our common stock in this offering at the public offering price and on the same terms as the other purchasers in this offering. However, because indications of interest are not binding\nagreements or commitments to purchase, the underwriters could determine to sell fewer shares to Sanofi than it indicated an interest in purchasing or sell no shares to Sanofi, and Sanofi could determine to purchase fewer shares than it indicated an\ninterest in purchasing or purchase no shares in this offering. </p>\n</div></div>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-7 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial\"><b><a name=\"supptoc579741_4\"></a>Risk factors </b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><i>Investing in our common stock involves a high degree of risk. You should carefully consider the risk factors described below and the risk factors incorporated by\nreference to our most recent Quarterly Report on Form <font style=\"white-space:nowrap\">10-Q</font> and Annual Report on Form <font style=\"white-space:nowrap\">10-K,</font> and any subsequent Quarterly Reports on Form\n<font style=\"white-space:nowrap\">10-Q</font> or Current Reports on Form <font style=\"white-space:nowrap\">8-K</font> we file after the date of this prospectus supplement, and all other information contained or incorporated by reference into this\nprospectus supplement and the accompanying prospectus, including our financial statements and the related notes, as updated by our subsequent filings under the Securities Exchange Act of 1934, as amended (the \u0093Exchange Act\u0094) and in any\nfree writing prospectus that we have authorized for use in connection with this offering before acquiring any of our common stock. These risks could have a material and adverse impact on our business, results of operations, financial condition and\ngrowth prospects, which may cause the trading price of our common stock to decline and you could lose all or part of your investment. </i></p> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial\"><b>Risks related to our\nequity securities and this offering </b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>The market price of our common stock has been and may continue to be highly volatile. </i></b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The market price of our common stock has experienced volatility since our initial public offering in October 2015 and is likely to continue to be volatile. Our stock\nprice could be subject to wide fluctuations in response to a variety of factors, including the following: </p> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">adverse results or delays in preclinical studies or clinical trials; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">reports of adverse events in clinical trials of our product candidates or in other products for the treatment of cardiovascular diseases or clinical trials of such products; </td></tr></table>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">inability to obtain additional funding; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any delay in filing an IND or NDA for any of our product candidates and any adverse development or perceived adverse development with respect to the FDA\u0092s review of that IND or NDA; </td></tr></table>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">failure to develop successfully and commercialize our product candidates; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any adverse developments relating to our Collaboration Agreement with Sanofi, or any failure to maintain our existing strategic collaborations or enter into new collaborations; </td></tr></table>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">failure by us or our licensors and strategic collaborators to prosecute, maintain or enforce our intellectual property rights; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">changes in laws or regulations applicable to future products; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">inability to obtain adequate product supply for our product candidates or the inability to do so at acceptable prices; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">adverse regulatory decisions affecting our product candidates or development programs; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">introduction of new products, services or technologies by our competitors; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">failure to meet or exceed financial projections we may provide to the public or to the investment community; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us, our strategic collaboration partner or our competitors; </td></tr></table>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-8 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; </td></tr></table>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">additions or departures of key scientific or management personnel; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">significant lawsuits, including patent or stockholder litigation; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">changes in the market valuations of similar companies; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">sales of our common stock by us or our stockholders in the future; and </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">trading volume of our common stock. </td></tr></table> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In addition, companies trading in the stock market in general, and the Nasdaq Global\nSelect Market in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the\nmarket price of our common stock, regardless of our actual operating performance. In the past, following periods of volatility in the market, securities class-action litigation has often been instituted against companies. Such litigation, if\ninstituted against us, could result in substantial costs and diversion of management\u0092s attention and resources, which could materially and adversely affect our business, financial condition, results of operations and growth prospects. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>We will have broad discretion in the use of proceeds from this offering and may invest or spend the proceeds in ways with which you do not agree or in ways that\nultimately may not increase the value of your investment. </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We will have broad discretion over the use of proceeds from this offering. You may not agree with\nour decisions, and our use of the proceeds may not yield any return on your investment. We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to fund research and development activities for our\ndevelopment programs, including, but not limited to, our planned Phase 3 <font style=\"white-space:nowrap\">EXPLORER-HCM</font> clinical trial of mavacamten and our planned Phase 2 clinical trial of <font style=\"white-space:nowrap\">MYK-491,</font> as\nwell as our other ongoing and planned clinical trials for mavacamten and <font style=\"white-space:nowrap\">MYK-491,</font> our ongoing preclinical, discovery and research programs and the expansion of our platform, and for working capital and other\ngeneral corporate purposes. Our failure to apply the net proceeds from this offering effectively could compromise our ability to pursue our growth strategy and we might not be able to yield a significant return, if any, on our investment of these\nnet proceeds. In addition, the net proceeds from this offering may not be sufficient for our anticipated uses, and we may need additional resources to progress our product candidates to the stage we expect. You will not have the opportunity to\ninfluence our decisions on how to use our net proceeds from this offering. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>If you purchase our common stock in this offering, you will incur immediate and\nsubstantial dilution in the book value of your shares. </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Investors purchasing shares of common stock in this offering will pay a price per share that\nsubstantially exceeds the pro forma book value per share of our tangible assets after subtracting our liabilities as of March\u00a031, 2018. As a result, investors purchasing shares of common stock in this offering will incur immediate dilution of\n$41.69 per share based on the assumed public offering price of $51.75 per share, which was the last reported sale price of our common stock on the Nasdaq Global Select Market on May\u00a018, 2018. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Further, investors purchasing shares of common stock in this offering will contribute approximately\u00a029% of the total amount invested by stockholders since our\ninception (or 32% of the total amount invested by our stockholders since our inception if the underwriters\u0092 option to purchase additional shares is exercised in full), but will own only approximately 9% of the shares of common stock outstanding\n(or 11% of the shares of common stock outstanding if the underwriters\u0092 option to purchase additional shares is exercised in full). For information on how the foregoing amounts were calculated, see \u0093Dilution.\u0094 </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-9 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">This dilution is due to the substantially lower price paid by our investors who purchased shares prior to this\noffering as compared to the price offered to investors in this offering, and the exercise price of stock options granted to our employees. The exercise of any of these options would result in additional dilution. As a result of the dilution to\ninvestors purchasing shares in this offering, investors may receive significantly less than the purchase price paid in this offering, if anything, in the event of our liquidation. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional\ndilution of the percentage ownership of our stockholders and could cause our stock price to fall. </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Additional capital will be needed in the future to\ncontinue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more\ntransactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may\nalso result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In addition, sales of a\nsubstantial number of shares of our outstanding common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce\nthe market price of our common stock. Significant portions of our outstanding shares of common stock are held by a relatively small number of stockholders. Sales by our stockholders of a substantial number of shares, or the expectation that such\nsales may occur, could significantly reduce the market price of our common stock. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We have also registered all shares of our common stock subject to options or other\nequity awards issued or reserved for future issuance under our equity incentive plans. As a result, these shares will be eligible for sale in the public market to the extent permitted by any applicable vesting requirements and the exercise of\noptions, and restrictions under applicable securities laws. In addition, our directors, executive officers and certain affiliates have established, or may in the future establish, programmed selling plans under Rule\n<font style=\"white-space:nowrap\">10b5-1</font> of the Exchange Act for the purpose of effecting sales of our common stock. If any of these events cause a large number of our shares to be sold in the public market, the sales could reduce the trading\nprice of our common stock and impede our ability to raise future capital. Moreover, certain holders of our common stock have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include\ntheir shares in registration statements that we may file for ourselves or other stockholders. In particular, we have filed a registration statement on Form <font style=\"white-space:nowrap\">S-3</font> registering for resale 9,184,352 shares of common\nstock held by entities affiliated with our major shareholder, Third Rock Ventures, which was declared effective by the SEC on July\u00a021, 2017. These shares, together with any additional shares that we may register for resale, can be freely sold\nin the public market. If these additional shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Pursuant to the 2015 Stock Option and Incentive Plan, we are authorized to grant stock options and other equity-based awards to our employees, directors and consultants.\nBeginning on January\u00a01, 2017, the number of shares available for future grant under the 2015 Stock Option and Incentive Plan automatically increases each year by up to 4% of all shares of our capital stock outstanding as of December\u00a031 of\nthe prior calendar year, subject to the ability of our board of directors to take action to reduce the size of the increase in any given year. In addition, pursuant to the 2015 Employee Stock Purchase Plan, we initially reserved 255,000 shares for\npurchase by eligible employees. Beginning on January\u00a01, 2017 and ending on January\u00a01, 2025, the number of shares available for future issuance under the 2015 Employee Stock Purchase Plan automatically increases each year by up to the\nlesser of 3,000,000 shares of common stock or 1% of all shares of our capital stock </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-10 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">\noutstanding as of December\u00a031 of the prior calendar year, subject to the ability of our board of directors to take action to reduce the size of the increase in any given year. Currently, we\nplan to register the increased number of shares available for issuance under the 2015 Stock Option and Incentive Plan and the 2015 Employee Stock Purchase Plan each year. If our board of directors elects to increase the number of shares available\nfor future grant under these plans by the maximum amount each year, our stockholders may experience additional dilution, which could cause our stock price to fall. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to\nstockholder approval. </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">As of March\u00a031, 2018, our executive officers, directors, five percent or greater stockholders and their affiliates beneficially\nown approximately 41.6% of our outstanding voting stock. In addition, Sanofi, our strategic collaboration partner and one of our existing stockholders (through its wholly owned subsidiary Aventis Inc.), has indicated an interest in purchasing up to\nan aggregate of approximately 200,000 shares of our common stock in this offering at the public offering price and on the same terms as the other purchasers in this offering. If Sanofi were to purchase 200,000 shares of our common stock, our\nexecutive officers, directors, five percent or greater stockholders and their affiliates will beneficially own approximately 33.5% of our outstanding voting stock upon the closing of this offering (assuming no exercise of the underwriters\u0092\noption to purchase additional shares and no exercise of outstanding options). These stockholders will have the ability to influence us through their ownership positions. These stockholders may be able to determine all matters requiring stockholder\napproval. For example, these stockholders, acting together, may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent\nor discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>If\nsecurities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, our stock price and trading volume could decline. </i></b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The trading market for our common stock will depend, in part, on the research and reports that securities or industry analysts publish about us or our business.\nSecurities and industry analysts may not publish an adequate amount of research on our company, which may negatively impact the trading price for our stock. In addition, if one or more of the analysts who cover us downgrade our stock or publish\ninaccurate or unfavorable research about our business, our stock price would likely decline. Further, if our operating results fail to meet the forecasts of analysts, our stock price would likely decline. If one or more of these analysts cease\ncoverage of our company or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of\ngain. </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the\ngrowth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable\nfuture. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>We could be subject to securities class action litigation. </i></b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is\nespecially relevant for us because biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management\u0092s\nattention and resources, which could harm our business. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-11 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Changes in tax law may adversely affect us or our investors. </i></b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the IRS and the\nU.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in\nthe future. It cannot be predicted whether, when, in what form, or with what effective dates, tax laws, regulations and rulings may be enacted, promulgated or issued, which could result in an increase in our or our shareholders\u0092 tax liability\nor require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-12 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial\"><b><a name=\"supptoc579741_5\"></a>Cautionary note regarding forward-looking statements </b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">This prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein, and any free writing prospectus that we have\nauthorized for use in connection with this offering, contain forward-looking statements. All statements other than statements of historical facts contained in this prospectus supplement, the accompanying prospectus and the documents incorporated by\nreference herein are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future\nresults, performance or achievements expressed or implied by the forward-looking statements. This prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein also contain estimates and other statistical data\nmade by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition,\nprojections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In some cases, you can identify forward-looking statements by terms such as \u0093may,\u0094 \u0093will,\u0094 \u0093should,\u0094 \u0093expect,\u0094 \u0093plan,\u0094\n\u0093anticipate,\u0094 \u0093could,\u0094 \u0093intend,\u0094 \u0093target,\u0094 \u0093project,\u0094 \u0093contemplates,\u0094 \u0093believes,\u0094 \u0093estimates,\u0094 \u0093predicts,\u0094 \u0093potential\u0094 or \u0093continue\u0094 or the\nnegative of these terms or other similar expressions. The forward-looking statements in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein, and any free writing prospectus that we\nhave authorized for use in connection with this offering, are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect\nour business, financial condition and results of operations. These forward-looking statements speak only as of the date of this prospectus supplement and are subject to a number of risks, uncertainties and assumptions, including those under the\nheading \u0093Risk factors\u0094 in this prospectus supplement and in the documents incorporated by reference herein, and elsewhere in this prospectus supplement. The events and circumstances reflected in our forward-looking statements may not be\nachieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not\npossible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained in this prospectus supplement, the accompanying\nprospectus or the documents incorporated by reference herein and therein, and any free writing prospectus that we have authorized for use in connection with this offering, whether as a result of any new information, future events, changed\ncircumstances or otherwise. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-13 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial\"><b><a name=\"supptoc579741_6\"></a>Use of proceeds </b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We estimate that we will receive net proceeds of approximately $181.8 million from the sale of 3,750,000 shares of our common stock offered in this offering, based on\nthe assumed public offering price of $51.75 per share, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. If the underwriters exercise their option to purchase up to an additional\n562,500 shares in full, we estimate that the net proceeds of the shares we sell in this offering will be approximately $209.1 million. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">A $1.00 increase (decrease)\nin the assumed public offering price of $51.75 per share would increase (decrease) the net proceeds from this offering by approximately $3.5 million, assuming that the number of shares we are offering, as set forth on the cover page of this\nprospectus supplement, remains the same, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. Each increase (decrease)\nof 500,000 in the number of shares we are offering would increase (decrease) the net proceeds to us from this offering by approximately $24.3\u00a0million, assuming that the assumed public offering price, as set forth on the cover page of this\nprospectus supplement, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We\nintend to use the net proceeds from this offering, together with our existing cash, cash equivalents and short-term and long-term investments, to fund research and development activities for our development programs, including, but not limited to,\nour planned Phase 3 <font style=\"white-space:nowrap\">EXPLORER-HCM</font> clinical trial of mavacamten and our planned Phase 2 clinical trial of <font style=\"white-space:nowrap\">MYK-491,</font> as well as our other ongoing and planned clinical trials\nfor mavacamten and <font style=\"white-space:nowrap\">MYK-491,</font> our ongoing preclinical, discovery and research programs and the expansion of our platform, and for working capital and other general corporate purposes. We expect our current cash,\ncash equivalents and investments, together with anticipated payments under our collaboration agreement with Sanofi and the anticipated net proceeds from this offering, to fund our planned operations into 2021. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We may also use a portion of the net proceeds to <font style=\"white-space:nowrap\">in-license,</font> acquire or invest in new businesses, technology or assets. Although\nwe have no specific agreements, commitments or understandings with respect to any <font style=\"white-space:nowrap\">in-license</font> or acquisition, we evaluate such opportunities and engage in related discussions with other business entities from\ntime to time. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The amounts and timing of our actual expenditures will depend on numerous factors, including the factors described under \u0093Risk factors\u0094 in\nthis prospectus supplement, the accompanying prospectus and in the documents incorporated by reference herein, as well as the amount of cash used in our operations. We may find it necessary or advisable to use the net proceeds for other purposes,\nand we will have broad discretion in the application of the net proceeds. Pending the uses described above, we plan to invest the net proceeds from this offering in short- and intermediate-term, interest-bearing obligations, investment-grade\ninstruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-14 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial\"><b><a name=\"supptoc579741_7\"></a>Dilution </b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">If you invest in our common stock in this offering, your ownership interest will be diluted to the extent of the difference between the public offering price per share\nof our common stock and the net tangible book value per share of our common stock immediately after this offering. The net tangible book value of our common stock as of March\u00a031, 2018 was approximately $217.2\u00a0million, or approximately\n$6.05\u00a0per share of common stock based upon 35,922,982\u00a0shares outstanding. Net tangible book value per share is equal to our total tangible assets, less our total liabilities, divided by the total number of shares of common stock\noutstanding as of March\u00a031, 2018. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Net tangible book value dilution per share to investors participating in this offering represents the difference between the\namount per share paid by purchasers of shares of common stock in this offering and the as adjusted net tangible book value per share of common stock immediately after completion of this offering. After giving effect to the issuance and sale by us of\n3,750,000\u00a0shares of our common stock at the assumed public offering price of $51.75\u00a0per share, which was the last reported sale price of our common stock on the Nasdaq Global Select Market on May\u00a018, 2018, and after deducting\nestimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma net tangible book value as of March\u00a031, 2018 would have been $398.9\u00a0million, or $10.06\u00a0per share of our common stock. This\nrepresents an immediate increase in net tangible book value of $4.01\u00a0per share to our existing stockholders and an immediate dilution in net tangible book value of $41.69\u00a0per share to new investors in this offering. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The following table illustrates this calculation on a per share basis: </p> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr>\n<td width=\"85%\"></td>\n<td valign=\"bottom\" width=\"3%\"></td>\n<td></td>\n<td></td>\n<td></td>\n<td valign=\"bottom\" width=\"3%\"></td>\n<td></td>\n<td></td>\n<td></td></tr>\n<tr bgcolor=\"#cceeff\" style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td style=\"BORDER-TOP:2.00pt solid #000000\" valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Assumed public offering price per share</p></td>\n<td style=\" BORDER-TOP:2.00pt solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td style=\"BORDER-TOP:2.00pt solid #000000\" valign=\"bottom\">\u00a0</td>\n<td style=\"BORDER-TOP:2.00pt solid #000000\" valign=\"bottom\">\u00a0</td>\n<td style=\"BORDER-TOP:2.00pt solid #000000\" valign=\"bottom\">\u00a0</td>\n<td style=\" BORDER-TOP:2.00pt solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td style=\"BORDER-TOP:2.00pt solid #000000\" valign=\"bottom\">$</td>\n<td align=\"right\" style=\"BORDER-TOP:2.00pt solid #000000\" valign=\"bottom\">51.75</td>\n<td nowrap=\"\" style=\"BORDER-TOP:2.00pt solid #000000\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Net tangible book value per share as of March\u00a031, 2018</p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">$</td>\n<td align=\"right\" valign=\"bottom\">6.05</td>\n<td nowrap=\"\" valign=\"bottom\"></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\"></td></tr>\n<tr bgcolor=\"#cceeff\" style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Increase in net tangible book value per share attributable to the offering</p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">4.01</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\"></td></tr>\n<tr style=\"font-size:1px; \">\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td>\n<td valign=\"bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td>\n<td>\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">As adjusted net tangible book value per share after giving effect to the offering</p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">$</td>\n<td align=\"right\" valign=\"bottom\">10.06</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"font-size:1px; \">\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td>\n<td valign=\"bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td>\n<td>\u00a0</td></tr>\n<tr bgcolor=\"#cceeff\" style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Dilution in net tangible book value per share to new investors in\nthis offering</p></td>\n<td style=\" BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td style=\" BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">$</td>\n<td align=\"right\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">41.69</td>\n<td nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\"></td></tr>\n</table> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">A $1.00 increase (decrease) in the assumed public offering price of $51.75\u00a0per share would increase (decrease) our as adjusted net\ntangible book value per share after this offering by approximately $0.08\u00a0and the dilution per share to investors participating in this offering would increase (decrease) by approximately $0.92, assuming that the number of shares we are\noffering, as set forth on the cover page of this prospectus supplement, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number\nof shares we are offering. A 500,000\u00a0share increase in the number of shares offered by us would increase our as adjusted net tangible book value per share after this offering by approximately $0.48\u00a0and the dilution per share to investors\nin this offering would decrease by approximately $0.48, assuming that the assumed public offering price, as set forth on the cover page of this prospectus supplement, remains the same, and after deducting estimated underwriting discounts and\ncommissions and estimated offering expenses payable by us. Similarly, a 500,000\u00a0share decrease in the number of shares offered by us would decrease our as adjusted net tangible book value per share after this offering by approximately $0.49 and\nthe dilution per share to investors in this offering would increase by approximately $0.49, assuming that the assumed public offering price, as set forth on the cover page of this prospectus supplement, remains the same, and after deducting\nestimated underwriting discounts and commissions and estimated offering expenses payable by us. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The as adjusted information is illustrative only, and we will adjust\nthis information based on the actual public offering price and other terms of this offering determined at pricing. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-15 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">If the underwriters exercise in full their option to purchase up to 562,500\u00a0additional shares of common stock at\nthe assumed public offering price of $51.75\u00a0per share, the pro forma net tangible book value after this offering would be $10.59\u00a0per share of our common stock, representing an increase of pro forma net tangible book value of $4.54\u00a0per\nshare to our existing stockholders and an immediate dilution of $0.53\u00a0per share to new investors purchasing shares in this offering. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The number of shares of\nour common stock to be outstanding immediately after this offering is based on 35,922,982 shares of our common stock outstanding as of March\u00a031, 2018. The number of shares outstanding as of March\u00a031, 2018 excludes: </p>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">3,793,364 shares of common stock issuable upon the exercise of stock options and awards outstanding as of March\u00a031, 2018, at a weighted average exercise price of $22.15 per share; </td></tr></table>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">170,420 shares of common stock issuable upon the exercise of outstanding stock options and awards granted subsequent to March\u00a031, 2018, at a weighted average exercise price of $42.23 per share; and\n</td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">2,164,614 shares of common stock reserved for future issuance under our 2015 Stock Option and Incentive Plan and our 2015 Employee Stock Purchase Plan as of March\u00a031, 2018. </td></tr></table>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Sanofi, our strategic collaboration partner and one of our existing stockholders (through its wholly owned subsidiary Aventis Inc.), has indicated an interest in\npurchasing up to an aggregate of approximately 200,000 shares of our common stock in this offering at the public offering price and on the same terms as the other purchasers in this offering. However, because indications of interest are not binding\nagreements or commitments to purchase, the underwriters could determine to sell fewer shares to Sanofi than it indicated an interest in purchasing or sell no shares to Sanofi, and Sanofi could determine to purchase fewer shares than it indicated an\ninterest in purchasing or purchase no shares in this offering. The above discussion and tables do not reflect any potential purchases in this offering by Sanofi. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-16 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial\"><b><a name=\"supptoc579741_8\"></a>Material U.S. federal income tax consequences to\n<font style=\"white-space:nowrap\">Non-U.S.</font> Holders </b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The following discussion is a summary of the material U.S. federal income tax consequences to <font style=\"white-space:nowrap\">Non-U.S.</font> Holders (as defined below) of the purchase, ownership and disposition of our common stock issued pursuant to this offering, but does not purport to be a complete analysis of all potential tax effects. The\neffects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or <font style=\"white-space:nowrap\">non-U.S.</font> tax laws are not discussed. This discussion is based on the U.S. Internal Revenue Code of\n1986, as amended (the \u0093Code\u0094), Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service (the \u0093IRS\u0094), in each case in effect as\nof the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a\n<font style=\"white-space:nowrap\">Non-U.S.</font> Holder of our common stock. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary\nposition to that discussed below regarding the tax consequences of the purchase, ownership and disposition of our common stock. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">This discussion is limited to <font style=\"white-space:nowrap\">Non-U.S.</font> Holders that hold our common stock as a \u0093capital asset\u0094 within the meaning of Section\u00a01221 of the Code (generally, property held for investment). This discussion does not address all U.S.\nfederal income tax consequences relevant to a <font style=\"white-space:nowrap\">Non-U.S.</font> Holder\u0092s particular circumstances, including the impact of the Medicare contribution tax on net investment income. In addition, it does not address\nconsequences relevant to <font style=\"white-space:nowrap\">Non-U.S.</font> Holders subject to special rules, including, without limitation: </p> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">U.S. expatriates and former citizens or long-term residents of the United States; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">persons subject to the alternative minimum tax; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">persons holding our common stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion transaction or other integrated investment; </td></tr></table>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">banks, insurance companies and other financial institutions; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">brokers, dealers or traders in securities; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">\u0093controlled foreign corporations,\u0094 \u0093passive foreign investment companies\u0094 and corporations that accumulate earnings to avoid U.S. federal income tax; </td></tr></table>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors therein); </td></tr></table>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\"><font style=\"white-space:nowrap\">tax-exempt</font> organizations or governmental organizations; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">persons deemed to sell our common stock under the constructive sale provisions of the Code; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as compensation; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\"><font style=\"white-space:nowrap\">tax-qualified\u00a0retirement\u00a0plans;\u00a0and</font> </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">\u0093qualified foreign pension funds\u0094 as defined in Section\u00a0897(l)(2) of the Code and entities all of the interests of which are held by qualified foreign pension funds. </td></tr></table>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">If an entity treated as a partnership for U.S. federal income tax purposes holds our common stock, the tax treatment of a partner in the partnership will depend on the\nstatus of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships holding our common stock and the partners in such partnerships should consult their tax advisors regarding the\nU.S. federal income tax consequences to them. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-17 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b>THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX\nADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT\nTAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR <font style=\"white-space:nowrap\">NON-U.S.</font> TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY. </b></p>\n<p style=\"margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial\"><b>Definition of a <font style=\"white-space:nowrap\">Non-U.S.</font> Holder </b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">For\npurposes of this discussion, a <font style=\"white-space:nowrap\">\u0093Non-U.S.</font> Holder\u0094 is any beneficial owner of our common stock that is neither a \u0093U.S. person\u0094 nor an entity treated as a partnership for U.S. federal income\ntax purposes. A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of the following: </p> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">an individual who is a citizen or resident of the United States; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">a corporation created or organized under the laws of the United States, any state thereof, or the District of Columbia; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">a trust that (1)\u00a0is subject to the primary supervision of a U.S. court and the control of one or more \u0093United States persons\u0094 (within the meaning of Section\u00a07701(a)(30) of the Code) or (2)\u00a0has a\nvalid election in effect to be treated as a United States person for U.S. federal income tax purposes. </td></tr></table> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial\"><b>Distributions </b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">If we make distributions of cash or property on our common stock, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid\nfrom our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of capital and first be applied against and\nreduce a <font style=\"white-space:nowrap\">Non-U.S.</font> Holder\u0092s adjusted tax basis in its common stock, but not below zero. Any excess will be treated as capital gain and will be treated as described below under \u0093\u0097Sale or other\ntaxable disposition.\u0094 </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Subject to the discussion below on effectively connected income, dividends paid to a <font style=\"white-space:nowrap\">Non-U.S.</font>\nHolder of our common stock will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty, provided the\n<font style=\"white-space:nowrap\">Non-U.S.</font> Holder furnishes a valid IRS Form <font style=\"white-space:nowrap\">W-8BEN</font> or <font style=\"white-space:nowrap\"><font style=\"white-space:nowrap\">W-8BEN-E</font></font> (or other applicable\ndocumentation) certifying qualification for the lower treaty rate). A <font style=\"white-space:nowrap\">Non-U.S.</font> Holder that does not timely furnish the required documentation, but that qualifies for a reduced treaty rate, may obtain a refund\nof any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. <font style=\"white-space:nowrap\">Non-U.S.</font> Holders should consult their tax advisors regarding their entitlement to benefits under any applicable\nincome tax treaty. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">If dividends paid to a <font style=\"white-space:nowrap\">Non-U.S.</font> Holder are effectively connected with the\n<font style=\"white-space:nowrap\">Non-U.S.</font> Holder\u0092s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the <font style=\"white-space:nowrap\">Non-U.S.</font> Holder maintains a\npermanent establishment in the United States to which such dividends are attributable), the <font style=\"white-space:nowrap\">Non-U.S.</font> Holder will be exempt from the U.S. federal withholding tax described above. To claim the exemption, the <font style=\"white-space:nowrap\">Non-U.S.</font> Holder must furnish to the applicable withholding agent a valid IRS Form <font style=\"white-space:nowrap\">W-8ECI,</font> certifying that the dividends are effectively connected with the <font style=\"white-space:nowrap\">Non-U.S.</font> Holder\u0092s conduct of a trade or business within the United States. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Any such effectively connected dividends will be\nsubject to U.S. federal income tax on a net income basis at the regular graduated rates. A <font style=\"white-space:nowrap\">Non-U.S.</font> Holder that is a corporation for U.S. federal income tax purposes also may\n</p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-18 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">\nbe subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected dividends, as adjusted for certain items.\nNon-U.S. Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules. </p> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial\"><b>Sale or other taxable disposition\n</b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Subject to the discussion below regarding backup withholding and FATCA, a <font style=\"white-space:nowrap\">Non-U.S.</font> Holder will not be subject to U.S.\nfederal income tax on any gain realized upon the sale or other taxable disposition of our common stock unless: </p> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the gain is effectively connected with the <font style=\"white-space:nowrap\">Non-U.S.</font> Holder\u0092s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the\n<font style=\"white-space:nowrap\">Non-U.S.</font> Holder maintains a permanent establishment in the United States to which such gain is attributable); </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the <font style=\"white-space:nowrap\">Non-U.S.</font> Holder is a nonresident alien individual present in the United States for 183 days or more during the taxable year of the disposition and certain other requirements\nare met; or </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">our common stock constitutes a U.S. real property interest (\u0093USRPI\u0094) by reason of our status as a U.S. real property holding corporation (\u0093USRPHC\u0094) for U.S. federal income tax purposes.\n</td></tr></table> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Gain described in the first bullet point above generally will be subject to U.S. federal income tax on a net income basis at the regular graduated\nrates. A <font style=\"white-space:nowrap\">Non-U.S.</font> Holder that is a corporation for U.S. federal income tax purposes also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax\ntreaty) on such effectively connected gain, as adjusted for certain items. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Gain described in the second bullet point above will be subject to U.S. federal income\ntax at a rate of 30% (or such lower rate specified by an applicable income tax treaty), which may be offset by certain U.S. source capital losses of the <font style=\"white-space:nowrap\">Non-U.S.</font> Holder (even though the individual is not\nconsidered a resident of the United States), provided the <font style=\"white-space:nowrap\">Non-U.S.</font> Holder has timely filed U.S. federal income tax returns with respect to such losses. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">With respect to the third bullet point above, we believe we currently are not, and do not anticipate becoming, a USRPHC. Because the determination of whether we are a\nUSRPHC depends, however, on the fair market value of our USRPIs relative to the fair market value of our <font style=\"white-space:nowrap\">non-U.S.</font> real property interests and our other business assets, there can be no assurance we currently\nare not a USRPHC or will not become one in the future. Even if we are or were to become a USRPHC, gain arising from the sale or other taxable disposition by a <font style=\"white-space:nowrap\">Non-U.S.</font> Holder of our common stock will not be\nsubject to U.S. federal income tax if our common stock is \u0093regularly traded,\u0094 as defined by applicable Treasury Regulations, on an established securities market, and such <font style=\"white-space:nowrap\">Non-U.S.</font> Holder owned,\nactually and constructively, 5% or less of our common stock throughout the shorter of the <font style=\"white-space:nowrap\">five-year</font> period ending on the date of the sale or other taxable disposition or the\n<font style=\"white-space:nowrap\">Non-U.S.</font> Holder\u0092s holding period. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><font style=\"white-space:nowrap\">Non-U.S.</font> Holders should consult their tax\nadvisors regarding any applicable tax treaties that may provide for different rules. </p> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial\"><b>Information reporting and backup withholding </b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Payments of dividends on our common stock will not be subject to backup withholding, provided the applicable withholding agent does not have actual knowledge or reason\nto know the holder is a United States person and the holder either certifies its <font style=\"white-space:nowrap\">non-U.S.</font> status, such as by furnishing a valid IRS Form <font style=\"white-space:nowrap\">W-8BEN,</font> <font style=\"white-space:nowrap\"><font style=\"white-space:nowrap\">W-8BEN-E</font></font> or <font style=\"white-space:nowrap\">W-8ECI,</font> or otherwise establishes an exemption. However, information returns are required to be filed with the IRS in\nconnection with any dividends on our common stock paid to the <font style=\"white-space:nowrap\">Non-U.S.</font> Holder, regardless of whether </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-19 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">\nany tax was actually withheld. In addition, proceeds of the sale or other taxable disposition of our common stock within the United States or conducted through certain U.S.-related brokers\ngenerally will not be subject to backup withholding or information reporting, if the applicable withholding agent receives the certification described above and does not have actual knowledge or reason to know that such holder is a United States\nperson, or the holder otherwise establishes an exemption. Proceeds of a disposition of our common stock conducted through a <font style=\"white-space:nowrap\">non-U.S.</font> office of a <font style=\"white-space:nowrap\">non-U.S.</font> broker that\ndoes not have certain enumerated relationships with the United States generally will not be subject to backup withholding or information reporting. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Copies of\ninformation returns that are filed with the IRS may also be made available under the provisions of an applicable treaty or agreement to the tax authorities of the country in which the <font style=\"white-space:nowrap\">Non-U.S.</font> Holder resides\nor is established. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit\nagainst a <font style=\"white-space:nowrap\">Non-U.S.</font> Holder\u0092s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. </p>\n<p style=\"margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial\"><b>Additional withholding tax on payments made to foreign accounts </b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Withholding\ntaxes may be imposed under Sections 1471 to 1474 of the Code (such Sections commonly referred to as the Foreign Account Tax Compliance Act (\u0093FATCA\u0094)) on certain types of payments made to <font style=\"white-space:nowrap\">non-U.S.</font>\nfinancial institutions and certain other <font style=\"white-space:nowrap\">non-U.S.</font> entities. Specifically, a 30% withholding tax may be imposed on dividends on, or gross proceeds from the sale or other disposition of, our common stock paid to\na \u0093foreign financial institution\u0094 or a <font style=\"white-space:nowrap\">\u0093non-financial</font> foreign entity\u0094 (each as defined in the Code), unless (1)\u00a0the foreign financial institution undertakes certain diligence and\nreporting obligations, (2)\u00a0the <font style=\"white-space:nowrap\">non-financial</font> foreign entity either certifies it does not have any \u0093substantial United States owners\u0094 (as defined in the Code) or furnishes identifying information\nregarding each substantial United States owner, or (3)\u00a0the foreign financial institution or <font style=\"white-space:nowrap\">non-financial</font> foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign\nfinancial institution and is subject to the diligence and reporting requirements in (1)\u00a0above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held\nby certain \u0093specified United States persons\u0094 or \u0093United States owned foreign entities\u0094 (each as defined in the Code), annually report certain information about such accounts, and withhold 30% on certain payments to <font style=\"white-space:nowrap\">non-compliant</font> foreign financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA\nmay be subject to different rules. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to payments of\ndividends on our common stock, and, beginning on January\u00a01, 2019, will apply to payments of gross proceeds from the sale or other disposition of such stock. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Prospective investors should consult their tax advisors regarding the potential application of withholding under FATCA to their investment in our common stock. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-20 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial\"><b><a name=\"supptoc579741_9\"></a>Underwriting </b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We are offering the shares of common stock described in this prospectus supplement through a number of underwriters. J.P. Morgan Securities LLC, Merrill Lynch, Pierce,\nFenner\u00a0&amp; Smith Incorporated, Credit Suisse Securities (USA) LLC and Wells Fargo Securities, LLC are acting as joint book-running managers of the offering and as representatives of the underwriters. We have entered into an underwriting\nagreement with the underwriters. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to the underwriters, and each underwriter has severally agreed to purchase, at the public offering price less the underwriting\ndiscounts and commissions set forth on the cover page of this prospectus supplement, the number of shares of common stock listed next to its name in the following table: </p> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr>\n<td width=\"89%\"></td>\n<td valign=\"bottom\" width=\"2%\"></td>\n<td></td>\n<td></td>\n<td></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:9pt\">\n<td style=\"BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\"><b>Name</b></td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td align=\"right\" colspan=\"2\" style=\"BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\"><b>Number\u00a0of<br/>shares</b></td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0</td></tr>\n<tr bgcolor=\"#cceeff\" style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">J.P. Morgan Securities LLC</p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Merrill Lynch, Pierce, Fenner &amp;\nSmith<br/>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Incorporated</p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\"></td></tr>\n<tr bgcolor=\"#cceeff\" style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Credit Suisse Securities (USA) LLC</p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Wells Fargo Securities, LLC</p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\"></td></tr>\n<tr style=\"font-size:1px; \">\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td>\n<td valign=\"bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td>\n<td>\u00a0</td></tr>\n<tr bgcolor=\"#cceeff\" style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Total</p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">3,750,000</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"font-size:1px; font-family:arial; font-size:10pt\">\n<td colspan=\"4\" valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000\">\u00a0</p></td>\n<td>\u00a0</td></tr>\n</table> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The underwriters are committed to purchase all the shares of common stock offered by us if they purchase any shares. The underwriting\nagreement also provides that if an underwriter defaults, the purchase commitments of <font style=\"white-space:nowrap\">non-defaulting</font> underwriters may also be increased or the offering may be terminated. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The underwriters propose to offer the shares of common stock directly to the public at the public offering price set forth on the cover page of this prospectus\nsupplement and to certain dealers at that price less a concession not in excess of $\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 per share. Any such dealers may resell shares to certain other brokers or dealers at a discount of up to\n$\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 per share from the public offering price. After the public offering of the shares, the offering price and other selling terms may be changed by the underwriters. Sales of shares made outside of the\nUnited States may be made by affiliates of the underwriters. The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the underwriters\u0092 right to reject any order in whole or in part. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The underwriters have an option to buy up to 562,500 additional shares of common stock from us. The underwriters have 30 days from the date of this prospectus supplement\nto exercise this option to purchase the additional shares. If any shares are purchased with this option, the underwriters will purchase shares in approximately the same proportion as shown in the table above. If any additional shares of common stock\nare purchased, the underwriters will offer the additional shares on the same terms as those on which the shares are being offered. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Sanofi, our strategic\ncollaboration partner and one of our existing stockholders (through its wholly owned subsidiary Aventis Inc.), has indicated an interest in purchasing up to an aggregate of approximately 200,000\u00a0shares of our common stock in this offering at\nthe public offering price and on the same terms as the other purchasers in this offering. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters could determine to sell fewer shares to Sanofi\nthan it indicated an interest in purchasing or sell no shares to Sanofi, and Sanofi could determine to purchase fewer shares than it indicated an interest in purchasing or purchase no shares in this offering. The underwriters will receive the same\nunderwriting discount on any shares purchased by Sanofi as they will on any other shares sold to the public in this offering. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-21 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The underwriting fee is equal to the public offering price per share of common stock less the amount paid by the\nunderwriters to us per share of common stock. The underwriting fee is $\u00a0\u00a0\u00a0\u00a0\u00a0 per share. The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters assuming both no\nexercise and full exercise of the underwriters\u0092 option to purchase additional shares of common stock. </p> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt\" width=\"100%\">\n<tr>\n<td width=\"80%\"></td>\n<td valign=\"bottom\" width=\"9%\"></td>\n<td></td>\n<td></td>\n<td></td>\n<td valign=\"bottom\" width=\"9%\"></td>\n<td></td>\n<td></td>\n<td></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:9pt\">\n<td style=\"BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td align=\"right\" colspan=\"2\" style=\"BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\"> <p align=\"right\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial\"><b>Without</b></p>\n<p align=\"right\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial\"><b>option\u00a0to</b></p> <p align=\"right\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial\"><b>purchase</b></p>\n<p align=\"right\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial\"><b>additional</b></p> <p align=\"right\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial\"><b>shares</b></p>\n<p align=\"right\" style=\"margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial\"><b>exercise</b></p></td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td align=\"right\" colspan=\"2\" style=\"BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\"> <p align=\"right\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial\"><b>With\u00a0full</b></p>\n<p align=\"right\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial\"><b>option\u00a0to</b></p> <p align=\"right\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial\"><b>purchase</b></p>\n<p align=\"right\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial\"><b>additional</b></p> <p align=\"right\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial\"><b>shares</b></p>\n<p align=\"right\" style=\"margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial\"><b>exercise</b></p></td>\n<td style=\" BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0</td></tr>\n<tr bgcolor=\"#cceeff\" style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Per share</p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td nowrap=\"\" valign=\"bottom\">$</td>\n<td align=\"right\" nowrap=\"\" valign=\"bottom\">\u00a0\u00a0\u00a0\u00a0</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td nowrap=\"\" valign=\"bottom\">$</td>\n<td align=\"right\" nowrap=\"\" valign=\"bottom\">\u00a0\u00a0\u00a0\u00a0</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:10pt\">\n<td style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial\">Total</p></td>\n<td style=\" BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">$</td>\n<td align=\"right\" nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\"></td>\n<td nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0</td>\n<td style=\" BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0\u00a0</td>\n<td nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">$</td>\n<td align=\"right\" nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\"></td>\n<td nowrap=\"\" style=\"BORDER-BOTTOM:1px solid #000000\" valign=\"bottom\">\u00a0</td></tr>\n</table> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We estimate that the total expenses of this offering, including registration, filing and listing fees, printing fees and legal and\naccounting expenses, but excluding the underwriting discounts and commissions, will be approximately $665,000. We have agreed to reimburse the underwriters for up to $25,000 for expenses relating to the clearance of this offering with the Financial\nIndustry Regulatory Authority, Inc. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">A prospectus in electronic format may be made available on the web sites maintained by one or more underwriters, or selling\ngroup members, if any, participating in the offering. The underwriters may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by\nthe representatives to underwriters and selling group members that may make Internet distributions on the same basis as other allocations. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We have agreed that we\nwill not offer, sell, issue, contract to sell, pledge or otherwise dispose of, directly or indirectly, or file with the SEC a registration statement under the Securities Act relating to, any shares of our common stock or securities convertible into\nor exchangeable or exercisable for any shares of our common stock, or publicly disclose the intention to make any offer, sale, pledge, disposition or filing, without the prior written consent of J.P. Morgan Securities LLC, Merrill Lynch, Pierce,\nFenner\u00a0&amp; Smith Incorporated, Credit Suisse Securities (USA) LLC and Wells Fargo Securities, LLC for a period of 90 days after the date of this prospectus supplement. The restrictions described in this paragraph do not apply to\n(a)\u00a0grants of employee stock options or other equity-based awards pursuant to the terms of our equity inventive plans, (b)\u00a0issuances of shares of our common stock or securities convertible into or exchangeable or exercisable for any shares\nof our common stock pursuant to the exercise of such options or other equity-based awards, (c)\u00a0issuances of shares of our common stock pursuant to the conversion or exchange of convertible or exchangeable securities or the exercise of options,\nin each case outstanding on the date hereof, (d)\u00a0the issuance of shares of our common stock in this offering, or (e)\u00a0the entry into any agreement providing for our issuance of common stock or securities exercisable or convertible into\ncommon stock in connection with (x)\u00a0our acquisition of the securities, business, intellectual property or other assets of any person or entity or pursuant to an employee benefit plan assumed by us in connection with any such acquisition, and\nthe issuance of any common stock or securities exercisable or convertible into common stock pursuant to any such agreement or (y)\u00a0the entry into any agreement relating to a joint venture, licensing transaction, collaboration or other strategic\ntransaction; provided, that the aggregate number of shares of common stock (and securities exercisable or convertible into common stock) that we may sell or issue or agree to sell or issue pursuant to this clause (e)\u00a0may not exceed 5.0% of the\ntotal outstanding shares of our capital stock following the completion of this offering; and provided in the case of clauses (b), (c) and (e), the recipients of such securities agree to be bound by a lockup letter in the form executed by our\ndirectors and officers. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-22 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Our officers and directors have agreed that they will not offer, sell, contract to sell, pledge or otherwise dispose\nof, directly or indirectly, any shares of our common stock or securities convertible into or exchangeable or exercisable for any shares of our common stock, enter into a transaction that would have the same effect, or enter into any swap, hedge or\nother arrangement that transfers, in whole or in part, any of the economic consequences of ownership of our common stock, whether any of these transactions is to be settled by delivery of our common stock or other securities, in cash or otherwise,\nor publicly disclose the intention to make any offer, sale, pledge or disposition, or to enter into any transaction, swap, hedge or other arrangement, without, in each case, the prior written consent of J.P. Morgan Securities LLC, Merrill Lynch,\nPierce, Fenner\u00a0&amp; Smith Incorporated, Credit Suisse Securities (USA) LLC and Wells Fargo Securities, LLC for a period of 90 days after the date of this prospectus supplement. If, prior to the expiration of such period, a request to release\nsecurities subject to a <font style=\"white-space:nowrap\">lock-up</font> agreement is received, J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner\u00a0&amp; Smith Incorporated, Credit Suisse Securities (USA) LLC and Wells Fargo Securities,\nLLC will consider, among other factors, such holder\u0092s reasons for requesting the release, the number of securities for which the release is being requested and market conditions at the time. The restrictions described in this paragraph do not\napply to: </p> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">a)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any shares of our common stock acquired by the <font style=\"white-space:nowrap\">lock-up</font> signatory in the open market; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">b)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the exercise with cash of stock options or other similar awards granted pursuant to our equity incentive plans, provided that such restrictions shall apply to any of the <font style=\"white-space:nowrap\">lock-up</font>\nsignatory\u0092s shares of common stock issued upon such exercise or the cashless exercise of stock options (the term cashless exercise being intended to include the surrender of a portion of the option shares or previously owned shares to the\nCompany to cover payment of the exercise price) for the purposes of exercising such stock options solely in the case of termination of employment or board service following death, disability or other than for cause (including any such transfer in\nrespect of tax liabilities arising from such exercise) if such options would otherwise expire; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">c)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the establishment of any contract, instruction or plan (\u0093Plan\u0094), that satisfies all of the requirements of Rule <font style=\"white-space:nowrap\">10b5-1</font> under the Exchange Act for the transfer of shares\nof common stock, provided that no sales of the <font style=\"white-space:nowrap\">lock-up</font> signatory\u0092s shares of common stock shall be made pursuant to such a Plan prior to the expiration of the applicable period referred to above;\n</td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">d)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">transfers of our common stock or other securities as a bona fide gift or gifts not involving a disposition for value or for bona fide estate planning purposes, as a bona fide gift to a charity or educational\ninstitution, transfers to a member or members of the <font style=\"white-space:nowrap\">lock-up</font> signatory\u0092s family or to a trust, the direct or indirect beneficiaries of which are the <font style=\"white-space:nowrap\">lock-up</font>\nsignatory and/or a member or members of the <font style=\"white-space:nowrap\">lock-up</font> signatory\u0092s family, by testate succession or intestate distribution, if the undersigned is a trust, to any beneficiary of the undersigned or to the\nestate of any such beneficiary, distributions not involving a disposition for value of shares of our common stock or such other securities to members, partners or stockholders of, or owner of a similar equity interest in, the <font style=\"white-space:nowrap\">lock-up</font> signatory or to any corporation, partnership or other person or entity that is a direct or indirect affiliate of the <font style=\"white-space:nowrap\">lock-up</font> signatory, or transfers of our common\nstock or any security convertible into or exchangeable for shares of our common stock that occurs by operation of law pursuant to a qualified domestic order or in connection with a divorce settlement or other court order provided that each donee,\ndistributee or transferee, as the case may be, agrees to be subject to the same restrictions as the <font style=\"white-space:nowrap\">lock-up</font> signatory; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">e)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the transfer of the <font style=\"white-space:nowrap\">lock-up</font> signatory\u0092s shares of our common stock or any security convertible into or exercisable or exchangeable for shares of our common stock to us\npursuant to any contractual arrangement in effect on the date of the <font style=\"white-space:nowrap\">lock-up</font> agreement that provides for the repurchase of the <font style=\"white-space:nowrap\">lock-up</font> signatory\u0092s shares of common\nstock or such other securities by us or in connection with the termination of the <font style=\"white-space:nowrap\">lock-up</font> signatory\u0092s employment or other service relationship with us; and </td></tr></table>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-23 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">f)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the sale or transfer of the <font style=\"white-space:nowrap\">lock-up</font> signatory\u0092s shares of our common stock under a trading plan (a \u0093Trading Plan\u0094) pursuant to Rule\n<font style=\"white-space:nowrap\">10b5-1</font> promulgated under the Exchange Act that has been entered into prior to the date hereof which has been provided to J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner\u00a0&amp; Smith Incorporated,\nCredit Suisse Securities (USA) LLC and Wells Fargo Securities, LLC or their legal counsel. </td></tr></table> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In the case of a transfer or distribution pursuant to\nclause (a), no filing under the Exchange Act or other public announcement shall be required or voluntarily made by or on behalf of the transferee during the applicable period referred to above with respect to the subsequent sales of such shares of\ncommon stock acquired by the <font style=\"white-space:nowrap\">lock-up</font> signatory in the offering or in the open market. In the case of any transfer or distribution pursuant to clause (b)\u00a0or (c), no filing under the Exchange Act or other\npublic announcement shall be required or voluntarily made during the applicable period referred to above. In the case of a transfer or distribution pursuant to clause (d), no filing under the Exchange Act or other public announcement shall be\nrequired or voluntarily made by any party (other than a filing on Form 5 after the expiration of the applicable period referred to above). In the case of a sale or transfer pursuant to clause (f), to the extent a public announcement or filing under\nthe Exchange Act, if any, is required of, or voluntarily made by or on behalf of, the <font style=\"white-space:nowrap\">lock-up</font> signatory or us regarding such sale or transfer, such announcement or filing shall include a statement that such\ntransfer is in accordance with an established Trading Plan. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We have agreed to indemnify the several underwriters against liabilities under the Securities Act, or\ncontribute to payments that the underwriters may be required to make in that respect. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Our common stock is listed on the Nasdaq Global Select Market under the symbol\n\u0093MYOK.\u0094 </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In connection with this offering, the underwriters may engage in stabilizing transactions, which involve making bids for, purchasing and selling\nshares of common stock in the open market for the purpose of preventing or retarding a decline in the market price of the common stock while this offering is in progress. These stabilizing transactions may include making short sales of the common\nstock, which involve the sale by the underwriters of a greater number of shares of common stock than they are required to purchase in this offering, and purchasing shares of common stock on the open market to cover positions created by short sales.\nShort sales may be \u0093covered\u0094 shorts, which are short positions in an amount not greater than the underwriters\u0092 option to purchase additional shares referred to above, or may be \u0093naked\u0094 shorts, which are short positions in\nexcess of that amount. The underwriters may close out any covered short position either by exercising their option to purchase additional shares, in whole or in part, or by purchasing shares in the open market. In making this determination, the\nunderwriters will consider, among other things, the price of shares available for purchase in the open market compared to the price at which the underwriters may purchase shares through the option to purchase additional shares. A naked short\nposition is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market that could adversely affect investors who purchase in this offering. To the extent that\nthe underwriters create a naked short position, they will purchase shares in the open market to cover the position. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The underwriters have advised us that, pursuant\nto Regulation M of the Securities Act, they may also engage in other activities that stabilize, maintain or otherwise affect the price of the common stock, including the imposition of penalty bids. This means that if the representatives of the\nunderwriters purchase common stock in the open market in stabilizing transactions or to cover short sales, the representatives can require the underwriters that sold those shares as part of this offering to repay the underwriting discounts and\ncommissions received by them. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">These activities may have the effect of raising or maintaining the market price of the common stock or preventing or retarding a\ndecline in the market price of the common stock, and, as a result, the price of the </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-24 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">\ncommon stock may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities, they may discontinue them at any time. The underwriters may\ncarry out these transactions on the Nasdaq Global Select Market, in the <font style=\"white-space:nowrap\"><font style=\"white-space:nowrap\">over-the-counter</font></font> market or otherwise. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In addition, in connection with this offering certain of the underwriters (and selling group members) may engage in passive market making transactions in our common\nstock on the Nasdaq Global Select Market prior to the pricing and completion of this offering. Passive market making consists of displaying bids on the Nasdaq Global Select Market no higher than the bid prices of independent market makers and making\npurchases at prices no higher than these independent bids and effected in response to order flow. Net purchases by a passive market maker on each day are generally limited to a specified percentage of the passive market maker\u0092s average daily\ntrading volume in the common stock during a specified period and must be discontinued when such limit is reached. Passive market making may cause the price of our common stock to be higher than the price that otherwise would exist in the open market\nin the absence of these transactions. If passive market making is commenced, it may be discontinued at any time. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Other than in the United States, no action has been\ntaken by us or the underwriters that would permit a public offering of the securities offered by this prospectus supplement in any jurisdiction where action for that purpose is required. The securities offered by this prospectus supplement may not\nbe offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under\ncircumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus supplement comes are advised to inform themselves about and to observe any restrictions\nrelating to the offering and the distribution of this prospectus supplement. This prospectus supplement does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which\nsuch an offer or a solicitation is unlawful. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Certain of the underwriters and their affiliates have provided in the past to us and our affiliates and may provide\nfrom time to time in the future certain commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received and may continue to receive\ncustomary fees and commissions. In addition, from time to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves or their customers, long or\nshort positions in our debt or equity securities or loans, and may do so in the future. </p> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial\"><b>Selling restrictions </b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors in the European Economic Area </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In\nrelation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a \u0093Relevant Member State\u0094), with effect from and including the date on which the Prospectus Directive is implemented in that\nRelevant Member State, no offer of shares of common stock may be made to the public in that Relevant Member State other than: </p> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">A.</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">B.</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), subject to obtaining the prior consent of the underwriters; or </td></tr></table>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">C.</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </td></tr></table> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">provided that no such offer of\nshares of common stock shall require the Company or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-25 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">\n16 of the Prospectus Directive and each person who initially acquires any shares of common stock or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and\nwith each of the underwriters and the Company that it is a \u0093qualified investor\u0094 within the meaning of the law in that Relevant Member State implementing Article 2(1)(e) of the Prospectus Directive. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In the case of any shares of common stock being offered to a financial intermediary as that term is used in Article 3(2) of the Prospectus Directive, each such financial\nintermediary will be deemed to have represented, acknowledged and agreed that the shares of common stock acquired by it in the offer have not been acquired on a <font style=\"white-space:nowrap\">non-discretionary</font> basis on behalf of, nor have\nthey been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares of common stock to the public other than their offer or resale in a Relevant Member State to qualified investors as so\ndefined or in circumstances in which the prior consent of the representatives have been obtained to each such proposed offer or resale. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">For the purposes of this\nprovision, the expression an \u0093offer of shares of common stock to the public\u0094 in relation to any shares of common stock in any Relevant Member State means the communication in any form and by means of sufficient information on the terms of\nthe offer and the shares of common stock to be offered so as to enable an investor to decide to purchase shares of common stock, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member\nState, the expression \u0093Prospectus Directive\u0094 means Directive 2003/71/EC (as amended, including by Directive 2010/73/EU), and includes any relevant implementing measure in the Relevant Member State. </p>\n<p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors in the United Kingdom </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In addition, in\nthe United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons who are \u0093qualified investors\u0094 (as defined in the Prospectus Directive)\u00a0(i) who\nhave professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \u0093Order\u0094) and/or (ii)\u00a0who are high net worth\ncompanies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d)\u00a0of the Order (all such persons together being referred to as \u0093relevant persons\u0094) or otherwise in circumstances which have\nnot resulted and will not result in an offer to the public of the shares of common stock in the United Kingdom within the meaning of the Financial Services and Markets Act 2000. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Any person in the United Kingdom that is not a relevant person should not act or rely on the information included in this document or use it as basis for taking any\naction. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons. </p>\n<p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors in Canada </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The shares of common stock\nmay be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument <font style=\"white-space:nowrap\">45-106</font> Prospectus Exemptions or subsection 73.3(1) of the\nSecurities Act (Ontario), and are permitted clients, as defined in National <font style=\"white-space:nowrap\">Instrument\u00a031-103</font> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares of common\nstock must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Securities\nlegislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or\ndamages are exercised by the purchaser within the time limit </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-26 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">\nprescribed by the securities legislation of the purchaser\u0092s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the\npurchaser\u0092s province or territory for particulars of these rights or consult with a legal advisor. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Pursuant to section 3A.3 of National Instrument <font style=\"white-space:nowrap\">33-105</font> Underwriting Conflicts (NI <font style=\"white-space:nowrap\">33-105),</font> the underwriters are not required to comply with the disclosure requirements of NI <font style=\"white-space:nowrap\">33-105</font>\nregarding underwriter conflicts of interest in connection with this offering. </p> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors in Switzerland </i></b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The shares of common stock may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (\u0093SIX\u0094) or on any other stock exchange\nor regulated trading facility in Switzerland. This document does not constitute a prospectus within the meaning of, and has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss\nCode of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other\noffering or marketing material relating to the shares of common stock or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Neither this document nor any other offering or marketing material relating to the offering, the Company, the shares of common stock have been or will be filed with or\napproved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares of common stock will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA (FINMA), and the offer of\nshares of common stock has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (\u0093CISA\u0094). The investor protection afforded to acquirers of interests in collective investment schemes under the\nCISA does not extend to acquirers of shares of common stock. </p> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors in the Dubai International Financial Centre (\u0093DIFC\u0094)\n</i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">This document relates to an Exempt Offer in accordance with the Markets Rules 2012 of the Dubai Financial Services Authority (\u0093DFSA\u0094). This\ndocument is intended for distribution only to persons of a type specified in the Markets Rules 2012 of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any documents\nin connection with Exempt Offers. The DFSA has not approved this prospectus supplement nor taken steps to verify the information set forth herein and has no responsibility for this document. The securities to which this document relates may be\nilliquid and/or subject to restrictions on their resale. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand the contents of this document you should consult an\nauthorized financial advisor. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">In relation to its use in the DIFC, this document is strictly private and confidential and is being distributed to a limited number of\ninvestors and must not be provided to any person other than the original recipient, and may not be reproduced or used for any other purpose. The interests in the securities may not be offered or sold directly or indirectly to the public in the DIFC.\n</p> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors in the United Arab Emirates </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The\nshares of common stock have not been, and are not being, publicly offered, sold, promoted or advertised in the United Arab Emirates (including the Dubai International Financial Centre) other than in compliance with the laws of the United Arab\nEmirates (and the Dubai International Financial Centre) governing the issue, offering </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-27 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">\nand sale of securities. Further, this prospectus does not constitute a public offer of securities in the United Arab Emirates (including the Dubai International Financial Centre) and is not\nintended to be a public offer. This prospectus has not been approved by or filed with the Central Bank of the United Arab Emirates, the Securities and Commodities Authority or the Dubai Financial Services Authority. </p>\n<p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors in Australia </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">This prospectus\nsupplement: </p> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">does not constitute a product disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001 (Cth) (the \u0093Corporations Act\u0094); </td></tr></table>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">has not been, and will not be, lodged with the Australian Securities and Investments Commission (\u0093ASIC\u0094), as a disclosure document for the purposes of the Corporations Act and does not purport to include the\ninformation required of a disclosure document under Chapter 6D.2 of the Corporations Act; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">does not constitute or involve a recommendation to acquire, an offer or\u00a0invitation for issue or sale, an offer or invitation to arrange the issue or sale, or an issue or sale, of interests to a \u0093retail\nclient\u0094 (as defined in section 761G of the Corporations Act and applicable regulations) in Australia; and </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">may only be provided in Australia to select investors who are able to demonstrate that they fall within one or more of the categories of investors (\u0093Exempt Investors\u0094) available under section 708 of the\nCorporations Act. </td></tr></table> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The shares of common stock may not be directly or indirectly offered for subscription or purchased or sold, and no invitations to\nsubscribe for or buy the shares of common stock may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to any shares of common stock may be distributed in Australia, except where disclosure\nto investors is not required under Chapter 6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the shares of common stock, you represent and warrant to us\nthat you are an Exempt Investor. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">As any offer of shares of common stock under this document will be made without disclosure in Australia under Chapter 6D.2 of the\nCorporations Act, the offer of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under Chapter 6D.2 if none of the exemptions in section 708 applies to that\nresale. By applying for the shares of common stock you undertake to us that you will not, for a period of 12 months from the date of issue of the shares of common stock, offer, transfer, assign or otherwise alienate those securities to investors in\nAustralia except in circumstances where disclosure to investors is not required under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC. </p>\n<p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors in Japan </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The shares of common stock\nhave not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Act. Accordingly, none of the shares of common stock nor any interest therein may be offered or sold, directly or indirectly, in\nJapan or to, or for the benefit of, any \u0093resident\u0094 of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for <font style=\"white-space:nowrap\">re-offering</font> or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the\nFinancial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant time. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-28 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors in Hong Kong </i></b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The shares of common stock have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)\u00a0to\n\u0093professional investors\u0094 as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b)\u00a0in other circumstances which do not result in the document being a\n\u0093prospectus\u0094 as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or\ndocument relating to the shares of common stock has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely\nto be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares of common stock which are or are intended to be disposed of only to persons outside Hong Kong\nor only to \u0093professional investors\u0094 as defined in the Securities and Futures Ordinance and any rules made under that Ordinance. </p> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Warning\n</i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer.\nIf you are in any doubt about any of the contents of this document, you should obtain independent professional advice.\u0094 </p> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors\nin Singapore </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other\ndocument or material in connection with the offer or sale, or invitation for subscription or purchase, of shares of common stock may not be circulated or distributed, nor may the shares of common stock be offered or sold, or be made the subject of\nan invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)\u00a0to an institutional investor under Section\u00a0274 of the Securities and Futures Act, Chapter 289 of Singapore (the\n\u0093SFA\u0094), (ii) to a relevant person pursuant to Section\u00a0275(1), or any person pursuant to Section\u00a0275(1A), and in accordance with the conditions specified in Section\u00a0275 of the SFA, or (iii)\u00a0otherwise pursuant to, and in\naccordance with the conditions of, any other applicable provision of the SFA. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Where the shares of common stock are subscribed or purchased under Section\u00a0275 of\nthe SFA by a relevant person which is: </p> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">a)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">a corporation (which is not an accredited investor (as defined in Section\u00a04A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals,\neach of whom is an accredited investor; or </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">b)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, </td></tr></table>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">securities (as defined in Section\u00a0239(1) of the SFA) of that corporation or the beneficiaries\u0092 rights and interest (howsoever described) in that trust shall\nnot be transferred within six months after that corporation or that trust has acquired the shares of common stock pursuant to an offer made under Section\u00a0275 of the SFA except: </p>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">a)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">to an institutional investor or to a relevant person defined in Section\u00a0275(2) of the SFA, or to any person arising from an offer referred to in Section\u00a0275(1A) or Section\u00a0276(4)(i)(B) of the SFA;\n</td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">b)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">where no consideration is or will be given for the transfer; </td></tr></table>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-29 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">c)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">where the transfer is by operation of law; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">d)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">as specified in Section\u00a0276(7) of the SFA; or </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">e)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore </td></tr></table>\n<p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors in Bermuda </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Shares of common stock may\nbe offered or sold in Bermuda only in compliance with the provisions of the Investment Business Act of 2003 of Bermuda which regulates the sale of securities in Bermuda. Additionally, <font style=\"white-space:nowrap\">non-Bermudian</font> persons\n(including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are permitted to do so under applicable Bermuda legislation. </p>\n<p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors in Saudi Arabia </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">This document may not\nbe distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Offers of Securities Regulations as issued by the board of the Saudi Arabian Capital Market Authority (\u0093CMA\u0094) pursuant to resolution number <font style=\"white-space:nowrap\"><font style=\"white-space:nowrap\">2-11-2004</font></font> dated 4\u00a0October 2004 as amended by resolution number <font style=\"white-space:nowrap\"><font style=\"white-space:nowrap\">1-28-2008,</font></font> as amended (the\n\u0093CMA Regulations\u0094). The CMA does not make any representation as to the accuracy or completeness of this document and expressly disclaims any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this\ndocument. Prospective purchasers of the securities offered hereby should conduct their own due diligence on the accuracy of the information relating to the securities. If you do not understand the contents of this document, you should consult an\nauthorised financial adviser. </p> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors in the British Virgin Islands </i></b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The shares of common stock are not being, and may not be offered to the public or to any person in the British Virgin Islands for purchase or subscription by or on\nbehalf of the Company. The shares of common stock may be offered to companies incorporated under the BVI Business Companies Act, 2004 (British Virgin Islands), \u0093BVI Companies\u0094), but only where the offer will be made to, and received by,\nthe relevant BVI Company entirely outside of the British Virgin Islands. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">This prospectus supplement has not been, and will not be, registered with the Financial\nServices Commission of the British Virgin Islands. No registered prospectus has been or will be prepared in respect of the shares of common stock for the purposes of the Securities and Investment Business Act, 2010 (\u0093SIBA\u0094) or the Public\nIssuers Code of the British Virgin Islands. </p> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors in China </i></b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">This prospectus supplement does not constitute a public offer of shares of common stock, whether by sale or subscription, in the People\u0092s Republic of China (the\n\u0093PRC\u0094). The shares of common stock are not being offered or sold directly or indirectly in the PRC to or for the benefit of, legal or natural persons of the PRC. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Further, no legal or natural persons of the PRC may directly or indirectly purchase any of the shares of common stock or any beneficial interest therein without\nobtaining all prior PRC\u0092s governmental approvals that are required, whether statutorily or otherwise. Persons who come into possession of this document are required by the issuer and its representatives to observe these restrictions. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-30 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors in Korea </i></b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The shares of common stock have not been and will not be registered under the Financial Investments Services and Capital Markets Act of Korea and the decrees and\nregulations thereunder (the \u0093FSCMA\u0094), and the shares of common stock have been and will be offered in Korea as a private placement under the FSCMA. None of the shares of common stock may be offered, sold or delivered directly or\nindirectly, or offered or sold to any person for <font style=\"white-space:nowrap\">re-offering</font> or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to the applicable laws and regulations of Korea, including\nthe FSCMA and the Foreign Exchange Transaction Law of Korea and the decrees and regulations thereunder (the \u0093FETL\u0094). Furthermore, the purchaser of the shares of common stock shall comply with all applicable regulatory requirements\n(including but not limited to requirements under the FETL) in connection with the purchase of the shares of common stock. By the purchase of the shares of common stock, the relevant holder thereof will be deemed to represent and warrant that if it\nis in Korea or is a resident of Korea, it purchased the shares of common stock pursuant to the applicable laws and regulations of Korea. </p> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to\nprospective investors in Malaysia </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">No prospectus or other offering material or document in connection with the offer and sale of the shares of common stock\nhas been or will be registered with the Securities Commission of Malaysia (\u0093Commission\u0094) for the Commission\u0092s approval pursuant to the Capital Markets and Services Act 2007. Accordingly, this prospectus supplement and any other\ndocument or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares of common stock may not be circulated or distributed, nor may the shares of common stock be offered or sold, or be made the subject\nof an invitation for subscription or purchase, whether directly or indirectly, to persons in Malaysia other than (i)\u00a0a closed end fund approved by the Commission; (ii)\u00a0a holder of a Capital Markets Services Licence; (iii)\u00a0a person who\nacquires the shares of common stock, as principal, if the offer is on terms that the shares of common stock may only be acquired at a consideration of not less than RM250,000 (or its equivalent in foreign currencies) for each transaction;\n(iv)\u00a0an individual whose total net personal assets or total net joint assets with his or her spouse exceeds RM3\u00a0million (or its equivalent in foreign currencies), excluding the value of the primary residence of the individual; (v)\u00a0an\nindividual who has a gross annual income exceeding RM300,000 (or its equivalent in foreign currencies) per annum in the preceding twelve months; (vi)\u00a0an individual who, jointly with his or her spouse, has a gross annual income of RM400,000 (or\nits equivalent in foreign currencies), per annum in the preceding twelve months; (vii)\u00a0a corporation with total net assets exceeding RM10\u00a0million (or its equivalent in a foreign currencies) based on the last audited accounts; (viii)\u00a0a\npartnership with total net assets exceeding RM10\u00a0million (or its equivalent in foreign currencies); (ix) a bank licensee or insurance licensee as defined in the Labuan Financial Services and Securities Act 2010; (x) an Islamic bank licensee or\ntakaful licensee as defined in the Labuan Financial Services and Securities Act 2010; and (xi)\u00a0any other person as may be specified by the Commission; provided that, in the each of the preceding categories (i)\u00a0to (xi), the distribution of\nthe shares of common stock is made by a holder of a Capital Markets Services Licence who carries on the business of dealing in securities. The distribution in Malaysia of this prospectus supplement is subject to Malaysian laws. This prospectus\nsupplement does not constitute and may not be used for the purpose of public offering or an issue, offer for subscription or purchase, invitation to subscribe for or purchase any securities requiring the registration of a prospectus with the\nCommission under the Capital Markets and Services Act 2007. </p> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective investors in Taiwan </i></b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The shares of common stock have not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities laws and\nregulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which constitutes an offer within the </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-31 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">\nmeaning of the Securities and Exchange Act of Taiwan that requires a registration or approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorised\nto offer, sell, give advice regarding or otherwise intermediate the offering and sale of the shares of common stock in Taiwan. </p> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial\"><b><i>Notice to prospective\ninvestors in South Africa </i></b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Due to restrictions under the securities laws of South Africa, the shares of common stock are not offered, and the offer shall not\nbe transferred, sold, renounced or delivered, in South Africa or to a person with an address in South Africa, unless one or other of the following exemptions applies: </p> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">i</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the offer, transfer, sale, renunciation or delivery is to: </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"4%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"3%\">(a)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">persons whose ordinary business is to deal in securities, as principal or agent; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"4%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"3%\">(b)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the South African Public Investment Corporation; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"4%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"3%\">(c)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">persons or entities regulated by the Reserve Bank of South Africa; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"4%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"3%\">(d)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">authorised financial service providers under South African law; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"4%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"3%\">(e)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">financial institutions recognised as such under South African law; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"4%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"3%\">(f)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">a wholly-owned subsidiary of any person or entity contemplated in (c), (d) or (e), acting as agent in the capacity of an authorised portfolio manager for a pension fund or collective investment scheme (in each case duly\nregistered as such under South African law); or </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"4%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"3%\">(g)</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any combination of the person in (a)\u00a0to (f); or </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"3%\">ii</td>\n<td style=\"font-size:8pt\" valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the total contemplated acquisition cost of the securities, for any single addressee acting as principal is equal to or greater than ZAR1,000,000. </td></tr></table>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">No \u0093offer to the public\u0094 (as such term is defined in the South African Companies Act, No.\u00a071 of 2008 (as amended or\n<font style=\"white-space:nowrap\">re-enacted)</font> (the \u0093South African Companies Act\u0094)) in South Africa is being made in connection with the issue of the shares of common stock. Accordingly, this document does not, nor is it intended to,\nconstitute a \u0093registered prospectus\u0094 (as that term is defined in the South African Companies Act) prepared and registered under the South African Companies Act and has not been approved by, and/or filed with, the South African Companies\nand Intellectual Property Commission or any other regulatory authority in South Africa. Any issue or offering of the shares of common stock in South Africa constitutes an offer of the shares of common stock in South Africa for subscription or sale\nin South Africa only to persons who fall within the exemption from \u0093offers to the public\u0094 set out in section 96(1)(a) of the South African Companies Act. Accordingly, this document must not be acted on or relied on by persons in South\nAfrica who do not fall within section 96(1)(a) of the South African Companies Act (such persons being referred to as \u0093SA Relevant Persons\u0094). Any investment or investment activity to which this document relates is available in South Africa\nonly to SA Relevant Persons and will be engaged in South Africa only with SA relevant persons. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">No South African residents or offshore subsidiary of a South African\nresident may subscribe for or purchase any of the shares of common stock or beneficially own or hold any of the shares of common stock unless specific approval has been obtained from the financial surveillance department of the South African Reserve\nBank (the \u0093SARB\u0094) by such persons or such subscription, purchase or beneficial holding or ownership is otherwise permitted under the South African Exchange Control Regulations or the rulings promulgated thereunder (including, without\nlimitation, the rulings issued by the SARB providing for foreign investment allowances applicable to persons who are residents of South Africa under the applicable exchange control laws of South Africa). </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-32 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial\"><b><a name=\"supptoc579741_10\"></a>Legal matters </b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Certain legal matters in connection with this offering will be passed upon for us by Goodwin Procter LLP, San Francisco, California. The underwriters are being\nrepresented in connection with this offering by Latham\u00a0&amp; Watkins LLP, Menlo Park, California. </p> <p style=\"margin-top:16pt; margin-bottom:0pt; font-size:16pt; font-family:arial\"><b><a name=\"supptoc579741_11\"></a>Experts </b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The financial statements incorporated in this Prospectus by reference to the Annual Report on Form <font style=\"white-space:nowrap\">10-K</font> for the year ended\nDecember\u00a031, 2017 have been so incorporated in reliance on the report of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </p>\n<p style=\"margin-top:16pt; margin-bottom:0pt; font-size:16pt; font-family:arial\"><b><a name=\"supptoc579741_12\"></a>Where you can find more information; incorporation by reference </b></p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial\"><b>Available information </b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We file annual, quarterly and current reports, proxy\nstatements and other information with the SEC. Information filed with the SEC by us can be inspected and copied at the Public Reference Room maintained by the SEC at 100 F Street, N.E., Washington, D.C. 20549. You may also obtain copies of this\ninformation by mail from the Public Reference Room of the SEC at prescribed rates. Further information on the operation of the SEC\u0092s Public Reference Room in Washington, D.C. can be obtained by calling the SEC at\n<font style=\"white-space:nowrap\"><font style=\"white-space:nowrap\"><font style=\"white-space:nowrap\">1-800-SEC-0330.</font></font></font> The SEC also maintains a web site that contains reports, proxy and information statements and other information\nabout issuers, such as us, who file electronically with the SEC. The address of that website is <i>http://www.sec.gov</i>. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Our web site address is\n<i>www.myokardia.com</i>. The information on our web site, however, is not, and should not be deemed to be, a part of this prospectus supplement or the accompanying prospectus. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">This prospectus supplement is part of an automatic registration statement on Form <font style=\"white-space:nowrap\">S-3</font> that we filed with the SEC and does not\ncontain all of the information in the registration statement. The full registration statement may be obtained from the SEC or us, as provided above. Forms of indenture and other documents establishing the terms of the offered securities are or may\nbe filed as exhibits to the registration statement. Statements in this prospectus supplement about these documents are summaries and each statement is qualified in all respects by reference to the document to which it refers. You should refer to the\nactual documents for a more complete description of the relevant matters. You may inspect a copy of the registration statement at the SEC\u0092s Public Reference Room in Washington, D.C. or through the SEC\u0092s website, as provided above. </p>\n<p style=\"margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial\"><b>Incorporation by reference </b></p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">The SEC\u0092s rules allow us to incorporate by\nreference information into this prospectus supplement, which means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is deemed to be part\nof this prospectus supplement and the accompanying prospectus, and subsequent information that we file with the SEC will automatically update and supersede that information. Any statement contained in a previously filed document incorporated by\nreference will be deemed to be modified or superseded for purposes of this prospectus supplement to the extent that a statement contained in this prospectus supplement modifies or replaces that statement. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">We incorporate by reference our documents listed below and any future filings made by us with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act,\nbetween the date of this prospectus supplement and the </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-33 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">\ntermination of the offering of the securities described in this prospectus supplement. We are not, however, incorporating by reference any documents or portions thereof, whether specifically\nlisted below or filed in the future, that are not deemed \u0093filed\u0094 with the SEC, including any information furnished pursuant to Items 2.02 or 7.01 of Form <font style=\"white-space:nowrap\">8-K</font> or related exhibits furnished pursuant to\nItem 9.01 of <font style=\"white-space:nowrap\">Form\u00a08-K.</font> </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">This prospectus supplement and the accompanying prospectus incorporate by reference the\ndocuments set forth below that have previously been filed with the SEC: </p> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">Annual Report on Form <font style=\"white-space:nowrap\">10-K</font> for the year ended December\u00a031, 2017, filed with the SEC on March\u00a08, 2018; </td></tr></table>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">Quarterly Report on Form <font style=\"white-space:nowrap\">10-Q</font> for the quarter ended March\u00a031, 2018, filed with the SEC on May\u00a08, 2018; </td></tr></table>\n<p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">The information specifically incorporated by reference into our Annual Report on Form <font style=\"white-space:nowrap\">10-K</font> for the year ended December\u00a031, 2017 from our definitive proxy statement on\nSchedule 14A (other than information furnished rather than filed), which was filed with the SEC on April\u00a017, 2018; </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">Current Reports on Form <font style=\"white-space:nowrap\">8-K</font> filed with the SEC on March\u00a05, 2018, March\u00a08, 2018 <font style=\"white-space:nowrap\">(Acc-no:</font> <font style=\"white-space:nowrap\"><font style=\"white-space:nowrap\">0001193125-18-075156)</font></font> (as to Item 8.01 only),\u00a0April\u00a04, 2018 (as to Item 5.02 only), and May\u00a021, 2018; and </td></tr></table> <p style=\"font-size:8pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"1%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">The description of our common stock contained in our registration statement on Form <font style=\"white-space:nowrap\">8-A</font> filed with the SEC on October\u00a027, 2015 under Section\u00a012(b) of the Exchange Act,\nincluding any amendments or reports filed for the purpose of updating such description. </td></tr></table> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">Upon request, we will provide, without charge, to each person,\nincluding any beneficial owner, to whom a copy of this prospectus supplement is delivered, a copy of the documents incorporated by reference into this prospectus supplement and the accompanying prospectus but not delivered with the prospectus. You\nmay request a copy of these filings, and any exhibits we have specifically incorporated by reference as an exhibit in this prospectus supplement, at no cost by writing or telephoning us at the following address: 333 Allerton Ave., South San\nFrancisco, CA 94080; telephone: <font style=\"white-space:nowrap\">(650)\u00a0741-0900.</font> </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">You may also access these documents free of charge on the SEC\u0092s\nwebsite at <i>www.sec.gov</i> or on our website at <i>www.myokardia.com</i>. Information contained on our website is not incorporated by reference into this prospectus supplement or the accompanying prospectus, and you should not consider any\ninformation on, or that can be accessed from, our website as part of this prospectus supplement or the accompanying prospectus. </p> <p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">This prospectus supplement and the\naccompanying prospectus are part of an automatic registration statement we filed with the SEC. We have incorporated exhibits into the registration statement. You should read the exhibits carefully for provisions that may be important to you. </p>\n<p style=\"margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">You should rely only on the information incorporated by reference or provided in this prospectus supplement and the accompanying prospectus. We have not authorized\nanyone to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus supplement, the accompanying prospectus or\nin the documents incorporated by reference is accurate as of any date other than the date on the front of this prospectus supplement or those documents. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial\">S-34 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>PROSPECTUS </b></p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<p align=\"center\" style=\"margin-top:0pt;margin-bottom:0pt\">\n<img alt=\"LOGO\" src=\"g579741g95t12.jpg\"/>\n</p> <p align=\"center\" style=\"margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman\"><b>Common Stock </b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman\"><b>Preferred Stock </b></p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman\"><b>Debt\nSecurities </b></p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman\"><b>Warrants </b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman\"><b>Units </b></p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p><center>\n<p style=\"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%\">\u00a0</p></center> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We may from time to time issue,\nin one or more series or classes, our common stock, preferred stock, debt securities, warrants and/or units. We may offer these securities separately or together in units. We will specify in the accompanying prospectus supplement the terms of the\nsecurities being offered. We may sell these securities to or through underwriters and also to other purchasers or through agents. We will set forth the names of any underwriters or agents, and any fees, conversions or discount arrangements, in the\naccompanying prospectus supplement. We may not sell any securities under this prospectus without delivery of the applicable prospectus supplement. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">You\nshould read this document and any prospectus supplement or amendment carefully before you invest in our securities. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Our common stock is listed on The\nNASDAQ Global Select Market under the symbol \u0093MYOK.\u0094 On March 6, 2018, the closing price for our common stock, as reported on The NASDAQ Global Select Market, was $57.95 per share. Our principal executive office is located at 333 Allerton\nAve., South San Francisco, California 94080. </p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p><center>\n<p style=\"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%\">\u00a0</p></center> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman\"><b>Investing in our securities\ninvolves a high degree of risk. You should review carefully the risks and uncertainties referenced under the heading \u0093<a Factors</a>\u0094 contained in this prospectus beginning on page 2\u00a0and any applicable\nprospectus supplement, and under similar headings in the other documents that are incorporated by reference into this prospectus. </b></p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman\"><b>This prospectus\nmay not be used to offer or sell securities unless accompanied by a prospectus supplement. </b></p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman\"><b>Neither the Securities and Exchange Commission nor any\nstate securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </b></p>\n<p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p><center> <p style=\"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%\">\u00a0</p></center>\n<p align=\"center\" style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>The date of this Prospectus is March 8, 2018. </b></p> <p style=\"font-size:50pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<p style=\"font-size:100pt; margin-top:0pt; margin-bottom:0pt\">\u00a0</p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>TABLE OF CONTENTS </b></p>\n<p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr>\n<td width=\"95%\"></td>\n<td valign=\"bottom\" width=\"3%\"></td>\n<td></td>\n<td></td>\n<td></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\">\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td align=\"center\" colspan=\"2\" style=\"border-bottom:1.00pt solid #000000\" valign=\"bottom\"><b>Page</b></td>\n<td valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a this Prospectus </a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">1</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a Factors</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">2</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a Statement Regarding Forward-Looking Statements</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">3</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a Company</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">5</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a of Earnings to Fixed Charges</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">6</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a of Proceeds</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">6</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a We May\u00a0Offer</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">7</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a of Capital Stock</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">7</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a of Debt Securities</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">13</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a of Warrants</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">20</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a of Units</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">21</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a of Distribution</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">24</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a Matters</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">27</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">27</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a You Can Find More Information</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">27</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><a by Reference</a></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">27</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n</table>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">i </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_1\"></a>ABOUT THIS PROSPECTUS </b></p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">This prospectus is part of an automatic registration statement that we filed with the Securities and Exchange Commission, or the SEC, using a\n\u0093shelf\u0094 registration process as a \u0093well-known seasoned issuer\u0094 as defined in Rule 405 under the Securities Act of 1933, as amended, or the Securities Act. Under this shelf registration process, we may from time to time sell any\ncombination of the securities described in this prospectus in one or more offerings. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">This prospectus provides you with a general description of the\nsecurities we may offer. Each time we sell securities, we will provide one or more prospectus supplements that will contain specific information about the terms of the offering. The prospectus supplement may also add, update or change information\ncontained in this prospectus. You should read both this prospectus and the accompanying prospectus supplement together with the additional information described under the heading \u0093Where You Can Find More Information\u0094 beginning on\npage\u00a027 of this prospectus. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">You should rely only on the information contained in or incorporated by reference in this prospectus, any accompanying\nprospectus supplement or in any related free writing prospectus filed by us with the SEC. We have not authorized anyone to provide you with different information. This prospectus and the accompanying prospectus supplement do not constitute an offer\nto sell or the solicitation of an offer to buy any securities other than the securities described in the accompanying prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such\noffer or solicitation is unlawful. You should assume that the information appearing in this prospectus, any prospectus supplement, the documents incorporated by reference and any related free writing prospectus is accurate only as of their\nrespective dates. Our business, financial condition, results of operations and prospects may have changed materially since those dates. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><i>Unless the\ncontext suggests otherwise, all references to \u0093us,\u0094 \u0093our,\u0094 \u0093MyoKardia,\u0094 \u0093we,\u0094 the \u0093Company\u0094 and similar designations refer to MyoKardia, Inc. and, where appropriate, our subsidiary. </i></p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">1 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_2\"></a>RISK FACTORS </b></p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Investing in our securities involves a high degree of risk. You should carefully consider the risks referenced below and described in the documents\nincorporated by reference in this prospectus and any prospectus supplement, as well as other information we include or incorporate by reference into this prospectus and any applicable prospectus supplement, before making an investment decision. Our\nbusiness, financial condition or results of operations could be materially adversely affected by the materialization of any of these risks. The trading price of our securities could decline due to the materialization of any of these risks, and you\nmay lose all or part of your investment. This prospectus and the documents incorporated herein by reference also contain forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those anticipated\nin these forward-looking statements as a result of certain factors, including the risks referenced below and described in the documents incorporated herein by reference, including (i)\u00a0our annual report on\n<font style=\"white-space:nowrap\">Form\u00a010-K</font> for the fiscal year ended December\u00a031, 2017, which is on file with the SEC and is incorporated herein by reference, and (ii)\u00a0other documents we file with the SEC that are deemed\nincorporated by reference into this prospectus. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">2 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_3\"></a>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </b></p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">This prospectus, including the documents that we incorporate by reference, contains forward-looking statements within the meaning of Section\u00a027A of the\nSecurities Act of 1933, as amended, or the Securities Act, and Section\u00a021E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Any statements about our expectations, beliefs, plans, objectives, assumptions or future events\nor performance are not historical facts and may be forward-looking. These statements are often, but are not always, made through the use of words or phrases such as \u0093may,\u0094 \u0093will,\u0094 \u0093could,\u0094 \u0093should,\u0094\n\u0093expects,\u0094 \u0093intends,\u0094 \u0093plans,\u0094 \u0093anticipates,\u0094 \u0093believes,\u0094 \u0093estimates,\u0094 \u0093predicts,\u0094 \u0093projects,\u0094 \u0093potential,\u0094 \u0093continue,\u0094 and similar expressions, or\nthe negative of these terms, or similar expressions. Accordingly, these statements involve estimates, assumptions, risks and uncertainties which could cause actual results to differ materially from those expressed in them. Any forward-looking\nstatements are qualified in their entirety by reference to the factors discussed throughout this prospectus and any accompanying prospectus supplement or the documents incorporated by reference herein, and in particular those factors referenced in\nthe section \u0093Risk Factors.\u0094 </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">This prospectus contains forward-looking statements that are based on our management\u0092s belief and assumptions\nand on information currently available to our management. These statements relate to future events or our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of\nactivity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not\nlimited to, statements about: </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the timing and success of, and our ability to generate positive data from, our planned pivotal Phase 3 clinical trial, EXPLORER\u0096HCM, of mavacamten (formerly known as <font style=\"white-space:nowrap\">MYK-461)</font>\nin symptomatic, obstructive HCM (oHCM) patients, our planned Phase 2 clinical trial, MAVERICK\u0096HCM, of mavacamten in symptomatic <font style=\"white-space:nowrap\">non-obstructive</font> HCM (nHCM) patients, our Phase 2 clinical trial,\nPIONEER\u0096HCM, of mavacamten in symptomatic, obstructive HCM patients, our Phase 1 clinical trials of <font style=\"white-space:nowrap\">MYK-491</font> in healthy volunteers and our Phase 1b clinical trial of\n<font style=\"white-space:nowrap\">MYK-491</font> in DCM patients; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">our ability to enroll patients in our clinical trials at the pace that we project; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">our ability to execute our clinical development plans and obtain regulatory approval for any of our product candidates without the need for large, outcome-based studies; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">our ability to identify and advance through clinical development any additional product candidates from our precision medicine platform, including from our <font style=\"white-space:nowrap\">HCM-2,</font> <font style=\"white-space:nowrap\">DCM-2</font> and <font style=\"white-space:nowrap\">LUS-1</font> programs; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">our ability to successfully maintain our strategic collaboration with Sanofi; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">our ability to obtain and maintain intellectual property protection for our precision medicine platform and our product candidates; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">our ability to successfully build a specialty sales force and commercial infrastructure to market mavacamten and any other product candidates from our programs, if approved, in the United States and any product\ncandidates from our other programs worldwide; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">our ability to compete with companies currently producing or engaged in the clinical development of treatments for the disease indications that we pursue; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">our reliance on third parties to conduct our clinical trials and to manufacture drug substance for use in our clinical trials; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">our ability to retain and recruit key personnel; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">our expectations regarding government and third-party payor coverage and reimbursement; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">our estimates of our expenses, ongoing losses, capital requirements, future revenue and our needs for or ability to obtain additional financing; </td></tr></table>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">3 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">our expectations regarding the time during which we will be an emerging growth company under the JOBS Act; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">our financial performance; and </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">developments and projections relating to our competitors or our industry. </td></tr></table> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">These forward-looking statements\nare neither promises nor guarantees of future performance due to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those indicated by these forward-looking\nstatements, including, without limitation the risk factors and cautionary statements described in other documents that we file from time to time with the SEC, specifically under \u0093Item 1A: Risk Factors\u0094 and elsewhere in our most recent\nAnnual Report on Form <font style=\"white-space:nowrap\">10-K</font> for the period ended December\u00a031, 2017, and our Current Reports on Form <font style=\"white-space:nowrap\">8-K</font> to the extent incorporated by reference in this prospectus,\nand the section of any accompanying prospectus supplement entitled \u0093Risk Factors.\u0094 </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The forward-looking statements in this prospectus and the\ndocuments incorporated by reference represent our views as of their respective dates. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at\nsome point in the future, we assume no obligation to update or revise any forward-looking statements except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of\nany date subsequent to the dates on which they were made. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">This prospectus and the documents incorporated by reference also contain estimates, projections\nand other information concerning our industry, our business, and the markets for certain diseases, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is\nbased on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless\notherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications,\ngovernment data and similar sources. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">4 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_4\"></a>THE COMPANY </b></p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We are a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the\ntreatment of serious and neglected rare cardiovascular diseases. Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle\ncontraction. We have used our precision medicine platform to generate a robust pipeline of therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy\u0097hypertrophic cardiomyopathy, or HCM, and dilated\ncardiomyopathy, or DCM. Our lead candidate, mavacamten, is initially being developed for the treatment of symptomatic oHCM. In a Phase 2 clinical trial, known as <font style=\"white-space:nowrap\">PIONEER-HCM,</font> mavacamten achieved statistically\nsignificant changes in the primary endpoint of post-exercise left ventricular outflow tract (LVOT) gradient from baseline and demonstrated improvements across key secondary endpoints including New York Heart Association classification, exercise\ncapacity as measured by peak oxygen consumption, or peak VO2, and change in dyspnea scores. In the first half of 2018, we plan to initiate three additional studies of mavacamten\u0097a pivotal Phase 3 clinical trial of oHCM patients known as <font style=\"white-space:nowrap\">EXPLORER-HCM;</font> a long-term extension trial of oHCM patients from our Phase 2 trial; and a Phase 2 clinical trial in a second potential indication for mavacamten, symptomatic,\n<font style=\"white-space:nowrap\">non-obstructive</font> HCM known as <font style=\"white-space:nowrap\">MAVERICK-HCM.</font> In 2016, mavacamten was granted Orphan Drug Designation by the U.S. Food and Drug Administration, or the FDA, for the\ntreatment of symptomatic oHCM. A second product candidate, <font style=\"white-space:nowrap\">MYK-491,</font> for the treatment of DCM, has completed its <font style=\"white-space:nowrap\"><font style=\"white-space:nowrap\">first-in-human</font></font>\nPhase 1 in healthy volunteers and we are currently enrolling patients in a Phase 1b clinical trial. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We have never been profitable and have incurred net\nlosses in each year since inception.\u00a0Our net loss for the years ended December\u00a031, 2017 and 2016 was $46.0\u00a0million and $13.2\u00a0million, respectively. As of December\u00a031, 2017, we had an accumulated deficit of\n$123.8\u00a0million. To date, we have not generated any product revenue. We do not expect to receive any revenue from any product candidates that we develop until we obtain regulatory approval and commercialize our products or enter into\ncollaborative agreements with third parties. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. As\nof December\u00a031, 2017, we had $276.4\u00a0million of cash and cash equivalents. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We qualify as an \u0093emerging growth company\u0094 as defined in\nthe Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. We\nwould cease to be an emerging growth company on the date that is the earliest of: (i)\u00a0the last day of the fiscal year in which we have total annual gross revenues of $1.07\u00a0billion or more; (ii)\u00a0December\u00a031, 2020; (iii)\u00a0the\ndate on which we have issued more than $1\u00a0billion in nonconvertible debt during the previous three years; or (iv)\u00a0the date on which we are deemed to be a large accelerated filer under the rules of the SEC. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We were incorporated in Delaware in June 2012. Our principal executive offices are located at 333 Allerton Ave., South San Francisco, California 94080. Our\ntelephone number is <font style=\"white-space:nowrap\">(650)\u00a0741-0900</font> and our <font style=\"white-space:nowrap\">e-mail</font> address is info@myokardia.com. Our Internet website address is <i>www.myokardia.com</i>. No portion of our website\nis incorporated by reference into this prospectus. We do not incorporate the information on or accessible through our website into this prospectus, and you should not consider any information on, or that can be accessed through, our website as part\nof this prospectus. Our common stock trades on The NASDAQ Global Select Market under the symbol \u0093MYOK\u0094. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We use various trademarks and trade\nnames in our business, including without limitation our corporate name and logo. All other trademarks or trade names referred to in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names\nin this prospectus may be referred to without the <sup style=\"font-size:85%; vertical-align:top\">\u00ae</sup> and \u0099 symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the\nfullest extent under applicable law, their rights thereto. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">5 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_5\"></a>RATIO OF EARNINGS TO FIXED CHARGES </b></p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The following table sets forth our ratio of earnings to fixed charges for the periods shown. You should read this table in conjunction with the financial\nstatements and notes incorporated by reference in this prospectus. We paid no dividends on preferred shares during the periods indicated. Therefore, the ratios of earnings to combined fixed charges and preferred dividends are the same as the ratios\nof earnings to fixed charges presented below. </p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt\" width=\"100%\">\n<tr>\n<td width=\"80%\"></td>\n<td valign=\"bottom\" width=\"3%\"></td>\n<td></td>\n<td></td>\n<td></td>\n<td valign=\"bottom\" width=\"3%\"></td>\n<td></td>\n<td></td>\n<td></td>\n<td valign=\"bottom\" width=\"3%\"></td>\n<td></td>\n<td></td>\n<td></td>\n<td valign=\"bottom\" width=\"3%\"></td>\n<td></td>\n<td></td>\n<td></td>\n<td valign=\"bottom\" width=\"3%\"></td>\n<td></td>\n<td></td>\n<td></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\">\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td align=\"center\" colspan=\"18\" style=\"border-bottom:1.00pt solid #000000\" valign=\"bottom\"><b>Years\u00a0Ended\u00a0December\u00a031,</b></td>\n<td valign=\"bottom\">\u00a0</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\">\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td align=\"center\" colspan=\"2\" style=\"border-bottom:1.00pt solid #000000\" valign=\"bottom\"><b>2017</b></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td align=\"center\" colspan=\"2\" style=\"border-bottom:1.00pt solid #000000\" valign=\"bottom\"><b>2016</b></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td align=\"center\" colspan=\"2\" style=\"border-bottom:1.00pt solid #000000\" valign=\"bottom\"><b>2015</b></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td align=\"center\" colspan=\"2\" style=\"border-bottom:1.00pt solid #000000\" valign=\"bottom\"><b>2014</b></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td align=\"center\" colspan=\"2\" style=\"border-bottom:1.00pt solid #000000\" valign=\"bottom\"><b>2013</b></td>\n<td valign=\"bottom\">\u00a0</td></tr>\n<tr bgcolor=\"#cceeff\" style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\"><b>Ratio of Earnings to Fixed Charges</b></p></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">N/A</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">N/A</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">N/A</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">N/A</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"bottom\">N/A</td>\n<td nowrap=\"\" valign=\"bottom\">\u00a0</td></tr>\n</table> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">For purposes of calculating the ratios in the table above, earnings consist of net loss before income taxes. Fixed charges\ninclude any interest expense on indebtedness and an estimate of the interest expense within rental expense. We had no indebtedness for any of the periods presented. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Due to our net losses for the years ended December\u00a031, 2017, 2016, 2015, 2014 and 2013, earnings were insufficient to cover fixed charges for such\nperiods and we are unable to disclose a ratio of earnings to fixed charges for such periods. The dollar amount of the deficiency in earnings available for fixed charges for the years ended December\u00a031, 2017, 2016, 2015, 2014 and 2013 was\napproximately $46.0 million, $13.2 million, 22.9\u00a0million, $16.8\u00a0million, and $12.7\u00a0\nmillion, respectively. </p> <p align=\"center\" style=\"margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_6\"></a>USE OF PROCEEDS </b></p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We intend to use the net proceeds from the sale of any securities offered under this prospectus for general corporate purposes unless otherwise indicated in\nthe applicable prospectus supplement. General corporate purposes may include research and development and clinical development costs to support the advancement of our product candidates and the expansion of our product candidate pipeline; working\ncapital; capital expenditures; office expansion; and other general corporate purposes. We may temporarily invest the net proceeds in a variety of capital preservation instruments, including short-term, investment-grade, interest-bearing instruments\nand U.S. government securities, or may hold such proceeds as cash, until they are used for their stated purpose. We have not determined the amount of net proceeds to be used specifically for such purposes.\u00a0As a result, management will retain\nbroad discretion over the allocation of net proceeds. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">6 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_7\"></a>SECURITIES WE MAY\u00a0OFFER </b></p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><i>This prospectus contains summary descriptions of the securities we may offer from time to time. These summary descriptions are not meant to be complete\ndescriptions of each security. The particular terms of any security will be described in the applicable prospectus supplement. </i></p> <p align=\"center\" style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_8\">\n</a>DESCRIPTION OF CAPITAL STOCK </b></p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><i>The following description of our common stock and preferred stock, together with the additional information we\ninclude in any applicable prospectus supplements, summarizes the material terms and provisions of the common stock and preferred stock that we may offer under this prospectus. The following description of our capital stock does not purport to be\ncomplete and is subject to, and qualified in its entirety by, our certificate of incorporation and bylaws, which are exhibits to the registration statement of which this prospectus forms a part, and by applicable law. The terms of our common stock\nand preferred stock may also be affected by Delaware law. </i></p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>Authorized Capital Stock </b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Our authorized capital stock consists of 150,000,000 shares of common stock, par value $0.0001 per share, and 5,000,000 shares of preferred stock, par value\n$0.0001 per share, all of which are undesignated preferred stock. As of March\u00a01, 2018, we had 35,923,637 shares of common stock outstanding and no shares of preferred stock outstanding. </p>\n<p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>Common Stock </b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The holders of our common stock are\nentitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends\ndeclared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other subscription\nrights or redemption or sinking fund provisions. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled\nto share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock. All outstanding shares are fully paid and nonassessable. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">When we issue shares of common stock under this prospectus, the shares will fully be paid and nonassessable and will not have, or be subject to, any\npreemptive or similar rights. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>Undesignated Preferred Stock </b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Our board of directors is authorized to issue up to 5,000,000 shares of undesignated preferred stock in one or more series without stockholder approval. Our\nboard of directors may determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The purpose of authorizing our board of directors to issue preferred stock in one or more series and determine the number of shares in the series and its\nrights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. Examples of rights and preferences that the Board may fix are: </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">dividend rights; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">conversion rights; </td></tr></table>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">7 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">voting rights; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">terms of redemption; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">liquidation preferences; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">sinking fund terms; and </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. </td></tr></table>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The existence of authorized but unissued shares of undesignated preferred stock may enable our board of directors to render more difficult or to discourage an\nattempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best\ninterests of us or our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the\nproposed acquirer, stockholder or stockholder group.\u00a0The rights of holders of our common stock described above, will be subject to, and may be adversely affected by, the rights of any preferred stock that we may designate and issue in the\nfuture. The issuance of shares of undesignated preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including\nvoting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We will incorporate by reference\nas an exhibit to the registration statement, which includes this prospectus, the form of any certificate of designation that describes the terms of the series of preferred stock we are offering. This description and the applicable prospectus\nsupplement will include: </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the title and stated value; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the number of shares authorized; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the liquidation preference per share; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the purchase price; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the dividend rate, period and payment date, and method of calculation for dividends; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">whether dividends will be cumulative or <font style=\"white-space:nowrap\">non-cumulative</font> and, if cumulative, the date from which dividends will accumulate; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the procedures for any auction and remarketing, if any; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the provisions for a sinking fund, if any; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase rights; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any listing of the preferred stock on any securities exchange or market; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">whether the preferred stock will be convertible into our common stock, and, if applicable, the conversion price, or how it will be calculated, and the conversion period; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price, or how it will be calculated, and the exchange period; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">voting rights, if any, of the preferred stock; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">preemptive rights, if any; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">restrictions on transfer, sale or other assignment, if any; </td></tr></table>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">8 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">whether interests in the preferred stock will be represented by depositary shares; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">a discussion of any material United States federal income tax considerations applicable to the preferred stock; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any limitations on issuance of any class or series of preferred stock ranking senior to or on a parity with the series of preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our\naffairs; and </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any other specific terms, preferences, rights or limitations of, or restrictions on, the preferred stock. </td></tr></table>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">When we issue shares of preferred stock under this prospectus, the shares will fully be paid and nonassessable and will not be subject to any preemptive or\nsimilar rights. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>Registration Rights </b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman\">The holders of certain shares of our common stock, or their permitted transferees, which we refer to as our registrable securities, are\nentitled to rights with respect to the registration of these securities under the Securities Act. These rights are provided under the terms of the investor rights agreement. The investor rights agreement includes demand registration rights,\nshort-form registration rights and piggyback registration rights. All fees, costs and expenses incurred in connection with registrations under the investor rights agreement will be borne by us, and all selling expenses, including underwriting\ndiscounts and selling commissions, will be borne by the holders of the shares being registered. The investor rights agreement does not provide for any penalties for delays in registering our registrable securities. We have filed a registration\nstatement on Form <font style=\"white-space:nowrap\">S-3</font> (File <font style=\"white-space:nowrap\">No.\u00a0333-219220)</font> registering for resale the remaining registrable securities under the investor rights agreement. The registration\nstatement was declared effective on July\u00a021, 2017. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Demand Registration Rights </i></b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman\">The holders of our registrable securities are entitled to demand registration rights. Under the terms of the investor rights agreement, we will\nbe required, upon the request of holders of at least 25% of our outstanding registrable securities, to file a registration statement with an anticipated offering amount of at least $3.0\u00a0million and use commercially reasonable efforts to effect\nthe registration of these shares for public resale. We are required to effect up to two registrations pursuant to this provision of the investor rights agreement. </p>\n<p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Short Form Registration Rights </i></b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman\">The holders of our registrable securities are also entitled to short form registration rights. Pursuant to the investor rights agreement, if we\nare eligible to file a registration statement on Form <font style=\"white-space:nowrap\">S-3,</font> upon the request of holders of at least 25% of our outstanding registrable securities to sell registrable securities with an anticipated aggregate\noffering amount of at least $1.0\u00a0million net of certain expenses related to the offering, we will be required to use our commercially reasonable efforts to effect a registration of such shares. We are required to effect up to two registrations\nin any twelve month period pursuant to this provision of the investor rights agreement. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Piggyback Registration Rights </i></b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman\">The holders of our registrable securities are entitled to piggyback registration rights. If we register any of our securities either for our\nown account or for the account of other security holders, the holders of our outstanding registrable securities are entitled to include their shares in the registration. Subject to certain exceptions contained in the investor rights agreement, we\nand the underwriters may limit the number of shares included in the underwritten offering if the underwriters determine that marketing factors require a limitation of the number of shares to be underwritten. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">9 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Indemnification </i></b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman\">Our investor rights agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of\nregistrable securities in the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them. </p>\n<p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Expenses of Registration </i></b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman\">We will\npay the registration expenses, subject to certain limited exceptions contained in the investor rights agreement, of the holders of the shares registered pursuant to the demand, short form and piggyback registration rights described above, including\nthe expenses of one counsel for the selling holders. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Expiration of Registration Rights </i></b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman\">The registration rights granted under the investor rights agreement will terminate upon the earlier of (i)\u00a0certain events constituting a\nsale of the company, (ii)\u00a0the consummation of a transaction or series of transactions in which a person, or a group of persons, acquires from our stockholders, shares representing more than 50% of our outstanding voting stock, (iii)\u00a0at\nsuch time when all registrable securities could be sold under Rule 144 of the Securities Act or a similar exemption without limitation during a three-month period without registration or (iv)\u00a0the third anniversary of our IPO. </p>\n<p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>Antitakeover Effects of Delaware Law and Provisions of our Restated Certificate of Incorporation and Amended and Restated Bylaws </b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Certain provisions of the Delaware General Corporation Law and of our restated certificate of incorporation and amended and restated bylaws could have the\neffect of delaying, deferring or discouraging another party from acquiring control of us. These provisions, which are summarized below, are expected to discourage certain types of coercive takeover practices and inadequate takeover bids and, as a\nconsequence, they might also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions are also designed in part to encourage anyone seeking to acquire\ncontrol of us to first negotiate with our board of directors. These provisions might also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that\nstockholders might otherwise deem to be in their best interests. However, we believe that the advantages gained by protecting our ability to negotiate with any unsolicited and potentially unfriendly acquirer outweigh the disadvantages of\ndiscouraging such proposals, including those priced above the then-current market value of our common stock, because, among other reasons, the negotiation of such proposals could improve their terms. </p>\n<p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><i>Delaware Takeover Statute </i></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We are subject to the\nprovisions of Section\u00a0203 of the Delaware General Corporation Law. In general, Section\u00a0203 prohibits a publicly held Delaware corporation from engaging in a \u0093business combination\u0094 with an \u0093interested stockholder\u0094 for a\nthree-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section\u00a0203, a business combination between a corporation and an interested\nstockholder is prohibited unless it satisfies one of the following conditions: </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">before the stockholder became interested, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\"> <p align=\"left\" style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt\">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the\ninterested stockholder owned at least 85% of the voting stock of the corporation </p></td></tr></table>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">10 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"8%\">\u00a0</td>\n<td valign=\"top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt\">\noutstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee\nstock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or </p></td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">at or after the time the stockholder became interested, the business combination was approved by our board of directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at\nleast <font style=\"white-space:nowrap\">two-thirds</font> of the outstanding voting stock which is not owned by the interested stockholder. </td></tr></table>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Section\u00a0203 defines a business combination to include: </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any merger or consolidation involving the corporation and the interested stockholder; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any sale, transfer, lease, pledge, exchange, mortgage or other disposition involving the interested stockholder of 10% or more of the assets of the corporation; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested\nstockholder; or </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. </td></tr></table>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">In general, Section\u00a0203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the\ncorporation and any entity or person affiliated with or controlling or controlled by the entity or person. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><i>Provisions of our Restated Certificate of\nIncorporation and Amended and Restated Bylaws </i></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Our restated certificate of incorporation and amended and restated bylaws include a number of provisions\nthat may have the effect of delaying, deferring or discouraging another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors\nrather than pursue <font style=\"white-space:nowrap\">non-negotiated</font> takeover attempts. These provisions include the items described below. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><i>Board\ncomposition and filling vacancies</i>. In accordance with our restated certificate of incorporation, our board is divided into three classes serving staggered three-year terms, with one class being elected each year. Our\u00a0restated certificate of\nincorporation also provides that directors may be removed only for cause and then only by the affirmative vote of the holders of 75% or more of the shares then entitled to vote at an election of directors. Furthermore, any vacancy on our board of\ndirectors, however occurring, including a vacancy resulting from an increase in the size of our board, may only be filled by the affirmative vote of a majority of our directors then in office even if less than a quorum. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><i>No written consent of stockholders</i>. Our restated certificate of incorporation provides that all stockholder actions are required to be taken by a vote\nof the stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the\namendment of our bylaws or removal of directors by our stockholder without holding a meeting of stockholders. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><i>Meetings of stockholders</i>. Our bylaws\nprovide that only a majority of the members of our board of directors then in office may call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting\nof stockholders. Our bylaws limit the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">11 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><i>Advance notice requirements</i>. Our bylaws establish advance notice procedures with regard to\nstockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing\nto our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90 days or more than 120 days prior to the first anniversary date\nof the annual meeting for the preceding year. The notice must contain certain information specified in our bylaws. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><i>Amendment to certificate of\nincorporation and bylaws</i>. As required by the Delaware General Corporation Law, any amendment of our restated certificate of incorporation must first be approved by a majority of our board of directors, and if required by law or our restated\ncertificate of incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment, and a majority of the outstanding shares of<i> </i>each class entitled to vote thereon as a class, except that the\namendment of the provisions relating to stockholder action, directors, limitation of liability and the amendment of our restated certificate of incorporation must be approved by not less than 75% of the outstanding shares entitled to vote on the\namendment, and not less than 75% of the outstanding shares of each class entitled to vote thereon as a class. Our bylaws may be amended by the affirmative vote of a majority vote of the directors then in office, subject to any limitations set forth\nin the\u00a0bylaws; and may also be amended by the affirmative vote of at least 75% of the outstanding shares entitled to vote on the amendment, or, if the board of directors recommends that the stockholders approve the amendment, by the affirmative\nvote of the majority of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><i>Undesignated\npreferred stock</i>. Our restated certificate of incorporation provides for authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board of directors to render more difficult or to\ndiscourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not\nin the best interests of us or our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other\nrights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our restated certificate of incorporation grants our board of directors broad power to establish the rights and preferences of authorized and unissued\nshares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights\u00a0and powers,\nincluding voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">12 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_9\"></a>DESCRIPTION OF DEBT SECURITIES </b></p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">This section describes the general terms and provisions of our debt securities that we may issue from time to time. We may issue debt securities, in one or\nmore series, as either senior or subordinated debt or as senior or subordinated convertible debt. While the terms we have summarized below will apply generally to any future debt securities we may offer under this prospectus, the applicable\nprospectus supplement or free writing prospectus will describe the specific terms of any debt securities offered through that prospectus supplement or free writing prospectus. The terms of any debt securities we offer under a prospectus supplement\nor free writing prospectus may differ from the terms we describe below. Unless the context requires otherwise, whenever we refer to the \u0093indentures,\u0094 we also are referring to any supplemental indentures that specify the terms of a\nparticular series of debt securities. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We will issue any senior debt securities under the senior indenture that we will enter into with the trustee named\nin the senior indenture. We will issue any subordinated debt securities under the subordinated indenture that we will enter into with the trustee named in the subordinated indenture. We have filed forms of these documents as exhibits to the\nregistration statement, of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this\nprospectus is a part or will be incorporated by reference from reports that we file with the SEC. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The indentures will be qualified under the Trust\nIndenture Act of 1939, as amended, or the Trust Indenture Act. We use the term \u0093trustee\u0094 to refer to either the trustee under the senior indenture or the trustee under the subordinated indenture, as applicable. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The following summaries of material provisions of the senior debt securities, the subordinated debt securities and the indentures are subject to, and\nqualified in their entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplement or free writing prospectus and any related free\nwriting prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete applicable indenture that contains the terms of the debt securities. Except as we may otherwise indicate, the terms of the senior\nindenture and the subordinated indenture are identical. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>General </i></b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We will describe in the applicable prospectus supplement or free writing prospectus the terms of the series of debt securities being offered, including: </p>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the title; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the principal amount being offered, and if a series, the total amount authorized and the total amount outstanding; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any limit on the amount that may be issued; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">whether or not we will issue the series of debt securities in global form, and, if so, the terms and who the depository will be; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the maturity date; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">whether and under what circumstances, if any, we will pay additional amounts on any debt securities held by a person who is not a United States person for tax purposes, and whether we can redeem the debt securities if\nwe have to pay such additional amounts; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the annual interest rate, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest\npayment dates or the method for determining such dates; </td></tr></table>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">13 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the terms of the subordination of any series of subordinated debt; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the place where payments will be payable; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">restrictions on transfer, sale or other assignment, if any; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">our right, if any, to defer payment of interest and the maximum length of any such deferral period; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the date, if any, after which, the conditions upon which, and the price at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms\nof those redemption provisions; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the date, if any, on which, and the price at which we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder\u0092s option, to purchase, the series\nof debt securities and the currency or currency unit in which the debt securities are payable; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">whether the indenture will restrict our ability or the ability of our subsidiaries to: </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">incur additional indebtedness; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">issue additional securities; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">create liens; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">pay dividends or make distributions in respect of our capital stock or the capital stock of our subsidiaries; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">redeem capital stock; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">place restrictions on our subsidiaries\u0092 ability to pay dividends, make distributions or transfer assets; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">make investments or other restricted payments; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">sell or otherwise dispose of assets; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">enter into sale-leaseback transactions; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">engage in transactions with stockholders or affiliates; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">issue or sell stock of our subsidiaries; or </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">effect a consolidation or merger; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">whether the indenture will require us to maintain any interest coverage, fixed charge, cash flow-based, asset-based or other financial ratios; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">a discussion of certain material or special United States federal income tax considerations applicable to the debt securities; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">information describing any book-entry features; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">provisions for a sinking fund purchase or other analogous fund, if any; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the applicability of the provisions in the indenture on discharge; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">whether the debt securities are to be offered at a price such that they will be deemed to be offered at an \u0093original issue discount\u0094 as defined in paragraph\u00a0(a) of Section\u00a01273 of the Internal\nRevenue Code of 1986, as amended; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S. dollars; and </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, including any additional events of default or covenants provided with respect to the debt securities, and any\nterms that may be required by us or advisable under applicable laws or regulations or advisable in connection with the marketing of the debt securities. </td></tr></table>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">14 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Conversion or Exchange Rights </i></b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We will set forth in the applicable prospectus supplement or free writing prospectus the terms on which a series of debt securities may be convertible into or\nexchangeable for our common stock, our preferred stock or other securities (including securities of a third-party). We will include provisions as to whether conversion or exchange is mandatory, at the option of the holder or at our option. We may\ninclude provisions pursuant to which the number of shares of our common stock, our preferred stock or other securities (including securities of a third-party) that the holders of the series of debt securities receive would be subject to adjustment.\n</p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Consolidation, Merger or Sale </i></b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Unless we\nprovide otherwise in the prospectus supplement or free writing prospectus applicable to a particular series of debt securities, the indentures will not contain any covenant that restricts our ability to merge or consolidate, or sell, convey,\ntransfer or otherwise dispose of all or substantially all of our assets. However, any successor to or acquirer of such assets must assume all of our obligations under the indentures or the debt securities, as appropriate. If the debt securities are\nconvertible into or exchangeable for other securities of ours or securities of other entities, the person with whom we consolidate or merge or to whom we sell all of our property must make provisions for the conversion of the debt securities into\nsecurities that the holders of the debt securities would have received if they had converted the debt securities before the consolidation, merger or sale. </p>\n<p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Events of Default Under the Indenture </i></b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Unless we\nprovide otherwise in the prospectus supplement or free writing prospectus applicable to a particular series of debt securities, the following are events of default under the indentures with respect to any series of debt securities that we may issue:\n</p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">if we fail to pay interest when due and payable and our failure continues for 90\u00a0days and the time for payment has not been extended; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">if we fail to pay the principal, premium or sinking fund payment, if any, when due and payable at maturity, upon redemption or repurchase or otherwise, and the time for payment has not been extended; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">if we fail to observe or perform any other covenant contained in the debt securities or the indentures, other than a covenant specifically relating to another series of debt securities, and our failure continues for\n90\u00a0days after we receive notice from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">if specified events of bankruptcy, insolvency or reorganization occur. </td></tr></table> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We will describe in each applicable\nprospectus supplement or free writing prospectus any additional events of default relating to the relevant series of debt securities. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">If an event of\ndefault with respect to debt securities of any series occurs and is continuing, other than an event of default specified in the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt\nsecurities of that series, by notice to us in writing, and to the trustee if notice is given by such holders, may declare the unpaid principal, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default\nspecified in the last bullet point above occurs with respect to us, the unpaid principal, premium, if any, and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on\nthe part of the trustee or any holder. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive\nany default or event of default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance\nwith the indenture. Any waiver shall cure the default or event of default. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">15 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Subject to the terms of the indentures, if an event of default under an indenture shall occur and be\ncontinuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the\ntrustee reasonable indemnity or security satisfactory to it against any loss, liability or expense. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and\nplace of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that: </p>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the direction so given by the holder is not in conflict with any law or the applicable indenture; and </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding.\n</td></tr></table> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">A holder of the debt securities of any series will have the right to institute a proceeding under the indentures or to appoint a receiver\nor trustee, or to seek other remedies if: </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the holder has given written notice to the trustee of a continuing event of default with respect to that series; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written request, and such holders have offered reasonable indemnity to the trustee or security\nsatisfactory to it against any loss, liability or expense or to be incurred in compliance with instituting the proceeding as trustee; and </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting directions within\n90\u00a0days after the notice, request and offer. </td></tr></table> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">These limitations do not apply to a suit instituted by a holder of debt securities if we\ndefault in the payment of the principal, premium, if any, or interest on, the debt securities, or other defaults that may be specified in the applicable prospectus supplement or free writing prospectus. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We will periodically file statements with the trustee regarding our compliance with specified covenants in the indentures. </p>\n<p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Modification of Indenture; Waiver </i></b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Subject to the\nterms of the indenture for any series of debt securities that we may issue, we and the trustee may change an indenture without the consent of any holders with respect to the following specific matters: </p>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">to fix any ambiguity, defect or inconsistency in the indenture; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">to comply with the provisions described above under \u0093Description of Our Debt Securities\u0097Consolidation, Merger or Sale;\u0094 </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture;\n</td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">to provide for the issuance of and establish the form and terms and conditions of the debt securities of any series as provided under \u0093Description of Our Debt Securities\u0097General,\u0094 to establish the form of\nany certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series of debt securities; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">to evidence and provide for the acceptance of appointment hereunder by a successor trustee; </td></tr></table>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">16 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">to provide for uncertificated debt securities and to make all appropriate changes for such purpose; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">to add to our covenants such new covenants, restrictions, conditions or provisions for the benefit of the holders, to make the occurrence, or the occurrence and the continuance, of a default in any such additional\ncovenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred to us in the indenture; or </td></tr></table> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">to change anything that does not materially adversely affect the interests of any holder of debt securities of any series. </td></tr></table>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">In addition, under the indentures, the rights of holders of a series of debt securities may be changed by us and the trustee with the written consent of the\nholders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, subject to the terms of the indenture for any series of debt securities that we may issue or as otherwise\nprovided in the prospectus supplement or free writing prospectus applicable to a particular series of debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities\naffected: </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">extending the stated maturity of the series of debt securities; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption or repurchase of any debt securities; or </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">reducing the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or waiver. </td></tr></table>\n<p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Discharge </i></b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Each indenture provides that, subject\nto the terms of the indenture and any limitation otherwise provided in the prospectus supplement or free writing prospectus applicable to a particular series of debt securities, we can elect to be discharged from our obligations with respect to one\nor more series of debt securities, except for specified obligations, including obligations to: </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">register the transfer or exchange of debt securities of the series; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">replace stolen, lost or mutilated debt securities of the series; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">maintain paying agencies; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">hold monies for payment in trust; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">recover excess money held by the trustee; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">compensate and indemnify the trustee; and </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">appoint any successor trustee. </td></tr></table> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">In order to exercise our rights to be discharged, we must deposit with the\ntrustee money or government obligations sufficient to pay all the principal of, any premium and interest on, the debt securities of the series on the dates payments are due. </p>\n<p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Form, Exchange and Transfer </i></b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We will issue the\ndebt securities of each series only in fully registered form without coupons and, unless we otherwise specify in the applicable prospectus supplement or free writing prospectus, in denominations of $1,000 and any integral multiple thereof. The\nindentures provide that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company or another depository named by us and\nidentified in a prospectus supplement or free writing prospectus with respect to that series. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">17 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">At the option of the holder, subject to the terms of the indentures and the limitations applicable to global\nsecurities described in the applicable prospectus supplement or free writing prospectus, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination\nand of like tenor and aggregate principal amount. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Subject to the terms of the indentures and the limitations applicable to global securities set forth in\nthe applicable prospectus supplement or free writing prospectus, holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed\nif so required by us or the security registrar, at the office of the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer\nor exchange, we will make no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We will name in the applicable prospectus supplement or free writing prospectus the security registrar, and any transfer agent in addition to the security\nregistrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except\nthat we will be required to maintain a transfer agent in each place of payment for the debt securities of each series. If we elect to redeem the debt securities of any series, we will not be required to: </p>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business 15\u00a0days before the day of mailing of a notice of redemption of any debt\nsecurities that may be selected for redemption and ending at the close of business on the day of the mailing; or </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part. </td></tr></table>\n<p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Information Concerning the Trustee </i></b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The trustee,\nother than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the trustee\nmust use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Subject to this provision, the\ntrustee is under no obligation to exercise any of the powers given it by the indentures at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might\nincur. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Payment and Paying Agents </i></b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Unless we\notherwise indicate in the applicable prospectus supplement or free writing prospectus, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities, or one or more\npredecessor securities, are registered at the close of business on the regular record date for the interest. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We will pay principal of and any premium and\ninterest on the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise indicate in the applicable prospectus supplement or free writing prospectus, we will make interest payments\nby check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable prospectus supplement or free writing prospectus, we will designate the corporate trust office of the trustee as our sole\npaying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement or free writing prospectus any other paying agents that we initially designate for the debt securities of a particular\nseries. We will maintain a paying agent in each place of payment for the debt securities of a particular series. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">18 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or\ninterest on any debt securities that remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment\nthereof. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Governing Law </i></b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The indentures and\nthe debt securities will be governed by and construed in accordance with the laws of the State of New York, except to the extent that the Trust Indenture Act is applicable. </p>\n<p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Ranking of Debt Securities </i></b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The subordinated debt\nsecurities will be subordinate and junior in priority of payment to certain of our other indebtedness to the extent described in a prospectus supplement or free writing prospectus. The subordinated indenture does not limit the amount of subordinated\ndebt securities that we may issue. It also does not limit us from issuing any other secured or unsecured debt. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The senior debt securities will rank\nequally in right of payment to all our other senior unsecured debt. The senior indenture does not limit the amount of senior debt securities that we may issue. It also does not limit us from issuing any other secured or unsecured debt. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">19 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_10\"></a>DESCRIPTION OF WARRANTS </b></p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The following description, together with the additional information we may include in any applicable prospectus supplements, summarizes the material terms and\nprovisions of the warrants that we may offer under this prospectus and the related warrant agreements and warrant certificates. While the terms summarized below will apply generally to any warrants that we may offer, we will describe the particular\nterms of any series of warrants in more detail in the applicable prospectus supplement. If we indicate in the prospectus supplement, the terms of any warrants offered under that prospectus supplement may differ from the terms described below.\nSpecific warrant agreements will contain additional important terms and provisions and will be incorporated by reference as an exhibit to the registration statement, which includes this prospectus. </p>\n<p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>General </b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We may issue warrants for the purchase of common\nstock, preferred stock and/or debt securities in one or more series. We may issue warrants independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from these securities.\n</p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We will evidence each series of warrants by warrant certificates that we will issue under a separate warrant agreement. We will enter into the warrant\nagreement with a warrant agent. We will indicate the name and address of the warrant agent in the applicable prospectus supplement relating to a particular series of warrants. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We will describe in the applicable prospectus supplement the terms of the series of warrants, including: </p>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the offering price and aggregate number of warrants offered; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the currency for which the warrants may be purchased; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">if applicable, the date on and after which the warrants and the related securities will be separately transferable; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may\nbe purchased upon such exercise; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these\nshares may be purchased upon such exercise; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreement and the warrants; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the terms of any rights to redeem or call the warrants; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the periods during which, and places at which, the warrants are exercisable; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the manner of exercise; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the dates on which the right to exercise the warrants will commence and expire; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the manner in which the warrant agreement and warrants may be modified; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">federal income tax consequences of holding or exercising the warrants; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the terms of the securities issuable upon exercise of the warrants; and </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any other specific terms, preferences, rights or limitations of or restrictions on the warrants. </td></tr></table>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">20 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_11\"></a>DESCRIPTION OF UNITS </b></p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We may issue units comprised of shares of common stock, shares of preferred stock, debt securities and warrants in any combination. We may issue units in such\namounts and in as many distinct series as we wish. This section outlines certain provisions of the units that we may issue. If we issue units, they will be issued under one or more unit agreements to be entered into between us and a bank or other\nfinancial institution, as unit agent. The information described in this section may not be complete in all respects and is qualified entirely by reference to the unit agreement with respect to the units of any particular series. The specific terms\nof any series of units offered will be described in the applicable prospectus supplement. If so described in a particular supplement, the specific terms of any series of units may differ from the general description of terms presented below. We urge\nyou to read any prospectus supplement related to any series of units we may offer, as well as the complete unit agreement and unit certificate that contain the terms of the units. If we issue units, forms of unit agreements and unit certificates\nrelating to such units will be incorporated by reference as exhibits to the registration statement, which includes this prospectus. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Each unit that we may\nissue will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a\nunit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date. The applicable prospectus supplement may describe: </p>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any provisions of the governing unit agreement; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the price or prices at which such units will be issued; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the applicable United States federal income tax considerations relating to the units; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units; and </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any other terms of the units and of the securities comprising the units. </td></tr></table> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The provisions described in this\nsection, as well as those described under \u0093Description of Capital Stock,\u0094 \u0093Description of Debt Securities\u0094 and \u0093Description of Warrants\u0094 will apply to the securities included in each unit, to the extent relevant and as\nmay be updated in any prospectus supplements. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>Issuance in Series </b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We may issue units in such amounts and in as many distinct series as we wish. This section summarizes terms of the units that apply generally to all series.\nMost of the financial and other specific terms of a particular series of units will be described in the applicable prospectus supplement. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>Unit\nAgreements </b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We will issue the units under one or more unit agreements to be entered into between us and a bank or other financial institution, as unit\nagent. We may add, replace or terminate unit agents from time to time. We will identify the unit agreement under which each series of units will be issued and the unit agent under that agreement in the applicable prospectus supplement. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">21 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The following provisions will generally apply to all unit agreements unless otherwise stated in the\napplicable prospectus supplement: </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Modification without Consent </i></b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We and the applicable unit agent may amend any unit or unit agreement without the consent of any holder: </p>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">to cure any ambiguity; any provisions of the governing unit agreement that differ from those described below; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">to correct or supplement any defective or inconsistent provision; or </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">to make any other change that we believe is necessary or desirable and will not adversely affect the interests of the affected holders in any material respect. </td></tr></table>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We do not need any approval to make changes that affect only units to be issued after the changes take effect. We may also make changes that do not adversely\naffect a particular unit in any material respect, even if they adversely affect other units in a material respect. In those cases, we do not need to obtain the approval of the holder of the unaffected unit; we need only obtain any required approvals\nfrom the holders of the affected units. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Modification with Consent </i></b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We may not amend any particular unit or a unit agreement with respect to any particular unit unless we obtain the consent of the holder of that unit, if the\namendment would: </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">impair any right of the holder to exercise or enforce any right under a security included in the unit if the terms of that security require the consent of the holder to any changes that would impair the exercise or\nenforcement of that right; or </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">reduce the percentage of outstanding units or any series or class the consent of whose holders is required to amend that series or class, or the applicable unit agreement with respect to that series or class, as\ndescribed below. </td></tr></table> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Any other change to a particular unit agreement and the units issued under that agreement would require the following\napproval: </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">If the change affects only the units of a particular series issued under that agreement, the change must be approved by the holders of a majority of the outstanding units of that series; or </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">If the change affects the units of more than one series issued under that agreement, it must be approved by the holders of a majority of all outstanding units of all series affected by the change, with the units of all\nthe affected series voting together as one class for this purpose. </td></tr></table> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">These provisions regarding changes with majority approval also apply to\nchanges affecting any securities issued under a unit agreement, as the governing document. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">In each case, the required approval must be given by written\nconsent. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Unit Agreements Will Not Be Qualified under Trust Indenture Act </i></b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">No unit agreement will be qualified as an indenture, and no unit agent will be required to qualify as a trustee, under the Trust Indenture Act. Therefore,\nholders of units issued under unit agreements will not have the protections of the Trust Indenture Act with respect to their units. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Mergers and\nSimilar Transactions Permitted; No Restrictive Covenants or Events of Default </i></b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The unit agreements will not restrict our ability to merge or\nconsolidate with, or sell our assets to, another corporation or other entity or to engage in any other transactions. If at any time we merge or consolidate with, or </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">22 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">\nsell our assets substantially as an entirety to, another corporation or other entity, the successor entity will succeed to and assume our obligations under the unit agreements. We will then be\nrelieved of any further obligation under these agreements. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The unit agreements will not include any restrictions on our ability to put liens on our\nassets, nor will they restrict our ability to sell our assets. The unit agreements also will not provide for any events of default or remedies upon the occurrence of any events of default. </p>\n<p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Governing Law </i></b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The unit agreements and the units\nwill be governed by Delaware law. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Form, Exchange and Transfer </i></b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We will issue each unit in global\u0097i.e., book-entry\u0097form only. Units in book-entry form will be represented by a global security registered in the\nname of a depositary, which will be the holder of all the units represented by the global security. Those who own beneficial interests in a unit will do so through participants in the depositary\u0092s system, and the rights of these indirect owners\nwill be governed solely by the applicable procedures of the depositary and its participants. We will describe book-entry securities, and other terms regarding the issuance and registration of the units in the applicable prospectus supplement. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Each unit and all securities comprising the unit will be issued in the same form. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">If we issue any units in registered, <font style=\"white-space:nowrap\">non-global</font> form, the following will apply to them. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The units will be issued in the denominations stated in the applicable prospectus supplement. Holders may exchange their units for units of smaller\ndenominations or combined into fewer units of larger denominations, as long as the total amount is not changed. </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">Holders may exchange or transfer their units at the office of the unit agent. Holders may also replace lost, stolen, destroyed or mutilated units at that office. We may appoint another entity to perform these functions\nor perform them ourselves. </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">Holders will not be required to pay a service charge to transfer or exchange their units, but they may be required to pay for any tax or other governmental charge associated with the transfer or exchange. The transfer\nor exchange, and any replacement, will be made only if our transfer agent is satisfied with the holder\u0092s proof of legal ownership. The transfer agent may also require an indemnity before replacing any units. </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">If we have the right to redeem, accelerate or settle any units before their maturity, and we exercise our right as to less than all those units or other securities, we may block the exchange or transfer of those units\nduring the period beginning 15\u00a0days before the day we mail the notice of exercise and ending on the day of that mailing, in order to freeze the list of holders to prepare the mailing. We may also refuse to register transfers of or exchange any\nunit selected for early settlement, except that we will continue to permit transfers and exchanges of the unsettled portion of any unit being partially settled. We may also block the transfer or exchange of any unit in this manner if the unit\nincludes securities that are or may be selected for early settlement. </td></tr></table> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Only the depositary will be entitled to transfer or exchange a unit\nin global form, since it will be the sole holder of the unit. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Payments and Notices </i></b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">In making payments and giving notices with respect to our units, we will follow the procedures as described in the applicable prospectus supplement. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">23 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_12\"></a>PLAN OF DISTRIBUTION </b></p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We may sell securities: </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">through underwriters; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">through dealers; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">through agents; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">directly to purchasers; or </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">through a combination of any of these methods or any other method permitted by law. </td></tr></table> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">In addition, we may issue\nthe securities as a dividend or distribution or in a subscription rights offering to our existing security holders. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We may directly solicit offers to\npurchase securities, or agents may be designated to solicit such offers. In the prospectus supplement relating to such offering, we will name any agent that could be viewed as an underwriter under the Securities Act and describe any commissions that\nwe must pay to any such agent. Any such agent will be acting on a best efforts basis for the period of its appointment or, if indicated in the applicable prospectus supplement, on a firm commitment basis. This prospectus may be used in connection\nwith any offering of our securities through any of these methods or other methods described in the applicable prospectus supplement. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The distribution of\nthe securities may be effected from time to time in one or more transactions: </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">at a fixed price, or prices, which may be changed from time to time; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">at market prices prevailing at the time of sale; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">at prices related to such prevailing market prices; or </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">at negotiated prices. </td></tr></table> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Each prospectus supplement will describe the method of distribution of the securities\nand any applicable restrictions. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The prospectus supplement with respect to the securities of a particular series will describe the terms of the offering\nof the securities, including the following: </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the name of the agent or any underwriters; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the public offering or purchase price; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any discounts and commissions to be allowed or paid to the agent or underwriters; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">all other items constituting underwriting compensation; </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any discounts and commissions to be allowed or paid to dealers; and </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">any exchanges on which the securities will be listed. </td></tr></table> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">If any underwriters or agents are used in the sale of\nthe securities in respect of which this prospectus is delivered, we will enter into an underwriting agreement, sales agreement or other agreement with them at the time of sale to them, and we will set forth in the prospectus supplement relating to\nsuch offering the names of the underwriters or agents and the terms of the related agreement with them. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">In connection with the offering of securities, we\nmay grant to the underwriters an option to purchase additional securities with an additional underwriting commission, as may be set forth in the accompanying prospectus supplement. If we grant any such option, the terms of such option will be set\nforth in the prospectus supplement for such securities. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">24 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">If a dealer is used in the sale of the securities in respect of which the prospectus is delivered, we will\nsell such securities to the dealer, as principal. The dealer, who may be deemed to be an \u0093underwriter\u0094 as that term is defined in the Securities Act, may then resell such securities to the public at varying prices to be determined by such\ndealer at the time of resale. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">If we offer securities in a subscription rights offering to our existing security holders, we may enter into a standby\nunderwriting agreement with dealers, acting as standby underwriters. We may pay the standby underwriters a commitment fee for the securities they commit to purchase on a standby basis. If we do not enter into a standby underwriting arrangement, we\nmay retain a dealer-manager to manage a subscription rights offering for us. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Agents, underwriters, dealers and other persons may be entitled under\nagreements which they may enter into with us to indemnification by us against certain civil liabilities, including liabilities under the Securities Act, and may be customers of, engage in transactions with or perform services for us in the ordinary\ncourse of business. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">If so indicated in the applicable prospectus supplement, we will authorize underwriters or other persons acting as our agents to\nsolicit offers by certain institutions to purchase securities from us pursuant to delayed delivery contracts providing for payment and delivery on the date stated in the prospectus supplement. Each contract will be for an amount not less than, and\nthe aggregate amount of securities sold pursuant to such contracts shall not be less nor more than, the respective amounts stated in the prospectus supplement. Institutions with whom the contracts, when authorized, may be made include commercial and\nsavings banks, insurance companies, pension funds, investment companies, educational and charitable institutions and other institutions, but shall in all cases be subject to our approval. Delayed delivery contracts will not be subject to any\nconditions except that: </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">the purchase by an institution of the securities covered under that contract shall not at the time of delivery be prohibited under the laws of the jurisdiction to which that institution is subject; and\n</td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">if the securities are also being sold to underwriters acting as principals for their own account, the underwriters shall have purchased such securities not sold for delayed delivery. The underwriters and other persons\nacting as our agents will not have any responsibility in respect of the validity or performance of delayed delivery contracts. </td></tr></table> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Offered\nsecurities may also be offered and sold, if so indicated in the prospectus supplement, in connection with a remarketing upon their purchase, in accordance with a redemption or repayment pursuant to their terms, or otherwise, by one or more\nremarketing firms, acting as principals for their own accounts or as agents for us. Any remarketing firm will be identified and the terms of its agreement, if any, with us and its compensation will be described in the applicable prospectus\nsupplement. Remarketing firms may be deemed to be underwriters in connection with their remarketing of offered securities. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Certain agents, underwriters\nand dealers, and their associates and affiliates, may be customers of, have borrowing relationships with, engage in other transactions with, or perform services, including investment banking services, for us or one or more of our respective\naffiliates in the ordinary course of business. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">In order to facilitate the offering of the securities, any underwriters may engage in transactions that\nstabilize, maintain or otherwise affect the price of the securities or any other securities the prices of which may be used to determine payments on such securities. Specifically, any underwriters may overallot in connection with the offering,\ncreating a short position for their own accounts. In addition, to cover overallotments or to stabilize the price of the securities or of any such other securities, the underwriters may bid for, and purchase, the securities or any such other\nsecurities in the open market. Finally, in any offering of the securities through a syndicate of underwriters, the underwriting syndicate may reclaim selling concessions allowed to an underwriter or a dealer for distributing the securities in the\noffering if the syndicate repurchases previously distributed securities in transactions to cover syndicate short positions, in stabilization transactions or otherwise. Any of these activities may stabilize or maintain the market price of the\nsecurities above independent market levels. Any such underwriters are not required to engage in these activities and may end any of these activities at any time. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">25 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We may engage in at the market offerings into an existing trading market in accordance with Rule 415(a)(4)\nunder the Securities Act. In addition, we may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement so\nindicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party may use securities pledged by us\nor borrowed from us or others to settle those sales or to close out any related open borrowings of stock, and may use securities received from us in settlement of those derivatives to close out any related open borrowings of stock. The third party\nin such sale transactions will be an underwriter and, if not identified in this prospectus, will be named in the applicable prospectus supplement (or a post-effective amendment). In addition, we may otherwise loan or pledge securities to a financial\ninstitution or other third party that in turn may sell the securities short using this prospectus and an applicable prospectus supplement. Such financial institution or other third party may transfer its economic short position to investors in our\nsecurities or in connection with a concurrent offering of other securities. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Under <font style=\"white-space:nowrap\">Rule\u00a015c6-1</font> of the\nExchange Act, trades in the secondary market generally are required to settle in three business days, unless the parties to any such trade expressly agree otherwise. The applicable prospectus supplement may provide that the original issue date for\nyour securities may be more than three scheduled business days after the trade date for your securities. Accordingly, in such a case, if you wish to trade securities on any date prior to the third business day before the original issue date for your\nsecurities, you will be required, by virtue of the fact that your securities initially are expected to settle in more than three scheduled business days after the trade date for your securities, to make alternative settlement arrangements to prevent\na failed settlement. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The securities may be new issues of securities and may have no established trading market. The securities may or may not be listed\non a national securities exchange. We can make no assurance as to the liquidity of or the existence of trading markets for any of the securities. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The\nspecific terms of any <font style=\"white-space:nowrap\">lock-up</font> provisions in respect of any given offering will be described in the applicable prospectus supplement. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The underwriters, dealers and agents may engage in transactions with us, or perform services for us, in the ordinary course of business for which they receive\ncompensation. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The anticipated date of delivery of offered securities will be set forth in the applicable prospectus supplement relating to each offer.\n</p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">26 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_13\"></a>LEGAL MATTERS </b></p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Certain legal matters in connection with this offering will be passed upon for us by Goodwin Procter LLP, San\u00a0Francisco, California. Any underwriters\nwill also be advised about the validity of the securities and other legal matters by their own counsel, which will be named in the prospectus supplement. </p>\n<p align=\"center\" style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_14\"></a>EXPERTS </b></p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The\nfinancial statements incorporated in this Prospectus by reference to the Annual Report on Form <font style=\"white-space:nowrap\">10-K</font> for the year ended December\u00a031, 2017 have been so incorporated in reliance on the report of\nPricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </p>\n<p align=\"center\" style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_15\"></a>WHERE YOU CAN FIND MORE INFORMATION </b></p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">This prospectus is part of a registration statement that we have filed with the SEC. Certain information in the registration statement has been omitted from\nthis prospectus in accordance with the rules of the SEC. We are subject to the information requirements of the Exchange Act and, in accordance therewith, file annual, quarterly and special reports, proxy statements and other information with the\nSEC. You may read and copy any document we file at the SEC\u0092s Public Reference Room\u00a0at 100 F Street, N.E., Washington, D.C. 20549. You may call the SEC at <font style=\"white-space:nowrap\"><font style=\"white-space:nowrap\"><font style=\"white-space:nowrap\">1-800-SEC-0330</font></font></font> for further information on the operation of the Public Reference Room. These documents also may be accessed through the SEC\u0092s electronic data gathering, analysis and retrieval\nsystem, or EDGAR, via electronic means, including the SEC\u0092s home page\u00a0on the Internet <i>(www.sec.gov</i>). </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We have the authority to designate\nand issue more than one class or series of stock having various preferences, conversion and other rights, voting powers, restrictions, limitations as to dividends, qualifications, and terms and conditions of redemption. See \u0093Description of\nCapital Stock.\u0094 We will furnish a full statement of the relative rights and preferences of each class or series of our stock which has been so designated and any restrictions on the ownership or transfer of our stock to any stockholder upon\nrequest and without charge. Written requests for such copies should be directed to Investor Relations, MyoKardia, Inc., 333 Allerton Ave., South San Francisco,\u00a0CA 94080; telephone: <font style=\"white-space:nowrap\">(650)\u00a0741-0900.</font>\nInformation contained on our website is not incorporated by reference into this prospectus and, therefore, is not part of this prospectus or any accompanying prospectus supplement. </p>\n<p align=\"center\" style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><a name=\"toc579741_16\"></a>INCORPORATION BY REFERENCE </b></p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The SEC allows us to incorporate by reference the information and reports we file with it, which means that we can disclose important information to you by\nreferring you to these documents. The information incorporated by reference is an important part of this prospectus, and information that we file later with the SEC will automatically update and supersede the information already incorporated by\nreference. We are incorporating by reference the documents listed below, which we have already filed with the SEC (SEC File <font style=\"white-space:nowrap\">No.\u00a0001-37609),</font> and any future filings we make with the SEC under Sections\n13(a), 13(c), 14 or 15(d) of the Exchange Act, including all filings made after the date of the filing of this registration statement and prior to the effectiveness of this registration statement, except as to any portion of any future report or\ndocument that is not deemed filed under such provisions, after the date of this prospectus and prior to the termination of this offering: </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">Annual Report on Form <font style=\"white-space:nowrap\">10-K</font> for the year ended December\u00a031, 2017, filed with the SEC on March\u00a08, 2018; </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">Current Reports on Form <font style=\"white-space:nowrap\">8-K</font> filed with the SEC on March 5, 2018 and March 8, 2018 (as to Item 8.01 only); and </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"5%\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"2%\">\u0095</td>\n<td valign=\"top\" width=\"1%\">\u00a0</td>\n<td align=\"left\" valign=\"top\">The description of our common stock contained in our registration statement on Form <font style=\"white-space:nowrap\">8-A</font> filed with the SEC on October\u00a027, 2015 under Section\u00a012(b) of the Exchange Act,\nincluding any amendments or reports filed for the purpose of updating such description. </td></tr></table>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">27 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Upon request, we will provide, without charge, to each person, including any beneficial owner, to whom a\ncopy of this prospectus is delivered, a copy of the documents incorporated by reference into this prospectus but not delivered with the prospectus. You may request a copy of these filings, and any exhibits we have specifically incorporated by\nreference as an exhibit in this prospectus, at no cost by writing or telephoning us at the following address: 333 Allerton Ave., South San Francisco, CA 94080; telephone: <font style=\"white-space:nowrap\">(650)\u00a0741-0900.</font> </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">You may also access these documents, free of charge on the SEC\u0092s website at <i>www.sec.gov</i> or on our website at <i>www.myokardia.com</i>. Information\ncontained on our website is not incorporated by reference into this prospectus, and you should not consider any information on, or that can be accessed from, our website as part of this prospectus or any accompanying prospectus supplement. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">This prospectus is part of a registration statement we filed with the SEC. We have incorporated exhibits into this registration statement. You should read the\nexhibits carefully for provisions that may be important to you. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">You should rely only on the information incorporated by reference or provided in this\nprospectus or any prospectus supplement. We have not authorized anyone to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the\ninformation in this prospectus or in the documents incorporated by reference is accurate as of any date other than the date on the front of this prospectus or those documents. </p>\n<p style=\"margin-top:0pt;margin-bottom:0pt ; font-size:8pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">28 </p>\n</div></center>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<h5 align=\"left\"><a of Contents</a></h5>\n<center><div align=\"left\" style=\"width:8.5in\">\n<p style=\"font-size:48pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:36pt; margin-bottom:0pt; font-size:18pt; font-family:arial\"><b><i>3,750,000 shares\n</i></b></p> <p style=\"font-size:24pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p> <p style=\"font-size:96pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p> <p style=\"font-size:36pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<p style=\"font-size:0pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p> <p align=\"center\" style=\"margin-top:0pt;margin-bottom:0pt\">\n<img alt=\"LOGO\" src=\"g579741g95t12.jpg\"/>\n</p> <p align=\"center\" style=\"margin-top:24pt; margin-bottom:0pt; font-size:18pt; font-family:arial\"><b><i>Common stock </i></b></p>\n<p align=\"center\" style=\"margin-top:60pt; margin-bottom:0pt; font-size:24pt; font-family:arial\"><b>Prospectus supplement </b></p> <p style=\"font-size:60pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:15pt\" width=\"100%\">\n<tr>\n<td width=\"18%\"></td>\n<td valign=\"bottom\"></td>\n<td width=\"28%\"></td>\n<td valign=\"bottom\" width=\"1%\"></td>\n<td width=\"20%\"></td>\n<td valign=\"bottom\" width=\"1%\"></td>\n<td width=\"31%\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:arial; font-size:15pt\">\n<td valign=\"top\"><b>J.P.\u00a0Morgan</b></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\"><b>BofA\u00a0Merrill\u00a0Lynch</b></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\"><b>Credit\u00a0Suisse</b></td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"right\" valign=\"top\"><b>Wells\u00a0Fargo\u00a0Securities</b></td></tr>\n</table> <p style=\"font-size:60pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<p style=\"margin-top:36pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial\">May\u00a0\u00a0\u00a0\u00a0\u00a0, 2018 </p>\n</div></center>\n</p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></p></body></html>\n</text>\n</description></filename></sequence></type></document>\n"}, "reportNo8": {"reportType": "8-K", "url": "https://www.sec.gov/Archives/edgar/data/1552451/000119312518168652/d574015d8k.htm", "dateOfReport": "2018-05-21", "content": "On May21, 2018, MyoKardia, Inc. (the \u0093Company\u0094) announced the\ndesign of its pivotal Phase 3 EXPLORER-HCM clinical trial to evaluate the use of its lead candidate, mavacamten, for the potential treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy\n(oHCM). The Company has incorporated input on the study design from the Division of Cardiovascular and Renal Products of the U.S. Food and Drug Administration (FDA), and plans to conduct this single pivotal study along with a long-term extension\nstudy to support registration. The Company expects to dose the first patient in the EXPLORER-HCM trial in the second quarter of 2018 and expects that data from the Phase 3 trial will be available in the second\nhalf of 2020. EXPLORER-HCM is a multi-national randomized double-blind study designed to assess the effects of a 30-week treatment of mavacamten versus placebo with a primary endpoint of clinical response. The clinical response endpoint is intended to broadly capture the potential benefits of treatment with mavacamten on how\npatients feel and function by utilizing both peak oxygen consumption (peak VO2) and New York Heart Association (NYHA) functional classification. Clinical response can be achieved by meeting\neither of two definitions: 1) an improvement of at least 1.5 mL/kg/min in peak VO2 accompanied by a reduction from baseline of at least one NYHA functional class or 2) an improvement from\nbaseline of 3.0 mL/kg/min or greater in peak VO2 without worsening in NYHA functional class. Approximately 220 patients will be enrolled and randomized on a 1:1 basis to receive either mavacamten or placebo. The\nEXPLORER-HCM trial design includes two opportunities for individualized dose adjustment throughout the 30-week treatment period. Patients in the active treatment arm\nwill start on a once-daily 5mg dose of mavacamten. At Weeks 8 and 14, daily doses may be increased to 10mg or 15mg, or remain unchanged, based on measurements of provoked left ventricular outflow tract (LVOT) gradient conducted at Weeks 6 and 12. A\nreduction in provoked LVOT gradient under 50 mmHg has been shown in the Company\u0092s Phase 2 PIONEER clinical trial to correlate to improvements in several clinical measurements, including NYHA class and peak VO2. All assessments and dose adjustments will be conducted in a blinded fashion. Patients will be allowed to maintain their HCM-related background medications\nfor the duration of the EXPLORER-HCM Phase 3 trial, including beta blockers or calcium channel blockers. Secondary endpoints in the Phase 3 EXPLORER-HCM trial will include the average change from baseline in post-exercise\npeak LVOT gradient, NYHA functional class, peak VO2, the proportion of patients achieving post-exercise peak LVOT gradient below 50 mmHg or 30 mmHg at Week 30 and patient-reported outcome\nmeasures. Exploratory endpoints will include changes in echocardiographic indices of cardiac structure and function, N-terminal pro b-type natriuretic peptide\n(NT-proBNP) concentrations, quality of life questionnaire scores and daily physical activity assessed using a wearable accelerometer. Throughout the EXPLORER-HCM study, patients will be monitored for adverse events and certain assessments will be performed. If at any time during the trial, a patient\u0092s plasma concentration is above an upper target range or\nLVEF falls below the normal range, doses of mavacamten may be decreased. Following the 30-week treatment period and eight-week post-treatment wash-out period, patients\nwill be able to participate in a long-term extension study of mavacamten. Forward-Looking Statements Statements in this Current Report on Form 8-K may include statements which are not historical facts and are considered\nforward-looking within the meaning of Section27A of the Securities Act of 1933, as amended, and Section21E of the Securities Exchange Act of 1934, as amended, which are usually identified by the use of words such as\n\u0093anticipates,\u0094 \u0093believes,\u0094 \u0093estimates,\u0094 \u0093expects,\u0094 \u0093intends,\u0094 \u0093may,\u0094 \u0093plans,\u0094 \u0093projects,\u0094 \u0093seeks,\u0094 \u0093should,\u0094 \u0093will,\u0094 and variations of such\nwords or similar expressions. These forward-looking statements are intended to be covered by the safe harbor provisions for forward-looking statements contained in Section27A of the Securities Act and Section21E of the Securities\nExchange Act. These forward-looking statements, including statements regarding the clinical and therapeutic potential of mavacamten, the initiation of patient dosing in the Phase 3 EXPLORER-HCM trial,\nmavacamten\u0092s ability to achieve applicable endpoints in the Phase 3 EXPLORER-HCM trial, the ability for patients who participate in the Phase 3 EXPLORER-HCM trial\nto participate in a long-term extension study, the availability of data from the Phase 3 EXPLORER-HCM trial, the potential for data from the Company\u0092s clinical trials of mavacamten to support a marketing\napplication, as well as the timing of these events, reflect the \n\n\nCompany\u0092s current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the Company and on assumptions made by\nthe Company. Although the Company believes that its plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, the Company can give no assurance that the plans,\nintentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond the\nCompany\u0092s control including, without limitation, risks associated with the development and regulation of the Company\u0092s product candidates, as well as those set forth in the Company\u0092s Quarterly Report on Form 10-Q for the quarter ended March31, 2018, and its other filings with the SEC. Except as required by law, the Company assumes no obligation to update publicly any forward-looking statements, whether as a result\nof new information, future events or otherwise. \n\n\nSIGNATURES \nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned\nhereunto duly authorized.  \n\n\n\n\n\n\n\n\nDate: May21, 2018\n\nMyoKardia, Inc.\n\n\n\n\n\n\n\nBy:\n\n /s/ Taylor Harris\n\n\n\n\n\nTaylor Harris\n\n\n\n\n\n Chief Financial Officer\n(principalfinancialand accounting officer)\n\n\nCompany\u0092s current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the Company and on assumptions made by\nthe Company. Although the Company believes that its plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, the Company can give no assurance that the plans,\nintentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond the\nCompany\u0092s control including, without limitation, risks associated with the development and regulation of the Company\u0092s product candidates, as well as those set forth in the Company\u0092s Quarterly Report on Form 10-Q for the quarter ended March31, 2018, and its other filings with the SEC. Except as required by law, the Company assumes no obligation to update publicly any forward-looking statements, whether as a result\nof new information, future events or otherwise. \n\nSIGNATURES \nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned\nhereunto duly authorized.  \n\n\n\n\n\n\n\n\nDate: May21, 2018\n\nMyoKardia, Inc.\n\n\n\n\n\n\n\nBy:\n\n /s/ Taylor Harris\n\n\n\n\n\nTaylor Harris\n\n\n\n\n\n Chief Financial Officer\n(principalfinancialand accounting officer)\n\nSIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned\nhereunto duly authorized. /s/ Taylor HarrisChief Financial Officer(principalfinancialand accounting officer)", "htmlOfReport": " <document>\n<type>8-K\n<sequence>1\n<filename>d574015d8k.htm\n<description>8-K\n<text>\n<html><head>\n<title>8-K</title>\n</head>\n<body bgcolor=\"WHITE\">\n<p style=\"line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000\">\u00a0</p>\n<p style=\"line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000\">\u00a0</p> <p align=\"center\" style=\"margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman\"><b>UNITED STATES </b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman\"><b>SECURITIES AND EXCHANGE COMMISSION </b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman\"><b>Washington, D.C. 20549 </b></p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p><center>\n<p style=\"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%\">\u00a0</p></center> <p align=\"center\" style=\"margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman\"><b>FORM <font style=\"white-space:nowrap\">8-K</font> </b></p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p><center>\n<p style=\"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%\">\u00a0</p></center> <p align=\"center\" style=\"margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman\"><b>CURRENT\nREPORT </b></p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman\"><b>Pursuant to Section\u00a013 or 15(d) </b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman\"><b>of the Securities Exchange Act of 1934 </b></p>\n<p align=\"center\" style=\"margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman\"><b>Date of Report (Date of earliest event reported): May\u00a021, 2018 </b></p>\n<p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p><center> <p style=\"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%\">\u00a0</p></center>\n<p align=\"center\" style=\"margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman\"><b>MYOKARDIA,\u00a0INC. </b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>(Exact name of registrant as specified in its charter) </b></p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p><center>\n<p style=\"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%\">\u00a0</p></center> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt\" width=\"100%\">\n<tr>\n<td width=\"34%\"></td>\n<td valign=\"bottom\"></td>\n<td width=\"32%\"></td>\n<td valign=\"bottom\" width=\"1%\"></td>\n<td width=\"32%\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td align=\"center\" valign=\"top\"><b>Delaware</b></td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"center\" valign=\"top\"><b><font style=\"white-space:nowrap\">001-37609</font></b></td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"center\" valign=\"top\"><b><font style=\"white-space:nowrap\">44-5500552</font></b></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\">\n<td align=\"center\" valign=\"top\"> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>(State or other jurisdiction</b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman\"><b>of incorporation)</b></p></td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"center\" valign=\"top\"> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>(Commission</b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman\"><b>File Number)</b></p></td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"center\" valign=\"top\"> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>(I.R.S. Employer</b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman\"><b>Identification No.)</b></p></td></tr>\n</table> <p align=\"center\" style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>333 Allerton Ave. </b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>South San Francisco, CA 94080 </b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>(Address of principal executive offices, including zip code) </b></p>\n<p align=\"center\" style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>(650) <font style=\"white-space:nowrap\">741-0900</font> </b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>(Registrant\u0092s telephone number, including area code) </b></p>\n<p align=\"center\" style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>Not Applicable </b></p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>(Former\nName or Former Address, if Changed Since Last Report) </b></p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p><center>\n<p style=\"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%\">\u00a0</p></center> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Check the appropriate box below\nif the <font style=\"white-space:nowrap\">Form\u00a08-K</font> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </p>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"4%\">\u2610</td>\n<td align=\"left\" valign=\"top\">Written communications pursuant to Rule\u00a0425 under the Securities Act (17 CFR 230.425) </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"4%\">\u2610</td>\n<td align=\"left\" valign=\"top\">Soliciting material pursuant to <font style=\"white-space:nowrap\">Rule\u00a014a-12</font> under the Exchange Act (17 CFR <font style=\"white-space:nowrap\">240.14a-12)</font> </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"4%\">\u2610</td>\n<td align=\"left\" valign=\"top\"><font style=\"white-space:nowrap\">Pre-commencement</font> communications pursuant to <font style=\"white-space:nowrap\">Rule\u00a014d-2(b)\u00a0under</font> the Exchange Act (17 CFR\n<font style=\"white-space:nowrap\">240.14d-2(b))</font> </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"4%\">\u2610</td>\n<td align=\"left\" valign=\"top\"><font style=\"white-space:nowrap\">Pre-commencement</font> communications pursuant to <font style=\"white-space:nowrap\">Rule\u00a013e-4(c)\u00a0under</font> the Exchange Act (17 CFR\n<font style=\"white-space:nowrap\">240.13e-4(c))</font> </td></tr></table> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Indicate by check mark whether the registrant is an emerging growth company as\ndefined in Rule 405 of the Securities Act of 1933 (\u00a7\u00a0230.405 of this chapter) or Rule <font style=\"white-space:nowrap\">12b-2</font> of the Securities Exchange Act of 1934 <font style=\"white-space:nowrap\">(\u00a7\u00a0240.12b-2</font> of\nthis chapter). </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Emerging growth company\u00a0\u00a0\u2612 </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or\nrevised financial accounting standards provided pursuant to Section\u00a013(a) of the Exchange Act.\u00a0\u00a0\u2612 </p> <p style=\"font-size:10pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<p style=\"line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000\">\u00a0</p> <p style=\"line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000\">\u00a0</p>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"9%\"><b>Item\u00a08.01</b></td>\n<td align=\"left\" valign=\"top\"><b>\u00a0Other Events. </b></td></tr></table> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">On May\u00a021, 2018, MyoKardia, Inc. (the \u0093Company\u0094) announced the\ndesign of its pivotal Phase 3 <font style=\"white-space:nowrap\">EXPLORER-HCM</font> clinical trial to evaluate the use of its lead candidate, mavacamten, for the potential treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy\n(oHCM). The Company has incorporated input on the study design from the Division of Cardiovascular and Renal Products of the U.S. Food and Drug Administration (FDA), and plans to conduct this single pivotal study along with a long-term extension\nstudy to support registration. The Company expects to dose the first patient in the <font style=\"white-space:nowrap\">EXPLORER-HCM</font> trial in the second quarter of 2018 and expects that data from the Phase 3 trial will be available in the second\nhalf of 2020. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><font style=\"white-space:nowrap\">EXPLORER-HCM</font> is a multi-national randomized double-blind study designed to assess the effects of a <font style=\"white-space:nowrap\">30-week</font> treatment of mavacamten versus placebo with a primary endpoint of clinical response. The clinical response endpoint is intended to broadly capture the potential benefits of treatment with mavacamten on how\npatients feel and function by utilizing both peak oxygen consumption (peak VO<sub style=\"font-size:85%; vertical-align:bottom\">2</sub>) and New York Heart Association (NYHA) functional classification. Clinical response can be achieved by meeting\neither of two definitions: 1) an improvement of at least 1.5 mL/kg/min in peak VO<sub style=\"font-size:85%; vertical-align:bottom\">2</sub> accompanied by a reduction from baseline of at least one NYHA functional class or 2) an improvement from\nbaseline of 3.0 mL/kg/min or greater in peak VO<sub style=\"font-size:85%; vertical-align:bottom\">2</sub> without worsening in NYHA functional class. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Approximately 220 patients will be enrolled and randomized on a 1:1 basis to receive either mavacamten or placebo. The\n<font style=\"white-space:nowrap\">EXPLORER-HCM</font> trial design includes two opportunities for individualized dose adjustment throughout the <font style=\"white-space:nowrap\">30-week</font> treatment period. Patients in the active treatment arm\nwill start on a once-daily 5mg dose of mavacamten. At Weeks 8 and 14, daily doses may be increased to 10mg or 15mg, or remain unchanged, based on measurements of provoked left ventricular outflow tract (LVOT) gradient conducted at Weeks 6 and 12. A\nreduction in provoked LVOT gradient under 50 mmHg has been shown in the Company\u0092s Phase 2 PIONEER clinical trial to correlate to improvements in several clinical measurements, including NYHA class and peak VO<sub style=\"font-size:85%; vertical-align:bottom\">2</sub>. All assessments and dose adjustments will be conducted in a blinded fashion. Patients will be allowed to maintain their <font style=\"white-space:nowrap\">HCM-related</font> background medications\nfor the duration of the <font style=\"white-space:nowrap\">EXPLORER-HCM</font> Phase 3 trial, including beta blockers or calcium channel blockers. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Secondary endpoints in the Phase 3 <font style=\"white-space:nowrap\">EXPLORER-HCM</font> trial will include the average change from baseline in post-exercise\npeak LVOT gradient, NYHA functional class, peak VO<sub style=\"font-size:85%; vertical-align:bottom\">2</sub>, the proportion of patients achieving post-exercise peak LVOT gradient below 50 mmHg or 30 mmHg at Week 30 and patient-reported outcome\nmeasures. Exploratory endpoints will include changes in echocardiographic indices of cardiac structure and function, <font style=\"white-space:nowrap\">N-terminal</font> pro <font style=\"white-space:nowrap\">b-type</font> natriuretic peptide\n(NT-proBNP) concentrations, quality of life questionnaire scores and daily physical activity assessed using a wearable accelerometer. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Throughout the <font style=\"white-space:nowrap\">EXPLORER-HCM</font> study, patients will be monitored for adverse events and certain assessments will be performed. If at any time during the trial, a patient\u0092s plasma concentration is above an upper target range or\nLVEF falls below the normal range, doses of mavacamten may be decreased. Following the <font style=\"white-space:nowrap\">30-week</font> treatment period and eight-week post-treatment <font style=\"white-space:nowrap\">wash-out</font> period, patients\nwill be able to participate in a long-term extension study of mavacamten. </p> <p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><i>Forward-Looking Statements </i></b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Statements in this Current Report on Form <font style=\"white-space:nowrap\">8-K</font> may include statements which are not historical facts and are considered\nforward-looking within the meaning of Section\u00a027A of the Securities Act of 1933, as amended, and Section\u00a021E of the Securities Exchange Act of 1934, as amended, which are usually identified by the use of words such as\n\u0093anticipates,\u0094 \u0093believes,\u0094 \u0093estimates,\u0094 \u0093expects,\u0094 \u0093intends,\u0094 \u0093may,\u0094 \u0093plans,\u0094 \u0093projects,\u0094 \u0093seeks,\u0094 \u0093should,\u0094 \u0093will,\u0094 and variations of such\nwords or similar expressions. These forward-looking statements are intended to be covered by the safe harbor provisions for forward-looking statements contained in Section\u00a027A of the Securities Act and Section\u00a021E of the Securities\nExchange Act. These forward-looking statements, including statements regarding the clinical and therapeutic potential of mavacamten, the initiation of patient dosing in the Phase 3 <font style=\"white-space:nowrap\">EXPLORER-HCM</font> trial,\nmavacamten\u0092s ability to achieve applicable endpoints in the Phase 3 <font style=\"white-space:nowrap\">EXPLORER-HCM</font> trial, the ability for patients who participate in the Phase 3 <font style=\"white-space:nowrap\">EXPLORER-HCM</font> trial\nto participate in a long-term extension study, the availability of data from the Phase 3 <font style=\"white-space:nowrap\">EXPLORER-HCM</font> trial, the potential for data from the Company\u0092s clinical trials of mavacamten to support a marketing\napplication, as well as the timing of these events, reflect the </p>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">\nCompany\u0092s current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the Company and on assumptions made by\nthe Company. Although the Company believes that its plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, the Company can give no assurance that the plans,\nintentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond the\nCompany\u0092s control including, without limitation, risks associated with the development and regulation of the Company\u0092s product candidates, as well as those set forth in the Company\u0092s Quarterly Report on Form <font style=\"white-space:nowrap\">10-Q</font> for the quarter ended March\u00a031, 2018, and its other filings with the SEC. Except as required by law, the Company assumes no obligation to update publicly any forward-looking statements, whether as a result\nof new information, future events or otherwise. </p>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>SIGNATURES </b></p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned\nhereunto duly authorized. </p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr>\n<td width=\"48%\"></td>\n<td valign=\"bottom\" width=\"1%\"></td>\n<td width=\"2%\"></td>\n<td valign=\"bottom\"></td>\n<td width=\"48%\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\">Date: May\u00a021, 2018</td>\n<td valign=\"bottom\">\u00a0</td>\n<td colspan=\"3\" valign=\"top\"><b>MyoKardia, Inc.</b></td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"16\"></td>\n<td colspan=\"2\" height=\"16\"></td>\n<td colspan=\"2\" height=\"16\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\">By:</td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\"> <p style=\"margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman\">/s/ Taylor Harris</p></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\">Taylor Harris</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\"> <p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Chief Financial Officer</p>\n<p style=\"margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman\"><b>(principal\u00a0financial\u00a0and accounting officer)</b></p></td></tr>\n</table>\n</p></p></p></body></html>\n</text>\n</description></filename></sequence></type></document>\n"}, "reportNo9": {"reportType": "10-Q", "url": "https://www.sec.gov/Archives/edgar/data/1552451/000156459018011870/myok-10q_20180331.htm", "dateOfReport": "2018-05-08", "content": {"isInThousands": "true", "isInMillions": "false", "balanceSheetTableCode": "<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">March 31,</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2018</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">December 31,</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2017</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">As Revised (Note 2)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Assets</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Current assets</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Cash and cash equivalents</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">183,865</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">224,571</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Short-term investments</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">39,822</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">31,933</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Receivable from collaboration partner</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,013</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Prepaid expenses and other current assets</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2,320</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,876</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Total current assets</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">226,007</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">259,393</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Property and equipment, net</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">4,030</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">3,147</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Long-term investments</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">35,621</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">19,900</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Other long-term assets</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">514</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">368</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Total assets</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">266,172</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">282,808</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Liabilities and stockholders\u2019 equity</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Current liabilities</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Accounts payable</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2,292</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2,301</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Accrued liabilities</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">10,628</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">11,639</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Prepayment from collaboration partner</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">7,701</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">4,432</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Deferred revenue</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">28,227</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">33,558</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Total current liabilities</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">48,848</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">51,930</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Other long-term liabilities</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">151</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">202</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Total liabilities</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">48,999</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">52,132</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Commitments and contingencies (Note 6)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Stockholders\u2019 equity</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Preferred stock, $0.0001 par value; 5,000,000 shares authorized; none</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0 issued and outstanding</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Common stock, $0.0001 par value, 150,000,000 and 150,000,000</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0 shares authorized at March 31, 2018 and December 31, 2017,</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0 respectively; 35,922,982 and 35,812,791 shares issued and outstanding</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0 at March 31, 2018 and December 31, 2017, respectively</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">4</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">4</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Additional paid-in capital</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">370,173</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">365,719</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Accumulated other comprehensive loss</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(329</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(192</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Accumulated deficit</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(152,675</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(134,855</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Total stockholders\u2019 equity</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">217,173</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">230,676</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Total liabilities and stockholders\u2019 equity</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">266,172</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">282,808</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n</table>", "operationsTableCode": "<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"6\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Three Months Ended</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">March 31,</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2018</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2017</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">As Revised (Note 2)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Collaboration and license revenue</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">5,331</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2,410</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Operating expenses:</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Research and development</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">16,618</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">11,917</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">General and administrative</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">7,313</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">5,476</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Total operating expenses</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">23,931</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">17,393</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Loss from operations</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(18,600</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(14,983</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Interest and other income, net</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">780</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">221</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Net loss</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(17,820</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(14,762</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Other comprehensive loss</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(137</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(55</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Comprehensive loss</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(17,957</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(14,817</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Net loss attributable to common stockholders</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(17,820</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(14,762</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Net loss per share attributable to common stockholders,</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0 basic and diluted</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(0.50</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(0.47</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Weighted average number of shares used to compute net loss</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0 per share attributable to common stockholders, basic and diluted</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">35,827,235</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">31,089,310</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n</table>", "warrantsTableCode": "False", "cashFlowTable": "<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"6\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.36%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Three Months Ended</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">March 31,</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2018</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2017</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">As Revised (Note 2)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Cash flow from operating activities:</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Net loss</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(17,820</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(14,762</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Stock-based compensation expense</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">3,631</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,405</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Depreciation</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">300</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">316</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Amortization of premiums on investments</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">22</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Change in operating assets and liabilities:</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Receivable from collaboration partner</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,013</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">45,000</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Prepaid expenses and other current assets</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(444</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(419</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Other long-term assets</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(146</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(105</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Accounts payable</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">212</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">629</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Accrued liabilities</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(1,257</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(1,613</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Prepayment from collaboration partner</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">3,269</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Other long-term liabilities</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(43</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(44</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Deferred revenue</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(5,331</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(2,410</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Net cash (used in) provided by operating activities</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(16,614</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">28,019</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Cash flow from investing activities:</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Purchases of investments</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(31,749</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(32,020</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Sales of investments</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">4,000</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Maturities of investments</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">8,000</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Purchases of property and equipment</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(1,188</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(185</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Proceeds from sale of equipment</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">39</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Net cash used in investing activities</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(24,898</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(28,205</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Cash flow from financing activities:</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Proceeds from exercise of stock options and employee stock purchase plan</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">806</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">21</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Payments of financing-related costs</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(38</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Net cash provided by (used in) financing activities</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">806</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(17</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Net decrease in cash, cash equivalents and restricted cash</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(40,706</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(203</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Cash, cash equivalents and restricted cash, beginning of period</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">224,857</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">136,056</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Cash, cash equivalents and restricted cash, end of period</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">184,151</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">135,853</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Non-cash investing and financing activities:</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Vesting of early exercised options and restricted stock</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">18</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">54</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Unpaid portion of property and equipment purchases included in period-end accounts</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0 payable and accrued liabilities</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">317</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">79</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n</table>"}, "htmlOfReport": " <document>\n<type>10-Q\n<sequence>1\n<filename>myok-10q_20180331.htm\n<description>10-Q\n<text>\n<!DOCTYPE HTML PUBLIC \"-//W3C//DTD HTML 4.01 Transitional//EN\" \"http://www.w3.org/TR/html4/loose.dtd\">\n\n<html>\n<head>\n<title>\nmyok-10q_20180331.htm\n</title>\n</head>\n<!-- NG Converter v4.0.8.21 -->\n<body>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<p style=\"border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;\">\u00a0</p>\n<p style=\"text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">UNITED STATES</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">SECURITIES AND EXCHANGE COMMISSION</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">WASHINGTON, DC 20549</p>\n<p style=\"margin-bottom:0pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;\">\u00a0</p>\n<p style=\"text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">FORM 10-Q</p>\n<p style=\"margin-bottom:0pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;\">\u00a0</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">(Mark One)</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';\"><font style=\"font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';\"></font><font style=\"font-size:10pt;font-family:'Times New Roman'\">\u2612</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr></table></div>\n<p style=\"text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">For the quarterly period ended March 31, 2018</p>\n<p style=\"text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">or</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';\"><font style=\"font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';\"></font><font style=\"font-size:10pt;font-family:'Times New Roman'\">\u2610</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr></table></div>\n<p style=\"text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">For the transition period from \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 to \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</p>\n<p style=\"text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Commission File Number: 001-37609</p>\n<p style=\"text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">MYOKARDIA, INC.</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">(Exact name of registrant as specified in its charter)</p>\n<p style=\"margin-bottom:0pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:49%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Delaware</p></td>\n<td style=\"width:2%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:49%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">44-5500552</p></td>\n</tr>\n<tr>\n<td style=\"width:49%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">(State or other jurisdiction of</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">incorporation or organization)</p></td>\n<td style=\"width:2%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:49%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">(I.R.S. Employer</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Identification No.)</p></td>\n</tr>\n</table></div>\n<p style=\"text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">333 Allerton Ave.</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">South San Francisco, CA</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">(Address of principal executive offices)</p>\n<p style=\"text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">94080</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">(Zip Code)</p>\n<p style=\"text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">(650) 741-0900</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">(Registrant\u2019s telephone number, including area code)</p>\n<p style=\"margin-bottom:0pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;\">\u00a0</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Indicate by check mark whether the registrant (1)\u00a0has filed all reports required to be filed by Section\u00a013 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)\u00a0has been subject to such filing requirements for the past 90 days.\u00a0Yes\u00a0<font style=\"font-family:'Times New Roman';\"><font style=\"font-size:9pt;font-family:'Times New Roman'\">\u2612</font></font>\u00a0No\u00a0<font style=\"font-family:'Times New Roman';\"><font style=\"font-size:9pt;font-family:'Times New Roman'\">\u2610</font></font></p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (\u00a7232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).\u00a0Yes\u00a0<font style=\"font-family:'Times New Roman';\"><font style=\"font-size:9pt;font-family:'Times New Roman'\">\u2612</font></font>\u00a0No\u00a0<font style=\"font-family:'Times New Roman';\"><font style=\"font-size:9pt;font-family:'Times New Roman'\">\u2610</font></font></p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of \u201clarge accelerated filer,\u201d \u201caccelerated filer,\u201d \u201csmaller reporting company,\u201d and \u201cemerging growth company\u201d in Rule 12b-2 of the Exchange Act.</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:20.56%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Large\u00a0accelerated\u00a0filer</p></td>\n<td style=\"width:1.14%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"width:51.96%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';\"><font style=\"font-size:9pt;font-family:'Times New Roman'\">\u2610</font></p></td>\n<td style=\"width:1.02%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0</p></td>\n<td style=\"width:22.32%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Accelerated\u00a0filer</p></td>\n<td style=\"width:1.02%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"width:1.98%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';\"><font style=\"font-size:9pt;font-family:'Times New Roman'\">\u2612</font></p></td>\n</tr>\n<tr>\n<td style=\"width:20.56%;\" valign=\"bottom\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Non-accelerated filer</p></td>\n<td style=\"width:1.14%;\" valign=\"bottom\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"width:51.96%;\" valign=\"bottom\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';\"><font style=\"font-size:9pt;font-family:'Times New Roman'\">\u2610</font><font style=\"font-family:Times New Roman;\">\u00a0\u00a0(Do not check if a smaller reporting company)</font></p></td>\n<td style=\"width:1.02%;\" valign=\"bottom\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0</p></td>\n<td style=\"width:22.32%;\" valign=\"bottom\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Smaller\u00a0reporting\u00a0company</p></td>\n<td style=\"width:1.02%;\" valign=\"bottom\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"width:1.98%;\" valign=\"bottom\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';\"><font style=\"font-size:9pt;font-family:'Times New Roman'\">\u2610</font></p></td>\n</tr>\n<tr>\n<td style=\"width:20.56%;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Emerging growth company\u00a0\u00a0\u00a0\u00a0 </p></td>\n<td style=\"width:1.14%;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;\">\u00a0</p></td>\n<td style=\"width:51.96%;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';\"><font style=\"font-size:9pt;font-family:'Times New Roman'\">\u2612</font></p></td>\n<td style=\"width:1.02%;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;\">\u00a0</p></td>\n<td style=\"width:22.32%;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;\">\u00a0</p></td>\n<td style=\"width:1.02%;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;\">\u00a0</p></td>\n<td style=\"width:1.98%;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;\">\u00a0</p></td>\n</tr>\n</table></div>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.\u00a0\u00a0\u00a0\u00a0 <font style=\"color:#000000;font-family:'Times New Roman';\"><font style=\"font-size:9pt;font-family:'Times New Roman'\">\u2612</font></font></p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).\u00a0Yes\u00a0<font style=\"font-family:'Times New Roman';\"><font style=\"font-size:9pt;font-family:'Times New Roman'\">\u2610</font></font>\u00a0No\u00a0<font style=\"font-family:'Times New Roman';\"><font style=\"font-size:9pt;font-family:'Times New Roman'\">\u2612</font></font></p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The number of outstanding shares of the registrant\u2019s common stock on May 5, 2018 was 35,966,061 shares.</p>\n<p style=\"border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU2\"></a><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">MYOKARDIA, INC.</font></p>\n<p style=\"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">TABLE OF CONTENTS</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:96%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td colspan=\"2\" style=\"width:4%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Page</p></td>\n</tr>\n<tr>\n<td style=\"width:96%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:underline;\">PART I\u2014FINANCIAL INFORMATION</font></a><font style=\"font-weight:normal;\"></font></p></td>\n<td style=\"width:1%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"width:3%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">3</p></td>\n</tr>\n<tr>\n<td style=\"width:96%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:28.6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:underline;\">Item\u00a01. Condensed Consolidated Financial Statements</font></a></p></td>\n<td style=\"width:1%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"width:3%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">3</p></td>\n</tr>\n<tr>\n<td style=\"width:96%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:48.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:underline;\">Condensed Consolidated Balance Sheets as of March 31, 2018 and December 31, 2017 (unaudited)</font></a></p></td>\n<td style=\"width:1%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"width:3%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">3</p></td>\n</tr>\n<tr>\n<td style=\"width:96%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:60.5pt;;text-indent:-12.25pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:underline;\">Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2018 and 2017 (unaudited)</font></a></p></td>\n<td style=\"width:1%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"width:3%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">4</p></td>\n</tr>\n<tr>\n<td style=\"width:96%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:60.5pt;;text-indent:-12.25pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:underline;\">Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2018 and 2017 (unaudited)</font></a></p></td>\n<td style=\"width:1%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"width:3%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">5</p></td>\n</tr>\n<tr>\n<td style=\"width:96%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:48.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:underline;\">Notes to Condensed Consolidated Financial Statements (unaudited)</font></a></p></td>\n<td style=\"width:1%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"width:3%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">6</p></td>\n</tr>\n<tr>\n<td style=\"width:96%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:28.6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:underline;\">Item\u00a02. Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations</font></a></p></td>\n<td style=\"width:1%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"width:3%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">19</p></td>\n</tr>\n<tr>\n<td style=\"width:96%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:28.6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:underline;\">Item\u00a03. Quantitative and Qualitative Disclosures About Market Risk</font></a></p></td>\n<td style=\"width:1%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:3%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">25</p></td>\n</tr>\n<tr>\n<td style=\"width:96%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:28.6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:underline;\">Item\u00a04. Controls and Procedures</font></a></p></td>\n<td style=\"width:1%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:3%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">25</p></td>\n</tr>\n<tr>\n<td style=\"width:96%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:underline;\">PART II\u2014OTHER INFORMATION</font></a><font style=\"font-weight:normal;\"></font></p></td>\n<td style=\"width:1%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"width:3%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">26</p></td>\n</tr>\n<tr>\n<td style=\"width:96%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:28.6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:underline;\">Item\u00a01. Legal Proceedings</font></a></p></td>\n<td style=\"width:1%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"width:3%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">26</p></td>\n</tr>\n<tr>\n<td style=\"width:96%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:28.6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:underline;\">Item\u00a01A. Risk Factors</font></a></p></td>\n<td style=\"width:1%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"width:3%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">26</p></td>\n</tr>\n<tr>\n<td style=\"width:96%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:28.6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:underline;\">Item\u00a02. Unregistered Sales of Equity Securities and Use of Proceeds</font></a></p></td>\n<td style=\"width:1%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"width:3%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">55</p></td>\n</tr>\n<tr>\n<td style=\"width:96%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:28.6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:underline;\">Item\u00a03. Defaults Upon Senior Securities</font></a></p></td>\n<td style=\"width:1%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"width:3%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">56</p></td>\n</tr>\n<tr>\n<td style=\"width:96%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:28.6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:underline;\">Item\u00a04. Mine Safety Disclosures</font></a></p></td>\n<td style=\"width:1%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"width:3%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">56</p></td>\n</tr>\n<tr>\n<td style=\"width:96%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:28.6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:underline;\">Item\u00a05. Other Information</font></a></p></td>\n<td style=\"width:1%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"width:3%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">56</p></td>\n</tr>\n<tr>\n<td style=\"width:96%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:28.6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:underline;\">Item\u00a06. Exhibits</font></a></p></td>\n<td style=\"width:1%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"width:3%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">56</p></td>\n</tr>\n<tr>\n<td style=\"width:96%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:underline;\">EXHIBIT INDEX</font></a><font style=\"font-weight:normal;\"></font></p></td>\n<td style=\"width:1%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:3%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">57</p></td>\n</tr>\n<tr>\n<td style=\"width:96%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:underline;\">SIGNATURES</font></a><font style=\"font-weight:normal;\"></font></p></td>\n<td style=\"width:1%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:3%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">58</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU3\"></a><a name=\"PART_IFINANCIAL_INFORMATION\"></a><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"PART_IFINANCIAL_INFORMATION\"></a>PART I\u2014FINANCI</font><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">AL INFORMATION </font></p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:10.27%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Item\u00a01.</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\"><a name=\"ITEM_1_FINANCIAL_STATEMENTS\"></a><a name=\"ITEM_1_FINANCIAL_STATEMENTS\"></a>Condensed Consolidated Financial Statements</p></td></tr></table></div>\n<p style=\"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">MYOKARDIA, INC.</p>\n<p style=\"text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"CONDENSED_CONSOLIDATED_BALANCE_SHEETS\"></a><a name=\"CONDENSED_CONSOLIDATED_BALANCE_SHEETS\"></a>Condensed Consolidated Balance Sheets</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">(In thousands, except share and per share amounts)</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">(Unaudited)</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">March 31,</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2018</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">December 31,</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2017</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">As Revised (Note 2)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Assets</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Current assets</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Cash and cash equivalents</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">183,865</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">224,571</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Short-term investments</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">39,822</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">31,933</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Receivable from collaboration partner</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,013</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Prepaid expenses and other current assets</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2,320</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,876</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Total current assets</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">226,007</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">259,393</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Property and equipment, net</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">4,030</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">3,147</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Long-term investments</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">35,621</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">19,900</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Other long-term assets</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">514</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">368</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Total assets</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">266,172</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">282,808</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Liabilities and stockholders\u2019 equity</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Current liabilities</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Accounts payable</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2,292</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2,301</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Accrued liabilities</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">10,628</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">11,639</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Prepayment from collaboration partner</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">7,701</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">4,432</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Deferred revenue</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">28,227</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">33,558</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Total current liabilities</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">48,848</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">51,930</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Other long-term liabilities</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">151</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">202</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Total liabilities</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">48,999</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">52,132</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Commitments and contingencies (Note 6)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Stockholders\u2019 equity</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Preferred stock, $0.0001 par value; 5,000,000 shares authorized; none</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0 issued and outstanding</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Common stock, $0.0001 par value, 150,000,000 and 150,000,000</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0 shares authorized at March 31, 2018 and December 31, 2017,</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0 respectively; 35,922,982 and 35,812,791 shares issued and outstanding</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0 at March 31, 2018 and December 31, 2017, respectively</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">4</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">4</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Additional paid-in capital</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">370,173</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">365,719</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Accumulated other comprehensive loss</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(329</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(192</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Accumulated deficit</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(152,675</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(134,855</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Total stockholders\u2019 equity</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">217,173</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">230,676</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Total liabilities and stockholders\u2019 equity</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">266,172</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">282,808</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">3</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU4\"></a><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">MYOKARDIA, INC.</font></p>\n<p style=\"text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"CONDENSED_CONSOLIDATED_STATEMENTS_OPERAT\"></a><a name=\"CONDENSED_CONSOLIDATED_STATEMENTS_OPERAT\"></a>Condensed Consolidated Statements of Operations and Comprehensive Loss</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">(In thousands, except share and per share amounts)</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">(Unaudited)</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"6\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Three Months Ended</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">March 31,</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2018</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2017</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">As Revised (Note 2)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Collaboration and license revenue</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">5,331</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2,410</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Operating expenses:</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Research and development</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">16,618</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">11,917</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">General and administrative</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">7,313</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">5,476</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Total operating expenses</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">23,931</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">17,393</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Loss from operations</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(18,600</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(14,983</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Interest and other income, net</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">780</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">221</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Net loss</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(17,820</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(14,762</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Other comprehensive loss</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(137</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(55</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Comprehensive loss</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(17,957</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(14,817</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Net loss attributable to common stockholders</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(17,820</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(14,762</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Net loss per share attributable to common stockholders,</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0 basic and diluted</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(0.50</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(0.47</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Weighted average number of shares used to compute net loss</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0 per share attributable to common stockholders, basic and diluted</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">35,827,235</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">31,089,310</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<p style=\"text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">4</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU5\"></a><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">MYOKARDIA, INC.</font></p>\n<p style=\"text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"CONDENSED_CONSOLIDATED_STATEMENTS_CASH_F\"></a><a name=\"CONDENSED_CONSOLIDATED_STATEMENTS_CASH_F\"></a>Condensed Consolidated Statements of Cash Flows</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">(In thousands)</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">(Unaudited)</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"6\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.36%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Three Months Ended</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">March 31,</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2018</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2017</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">As Revised (Note 2)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Cash flow from operating activities:</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Net loss</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(17,820</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(14,762</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Stock-based compensation expense</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">3,631</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,405</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Depreciation</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">300</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">316</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Amortization of premiums on investments</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">22</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Change in operating assets and liabilities:</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Receivable from collaboration partner</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,013</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">45,000</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Prepaid expenses and other current assets</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(444</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(419</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Other long-term assets</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(146</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(105</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Accounts payable</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">212</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">629</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Accrued liabilities</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(1,257</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(1,613</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Prepayment from collaboration partner</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">3,269</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Other long-term liabilities</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(43</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(44</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Deferred revenue</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(5,331</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(2,410</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Net cash (used in) provided by operating activities</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(16,614</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">28,019</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Cash flow from investing activities:</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Purchases of investments</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(31,749</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(32,020</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Sales of investments</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">4,000</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Maturities of investments</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">8,000</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Purchases of property and equipment</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(1,188</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(185</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Proceeds from sale of equipment</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">39</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Net cash used in investing activities</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(24,898</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(28,205</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Cash flow from financing activities:</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Proceeds from exercise of stock options and employee stock purchase plan</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">806</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">21</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Payments of financing-related costs</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(38</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Net cash provided by (used in) financing activities</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">806</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(17</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Net decrease in cash, cash equivalents and restricted cash</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(40,706</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(203</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Cash, cash equivalents and restricted cash, beginning of period</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">224,857</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">136,056</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Cash, cash equivalents and restricted cash, end of period</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">184,151</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">135,853</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Non-cash investing and financing activities:</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Vesting of early exercised options and restricted stock</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">18</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">54</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Unpaid portion of property and equipment purchases included in period-end accounts</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0 payable and accrued liabilities</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">317</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">79</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<p style=\"text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;\">\u00a0</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">5</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU6\"></a><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">MYOKARDIA, INC.</font></p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"NOTES_TO_CONDENSED_CONSOLIDATED_FINANCIA\"></a><a name=\"NOTES_TO_CONDENSED_CONSOLIDATED_FINANCIA\"></a>Notes to Condensed Consolidated Financial Statements</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">(Unaudited)</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">1. Organization</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">MyoKardia, Inc. (the \u201cCompany\u201d) is a clinical-stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. The Company\u2019s initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company has used its precision medicine platform to generate a robust pipeline of therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy\u2014hypertrophic cardiomyopathy (\u201cHCM\u201d), and dilated cardiomyopathy (\u201cDCM\u201d).\u00a0\u00a0The Company was incorporated on June\u00a08, 2012 in Delaware and its corporate headquarters and operations are located in South San Francisco, California.</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">Liquidity</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The Company has incurred significant operating losses since inception and has an accumulated deficit of $152.7 million as of March 31, 2018. The Company has relied on its ability to fund its operations through private and public equity financings, and to a lesser extent through a license and collaboration arrangement with its collaboration partner, Sanofi S.A. (\u201cSanofi\u201d) through its subsidiary, Aventis, Inc.\u00a0The Company has not yet received regulatory approval to commercialize or sell any product and does not have customers. Management expects operating losses and negative operating cash flows to continue for the foreseeable future.\u00a0As the Company continues to incur losses, the transition to profitability is dependent upon the successful development, approval, and commercialization of its products and product candidates and the achievement of a level of revenues adequate to support its cost structure.\u00a0The <font style=\"Background-color:#FFFFFF;\">Company\u2019s ultimate success depends on the outcome of its research and development activities. The Company expects to incur additional losses and negative cash flows for the foreseeable future and it anticipates the need to raise additional capital to fully implement its business plan. The Company intends to raise such capital through the issuance of additional equity, debt and/or strategic alliances with partner companies. As of March 31, 2018, the Company had $259.3 million of cash, cash equivalents and short and long-term investments and management believes the existing cash, cash equivalents and short and long-term investments will be sufficient to meet the Company\u2019s anticipated operating and capital expenditure requirements for the twelve months following the date of this Form 10-Q. </font>Management\u2019s belief with respect to its ability to fund operations is based on estimates that are subject to risks and uncertainties.\u00a0If actual results are different from management\u2019s estimates, the Company may need to seek additional funding. </p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">2. Basis of Presentation and Summary of Significant Accounting Policies</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">Basis of Presentation</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The accompanying condensed consolidated financial statements are unaudited, include the Company\u2019s accounts and those of its wholly-owned subsidiary and have been prepared in conformity with accounting principles generally accepted in the United States of America (\u201cGAAP\u201d). <font style=\"color:#000000;\">All significant intercompany balances and transactions have been eliminated in consolidation.\u00a0See \u201c</font><font style=\"font-style:italic;color:#000000;\">Adopted Accounting Pronouncements \u2013 Revenue Recognition</font><font style=\"color:#000000;\">\u201d below for a discussion of certain revisions to prior period financial statements made in connection with the Company\u2019s adoption of new revenue recognition guidance.</font></p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The Company currently operates in one business segment, which is the identification, development and commercialization of <font style=\"color:#000000;\">therapies for the treatment of serious and neglected rare </font>cardiovascular diseases and has a single reporting and operating unit. These interim statements, in the opinion of management, reflect all normal recurring adjustments necessary for the fair presentation of the Company\u2019s financial position and results of operations for the interim periods ended March 31, 2017 and 2018.\u00a0\u00a0</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year or any interim period and should be read in conjunction with the audited financial statements for the year ended December\u00a031, 2017 and the notes thereto, which are included in the Company\u2019s Annual Report on Form\u00a010-K as of and for the year ended December\u00a031, 2017.\u00a0The significant accounting policies used in preparation of these condensed consolidated financial statements for the three months ended March 31, 2018 are consistent with those discussed in Note 2 to the consolidated financial statements in the Company\u2019s 2017 Annual Report on Form 10-K and are updated below as necessary.<font style=\"color:#000000;\"> </font></p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">Reclassifications</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The cash and cash equivalents on the condensed consolidated statements of cash flows for the three-month period ended March 31, 2017 has been reclassified to include restricted cash to conform to the current period\u2019s presentation. Such reclassifications did not impact the Company\u2019s net loss or financial position.</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">6</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">MYOKARDIA, INC.</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Notes to Condensed Consolidated Financial Statements\u2014(Continued)</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">(Unaudited)</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\"><a name=\"_Hlk512437959\"></a><a name=\"_AEIOULastRenderedPageBreakAEIOU7\"></a><font style=\"font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">Use of Estimates</font></p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, other comprehensive gain (loss) and the related disclosures.\u00a0\u00a0On an ongoing basis, management evaluates its estimates, including estimates related to license and collaboration revenues, accrued clinical trial and manufacturing development expenses and stock-based compensation expense. Significant estimates in these condensed consolidated financial statements include estimates made in connection with accrued research and development expenses, stock-based compensation expense and revenue.\u00a0\u00a0The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances.\u00a0\u00a0Actual results may differ from those estimates or assumptions.</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_cp_text_1_26\"></a><a name=\"_cp_text_1_26\"></a>Significant accounting policies are described in Note 2 to the consolidated financial statements as of and for the year ended December 31, 2017 included in the Annual Report.\u00a0\u00a0There have been no changes to the Company\u2019s significant accounting policies during the three months ended March 31, 2018, except\u00a0as described below.</p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Adopted Accounting Pronouncements - Revenue Recognition</p>\n<p style=\"Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;\">\u00a0</p>\n<p style=\"Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Effective January 1, 2018, the Company adopted Accounting Standards Codification Topic 606,\u00a0<font style=\"font-style:italic;\">Revenue from Contracts with Customers</font>\u00a0(\u201cASC 606\u201d) using the full retrospective transition method.\u00a0\u00a0This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.\u00a0\u00a0Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.\u00a0\u00a0To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.\u00a0\u00a0The Company only applies the five-step model to contracts when it is probable that Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.\u00a0\u00a0At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct.\u00a0\u00a0The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p>\n<p style=\"Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">Licenses of intellectual property<font style=\"font-style:normal;\">:\u00a0\u00a0 Upon the inception of a Collaboration Agreement, if the license to the Company\u2019s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring proportional performance for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of proportional performance each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.\u00a0\u00a0</font></p>\n<p style=\"Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">Milestone payments<font style=\"font-style:normal;\">:\u00a0\u00a0At the inception of each arrangement that includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. Whichever method is used, it should be consistently applied throughout the life of the contract; however, it is not necessary for the Company to use the same approach for all contracts. The Company expects to use the most likely amount method for development and regulatory milestone payments. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </font></p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">7</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">MYOKARDIA, INC.</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Notes to Condensed Consolidated Financial Statements\u2014(Continued)</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">(Unaudited)</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU8\"></a><font style=\"font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">Royalties</font><font style=\"font-style:normal;\">:\u00a0\u00a0For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties </font><font style=\"font-style:normal;\">relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has no</font><font style=\"font-style:normal;\">t recognized any royalty revenue resulting from its collaboration arrangement.</font></p>\n<p style=\"Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Up-front payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company\u2019s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.</p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">Impact of Adoption \u2013 ASC 606</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:6pt;\">\u00a0</p>\n<p style=\"Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The Company entered into a license and collaboration agreement that became effective in August 2014, which is within the scope of ASC 606, under which it has licensed certain rights to its HCM-1 (which includes mavacamten), HCM-2 and DCM-1 (which includes MYK-491) programs to Sanofi, and may enter into other such arrangements in the future. The terms of the arrangement include payment to the Company of one or more of the following: non-refundable, up-front license fees, development and regulatory and commercial milestone payments, and royalties on net sales of licensed products.</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The Company has applied the five-step model of the new standard to the Company\u2019s contract with Sanofi, as it is the only contract that will be impacted by the adoption of the new revenue standards. The Company has implemented the new revenue standards using the full retrospective transition method and has revised its comparative financial statements as if ASC 606 had been effective for those periods.</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The following tables summarize the financial statement line items that were affected due to <font style=\"color:#000000;\">the Company\u2019s implementation of ASC 606 </font>(in thousands, except for share and per share amounts)<font style=\"letter-spacing:-0.1pt;\">: </font></p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Condensed Consolidated Balance Sheet</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"10\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.06%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">As of</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">December 31, 2017</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">As Originally Reported</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Effect of Change</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">As Revised</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Deferred revenue - current</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">22,500</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">11,058</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">33,558</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Accumulated deficit</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(123,797</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(11,058</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(134,855</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">8</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">MYOKARDIA, INC.</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Notes to Condensed Consolidated Financial Statements\u2014(Continued)</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">(Unaudited)</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU9\"></a><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Condensed Consolidated Statement of Operations and Comprehensive Loss</font></p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"10\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.06%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Three Months Ended</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">March 31, 2017</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">As Originally Reported</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Effect of Change</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">As Revised</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Collaboration and license revenue</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">5,625</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(3,215</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2,410</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Operating expenses:</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Research and development</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">11,917</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">11,917</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">General and administrative</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">5,476</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">5,476</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Total operating expenses</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">17,393</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">17,393</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Loss from operations</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(11,768</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(3,215</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(14,983</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Interest and other income, net</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">221</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">221</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Net loss</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(11,547</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(3,215</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(14,762</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Other comprehensive loss</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(55</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(55</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Comprehensive loss</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(11,602</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(3,215</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(14,817</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Net loss attributable to common stockholders</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(11,547</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(3,215</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(14,762</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Net loss per share attributable to common stockholders,</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0 basic and diluted</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(0.37</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(0.10</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(0.47</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Weighted average number of shares used to compute net loss</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0 per share attributable to common stockholders, basic and diluted</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">31,089,310</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">31,089,310</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">31,089,310</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Condensed Consolidated Statement of Cash Flows</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"10\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.06%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Three Months Ended</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">March 31, 2017</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">As Originally Reported</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Effect of Change</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">As Revised</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Net loss</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(11,547</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(3,215</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(14,762</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Deferred revenue</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(5,625</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">3,215</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(2,410</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Cash, cash equivalents and restricted cash, beginning of period</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">135,797</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">259</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">136,056</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Cash, cash equivalents and restricted cash, end of period</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">135,594</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">259</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">135,853</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The change to net loss and deferred revenue in the condensed consolidated statement of cash flows, as revised above, reflects (i) the Company\u2019s determination that the Sanofi continuation payment of $45.0 million received in January 2017 relates to three performance obligations that were previously accounted for as one combined unit of accounting and (ii) the result of the Company utilizing a cost-based input method to measure proportional performance for each interim period during the year ending December 31, 2017, instead of straight-line. </p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">Impact of Adoption \u2013 ASU 2016-18</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">As discussed in \u201cAdopted Accounting Pronouncements \u2013 Other\u201d below, the change to cash, cash equivalents and restricted cash in the table above reflects the Company\u2019s implementation of ASU 2016-18 whereby amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning of period and end of period total amounts shown on the statement of cash flows.\u00a0\u00a0The Company implemented this change using a retrospective transition method.</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">9</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">MYOKARDIA, INC.</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Notes to Condensed Consolidated Financial Statements\u2014(Continued)</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">(Unaudited)</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU10\"></a><font style=\"color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The following table summarizes the cash balances</font><font style=\"color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"> that were affected due to the </font><font style=\"color:#000000;\">Company\u2019s implementation of ASU 2016-18 </font><font style=\"color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(in </font><font style=\"color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">thousands):</font></p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Condensed Consolidated Statement of Cash Flows</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:5pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:5pt;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.76%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">March 31, 2018</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">December 31, 2017</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">March 31, 2017</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">December 31, 2016</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.76%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">As Revised</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">As Revised</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">As Revised</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">As Revised</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.76%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Cash and cash equivalents</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">183,865</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">224,571</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">135,594</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">135,797</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.76%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Restricted cash \u2013 noncurrent</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">286</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">286</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">259</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">259</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.76%; border-bottom:double 2.5pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Total cash, cash equivalents and restricted cash</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">184,151</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">224,857</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">135,853</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">136,056</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Adopted Accounting Pronouncements \u2013 Other</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In May 2017, the <font style=\"color:#000000;\">Financial Accounting Standards Board (\u201c</font>FASB\u201d) issued <font style=\"font-style:italic;color:#000000;\">ASU No. 2017-09\u2014Compensation\u2014Stock Compensation (Topic 718): Scope of Modification Accounting.</font><font style=\"color:#000000;\"> The amendments in this ASU provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718 to address diversity in practice. An entity should account for the effects of a modification unless all the three specified conditions are met. The current disclosure requirements in Topic 718 apply regardless of whether an entity is required to apply modification accounting under the amendments in this ASU. The amendments in this ASU are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017, with early adoption permitted. The amendments in this ASU should be applied prospectively to an award modified on or after the adoption date. The adoption of this standard did not have a material impact on the Company\u2019s consolidated financial statements</font>. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In November 2016, the FASB issued <font style=\"font-style:italic;color:#000000;\">ASU</font><font style=\"font-style:italic;\"> No. 2016-18 (Topic 230), Restricted Cash, Statement of Cash Flows</font>. This ASU 2016-18 requires that a state<font style=\"color:#000000;\">ment of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 is effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years, with early adoption permitted. The amendments in this ASU should be applied using a retrospective transition method to each period presented. Other than the change in presentation in the accompanying consolidated statements of cash flows, the adoption of this guidance had no effect on the Company\u2019s financial position, results of operations or liquidity.</font></p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Recent Accounting Pronouncements</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company\u2019s consolidated financial statements upon adoption. Under the Jumpstart Our Business Startups Act of 2012, as amended (the \u201cJOBS Act\u201d), the Company meets the definition of an emerging growth company, and has irrevocably elected to opt out of the extended transition period for complying with new or revised accounting standards pursuant to Section\u00a0107(b) of the JOBS Act.</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In <font style=\"color:#000000;\">February</font> 2016, the FASB issued <font style=\"font-style:italic;\">ASU No. 2016-02 (Topic 842), Leases.</font> This ASU<font style=\"Background-color:#F4F6F8;color:#3C3C3D;\"> </font><font style=\"color:#000000;\">modifies\u00a0lease\u00a0accounting for lessees to increase transparency and comparability by recording\u00a0lease\u00a0assets and liabilities for operating\u00a0leases\u00a0and disclosing key information about\u00a0leasing\u00a0arrangements. The Company will adopt ASU 2016-02 in its first quarter of 2019 utilizing the modified retrospective transition method. While the Company is currently evaluating the timing and impact of adopting ASU 2016-02, currently the Company anticipates recording\u00a0lease\u00a0assets and liabilities for its three facilities in South San Francisco and is currently evaluating and estimating the financial statement impact. It is not expected to have a material impact to the Company\u2019s Consolidated Statements of Operations and the Company has not quantified the impact to its Consolidated Balance Sheets. However, the ultimate impact of adopting ASU 2016-02 will depend on the Company\u2019s\u00a0lease portfolio as of the adoption date</font>.</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In February 2018, the FASB issued <font style=\"font-style:italic;\">ASU No. 2018-05 (Topic 740) Income Taxes, Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118</font>.\u00a0\u00a0The update provides guidance that gives entities the option to reclassify to retained earnings tax effects related to items in accumulated other comprehensive income (OCI) that the FASB refers to as having been stranded in accumulated OCI as a result of tax reform. Entities can early adopt the guidance in any interim or annual period for which financial statements have not yet been issued and apply it either (1) in the period of adoption or (2) retrospectively to each period in which the income tax effects of the Tax Cuts and Jobs Act related to items in accumulated OCI are recognized.\u00a0 The adoption of this standard is not expected to have a material impact to the Company\u2019s financial statements.</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">10</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">MYOKARDIA, INC.</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Notes to Condensed Consolidated Financial Statements\u2014(Continued)</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">(Unaudited)</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">3. Sanofi License and Collaboration Agreement</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Sanofi (Aventis Inc.)</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In August 2014, the Company entered into an exclusive License and Collaboration Agreement (\u201cCollaboration Agreement\u201d) with Aventis Inc., a wholly-owned subsidiary of Sanofi, for the research, development and potential commercialization of pharmaceutical products for the treatment, prevention and diagnosis of hypertrophic and dilated cardiomyopathy, as well as potential additional indications.\u00a0\u00a0The Company has determined that Sanofi is a related party of the Company due to its close collaborative relationship and that it is the Company\u2019s only partner.\u00a0\u00a0In addition, Sanofi is a beneficial shareholder of the Company\u2019s common stock.</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Under the Collaboration Agreement, the Company granted Sanofi royalty-bearing licenses to develop and commercialize products resulting from its lead candidate programs HCM-1, HCM-2 and DCM-1. The licenses provide Sanofi with worldwide rights in the case of DCM-1 and rights outside the United States with respect to the HCM-1 and HCM-2 programs. The terms of the Collaboration Agreement also state that the Company is responsible for conducting research and development activities through early human efficacy studies for all three programs, except for specified research activities to be conducted by Sanofi. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Upon entering into this agreement, the Company received an up-front non-refundable cash payment of $35.0 million and Sanofi made an up-front equity purchase of $10.0 million (additional equity investments from Sanofi totaling $14.0 million were received subsequent to the effective date of the Collaboration Agreement). The Company was also eligible to receive additional payments and services, as follows: (1) a one-time, non-refundable payment of $25.0 million contingent upon submission of an Investigational New Drug (\u201cIND\u201d) application before certain regulatory authority(ies) for its DCM-1 program; (2) up to $45.0 million in funding from Sanofi of approved in-kind research and clinical activities; (3) a non-refundable continuation payment of $45.0 million contingent upon Sanofi\u2019s notification of its decision to continue the agreement beyond December 31, 2016; and, (4) up to $15.0 million in research and development funding per program if studies leading to proof-of-concept (\u201cPOC\u201d) are extended beyond December 31, 2018. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_Hlk513283075\"></a>During the fourth quarter of 2016, the Company submitted an IND application to the U.S. Food and Drug Administration and as a result, the Company received the $25.0 million milestone payment from Sanofi.\u00a0\u00a0</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In December 2016, Sanofi provided notice to the Company of its election to continue the collaboration through December 31, 2018 pursuant to the terms of the Collaboration Agreement. In connection with Sanofi\u2019s decision to continue the collaboration, the Company received the $45.0 million milestone payment.</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The Company is also entitled to receive tiered royalties ranging from the mid-single digits to the mid-teens on net sales of certain HCM-1, HCM-2 and DCM-1 finished products outside the United States and on net sales of certain DCM-1 finished products in the United States. Sanofi is eligible to receive tiered royalties ranging from the mid-single digits to the low-teens on net sales of certain HCM-1 and HCM-2 finished products in the United States.</p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">Revenue Recognition</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The Company evaluated the Collaboration Agreement under ASC 606 and determined that it had the following performance obligations:<font style=\"color:#000000;\"> (1) the licenses of intellectual property for each of the HCM-1, HCM-2 and DCM-1 programs, and (2) the performance of research and development services, including regulatory support, for each of the three programs.\u00a0\u00a0The Company considered whether the licenses have standalone functionality and are capable of being distinct; however, given the fact that the research and development services are of such a specialized nature that can only be performed by the Company and Sanofi cannot benefit from the intellectual property licenses without the Company\u2019s performance, the Company determined that the intellectual property licenses are not distinct from the research and development services and thus the license and research and development services for each program are combined into three separate performance obligations.</font></p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">Contract Term</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU11\"></a>For revenue recognition purposes, the Company determined that the Collaboration Agreement is a period to period contract for which the Company had enforceable rights and obligations from inception through December 31, 2016.\u00a0\u00a0Sanofi had the right to terminate the Collaboration Agreement prior to December 31, 2016 or to extend the contract term through December 31, 2018.\u00a0\u00a0If </p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">11</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">MYOKARDIA, INC.</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Notes to Condensed Consolidated Financial Statements\u2014(Continued)</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">(Unaudited)</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Sanofi had elected to terminate the agreement, the termination would have had taken effect on December 31, 2016 and all licensed rights would have reverted to the Company. The Company did not have any obligation to reimburse Sanofi any portio</font><font style=\"color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">n of the payments received if Sanofi had terminated the agreement.</font></p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In December 2016, Sanofi elected to continue the Collaboration Agreement through an extended term ending December 31, 2018 and made the $45.0 million continuation payment to the Company. The Company determined that the extended term was to be treated as a separate contract because such an extension was not probable at the inception of the contract, the extension represents additional goods and services, and such activities are priced commensurate to the effort required and do not involve any significant discount. It was also concluded that the extended term provides the Company with enforceable rights and obligations for the two-year period ending December 31, 2018.\u00a0\u00a0</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Because Sanofi retains the option in the Collaboration Agreement to extend the arrangement, neither party is committed to perform and the contract does not have enforceable rights and obligations beyond December 31, 2018.</p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">Transaction Price<font style=\"font-style:normal;color:#000000;\">\u00a0</font><font style=\"font-style:normal;\"> </font><font style=\"font-style:normal;color:#000000;\">\u00a0</font><font style=\"font-style:normal;\"> </font></p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The Company\u2019s assessment of the transaction price included an analysis of amounts it expected to be entitled for providing goods or services to the customer which at contract inception consisted of the upfront cash payment, valued at $34.3 million, net of the fair value of $0.7 million allocated to the option provided to Sanofi to acquire equity, and variable consideration of $25.0 million, subject to an IND application.\u00a0\u00a0Sanofi paid the Company the $25.0 million milestone upon the Company\u2019s application for the IND. In 2016, after the IND application was made and when the Company determined it was deemed probable that significant reversal in the amount of cumulative revenue recognized will not occur, the Company included this amount in the transaction price.\u00a0\u00a0As of December 31, 2016, all performance obligations associated with the initial term were satisfied.\u00a0\u00a0 <font style=\"color:#000000;\">\u00a0</font>\u00a0\u00a0 </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The extended term (from January 1, 2017 to December 31, 2018) has a fixed fee of $45.0 million, paid by Sanofi contemporaneously with the notice of continuation of the contract.\u00a0\u00a0The Company therefore determined that the transaction price for this extended term is $45.0 million. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">As previously noted above, the Collaboration Agreement also includes up to $45.0 million in funding from Sanofi of approved in-kind research and clinical activities. Sanofi is the decision maker on how to provide these services and such services are used in the development of joint program technology which is co-owned by both parties. As such the Company concluded that these in-kind contributions do not constitute consideration paid by Sanofi to the Company.\u00a0\u00a0</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Any consideration related to sales-based royalties will be recognized when the related sales occur and therefore have also been excluded from the transaction price.\u00a0\u00a0 </p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">Methodology for Recognition</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Since the Company has determined that the three performance obligations are satisfied over time, the Company has selected a single revenue recognition method that it believes most faithfully depicts the Company\u2019s performance in transferring control of the services. ASC 606 allows entities to choose between two methods to measure progress toward complete satisfaction of a performance obligation:\u00a0\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1. Output methods - recognize revenue on the basis of direct measurements of the value to the customer of the goods or services transferred to date relative to the remaining goods or services promised under the contract (e.g. surveys of performance completed to date, appraisals of results achieved, milestones reached, time elapsed, and units produced or units delivered); or </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2. Input methods - recognize revenue on the basis of the entity\u2019s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. </p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">12</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">MYOKARDIA, INC.</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Notes to Condensed Consolidated Financial Statements\u2014(Continued)</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">(Unaudited)</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU12\"></a><font style=\"color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The Company concluded that it will utilize a cost-based input method to measure proportional performance and to calculate the corresponding amount of revenue to recognize. The Company believes th</font><font style=\"color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">is is the best measure of progress because other measures do not reflect how the Company executes its performance obligations under the contract with Sanofi. In applying the cost-based input methods of revenue recognition, the Company uses actual costs inc</font><font style=\"color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">urred relative to budgeted costs to fulfill the combined performance obligations. Revenue will be recognized based on actual costs incurred as a percentage of total actual and budgeted costs as the Company completes its performance obligations, which will </font><font style=\"color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">be fulfilled by December 31, 2018. A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company\u2019s performance obligations. In making such estimates, significant judgment is required to evaluate ass</font><font style=\"color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">umptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company\u2019s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significan</font><font style=\"color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">t change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods. </font></p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">For the three months ended March 31, 2017 and 2018, the Company recognized $2.4 million and $5.3 million of license and collaboration revenue, respectively.\u00a0\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The following table presents changes in the Company\u2019s contract assets and liabilities, which excludes research and development reimbursements under the mavacamten registration program plan, for the three months ended March 31, 2017 and 2018 (in thousands):</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"14\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.12%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Three Months Ended March 31, 2018</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Balance at</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Beginning\u00a0of\u00a0Period</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Additions</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Deductions</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Balance at End</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">of Period</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Contract liabilities:</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.5%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Deferred revenue</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">33,558</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.5%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(5,331</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">28,227</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"14\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.12%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Three Months Ended March 31, 2017</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Balance at</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Beginning\u00a0of\u00a0Period</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Additions</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Deductions</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Balance at End</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">of Period</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Contract assets:</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.5%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Receivable from collaboration partner</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">45,000</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.5%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(45,000</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Contract liabilities:</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.5%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Deferred revenue</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">45,000</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.5%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(2,410</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">42,590</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Deferred revenue of $28.2 million as of March 31, 2018 consists of the $45.0 million continuation payment received in January 2017, less $16.8 million recognized during the five quarters ending March 31, 2018.\u00a0\u00a0The $28.2 million in deferred revenue will be recognized through December 31, 2018 as the performance obligations are satisfied. </p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">Registration Program Plan Cost Sharing</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_Hlk506842557\"></a>In addition to amounts due to the Company under the Collaboration Agreement, Sanofi is <a name=\"_Hlk506842557\"></a>conditionally responsible for sharing one half of the registration program plan (\u201cRPP\u201d) costs after the clinical proof of concept is established for each of the HCM-1, HCM-2 and DCM-1 programs. Effective October 2017, Sanofi is sharing RPP costs for the mavacamten program during the remainder of the contract term. Registration program costs are subject to review and approval by the Company and Sanofi and include amounts incurred relating to clinical trials, development and manufacturing of, and obtaining regulatory approvals for mavacamten and include direct employee costs and direct out-of-pocket costs incurred, by or on behalf of a party, that are specifically identifiable or reasonably and directly allocable to those activities.\u00a0\u00a0</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Estimated reimbursements are invoiced to Sanofi before each interim period based on budgeted amounts.\u00a0\u00a0These estimates consist of one half of the Company\u2019s mavacamten development budget in excess of Sanofi\u2019s mavacamten development budget each interim period. After each period end, a review of the actual expenses occurs and adjustments to future invoices are applied as a result of an analysis of the budgeted versus incurred expenses. Actual amounts received from Sanofi for the applicable period are recorded by the Company to reduce its research and development expenses each interim period.\u00a0\u00a0</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">13</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">MYOKARDIA, INC.</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Notes to Condensed Consolidated Financial Statements\u2014(Continued)</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">(Unaudited)</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU13\"></a><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The Company recorded a $1.0 million and $0 receivable for reimbursable RPP expenses, as of December 31, 2017 and March 31, 2018, respectively, which is recorded as receivable from collaboration </font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">partner and included in current assets in the condensed consolidated balance sheets. The Company received $4.4 million and $6.1 million as prepayments from collaboration partner as of December 31, 2017 and March 31, 2018, respectively, which is included in</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"> current liabilities in the condensed consolidated balance sheets. The Company recorded $0 and $2.8 million as reductions to research and development expenses for the three months ending March 31, 2017 and 2018, respectively. </font></p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The following table presents the RPP related receivables and prepayments (in thousands):</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Balance at</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">December 31, 2017</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Payments</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Received from</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Sanofi under RPP</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Actual<font style=\"font-family:Calibri;\">\u00a0</font>Expenses</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Incurred\u00a0During</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">the Quarter</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Balance at</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">March 31, 2018</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Receivable from collaboration partner</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,013</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,013</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Prepayment from collaboration partner</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">4,432</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">6,090</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(2,821</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">7,701</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">4. Fair Value Measurements</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Financial assets and liabilities are recorded at fair value. The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Level 1\u2014Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Level 2\u2014Inputs other than quoted market prices included in Level 1 are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument\u2019s anticipated life.</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Level 3\u2014Inputs reflect management\u2019s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The following table sets forth the Company\u2019s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"14\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Fair Value Measurements at March 31, 2018</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Total</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Level 1</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Level 2</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Level 3</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Assets</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Money market funds</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">183,714</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">183,714</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">U.S. government agency obligations</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">23,875</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">23,875</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Corporate securities</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">51,568</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">51,568</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Total</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">259,157</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">183,714</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">75,443</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"14\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Fair Value Measurements at December 31, 2017</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Total</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Level 1</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Level 2</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Level 3</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Assets</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Money market funds</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">223,568</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">223,568</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">U.S. government agency obligations</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">27,878</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">27,878</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Corporate securities</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">23,955</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">23,955</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Total</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">275,401</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">223,568</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">51,833</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">14</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">MYOKARDIA, INC.</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Notes to Condensed Consolidated Financial Statements\u2014(Continued)</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">(Unaudited)</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU14\"></a><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The following table is a summary of amortized cost, unrealized gain and loss, and fair value of the Company\u2019s marketable securities by contractual maturities (in </font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">thousands):</font></p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"14\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.04%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Fair Value Measurements at March 31, 2018</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Amortized\u00a0Cost</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Unrealized\u00a0Gain</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Unrealized\u00a0Loss</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Fair\u00a0Value</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Cash equivalents (due within 90 days)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">183,714</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">183,714</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Short-term investments (due within one year)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">39,998</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(176</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">39,822</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Long-term investments (due between one and two years)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">35,769</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(148</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">35,621</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Total</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">259,481</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(324</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">259,157</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"14\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.04%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Fair<font style=\"font-family:Calibri;\">\u00a0</font>Value\u00a0Measurements\u00a0at\u00a0December\u00a031,\u00a02017</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Amortized\u00a0Cost</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Unrealized\u00a0Gain</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Unrealized\u00a0Loss</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Fair\u00a0Value</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Cash equivalents (due within 90 days)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">223,568</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">223,568</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Short-term investments (due within one year)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">32,010</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(77</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">31,933</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Long-term investments (due between one and two years)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">20,010</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(110</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">19,900</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Total</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">275,588</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(187</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">275,401</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">5. Balance Sheet Components</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Property and Equipment</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Property and equipment consist of the following (in thousands):</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">March 31,</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2018</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">December 31,</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2017</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Scientific equipment</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">7,102</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">5,935</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Furniture and equipment</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,071</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,064</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Capitalized software</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">278</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">278</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Leasehold improvements</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">340</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">331</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Total</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">8,791</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">7,608</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Less: Accumulated depreciation</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(4,761</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(4,461</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr style=\"height:12.2pt;\">\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Property and equipment, net</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">4,030</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">3,147</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Depreciation expense was $0.3 million and $0.3 million for the three months ended March 31, 2018 and 2017, respectively.</p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Accrued Liabilities</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Accrued liabilities consist of the following (in thousands):</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">March 31,</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2018</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">December 31,</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2017</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Clinical research and development</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">6,967</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">5,981</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Payroll related liabilities</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2,817</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">4,412</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Other</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">844</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,246</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Total accrued liabilities</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">10,628</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">11,639</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;\">\u00a0</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">15</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">MYOKARDIA, INC.</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Notes to Condensed Consolidated Financial Statements\u2014(Continued)</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">(Unaudited)</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU15\"></a><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">6. Commitments and Contingencies</font></p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Purchase Commitments</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The Company conducts product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. The Company has contractual arrangements with these organizations; however, these contracts are generally cancelable on 30 days\u2019 notice and the obligations under these contracts are largely based on services performed.</p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Facility Leases</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">On June\u00a029, 2012, the Company entered into a 66-month lease for approximately 12,000 square feet of office and laboratory space in South San Francisco with annual payments of approximately $0.5 million. In connection with this lease agreement, the Company also entered into a shared facilities and services agreement with Global Blood Therapeutics, Inc. (\u201cGBT\u201d), a co-tenant in the office building. In October 2014, the Company entered into a lease assignment agreement with the owner of the building and GBT to allow GBT to sublease the Company\u2019s portion of the building beginning in March 2015. For the three months ended March 31, 2018 and 2017, the Company recorded approximately $0.1 million and $0.1 million, respectively, of sublease income and $0.1 million and $0.1 million, respectively, of sublease expense, which is recorded in interest and other income, net in the consolidated statements of operations and comprehensive loss.</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">On September\u00a015, 2014, the Company entered into a five-year lease for approximately 34,400 square feet of office and laboratory space in South San Francisco. The Company may extend the lease for an additional three-year term. The initial annual lease payments are $1.3 million, increasing to $1.6 million in the final year of the agreement. The lease period commenced in January 2015. The Company received a lease abatement for the first three months of the lease term, which is recorded as deferred rent and recognized over the lease term. On October 1, 2017, the Company entered into an additional 25-month sublease agreement for approximately 8,000 square feet of office space in South San Francisco with annual payments of approximately $0.3 million. The lease period commenced on October 1, 2017 and expires on October 31, 2019. On January 1, 2018, the Company expanded its office and laboratory space at the same location in South San Francisco by 6,000 square feet for an approximate annual cost of $0.4 million.</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The Company has provided deposits for letters of credit totaling $0.3 million to secure its obligations under its leases, which have been classified as other long-term assets in the Company\u2019s consolidated balance sheet as of March 31, 2018.</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Rent expense, net was $0.4 million and $0.3 million for the three months ended March 31, 2018 and 2017, respectively.</p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Contingencies</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">From time to time, the Company may have contingent liabilities that arise in the ordinary course of business activities. The Company accrues for such a liability when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.  There were no contingent liabilities requiring accrual or disclosure as of March 31, 2018 or December 31, 2017.</p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Guarantees and Indemnifications</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The Company enters into standard indemnification arrangements in the ordinary course of business.</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Pursuant to certain of these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third-party with respect to the Company\u2019s technology. The term of these indemnification arrangements is generally perpetual. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future, but have not yet been made.</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">16</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">MYOKARDIA, INC.</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Notes to Condensed Consolidated Financial Statements\u2014(Continued)</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">(Unaudited)</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU16\"></a><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The Company indemnifies its officers and directors for certain events or occurrences, subject to certain li</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">mits, while the officer or director is or was serving at the Company\u2019s request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws, and agreements providing for indemnification entered into w</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">ith its officers and directors. The term of the indemnification period lasts as long as an officer or director may be subject to any proceeding arising out of acts or omissions of such officer or director in such capacity.</font></p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The maximum amount of potential future indemnification of directors and officers is unlimited; however, the Company currently holds director and officer liability insurance. This insurance allows the transfer of risk associated with its exposure and may enable it to recover a portion of any future amounts paid.</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations for any period presented.</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">7. Stockholders\u2019 Equity</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Common Stock Reserved for Issuance</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The Company has reserved shares of common stock for issuance as follows:</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">March 31,</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2018</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">December 31,</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2017</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Options and awards issued and outstanding</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">3,793,364</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2,964,549</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Shares available for issuance under 2015 Stock Option and Incentive Plan</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,357,043</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">863,538</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Shares available for issuance under 2015 Employee Stock Purchase Plan</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">807,571</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">449,444</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Total</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">5,957,978</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">4,277,531</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">8. Stock-Based Compensation</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The Company classifies stock-based compensation expense in the accompanying condensed consolidated statements of operations and comprehensive loss based on the department to which a recipient belongs. The following table sets forth stock-based compensation expense related to options granted to employees and consultants for all periods presented (in thousands):</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"6\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Three<font style=\"font-family:Calibri;\">\u00a0</font>Months\u00a0Ended</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">March 31,</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2018</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2017</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Research and development</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,591</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">590</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">General and administrative</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2,040</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">815</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Total</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">3,631</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,405</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The following summarizes option and other equity award activity under the 2012 Equity Incentive Plan and 2015 Stock Option and Incentive Plan:</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Shares Subject to</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Weighted Average</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Outstanding</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Options and Awards</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Exercise\u00a0Price</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">per\u00a0Share</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Balance at December 31, 2017</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2,964,549</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">11.54</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Options and awards granted</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">991,932</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">52.05</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Options exercised</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(110,961</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">7.26</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Options and awards canceled</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(52,156</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">19.13</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Balance at March 31, 2018</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">3,793,364</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">22.15</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In relation to stock options to purchase common stock that vest upon the achievement of performance criteria, $153,000 and $174,000 <font style=\"color:#000000;\">in stock-based compensation expense was recorded for the three months ended March 31, 2018 and 2017, respectively. </font>The Company begins to recognize expenses related to these options during the period upon concluding that certain performance criteria are considered probable.</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">17</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">MYOKARDIA, INC.</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Notes to Condensed Consolidated Financial Statements\u2014(Continued)</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">(Unaudited)</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">9. Net Loss per Share Attributable to Common Stockholders</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share amounts):</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"6\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.36%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Three Months Ended</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">March 31,</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2018</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2017</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">As Revised (Note 2)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Numerator:</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Net loss</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(17,820</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(14,762</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Net loss attributable to common stockholders, basic and diluted</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(17,820</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(14,762</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Denominator:</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Weighted average shares outstanding</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">35,889,835</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">31,428,564</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Less: weighted average shares subject to repurchase</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(62,600</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(339,254</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Weighted average shares used to compute basic and diluted net</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0 loss per share</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">35,827,235</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">31,089,310</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Net loss per share attributable to common stockholders, basic</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0 and diluted</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(0.50</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(0.47</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"6\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.36%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">As of March 31,</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2018</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2017</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Common stock subject to repurchase</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">51,767</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">298,915</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Stock options to purchase common stock</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">3,793,364</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">3,183,304</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">As of March 31, 2018, the Company has contributions from plan participants of $367,000 under the 2015 ESPP, which if converted, would be equivalent to 11,066 shares based on 85% of the stock price at the beginning of the offering period. As of March 31, 2017, the Company had contributions from plan participants of $338,400 under the 2015 Employee Stock Purchase Plan, which if converted, would have been equivalent to 29,381 shares based on 85% of the stock price at the beginning of the offering period.</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">10. Income taxes</p>\n<p style=\"Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#222222;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (\u201cTax Act\u201d) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a corporate tax rate decrease from 35% to 21% effective for tax years beginning after December 31, 2017, the transition of U.S. international taxation from a worldwide tax system to a territorial system, and a one-time transition tax on the mandatory deemed repatriation of cumulative foreign earnings as of December 31, 2017.\u00a0</p>\n<p style=\"Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#222222;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Also on December 22, 2017, Staff Accounting Bulletin No. 118 (\u201cSAB 118\u201d) was issued to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Act. For the three months ended March 31, 2018, the Company noted no additional guidance or information that affects the provisional amounts initially recorded at zero for the transition tax and the remeasurement of the deferred tax assets for the year ended December 31, 2017. As a result, the Company recorded no adjustment to the transition tax and the remeasurement of the deferred tax assets. The Company will continue to monitor and analyze any additional guidance and information that may be issued by the federal and state tax authorities. Any subsequent adjustment to these amounts will be recorded to current tax expense in the 2018 interim period during which the analysis is complete.\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10.27%;text-indent:-10.27%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10.27%;text-indent:-10.27%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10.27%;text-indent:-10.27%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">18</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:10.27%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Item\u00a02.</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU17\"></a><a name=\"ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F\"></a><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"></font><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F\"></a>Management\u2019s Discussion and Analysis o</font><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">f Financial Condition and Results of Operation</font></p></td></tr></table></div>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\"><a name=\"_cp_text_1_89\"></a><a name=\"_cp_text_1_91\"></a>You should read the following management\u2019s discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and notes thereto included in Part I, Item\u00a01 of this Quarterly Report on Form 10-Q and with our audited consolidated financial statements and notes thereto for the year ended December\u00a031, 2017, <a name=\"_cp_text_1_89\"></a>included in our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the U.S. Securities and Exch<a name=\"_cp_text_1_91\"></a>ange Commission (SEC) on March 8, 2018 (the \u201cAnnual Report\u201d).</p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Special note regarding forward-looking statements</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_cp_text_1_92\"></a><a name=\"_cp_text_1_94\"></a><a name=\"_cp_text_1_95\"></a><a name=\"_cp_text_1_96\"></a>This report contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed in these forward-looking statements. <a name=\"_cp_text_1_92\"></a>The statements contained in this report that are not purely historical are forward-looking statements within the meaning of Section\u00a027A of the Securities Act of 1933, as amended (the \u201cSecurities Act\u201d) and Section\u00a0<a name=\"_cp_text_1_94\"></a>21E of the Securities Exchange Act of 1934, as amended (<a name=\"_cp_text_1_95\"></a>the \u201c<a name=\"_cp_text_1_96\"></a>Exchange Act\u201d). Forward-looking statements are often identified by the use of words such as, but not limited to, \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrategy,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould\u201d and similar expressions or variations intended to identify forward-looking statements. These statements are based on the beliefs and assumptions of our management based on information currently available to management. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in the section titled \u201cRisk Factors\u201d included under Part II, Item\u00a01A below. Furthermore, such forward-looking statements speak only as of the date of this report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.</p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Overview</p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_cp_text_1_100\"></a>We are a clinical-stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. We have used our precision medicine platform to generate a robust pipeline of therapeutic programs for the <a name=\"_cp_text_1_100\"></a>chronic treatment of the two most common forms of heritable cardiomyopathy\u2014hypertrophic cardiomyopathy, or HCM, and dilated cardiomyopathy, or DCM. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;letter-spacing:-0.15pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">A Phase 2 clinical trial of <font style=\"color:#000000;\">mavacamten</font>, our product candidate for the treatment of HCM, demonstrated improvements in signs and symptoms of symptomatic, obstructive HCM (\u201coHCM\u201d), and we plan to advance mavacamten into a pivotal Phase 3 clinical trial in the second quarter of 2018. Using our precision medicine development strategy, we believe that we have effectively generated clinical proof of mechanism for <font style=\"color:#000000;\">mavacamten</font> in both healthy volunteers and in HCM patients, and intend to pursue a similar path for MYK-491, our product candidate for DCM, and for mavacamten in a second indication in symptomatic, non-obstructive HCM (\u201cnHCM\u201d). MYK-491 is being studied in a Phase 1b single-ascending dose clinical trial that is currently underway in DCM patients with stable heart failure, based on results from a completed Phase 1 clinical trial in healthy volunteers. Additionally, we are currently enrolling patients in our Phase 2 clinical trial of mavacamten in nHCM patients.</p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Financial Overview</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We have not generated net income from operations, and, as of March 31, 2018, we had an accumulated deficit of $152.7 million, primarily as a result of research and development and general and administrative expenses. To date, all our revenue has been derived from non-refundable payments under the license and collaboration agreement we entered into with Aventis Inc., a wholly-owned subsidiary of Sanofi S.A. (\u201cSanofi\u201d), in August 2014, which we refer to as the Collaboration Agreement, and we have not yet generated any revenue from product sales. We have never been profitable and have incurred net losses in each year since commencement of our operations. We expect to incur significant and increasing losses from operations for the foreseeable future, and we can provide no assurance that we will ever generate significant revenue or profits.</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU18\"></a>Through March 31, 2018, we have financed our operations through an initial public offering (\u201cIPO\u201d), two follow-on public offerings, private placements of redeemable convertible preferred stock and funds received in connection with the Collaboration Agreement with Sanofi.\u00a0\u00a0We received net proceeds of $93.9 million from the sale of shares of our Series A, A-1 and B redeemable convertible preferred stock. On November 3, 2015, we completed our IPO of 6,253,125 shares of common stock at an offering price of $10.00\u00a0per share, resulting in net proceeds of approximately $55.6 million, after deducting underwriting discounts, commissions and offering costs. On October 3, 2016, we completed a follow-on public offering of 4,370,000 shares of common stock at an offering price of $15.00 per share, resulting in net proceeds of approximately $61.1 million, after deducting underwriting discounts, </p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">19</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">commissions and offering costs. On August 14, 2017, we completed another follow-on public offering of 4,025,000 share</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">s of common stock at an offering price of $35.50 per share, resulting in net proceeds of approximately $133.9 million, after deducting underwriting discounts, commissions and offering costs. In connection with the Collaboration Agreement, we have received </font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$130.5 million from Sanofi, consisting of a $35.0 million upfront payment, a $25.0 million </font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">milestone payment for the submission of an Investigational New Drug (\u201cIND\u201d) application for MYK-491 with the U.S. government\u2019s Food and Drug Administration (\u201cFDA\u201d) i</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">n November 2016</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">, a $45.0 million continuation payment from Sanofi in January 2017</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"> and $17.8 million in reimbursements and prepayments for research and development costs under a Registration Program Plan (\u201cRPP\u201d) for mavacamten</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">. As of March 31, 2018, we had </font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">cash and cash equivalents of $183.9 million, short-term investments of $39.8 million and long-term investments of $35.6 million.</font></p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_cp_text_1_107\"></a><a name=\"_cp_text_1_109\"></a>We have no manufacturing facilities and all of our manufacturing activities are contracted out to a third party. We currently utilize third-party <a name=\"_cp_text_1_107\"></a>clinical research organizations (\u201c<a name=\"_cp_text_1_109\"></a>CROs\u201d) to carry out our clinical development and trials. We do not yet have a sales organization.</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_cp_text_1_111\"></a>We expect to incur substantial expenditures in the foreseeable future for the advancement of our precision medicine platform, the development and potential commercialization of <font style=\"color:#000000;\">mavacamten</font> and MYK-491, and the discovery, development and potential commercialization of any additional product candidates we may pursue. Specifically, we expect to continue to incur <a name=\"_cp_text_1_111\"></a>substantial expenses in connection with our ongoing clinical trials of <font style=\"color:#000000;\">mavacamten, including a Phase 3 pivotal trial in symptomatic oHCM, a Phase 2 clinical trial in symptomatic nHCM,</font> and any additional Phase 2 and Phase\u00a03 clinical trials that we may conduct for <font style=\"color:#000000;\">mavacamten</font>, as well as our ongoing and planned clinical development activities for MYK-491. We will need substantial additional funding to support our operating activities as we advance <font style=\"color:#000000;\">mavacamten</font>, MYK-491, and other potential product candidates through clinical development, seek regulatory approval and proceed to commercialization. Adequate funding may not be available to us on acceptable terms, or at all.</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The research and development expenses incurred in the development and potential commercialization of <font style=\"color:#000000;\">mavacamten</font>, MYK-491 and other product candidates are net of $2.8 million and $0 million in mavacamten RPP credits in the periods presented below (in thousands):</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.1%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"6\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.02%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Three Months Ended</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">March 31,</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.1%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2018</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2017</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.1%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Mavacamten</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.56%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">7,940</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.56%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">4,976</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.1%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">MYK-491</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.56%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2,820</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.56%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2,875</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.1%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Other</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">5,858</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">4,066</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.1%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Total research and development expenses:</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">16,618</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">11,917</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Sanofi License and Collaboration Agreement</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In August 2014, we entered into the Collaboration Agreement with Sanofi that covers three main research programs: our first program in HCM (referred to as HCM-1), a second program in HCM (referred to as HCM-2) and our first program in DCM (referred to as DCM-1). For purposes of this presentation, we refer to Sanofi as our co-party to the Collaboration Agreement.</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Under the Collaboration Agreement, we are responsible for conducting research and development activities through early human efficacy studies, except for specified research activities to be conducted by Sanofi. Thereafter, we will lead worldwide development and U.S. commercial activities for the <font style=\"color:#000000;\">HCM-1</font> and HCM-2 programs, Sanofi will lead global development and commercial activities for DCM-1 and Sanofi will lead commercial activities for the <font style=\"color:#000000;\">HCM-1</font> and HCM-2 programs where it has commercialization rights outside of the U.S.\u00a0\u00a0Sanofi also has the option to co-promote the <font style=\"color:#000000;\">HCM-1</font> and HCM-2 programs in the United States only in the event of a potential expanded cardiovascular disease indication outside of the genetically targeted indications. We have co-commercialization rights to DCM-1 in the United States, at our option.</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We are entitled to receive tiered royalties ranging from the mid-single digits to the mid-teens on net sales of certain HCM-1, HCM-2 and DCM-1 finished products outside the United States and on net sales of certain DCM-1 finished products in the United States. Sanofi is eligible to receive tiered royalties ranging from the mid-single digits to the low-teens on net sales of certain HCM-1 and HCM-2 finished products in the United States.</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">20</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU19\"></a><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Under the Collaboration Agreement, Sanofi agreed to provide upfront and milestone payments, equity investments and research and development support. As of March 31, 2018, we have received from Sanofi an initial non-refundable upfr</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">ont cash payment of $35.0 million and equity investments of $10.0 million in exchange for Series\u00a0A-1 redeemable convertible preferred stock, a $25.0 million milestone-based payment and a $45.0 million continuation payment. In addition, we have received equ</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">ity funding outside of the original agreement of $5.0 million in exchange for Series\u00a0B redeemable convertible preferred stock and $9.0 million in exchange for shares of our common stock in our IPO. We are also eligible to receive up to $45.0 million of app</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">roved in-kind research and clinical activities, for which eligibility expires on December 31, 2018</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">.</font></p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Critical Accounting Policies and Significant Judgments and Estimates</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">This discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_cp_text_1_115\"></a><a name=\"_cp_text_1_115\"></a>Our significant accounting policies are fully described in Note 2 of our Annual Report.\u00a0\u00a0We believe that the accounting policies discussed in our Annual Report are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management\u2019s judgments and estimates. There have been no changes to our significant accounting policies during the three months ended March 31, 2018, except\u00a0with\u00a0respect\u00a0to\u00a0changes\u00a0in\u00a0our\u00a0revenue recognition policy upon the adoption of <font style=\"font-style:italic;Background-color:#FFFFFF;color:#000000;\">ASU No. 2014-09</font><font style=\"Background-color:#FFFFFF;color:#000000;\">,\u00a0</font><font style=\"font-style:italic;Background-color:#FFFFFF;color:#000000;\">Revenue from Contracts with Customers (Topic\u00a0606)</font>.</p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Components of Operating Results</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Collaboration and License Revenue</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We generate revenue from the Collaboration Agreement with Sanofi for the development and commercialization of products under the collaboration.</p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Operating Expense</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:2.31%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">Research and Development Expenses</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Research and development expenses consist of salaries and benefits, including stock-based compensation, lab supplies and facility costs, and fees paid to CROs to conduct certain research and development activities on our behalf. Amounts incurred in connection with collaboration and license agreements are also included in research and development expense. Payments made prior to the receipt of goods or services are capitalized until the goods or services are received.</p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:2.27%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">General and Administrative Expenses</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">General and administrative expenses consist principally of salaries and benefits, including stock based compensation, professional fees for legal, consulting, audit and tax services, market research, rent and other general operating expenses not otherwise classified as research and development expenses.</p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Interest and Other Income, Net</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Interest and other income, net consists primarily of interest income earned on our cash and cash equivalents, short-term investments and long-term investments.</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">21</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU20\"></a><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Results of Operations</font></p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\"><a name=\"_Hlk512003308\"></a>Comparison of the Three-Month Periods Ended March 31, 2018 and 2017 </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The following table compares the operating results (in thousands):</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.32%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"6\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.02%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Three Months Ended</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">March 31,</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.32%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2018</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2017</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-bottom:solid 0.75pt #000000;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Increase/(Decrease)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.32%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">As Revised (Note 2)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.32%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Collaboration and license revenue</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">5,331</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2,410</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2,921</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.32%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Operating expenses:</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.32%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Research and development</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">16,618</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">11,917</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">4,701</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.32%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">General and administrative</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">7,313</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">5,476</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,837</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.32%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Total operating expenses</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">23,931</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">17,393</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">6,538</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.32%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Loss from operations</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(18,600</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(14,983</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">3,617</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.32%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Interest and other income, net</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">780</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">221</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">559</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.32%; border-bottom:double 2.5pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Net loss and comprehensive loss</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(17,820</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(14,762</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">3,058</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-top:8pt;margin-bottom:0pt;text-indent:2.27%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">Collaboration and License Revenue</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Collaboration and license revenue increased $2.9 million, from $2.4 million to $5.3 million for the three months ended March 31, 2017 and 2018, respectively. The amounts for the periods ended March 31, 2017 and 2018 relate to revenue we recognized from the continuation payment of $45.0 million under the Collaboration Agreement.\u00a0\u00a0Revenues have been retroactively restated to reflect implementation of the ASU 606 revenue standard and as revised reflect a higher level of research and development efforts incurred and expected to be incurred in 2018 as compared to the same period in 2017.</p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:2.27%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">Research and Development Expenses</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_Hlk512949988\"></a>Research and development expenses increased $4.7 million, or 39%, from $11.9 million for the three months ended March 31, 2017 to $16.6 million for the three months ended March 31, 2018. The increase in research and development expenses was primarily due to a $3.0 million increase in clinical expenses, a $1.3\u00a0million increase in personnel expenses as a result of an increase in employee headcount, a $1.0 million increase in stock compensation expense, a $0.9 million increase in contract research, chemistry and biology expenses for discovery and pre-clinical programs including HCM-2 and a back-up compound within the DCM-1 program, a $0.6\u00a0million increase in drug manufacturing costs for mavacamten and MYK-491, and miscellaneous other expenses of $0.7 million, offset by $2.8 million in RPP credits from Sanofi.</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We expect research and development expenses to increase in future periods as we continue to develop our lead product candidate, mavacamten, in clinical trials and to conduct preclinical and subsequent clinical activities for MYK-491, HCM-2, additional mechanisms within DCM, and other back-up programs. As product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials, we expect that our research and development expenses will increase substantially in the future.</p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:2.27%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">General and Administrative Expenses</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">General and administrative expenses increased by $1.8 million, or 34%, from $5.5 million for the three months ended March 31, 2017 to $7.3 million for the three months ended March 31, 2018. The increase in general and administrative expenses was primarily due to an increase in stock compensation expense of $1.2 million and a $0.6 million increase in personnel expenses due to an increase in employee headcount. We expect general and administrative expenses to continue to increase in future periods, reflecting both the increased costs in connection with the continued clinical development and potential future commercialization of mavacamten, the ongoing and planned clinical development of MYK-491, as well as an expanded infrastructure and increased professional fees.</p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:2.27%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">Interest and Other Income, Net</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Interest and other income, net increased by $559,000 or 253%, from $221,000 for the three months ended March 31, 2017 to $780,000 for the period ended March 31, 2018. The increase in interest income was primarily due to a higher balance of cash, cash equivalents and investments.\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">22</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU21\"></a><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Liquidity and Capital Resources</font></p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Since our inception, we have financed our operations primarily through private placements of our equity securities, payments received in connection with the Collaboration Agreement, and our public offerings of common stock. A<font style=\"letter-spacing:-0.1pt;\">s of March 31, 2018, we had cash and cash equivalents of $183.9 million, </font><font style=\"color:#000000;\">short-term investments of $39.8 million and long-term investments of $35.6 million, w</font><font style=\"letter-spacing:-0.1pt;\">hich we believe will be sufficient to fund our planned operations through at least the next twelve months from the date of this filing.\u00a0\u00a0</font>To date, we have not generated any revenue from product sales. We do not know when, or if, we will generate any revenue from product sales and do not expect to generate significant revenue from product sales unless and until we obtain regulatory approval of and commercialize <font style=\"color:#000000;\">mavacamten</font>, MYK-491 or other product candidates.</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We expect that our existing cash and cash equivalents will provide sufficient funds to sustain operations through at least the next 12 months from the date of this filing based on our existing business plan. However, we expect to incur substantial expenditures in the foreseeable future for the advancement of our precision medicine platform, the development and potential commercialization of <font style=\"color:#000000;\">mavacamten</font> and MYK-491, and the discovery, development and potential commercialization of any additional product candidates we may pursue. Specifically, we have incurred substantial expenses in connection with our Phase 1 clinical trials of <font style=\"color:#000000;\">mavacamten</font> and expect to continue to incur substantial expenses in connection with our ongoing Phase\u00a02 clinical trial of <font style=\"color:#000000;\">mavacamten in oHCM</font> and any additional Phase\u00a02 and Phase 3 clinical trials that we may conduct for <font style=\"color:#000000;\">mavacamten</font>, as well as our ongoing and planned clinical development activities for MYK-491. Furthermore, if our planned Phase\u00a02 and potential Phase 3 clinical trials for <font style=\"color:#000000;\">mavacamten</font> are successful, or our other product candidates, including MYK-491, enter into later stage clinical trials or more advanced discovery and development stages, we will need to raise additional capital in order to further advance our product candidates towards regulatory approval.</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We will continue to require additional financing to develop our product candidates and fund operations for the foreseeable future through equity or debt financings, collaborative or other arrangements with corporate sources, or through other sources of financing. Adequate additional funding may not be available to us on acceptable terms or at all. Our failure to raise capital as and when needed could have a negative impact on our financial condition and our ability to pursue our business strategies. We anticipate that we will need to raise substantial additional capital, the requirements of which will depend on many factors, including:</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the rate of progress and the costs of, and our ability to generate positive date from, our ongoing and planned clinical trials of mavacamten and MYK-491;</font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><a name=\"_cp_blt_1_129\"></a><a name=\"_cp_text_1_130\"></a><font style=\"font-family:Times New Roman;\">our ability to receive additional payments from Sanofi pursuant to the Collaboration Agreement and timing thereof;</font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the number of product candidates that we intend to develop using our precision medicine platform;</font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the costs of research and preclinical studies to support the advancement of other product candidates into clinical development;</font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the timing of, and costs involved in, executing our clinical development plans, seeking and obtaining approvals from the FDA and comparable foreign regulatory authorities, including the potential by the FDA or comparable regulatory authorities to require that we perform more studies than those that we currently expect;</font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the costs of preparing to manufacture </font><font style=\"color:#000000;font-family:Times New Roman;\">mavacamten</font><font style=\"font-family:Times New Roman;\"> on a larger scale, and to manufacture MYK-491 for clinical development;</font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the costs of commercialization activities if </font><font style=\"color:#000000;font-family:Times New Roman;\">mavacamten</font><font style=\"font-family:Times New Roman;\"> or any future product candidate is approved, including the formation of a sales force;</font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the degree and rate of market acceptance of any products launched by us or our partners;</font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">our need and ability to hire additional personnel;</font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">our ability to enter into additional collaboration, licensing, commercialization or other arrangements and the terms and timing of such arrangements; and</font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the emergence of competing technologies or other adverse market developments.</font></p></td></tr></table></div>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We may seek funds through borrowings or additional rounds of financing, including private or public equity or debt offerings and collaborative arrangements with corporate partners. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials.</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">23</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU22\"></a><font style=\"font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Cash Flows</font></p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The following table sets forth the primary sources and uses of cash for each of the periods presented below (in thousands):</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"6\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Three Months Ended</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">March 31,</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2018</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2017</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"6\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">(in thousands)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Cash Flows from Continuing Operations:</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Net cash (used in) provided by operating activities</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(16,614</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">28,019</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Net cash used in investing activities</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(24,898</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(28,205</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Net cash provided by (used in) financing activities</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">806</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(17</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Net decrease in cash, cash equivalents and restricted cash</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(40,706</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(203</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">)</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-top:8pt;margin-bottom:0pt;text-indent:2.27%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">Cash Provided by/ Used in Operating Activities</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Net cash used in operating activities for the three months ended March 31, 2018 was $16.6 million, and was primarily due to the net loss for the period of $17.8 million and stock-based compensation expense of $3.6 million, and was also affected by changes in operating assets and liabilities, including a decrease in deferred revenue of $5.3\u00a0million partially offset by an increase in prepayment from collaboration partner of $3.3 million.</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Net cash provided by operating activities for the three months ended March 31, 2017 was $28.0 million, and was primarily due to the $45.0 million continuation payment received from Sanofi, partially offset by the net loss for the period of $13.9 million, and was also affected by stock-based compensation expense of $1.4 million and changes in operating assets and liabilities, including a decrease in deferred revenue of $3.3 million and a decrease in accrued liabilities of $1.6 million.</p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:2.27%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">Cash Used in Investing Activities</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Cash used in investing activities for the three months ended March 31, 2018 consisted primarily of purchases of investments of $32.0\u00a0million and investments in equipment of $1.2 million, offset by maturities of investments of $8.0 million. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Cash used in investing activities for the three months ended March 31, 2017 consisted primarily of purchases of investments of $32.0\u00a0million and investments in equipment of $0.2 million, offset by sales of investments of $4.0 million.  </p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:2.27%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">Cash Used in Financing Activities</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Cash provided by financing activities for the three months ended March 31, 2018 consisted of funds received as a result of common stock option exercises of $0.8 million.</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Cash used in financing activities for the three months ended March 31, 2017 consisted of payments of financing-related costs, offset by funds received as a result of common stock option exercises.</p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Contractual Obligations and Other Commitments</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_cp_text_1_142\"></a>There have been no material changes outside the ordinary course of our business to our contractual obligations during the three months end<a name=\"_cp_text_1_142\"></a>ed March 31, 2018, as compared to those disclosed in our Annual Report.</p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Off-Balance Sheet Arrangements</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Since our inception, we have not engaged in any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">24</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU23\"></a><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Jumpstart Our Business Startups Act of 2012 </font></p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The JOBS Act permits an \u201cemerging growth company\u201d such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We are choosing to \u201copt out\u201d of this provision and, as a result, we will comply with new or revised accounting standards as required when they are adopted. This decision to opt out of the extended transition period under the JOBS Act is irrevocable. See Note 2, Summary of Significant Accounting Policies, to our consolidated financial statements appearing in our Annual Report regarding recent accounting pronouncements and Note 2 of the Notes to Condensed Consolidated Financial Statements in this document for revisions to those policies.</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:10.27%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Item\u00a03.</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\"><a name=\"QUANTITATIVE_QUALITATIVE_DISCLOSURES_ABO\"></a><a name=\"QUANTITATIVE_QUALITATIVE_DISCLOSURES_ABO\"></a>Quantitative and Qualitative Disclosures about Market Risk</p></td></tr></table></div>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The market risk inherent in our financial instruments represents the potential loss arising from adverse changes in interest rates or exchange rates. As of March 31, 2018, we had cash and cash equivalents of $183.9 million, consisting of interest-bearing money market accounts, short-term investments of $39.8 million, consisting of corporate securities, and long-term investments of $35.6 million, consisting of United States government agency obligations, which would be affected by changes in the general level of United States interest rates. However, due to the low- risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair value of our cash and cash equivalents. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In addition, <font style=\"color:#000000;\">we are also exposed to foreign currency exchange rate risk inherent in our contracts with research institutions and contract research organizations as certain services are performed by them outside the United States. W</font>e have payments due to one Australian vendor in foreign currency. A significant movement in the Australian dollar may have a material impact on our financial position in the future.</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We do not believe that inflation, interest rate changes or exchange rate fluctuations had a significant impact on our results of operations for any periods presented.</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:10.27%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Item\u00a04.</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\"><a name=\"ITEM_4_CONTROLS_PROCEDURES\"></a><a name=\"ITEM_4_CONTROLS_PROCEDURES\"></a>Controls and Procedures</p></td></tr></table></div>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Evaluation of Disclosure Controls and Procedures</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The term \u201cdisclosure controls and procedures,\u201d as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC\u2019s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company\u2019s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their control objectives.</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2018, the end of the period covered by this Quarterly Report on Form 10-Q. Based upon such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.</p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Changes in Internal Control over Financial Reporting</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">There was no change in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;\">\u00a0</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">25</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU24\"></a><a name=\"PART_II_OR_INFORMATION\"></a><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"PART_II_OR_INFORMATION\"></a>PART II \u2013 OTHE</font><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">R INFORMATION</font></p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:10.27%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Item\u00a01.</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\"><a name=\"ITEM_1_LEGAL_PROCEEDINGS\"></a><a name=\"ITEM_1_LEGAL_PROCEEDINGS\"></a>Legal Proceedings</p></td></tr></table></div>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We are not currently a party to any material litigation or other material legal proceedings.</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:10.27%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Item\u00a01A.</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\"><a name=\"ITEM_1A_RISK_FACTORS\"></a><a name=\"ITEM_1A_RISK_FACTORS\"></a>RISK FACTORS</p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;\">You should consider carefully the following risk factors, together with all the other information in this report, including our consolidated financial statements and notes thereto, and in our other public filings with the SEC.\u00a0\u00a0<font style=\"Background-color:#FFFFFF;color:#000000;\">The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the risk factors described when evaluating our business.</font> </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Risks Related to Our Limited Operating History, Financial Condition and Capital Requirements </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We are an early-stage company. We were incorporated and commenced operations in June 2012. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, developing our technology, creating and expanding on our precision medicine platform, identifying potential product candidates, undertaking preclinical studies for our programs, completing Phase 1 and Phase 2 clinical trials for our most advanced product candidate, mavacamten, planning Phase 3 clinical development of mavacamten and commencing Phase 1 clinical development of our second product candidate, MYK-491. We have not yet demonstrated our ability to successfully complete the clinical development of a product candidate, including the completion of any clinical trials designed to support the registration of a product candidate, obtain marketing approvals, manufacture a commercial scale medicine, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Typically, it takes many years to develop a new medicine from the time it is discovered to when it is available for treating patients. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In addition, as a new business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to transition from a company with a research focus to a company capable of supporting larger scale clinical development and commercial activities. If we are not successful in such a transition, our business, results and financial condition will be harmed. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">We have a history of significant losses and may not achieve or sustain profitability and, as a result, you may lose all or part of your investment. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Our initial product candidates, mavacamten and MYK-491, are in various stages of clinical testing and we must conduct significant additional clinical trials before we can seek the regulatory approvals necessary to begin commercial sales of these or any other product candidates we may develop. We have incurred operating losses in each year since our inception due to costs incurred in connection with our research and development activities and general and administrative costs associated with our operations. Our net loss for the three months ended March 31, 2018 and 2017 was $17.8\u00a0million and $13.9 million, respectively. As of March 31, 2018, we had an accumulated deficit of $152.7 million. We expect to incur increasing losses for several years as we continue our research activities and conduct development of, and seek regulatory approvals for, our initial product candidates, and commercialize any approved drugs. If our product candidates fail in clinical trials or do not gain regulatory approval, or if our product candidates do not achieve market acceptance, we will not be profitable. If we fail to become and remain profitable, or if we are unable to fund our continuing losses, you could lose all or part of your investment. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">We have never generated any revenue from product sales and may never be profitable. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Our ability to generate revenue and achieve profitability depends on our ability, alone or with strategic collaborators, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, our product candidates. We do not anticipate generating revenues from product sales for the foreseeable future, if ever. Our ability to generate future revenue from product sales depends heavily on our success in: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">completing research and preclinical and clinical development of our product candidates; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">seeking and obtaining regulatory approvals to market product candidates for which we complete clinical trials; </font></p></td></tr></table></div>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">26</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU25\"></a><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"></font><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"></font><font style=\"font-family:Times New Roman;\">developing a sustainable, scalable, reproducible and transferable manufacturing process for our product candidates; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">establishing and maintaining supply and manufacturing relationships with third parties that can provide adequate (in amount and quality) products and services to support clinical development and the market demand, if any, for our product candidates, if approved; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">launching and commercializing product candidates for which we obtain regulatory approval, either through a collaboration or, if launched independently, by establishing a sales force, marketing and distribution infrastructure; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">obtaining market acceptance of our product candidates and the use of precision medicine as a viable treatment option for cardiovascular diseases; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">addressing any competing technological and market developments; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">implementing additional internal systems and infrastructure, as needed; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">identifying and validating new product candidates from our platform; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">maintaining our existing collaboration agreement with Sanofi and negotiating favorable terms in any new collaboration, licensing or other arrangements into which we may enter; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how; and </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">attracting, hiring and retaining qualified personnel who are suitable to our culture and mission. </font></p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_cp_text_1_159\"></a><a name=\"_cp_text_1_160\"></a><a name=\"_cp_text_1_161\"></a><a name=\"_cp_text_1_163\"></a><a name=\"_cp_text_1_164\"></a><a name=\"_cp_text_1_166\"></a>Even if one or more of the product candidates that we are developing is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Our expenses could increase beyond our expectations if we are requir<a name=\"_cp_text_1_159\"></a>ed by the U.S. Food and Drug Administration (<a name=\"_cp_text_1_160\"></a>the \u201c<a name=\"_cp_text_1_161\"></a>FDA\u201d)<a name=\"_cp_text_1_163\"></a>, the European Medicines Agency (<a name=\"_cp_text_1_164\"></a>the \u201c<a name=\"_cp_text_1_166\"></a>EMA\u201d) or other regulatory agencies, domestic or foreign, to perform clinical trials and other studies in addition to those that we currently anticipate. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">We will need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We are currently advancing <font style=\"color:#000000;\">mavacamten</font> and MYK-491, our initial product candidates, through clinical development, and conducting preclinical discovery and development activities in our other programs. Drug development is expensive, and we expect our research and development expenses to increase substantially in connection with our ongoing activities, particularly as we advance our product candidates in clinical trials.</p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">As of March 31, 2018, our cash and cash equivalents, including investments, were $259.3 million. We intend to use our cash and cash equivalents to fund the advancement of our <font style=\"color:#000000;\">mavacamten</font> clinical development program, including our upcoming Phase 3 clinical trial in symptomatic oHCM patients and our planned additional clinical trials of mavacamten, the progression of MYK-491 through clinical proof-of-concept, our ongoing preclinical, discovery and research programs and the expansion of our platform, as well as for working capital and general corporate purposes. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic and licensing arrangements or a combination of these approaches. In any event, we will require additional capital to obtain regulatory approval for, and to commercialize, <font style=\"color:#000000;\">mavacamten</font>, MYK-491 or any other product candidates we may identify and develop. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Our funding requirements and the timing of our need for additional capital are subject to change based on a number of factors, including: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the rate of progress and the cost of our ongoing and planned clinical trials of </font><font style=\"color:#000000;font-family:Times New Roman;\">mavacamten</font><font style=\"font-family:Times New Roman;\"> and MYK-491; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">our ability to successfully maintain our collaboration with Sanofi, and the amount and timing of any subsequent payments we may receive pursuant to the collaboration;</font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the number of product candidates that we intend to develop using our precision medicine platform; </font></p></td></tr></table></div>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">27</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU26\"></a><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"></font><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"></font><font style=\"font-family:Times New Roman;\">the costs of research and preclinical studies to support the advancement of other product candidates into clinical develop</font><font style=\"font-family:Times New Roman;\">ment; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the timing of, and costs involved in, seeking and obtaining approvals from the FDA and comparable foreign regulatory authorities, including the potential by the FDA or comparable regulatory authorities to require that we perform more studies than those that we currently expect; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the costs of preparing to manufacture </font><font style=\"color:#000000;font-family:Times New Roman;\">mavacamten</font><font style=\"font-family:Times New Roman;\"> on a larger scale, and to manufacture MYK-491 for further clinical development; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the costs of commercialization activities if </font><font style=\"color:#000000;font-family:Times New Roman;\">mavacamten</font><font style=\"font-family:Times New Roman;\"> or any future product candidate is approved, including the formation of a sales force; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the degree and rate of market acceptance of any products launched by us or our partners; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">our need and ability to hire additional personnel; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">our ability to enter into additional collaboration, licensing, commercialization or other arrangements and the terms and timing of such arrangements; and </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the emergence of competing technologies or other adverse market developments. </font></p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible securities would dilute all of our stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at a different stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any product candidates or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially and adversely affect our business, financial condition and results of operations. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\"><font style=\"Background-color:#FFFFFF;\">Our reported financial results may be adversely affected by changes in accounting principles generally accepted in the U.S. </font></p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"Background-color:#FFFFFF;\">We prepare our financial statements in conformity with accounting principles generally accepted in the U.S. These accounting principles are subject to interpretation by the Financial Accounting Standards Board (\u201cFASB\u201d) and the Securities and Exchange Commission. A change in these policies or interpretations could have a significant effect on our reported financial results, may retroactively affect previously reported results, could cause unexpected financial reporting fluctuations, and may require us to make costly changes to our operational processes and accounting systems. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers which supersedes nearly all existing U.S. GAAP revenue recognition guidance. The new standard and its amendments will be effective for our fiscal year 2018 with early adoption permitted for our fiscal year 2017. Although we are currently in the process of evaluating the impact of ASU 2014-09 on our consolidated financial statements, it could change the way we account for certain of our revenue transactions. Thus, adoption of the standard could have a significant impact on our financial statements and may retroactively affect the accounting treatment of transactions completed before adoption. See \u201cNote 2 \u2013 </font><font style=\"color:#000000;\">Summary of Significant Accounting Policies</font><font style=\"Background-color:#FFFFFF;\">\u201d for additional discussion of the accounting changes.</font></p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">28</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU27\"></a><font style=\"font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Risks Related to Our Precision Medicine</font><font style=\"font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\"> Platform and the Discovery and Development of Our Product Candidates </font></p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">The precision medicine approach we are taking to discover and develop drugs for heritable cardiovascular diseases is novel and may never lead to marketable products. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We have concentrated our therapeutic product research and development efforts on the application of precision medicine to the treatment of heritable cardiovascular diseases, and our future success depends on the successful development of products based on our precision medicine platform and the continued development of this platform. We believe we are the first company to apply precision medicine to the treatment of cardiovascular disease, and neither we nor any other company has received regulatory approval to market therapeutics specifically targeting any form of heritable cardiomyopathy. The scientific discoveries that form the basis for our efforts to discover and develop product candidates are novel, and the scientific evidence to support the feasibility of developing product candidates based on these discoveries is both preliminary and limited. If we do not successfully develop and commercialize product candidates based upon our technological approach, we will not become profitable and the value of our common stock may decline. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Further, our focus solely on precision medicine for the development of drugs for heritable cardiomyopathies as opposed to multiple, more proven technologies for drug development increases the risks associated with the ownership of our common stock. If we are not successful in developing any product candidates using our precision medicine platform, we may be required to change the scope and direction of our product development activities. In that case, we may not be able to identify and implement successfully an alternative product development strategy, which would materially and adversely affect our business, financial condition and results of operations. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">We depend heavily on the success of mavacamten and MYK-491, our initial product candidates. Other than mavacamten and MYK-491, all of our other programs are in discovery or preclinical development. Preclinical testing and clinical trials of our product candidates may not be successful. If we are unable to commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_cp_text_1_170\"></a><a name=\"_cp_text_1_171\"></a><a name=\"_cp_text_1_172\"></a>We have invested a significant portion of our efforts and financial resources in the identification of our initial product candidates, <font style=\"color:#000000;\">mavacamten</font> for the treatment of hypertro<a name=\"_cp_text_1_170\"></a>phic cardiomyopathy (\u201c<a name=\"_cp_text_1_171\"></a>HCM\u201d) and MYK-491 for the treatment of dilated cardiomyopathy (\u201cDCM\u201d). We are currently evaluating <font style=\"color:#000000;\">mavacamten</font><a name=\"_cp_text_1_172\"></a> and MYK-491 in clinical trials, and, if these product candidates fail to demonstrate safety or efficacy in their respective target indications to the satisfaction of the FDA or other comparable regulatory authorities, we will need to identify and rely on other product candidates or target indications, or both, for clinical development. All of our other programs are still in discovery or preclinical development. Our ability to generate revenue from product sales, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of <font style=\"color:#000000;\">mavacamten</font>, MYK-491 or other product candidates that we may identify from our precision medicine platform. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The success of <font style=\"color:#000000;\">mavacamten</font>, MYK-491 and any other product candidates that we discover and develop will depend on many factors, including the following: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">timely and successful initiation of, enrollment in, and completion of, clinical trials, </font><font style=\"Background-color:#FFFFFF;color:#000000;font-family:Times New Roman;\">including our Phase 2 and Phase 3 clinical trials of </font><font style=\"color:#000000;font-family:Times New Roman;\">mavacamten</font><font style=\"Background-color:#FFFFFF;color:#000000;font-family:Times New Roman;\"> in HCM, our Phase 1b and Phase 2 clinical trials of MYK-491 in DCM and any additional clinical trials of these product candidates</font><font style=\"font-family:Times New Roman;\">; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">our ability to receive, and the timing of receipt of, any marketing approvals from applicable regulatory authorities; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">obtaining and maintaining patent and trade secret protection and non-patent exclusivity for our product candidates; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">launching commercial sales of our products, if and when approved, whether alone or in collaboration with others; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">acceptance of our products, if and when approved, by patients, the medical community and third-party payors; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">effectively competing with other therapies; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">a continued acceptable safety profile of our products following approval; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">enforcing and defending intellectual property rights and claims; and </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">achieving desirable medicinal properties for the intended indications. </font></p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business. </p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">29</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU28\"></a><font style=\"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">Preclinical and clinical drug development involves a lengthy and expensive process with an uncertain outcome, and observations and results from earlier studies and trials may not be applica</font><font style=\"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">ble or predictive in future clinical trials. </font></p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Preclinical and clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the preclinical development or clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. For example, although our preclinical observations and data generated from our Phase 1 and Phase 2 clinical trials of <font style=\"color:#000000;\">mavacamten</font> support our hypothesis that <font style=\"color:#000000;\">mavacamten</font> has the potential to reduce cardiac muscle contractility and our belief that such data have demonstrated clinical proof of mechanism in both HCM patients and healthy volunteers, we have not completed clinical trials of <font style=\"color:#000000;\">mavacamten</font> in larger populations. In addition, our precision medicine platform is based on a translational medicine approach. Translational medicine, or the application of basic scientific findings to develop therapeutics that promote human health, is subject to a number of inherent risks. In particular, scientific hypotheses formed from preclinical or early clinical observations may prove to be incorrect, and the data generated in animal models or observed in limited patient populations may be of limited value, and may not be applicable in clinical trials conducted under the controlled conditions required by applicable regulatory requirements and our protocols. The initial clinical data from our Phase 1 and Phase 2 clinical trials of <font style=\"color:#000000;\">mavacamten</font> are preliminary in nature, and the clinical development of <font style=\"color:#000000;\">mavacamten</font> is not complete. Early positive data may not be repeated or observed in ongoing or future trials involving our product candidates. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. There is a high failure rate for drugs and biologics proceeding through clinical trials, particularly in the field of cardiovascular medicine. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies, and any such setbacks in our clinical development could have a material adverse effect on our business and operating results. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">We may encounter substantial delays in our clinical trials or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates in humans. Clinical testing is expensive, time-consuming and uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of testing. We may experience delays in our ongoing clinical trials and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all. Additionally, although we believe that our precision medicine approach should eliminate the need for <font style=\"color:#000000;\">mavacamten</font> to undergo the large outcomes-based studies that are often required for cardiovascular drugs as a condition to regulatory approval by the FDA or other regulatory authorities, regulatory authorities may nevertheless require us to conduct additional trials or generate additional data, including potential trials studying the interaction of our product candidates with other therapeutics commonly administered in the patient populations we are seeking to treat, which would increase the time and cost of our clinical development process.\u00a0\u00a0Furthermore, we will need to conduct larger clinical trials, and the FDA may subsequently require us to evaluate a larger number of patients than we presently anticipate, or to assess other endpoints besides those presently contemplated, in order to support regulatory approval.</p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Clinical trials can be delayed for a variety of reasons, including: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">delays in reaching a consensus with regulatory agencies on trial design; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><a name=\"_cp_text_1_177\"></a><a name=\"_cp_text_1_179\"></a><font style=\"font-family:Times New Roman;\">delays in obtaining required <a name=\"_cp_text_1_177\"></a>Institutional Review Board (\u201c<a name=\"_cp_text_1_179\"></a>IRB\u201d) approval at each clinical trial site; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">delays in recruiting suitable patients to participate in our clinical trials; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">imposition of a clinical hold by regulatory agencies, including after an inspection of our clinical trial operations or trial sites; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">failure by our CROs, other third parties or us to adhere to clinical trial requirements; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><a name=\"_cp_text_1_181\"></a><a name=\"_cp_text_1_183\"></a><font style=\"font-family:Times New Roman;\">failure by us or our CROs or other third-party contractors to perform clinical trials in accordance with the FDA\u2019s good clinical p<a name=\"_cp_text_1_181\"></a>ractice (\u201c<a name=\"_cp_text_1_183\"></a>GCP\u201d) requirements or applicable regulatory guidelines in other countries; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">delays in the testing, validation, manufacturing and delivery of our product candidates to the clinical sites; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">delays in having patients complete participation in a study or return for post-treatment follow-up; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">clinical trial sites deviating from a trial protocol or dropping out of a trial; </font></p></td></tr></table></div>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">30</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU29\"></a><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"></font><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"></font><font style=\"font-family:Times New Roman;\">clinical trial subjects failing to comply with the trial regimen or dropping out of a trial; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">adding new clinical trial sites; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">failure to manufacture or supply sufficient quantities of product candidates for use in clinical trials; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits;\u00a0or </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols. </font></p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_cp_text_1_185\"></a><a name=\"_cp_text_1_187\"></a>We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, or suspension o<a name=\"_cp_text_1_185\"></a>r termination is recommended by the Data Safety Monitoring Board (\u201c<a name=\"_cp_text_1_187\"></a>DSMB\u201d) for such trial or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"Background-color:#FFFFFF;\">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or other regulatory authorities. The FDA or other regulatory authorities may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or other regulatory authorities may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or other regulatory authorities, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</font></p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenues from product sales, regulatory and commercialization milestones and royalties. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">If the results of our clinical trials are inconclusive or if there are safety concerns or adverse events associated with our product candidates, we may: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">be delayed in obtaining marketing approval for our product candidates, if at all; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">obtain approval for indications or patient populations that are not as broad as intended or desired; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">obtain approval with labeling that includes significant restrictions on use or distribution of the drug; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">require safety warnings in the label and/or require risk management plan post-approval; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><a name=\"_cp_text_1_189\"></a><a name=\"_cp_text_1_190\"></a><font style=\"font-family:Times New Roman;\">have regulatory authorities withdraw their approval of the product or impose restrictions on its distribution in the form of a modified risk evaluation and <a name=\"_cp_text_1_189\"></a>mitigation strategy (\u201c<a name=\"_cp_text_1_190\"></a>REMS\u201d); </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">be subject to the addition of labeling statements, such as warnings or contraindications; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">be sued;\u00a0or </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">experience damage to our reputation. </font></p></td></tr></table></div>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">31</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU30\"></a><font style=\"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">We may find it difficult to enroll patients in our clinical trials, w</font><font style=\"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">hich could delay or prevent clinical trials of our product candidates. </font></p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timing to commence and complete our clinical trials depends on the speed at which we can recruit patients to participate in testing our product candidates. If patients are unwilling to participate in our clinical trials because of a lack of familiarity with our approach to the treatment of cardiovascular diseases, negative publicity from adverse events in biotechnology or the fields of precision medicine or cardiovascular disease or for other reasons, including competitive clinical trials for similar patient populations, our timelines for recruiting patients, conducting clinical trials and obtaining regulatory approval of potential products may be delayed. These delays could result in increased costs, delays in advancing our product development, delays in testing the effectiveness of our technology or termination of our clinical trials altogether. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics to achieve diversity in a study, to complete our clinical trials in a timely manner. Patient enrollment is affected by factors including: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">severity of the disease under investigation; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">design of the clinical trial protocol; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">size and nature of the patient population; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">eligibility criteria for the clinical trial in question; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">perceived risks and benefits of the product candidate under study in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">proximity and availability of clinical trial sites for prospective patients; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">availability of competing therapies and clinical trials; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">efforts to facilitate timely enrollment in clinical trials; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">patient referral practices of physicians; and </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">ability to monitor patients adequately during and after treatment. </font></p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In particular, each of the conditions in which we plan to evaluate our current product candidates is a rare genetic disorder with limited patient pools from which to draw for clinical trials. To date, the HCM and DCM patient populations have not been extensively evaluated in clinical trials. As a result, enrollment in our ongoing and planned clinical trials is difficult to predict and may take longer or cost more than we anticipate. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We plan to seek initial marketing approval in the United States. We may not be able to initiate or continue clinical trials if we cannot enroll a sufficient number of eligible patients to participate in the clinical trials required by the FDA or other regulatory agencies. Our ability to successfully initiate, enroll and complete a clinical trial in any foreign country is subject to numerous risks unique to conducting business in foreign countries, including: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">difficulty in establishing or managing relationships with CROs and physicians; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">different standards for the conduct of clinical trials; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">our inability to locate qualified local consultants, physicians and partners; and </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and biotechnology products and treatment. </font></p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay, limit or terminate ongoing or planned clinical trials, any of which would have an adverse effect on our business. </p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">32</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU31\"></a><font style=\"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">We may not be successful in our efforts to identify or discover potential product candidates. </font></p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The success of our business depends primarily upon our ability to identify, develop and commercialize therapeutics for the treatment of genetic cardiovascular diseases based on our precision medicine approach. A key element of our strategy is to use our precision medicine platform to identify and study compounds that can be used to correct or offset the abnormal contraction caused by HCM and DCM. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the research methodology used may not be successful in identifying appropriate biomarkers or potential product candidates; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">our initial hypotheses based on our preclinical or early clinical observations may not be supported by later clinical results; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">potential product candidates may, on further study, be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval; or </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">research programs to identify new product candidates require substantial technical, financial and human resources. We may choose to focus our efforts and resources on a potential product candidate that ultimately proves to be unsuccessful. </font></p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">If we are unable to identify suitable compounds for preclinical and clinical development, we may be forced to abandon our development efforts for a research program or programs and we will not be able to obtain product revenues in future periods, which likely would result in significant harm to our financial position and adversely impact our stock price. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">We may not be able to successfully use the Sarcomeric Human Cardiomyopathy Registry, or SHaRe, to identify or recruit patients for our clinical trials or to develop targeted precision therapeutics for the treatment of heritable cardiomyopathies. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We rely, and expect to continue to rely, on genetic and clinical data gathered through SHaRe to provide us with insight into risk profiles and disease progression in heritable cardiomyopathies. Although the body of information in SHaRe is growing, we may face challenges collecting additional data through SHaRe in the future for a variety of reasons, including: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">insufficient funding to support the research necessary to generate patient data for SHaRe; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">our failure to maintain existing relationships and establish new relationships with clinical investigators and research institutions whose activities support SHaRe and provide us with access to patient data; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">our failure to maintain or increase interest in SHaRe within our target patient communities; and </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">third parties may generate competing databases to which we do not have access. </font></p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Additionally, the predictive value of the information generated through SHaRe to date may be limited. Although we expect to use these data to define and identify patient subgroups most likely to respond to our product candidates, our initial hypotheses regarding these data may prove to be incorrect, or our patient selection strategies based on our analysis of these data may fail to yield suitable patients for evaluation in our clinical trials or suitable indications and product candidates for clinical development. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Any of our product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory approval, limit the scope of any approved label or market acceptance or result in other significant negative consequences following marketing approval, if any<font style=\"font-weight:normal;font-style:normal;\">.</font></p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Adverse events or other unintended side effects or safety signals caused by our product candidates could cause us, IRBs or ethics committees, clinical trial sites or regulatory authorities to interrupt, delay or halt clinical trials and could result in the denial of regulatory approval. For example, through additional studies, we may determine that although <font style=\"color:#000000;\">mavacamten</font> has been shown to be specific to striated muscle, which includes both skeletal and cardiac muscle, and selective for cardiac muscle, it may target myosin in skeletal muscle, which could result in unintended adverse effects. We have observed adverse events in our clinical trials of <font style=\"color:#000000;\">mavacamten</font>. Results of our ongoing and planned trials could reveal a high and unacceptable severity and prevalence of these or other adverse events in subjects treated with our product candidates. Additionally, if the adverse events we have observed are deemed to be unacceptable or other unacceptable side effects or safety signals are observed in any ongoing or subsequent preclinical studies or clinical trials of our product candidates, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. Any adverse effects encountered in our preclinical studies or clinical trials, whether or not drug-related, could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims.\u00a0\u00a0Additionally, adverse effects may represent safety signals that could influence the benefit-risk assessment for further development or commercialization of a product candidate and may warrant further clinical or nonclinical investigation, consultation with health authorities, changes to product labeling or guidelines for its safe use, or other scientific or regulatory actions.\u00a0\u00a0Any of these occurrences may harm our business, financial condition and prospects significantly.</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">33</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU32\"></a><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Further, if any of our future products, if and when appro</font><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">ved for commercial sale, cause serious or unexpected adverse events, a number of potentially significant negative consequences could result, including:</font></p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">regulatory authorities may withdraw their approval of the product or impose restrictions on its distribution in the form of a REMS or provide a medication guide outlining the risks of such side effects for distribution to patients;</font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">regulatory authorities may require the addition of labeling statements, such as warnings or contraindications;</font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">we may be required to change the way the product is administered or conduct additional clinical trials;</font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">we could be sued and held liable for harm caused to patients; or</font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">our reputation may suffer.</font></p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Any of these events could prevent us or our partners from achieving or maintaining market acceptance of the affected product and could substantially increase the costs of commercializing our future products and impair our ability to generate revenues from the commercialization of these products.</p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Risks Related to Government Regulation </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">We currently do not have regulatory approval to market any of our product candidates. The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The time required to obtain approval by the FDA, EMA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate\u2019s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Our product candidates could fail to receive regulatory approval for many reasons, including the following: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">we may be unable to demonstrate that a product candidate\u2019s clinical and other benefits outweigh its safety risks; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><a name=\"_cp_text_1_192\"></a><a name=\"_cp_text_1_194\"></a><font style=\"font-family:Times New Roman;\">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a <a name=\"_cp_text_1_192\"></a>New Drug Application (\u201c<a name=\"_cp_text_1_194\"></a>NDA\u201d) or other submission or to obtain regulatory approval in the United States or elsewhere; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the FDA or comparable foreign regulatory authorities may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; or</font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </font></p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">This lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market <font style=\"color:#000000;\">mavacamten</font>, MYK-491 or any other product candidate we may develop, which would significantly harm our business, results of operations and prospects. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">34</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU33\"></a><font style=\"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">Even if we complete the necessary preclinical studies and clinical </font><font style=\"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">trials, we cannot predict when or if we will obtain regulatory approval to commercialize a product candidate or the approval may be for a more limited indication than we expect. </font></p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We cannot commercialize a product until the appropriate regulatory authorities have reviewed and approved the product candidate. Even if our product candidates demonstrate safety and efficacy in clinical trials, the regulatory agencies may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period of product development, clinical trials and the review process. Regulatory agencies also may approve a treatment candidate for fewer or more limited indications than requested or may grant approval subject to the performance of post-marketing studies. In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our treatment candidates. If we are unable to obtain regulatory approval for our product candidates for use in the treatment of heritable cardiomyopathies, our business may suffer. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">Failure to obtain marketing approval in international jurisdictions would prevent our products from being marketed in such jurisdictions. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In order to market and sell our products in the European Union and many other jurisdictions, we or our third-party collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United\u00a0States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We or these third parties may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval in other jurisdictions. We may not be able to file for marketing approvals, and even if we do, we may not obtain necessary approvals to commercialize our medicines in any market. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_cp_text_1_197\"></a><a name=\"_cp_text_1_199\"></a>Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to extensive and ongoing regulatory requirements and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, <a name=\"_cp_text_1_197\"></a>current Good Manufacturing Practice (\u201c<a name=\"_cp_text_1_199\"></a>cGMP\u201d) requirements relating to quality control, quality assurance and corresponding maintenance of records and documents, and requirements regarding the distribution of samples to physicians and recordkeeping. For example, the holder of an approved NDA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the NDA. The holder of an approved NDA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In addition, product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP and adherence to commitments made in the NDA and other marketing authorizations. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the medicine. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The FDA closely regulates the post-approval marketing and promotion of medicines to ensure that they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers\u2019 communications regarding off-label use and if we do not market our medicines for their approved indications, we may be subject to enforcement action for off-label marketing. </p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">35</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU34\"></a><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In addition, later discovery of previously unknown problems with our medicines, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in various negative consequences, including: </font></p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">restrictions on the labeling, marketing or manufacturing of the product; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">restrictions on distribution or use of the product; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">requirements to conduct post-marketing clinical trials or holds on ongoing or planned clinical trials; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">warning or untitled letters; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">withdrawal of the medicines from the market; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">refusal by the FDA or comparable foreign regulatory authorities to approve pending applications or supplements to approved applications that we submit; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">mandatory or voluntary recalls; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">fines, restitution or disgorgement of profits or revenue; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">suspension or withdrawal of marketing approvals; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">refusal to permit the import or export of our medicines; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">product seizure or detention; and </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">injunctions or the imposition of civil or criminal penalties. </font></p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The FDA\u2019s policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenues. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">We may seek one or more special designations from regulatory authorities for our product candidates, including Breakthrough Therapy Designation, Fast Track Designation or Orphan Drug Designation. These designations may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.</p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We may seek one or more special designations from regulatory authorities for our product candidates, including Breakthrough Therapy Designation, Fast Track Designation or Orphan Drug Designation. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">A breakthrough therapy is defined as a product that is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically important endpoints, such as substantial treatment effects observed early in clinical development. For products that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Products designated as breakthrough therapies by the FDA can also be eligible for accelerated approval. If a product is intended for the treatment of a serious or life-threatening condition and the product demonstrates the potential to address unmet medical needs for this condition, the product sponsor may apply for Fast Track Designation.</p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The FDA has broad discretion whether or not to grant these designations, so even if we believe a particular product candidate is eligible for a particular designation, we cannot assure you that the FDA would decide to grant it. Accordingly, even if we believe one of our product candidates meets the criteria for a designation, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a particular designation for a product candidate may not result in a faster development process, review or approval compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the products no longer meet the conditions for qualification and rescind the breakthrough designation. Further, the FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data from a clinical development program.</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">36</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU35\"></a><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Regulatory authorities in some jurisdictions, including the United States and Eu</font><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">rope, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a pat</font><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">ient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in</font><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"> the United States. In the United States, Orphan Drug Designation entitles a party to incentives such as tax advantages and user-fee waivers. \u00a0In April 2016, the FDA granted Orphan Drug Designation for </font><font style=\"color:#000000;\">mavacamten</font><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"> for use in the treatment of symptomatic obs</font><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">tructive HCM.</font></p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"Background-color:#FFFFFF;\">In addition, if a product that has Orphan Drug Designation subsequently receives the first approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which in the United States means that the FDA may not approve any other applications to market the same drug for the same indication for seven years, except in limited circumstances.</font><font style=\"Background-color:#FFFFFF;font-size:12pt;\">\u00a0</font><font style=\"color:#000000;\">The exclusivity granted under any Orphan Drug Designations that we have received or may receive may not effectively protect the product candidate from competition.\u00a0\u00a0</font><font style=\"Background-color:#FFFFFF;\">Although we have received Orphan Drug Designation from the FDA for </font>mavacamten<font style=\"Background-color:#FFFFFF;\"> for use in the treatment of symptomatic obstructive HCM, we may not be the first to obtain marketing approval of this drug for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity, that exclusivity may not effectively protect the product from competition </font><font style=\"color:#000000;\">because different drugs </font><font style=\"Background-color:#FFFFFF;\">with different active moieties</font><font style=\"Background-color:#FFFFFF;font-size:12pt;\">\u00a0</font><font style=\"color:#000000;\">can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve another drug </font><font style=\"Background-color:#FFFFFF;\">with the same active moiety </font><font style=\"color:#000000;\">for the same condition if the FDA concludes that the later drug is clinically superior, in that it is shown to be safer, more effective or makes a major contribution to patient care. </font><font style=\"Background-color:#FFFFFF;\">Orphan Drug Designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</font><font style=\"Background-color:#FFFFFF;font-size:12pt;\">\u00a0 </font><font style=\"color:#000000;\">Any inability to secure or maintain Orphan Drug Designation or the exclusivity benefits of this designation would have an adverse impact on our ability to develop and commercialize our product candidates.</font></p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Risks Related to Our Reliance on Third Parties </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">We are substantially dependent upon our collaboration agreement with Sanofi for the development and eventual commercialization of mavacamten, MYK-491 and any product candidates from our HCM-2 program. If this collaboration is unsuccessful or is terminated, we may be unable to commercialize certain product candidates and we will not receive additional funding from this relationship<font style=\"font-style:normal;\">.</font> </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We depend upon our license and collaboration agreement with Aventis Inc., a wholly-owned subsidiary of Sanofi S.A., which we refer to as the Collaboration Agreement, for financial and scientific resources related to the clinical development and commercialization of product candidates under our <font style=\"color:#000000;\">mavacamten</font>, MYK-491 and HCM-2 programs. While Sanofi has obligations to fund various research and development activities under the collaboration and with respect to the commercialization of product candidates in selected territories under certain programs under the Collaboration Agreement, our ability to receive funding from this relationship will depend upon the ability and willingness of Sanofi to successfully meet its responsibilities under our Collaboration Agreement and continue the collaboration. We may not receive some or all of the financial and scientific resources that we currently expect to receive under our Collaboration Agreement. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Our ability to generate additional funding from our Collaboration Agreement may be impaired by several factors including: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">Sanofi may shift its priorities and resources away from our programs due to a change in business strategies, or a merger, acquisition, sale or downsizing of its company or business unit; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">Sanofi may cease development and commercialization activities in therapeutic areas which are the subject of our collaboration; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">Sanofi may change the success criteria for a particular program or potential product candidate, thereby delaying or ceasing development of such program or candidate; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">Sanofi may exercise its rights to terminate the collaboration; or </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">a dispute may arise between us and Sanofi concerning financial obligations or the research, development or commercialization of a program or product candidate, resulting in a delay in payments or termination of a program and possibly resulting in costly litigation or arbitration which may divert management attention and resources. </font></p></td></tr></table></div>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">37</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU36\"></a><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Specifically, with respect to termination, the initial term of the research program under our Collaboration Agreement</font><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"> with Sanofi is set to end on December\u00a031, 2018. At any time after December\u00a031, 2018, Sanofi may, upon prior written notice to us, terminate the Collaboration Agreement for convenience in its entirety or on a region-by-region or program-by-program basis wi</font><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">th respect to selected regions or programs. The Collaboration Agreement is also subject to termination by either party upon a material breach by the other party, subject to a notice and cure period, or upon a bankruptcy, insolvency or similar event affecti</font><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">ng the other party. </font></p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">If our Collaboration Agreement with Sanofi is terminated, then, depending on the event: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the development of our product candidates subject to the Collaboration Agreement may be terminated or significantly delayed; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">our cash expenditures could increase significantly if it is necessary for us to hire additional employees and allocate internal resources to the development and commercialization of product candidates that were previously funded, or expected to be funded, by Sanofi; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">we would bear all of the risks and costs related to the further development and commercialization of product candidates that were previously the subject of the Collaboration Agreement; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">in order to fund further development and commercialization, we may need to seek out and establish alternative strategic collaborations with third-party partners, which may not be possible; or </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">we may not be able to do so on terms which are acceptable to us, in which case it may be necessary for us to limit the size or scope of one or more of our programs or increase our expenditures and seek additional funding by other means. </font></p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Any of these events would have a material adverse effect on our results of operations and financial condition. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">We expect to rely on third parties to conduct some or all aspects of our protocol development, research and preclinical and clinical testing, and these third parties may not perform satisfactorily. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We do not expect to independently conduct all aspects of our protocol development, research and preclinical and clinical testing. We currently rely, and expect to continue to rely, on third parties with respect to these items. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_cp_text_1_203\"></a><a name=\"_cp_text_1_204\"></a>Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it could delay our product development activities. Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibility to ensure compliance with all required regulations and study protocols. For product candidates that we develop and commercialize on our own, we will remain responsible for ensuring that each of our preclinical studies and clinical trials are conducted in accordance with the study plan and protocols. We and our third-party contractors and CROs are required to comply with GCP regulations, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the <a name=\"_cp_text_1_203\"></a>European Economic Area (\u201c<a name=\"_cp_text_1_204\"></a>EEA\u201d), and comparable foreign regulatory authorities for all products in clinical development. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our third-party contractors or CROs fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our studies in accordance with regulatory requirements or our stated study plans and protocols, we will be delayed in completing, or may not be able to complete, the preclinical and clinical studies required to support future Investigational New Drug Application (IND) submissions and approval of our product candidates. Any of these events could lead to clinical study delays or failure to obtain regulatory approval, or impact our ability to successfully commercialize future products. Some of these events could be the basis for FDA action, including injunction, request for voluntary recall, seizure or total or partial suspension of production. </p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">38</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU37\"></a><font style=\"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">We contract with third parties for the manuf</font><font style=\"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">acture of our product candidates for preclinical and clinical testing and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or medicine</font><font style=\"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">s or that such supply will not be available to us at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts. </font></p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We do not have any manufacturing facilities. We currently rely, and expect to continue to rely, on third-party manufacturers for the manufacture of our product candidates for preclinical and clinical testing and for the commercial supply of any of these product candidates for which we or our collaborators obtain marketing approval. To date, we have obtained materials for mavacamten for our clinical trials from third-party manufacturers, <font style=\"Background-color:#FFFFFF;color:#000000;\">and we intend to rely on third-party manufacturers for our planned Phase 2 and Phase 3 clinical development activities for mavacamten and Phase 1b and Phase 2 clinical trials of MYK-491</font>. We do not have a long-term supply agreement with the third-party manufacturers, and we purchase our required drug supply on a purchase order basis. We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms.\u00a0\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured the product candidates ourselves, including: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the inability to negotiate manufacturing agreements with third parties under commercially reasonable terms; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">reduced control as a result of using third-party manufacturers for all aspects of manufacturing activities; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">reliance on the third party for regulatory compliance, quality assurance, and safety and pharmacovigilance reporting; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the possible breach of the manufacturing agreement by the third party; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us;\u00a0and </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">disruptions to the operations of our third-party manufacturers or suppliers caused by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier. </font></p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The facilities used by our contract manufacturers to manufacture any of our future products must be evaluated by the FDA pursuant to inspections that will be conducted after we submit an NDA to the FDA. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with the cGMP regulation for manufacture of both active drug substances and finished drug products. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities or our marketing applications will not be approved. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority finds deficiencies with or does not approve these facilities for the manufacture of our product candidates or if it finds deficiencies or withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or voluntary recalls of product candidates or medicines, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our medicines and harm our business and results of operations. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Any products that we may develop may compete with our other product candidates and products and the products of third parties for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently have arrangements in place for a redundant supply of bulk drug substances. If any one of our current contract manufacturers cannot perform as agreed, we may be required to replace that manufacturer. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we may incur added costs and delays in identifying and qualifying any such replacement. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Our current and anticipated future dependence upon others for the manufacture of our product candidates or medicines may adversely affect our future profit margins and our ability to commercialize any medicines that receive marketing approval on a timely and competitive basis. </p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">39</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU38\"></a><font style=\"font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Risks Related to Our Intellectual Prope</font><font style=\"font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">rty </font></p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">If we are unable to obtain and maintain patent protection for our medicines and technology, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize medicines and technology similar or identical to ours, and our ability to successfully commercialize our medicines and technology may be adversely affected. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Our commercial success will depend, in part, on our ability to obtain and maintain patent protection in the United States and other countries with respect to our proprietary products and technology. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel technologies and medicines that are important to our business. To date, we own three issued United States patents that cover our proprietary technology or product candidates. We cannot be certain that we will secure any additional rights to any issued patents with claims that cover any of our proprietary technology or product candidates. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In addition to seeking patents for some of our technology and medicines, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. With respect to our proprietary molecularly targeted small molecule drugs, we consider trade secrets and know-how to be our primary intellectual property. Trade secrets and know-how can be difficult to protect. In particular, we anticipate that with respect to our precision medicine platform, these trade secrets and know-how will over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology, and the movement of personnel skilled in the art from academic to industry scientific positions. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be harmed. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_cp_text_1_206\"></a>Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and\u00a0<font style=\"font-style:italic;\">inter partes</font>\u00a0reexamination proceedings before the <a name=\"_cp_text_1_206\"></a>U.S. Patent and Trademark Office, or the U.S. PTO, and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. </p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">40</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU39\"></a><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combinatio</font><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">n therapy, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on comm</font><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">ercially reasonable terms or at all. </font></p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys\u2019 fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid, is unenforceable and/or is not infringed, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. Interference proceedings provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. In the future, we may have ownership disputes arising, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU40\"></a>If we or one of our licensing partners initiated legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the U.S. PTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. </p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">41</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Such mechanisms include re-examination, post grant review, and equivalent proceedings in foreign juri</font><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">sdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is u</font><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">npredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of inva</font><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">lidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection would have a material adverse impact on our business. </font></p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">As is common in the biotechnology and pharmaceutical industry, we employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employee\u2019s former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Risks Related to Commercialization and the Market for Our Product Candidates </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">If the market opportunities for our product candidates are smaller than we believe they are or if we are unable to market our products to expanded patient populations, our revenues may be adversely affected and our business may suffer. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We focus our research and product development efforts on treatments for heritable cardiomyopathies, and our targeted indications are rare genetic diseases. In particular, we estimate that approximately 630,000 people in the United States have a form of HCM, and that approximately 360,000 people in the United States have a form of genetic DCM. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on estimates derived from primary research with physicians and payors, analysis of medical journals and peer-reviewed literature, the work of third-party consultants and other publicly- or non-publicly-available data sources. These estimates may prove to be incorrect and new studies may change the estimated incidence or prevalence of our targeted disease indications. The number of patients in the United States, Europe and elsewhere may turn out to be lower than expected, may not be otherwise amenable to treatment with our products, and new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Additionally, because the target patient populations of our product candidates are small, we must be able to successfully identify patients and achieve a significant market share to achieve or maintain profitability and growth. Although we plan to use SHaRe to identify and select patients who are suitable for treatment with our products, if approved, we may not be able to identify or target a sufficient number of patients through SHaRe or our sales and marketing efforts to achieve the necessary market share. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">Even if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">If any of our product candidates receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. For example, current cardiovascular disease treatments such as beta blockers, non-dihydropyridine calcium channel blockers and disopyramide are well-established in the medical community, and doctors may continue to rely on these treatments. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">efficacy and potential advantages compared to alternative treatments; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the ability to offer our medicines for sale at competitive prices; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">convenience and ease of administration compared to alternative treatments; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </font></p></td></tr></table></div>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">42</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU41\"></a><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"></font><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"></font><font style=\"font-family:Times New Roman;\">the strength of marketing and distribution support; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">sufficient third-party coverage or reimbursement; and </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the prevalence and severity of any side effects. </font></p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Any failure to achieve or maintain sufficient market acceptance of <font style=\"color:#000000;\">mavacamten</font>, MYK-491 or any of our other product candidates, if approved, could significantly harm our business, prospects, financial condition and results of operations.</p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any revenues. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We have no experience marketing or selling our product candidates. To successfully commercialize any products that may result from our development programs, we will need to develop these capabilities, either on our own or with others. We may enter into collaborations with other entities to utilize their mature marketing and distribution capabilities, but we may be unable to enter into marketing agreements on favorable terms, if at all. If our future collaborations do not commit sufficient resources to commercialize our future products, if any, and we are unable to develop the necessary marketing capabilities on our own, we will be unable to generate sufficient product revenue to sustain our business. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">The insurance coverage and reimbursement status of newly-approved products targeting small patient populations is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford expensive treatments, such as endothelin receptor antagonists used in the treatment of certain cardiovascular diseases. Sales of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. Additionally, therapies directed at small patient populations, such as our product candidates, may be more expensive, and reimbursement options for these therapies may be more limited. If reimbursement or coverage is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_cp_text_1_208\"></a><a name=\"_cp_text_1_209\"></a>There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products and for products whose targeted patient populations are small. In the United States, the principal decisions about reimbursement for new medicines are typicall<a name=\"_cp_text_1_208\"></a>y made by the Centers for Medicare\u00a0&amp; Medicaid Services (\u201c<a name=\"_cp_text_1_209\"></a>CMS\u201d), an agency within the U.S. Department of Health and Human Services, as CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payors tend to follow CMS to a substantial degree. It is difficult to predict what CMS or third-party payors will decide with respect to reimbursement and coverage for fundamentally novel products such as ours, as there is no body of established practices and precedents for these new products. Reimbursement agencies in Europe may be more conservative than CMS. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada, and other countries may put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In general, the prices of medicines under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for medicines, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Moreover, increasing efforts by governmental and third-party payors, in the United States and abroad, to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. </p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">43</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU42\"></a><font style=\"font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Risk Related to Our Business and Industry </font></p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">We may be subject to healthcare laws, regulation and enforcement, and our failure to comply with these laws could harm our results of operations and financial conditions. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Although we do not currently have any products on the market, if we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations may be directly, or indirectly through our customers and third-party payors, subject to various U.S. federal and state fraud and abuse, patient privacy laws and other healthcare regulatory laws, and to additional healthcare, statutory and regulatory requirements and enforcement by foreign regulatory authorities in jurisdictions in which we conduct our business. Healthcare providers, physicians and others play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. These laws may impact, among other things, our proposed sales, marketing and education programs and constrain the business of financial arrangements and relationships with healthcare providers, physicians and other parties through which we market, sell and distribute our products for which we obtain marketing approval. The laws that may affect our ability to operate include: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the U.S. federal False Claims Act, which imposes civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><a name=\"_cp_text_1_211\"></a><a name=\"_cp_text_1_213\"></a><font style=\"font-family:Times New Roman;\">the U.S. federal Health Insurance Portability and Accountability <a name=\"_cp_text_1_211\"></a>Act of 1996 (\u201c<a name=\"_cp_text_1_213\"></a>HIPAA\u201d) which imposes criminal and civil liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><a name=\"_cp_text_1_215\"></a><a name=\"_cp_text_1_217\"></a><font style=\"font-family:Times New Roman;\">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health <a name=\"_cp_text_1_215\"></a>Act of 2009 (\u201c<a name=\"_cp_text_1_217\"></a>HITECH\u201d) and its implementing regulations, and as amended again by the final HIPAA omnibus rule, Modifications to the HIPAA Privacy, Security, Enforcement and Breach Notification Rules Under HITECH and the Genetic Information Nondiscrimination Act; Other Modifications to the HIPAA Rules, published in January 2013, which imposes certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without appropriate authorization on covered entities subject to the rule, such as health plans, healthcare clearinghouses and healthcare providers as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><a name=\"_cp_text_1_219\"></a><a name=\"_cp_text_1_221\"></a><font style=\"font-family:Times New Roman;\">the U. S. Federal Food, Drug, and <a name=\"_cp_text_1_219\"></a>Cosmetic Act (\u201c<a name=\"_cp_text_1_221\"></a>FDCA\u201d) which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><a name=\"_cp_text_1_226\"></a><font style=\"font-family:Times New Roman;\">the U. S. legislation commonly referred to as the Physician Payments Sunshine Act, <a name=\"_cp_text_1_226\"></a>enacted as part of the ACA and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children\u2019s Health Insurance Program to report annually to CMS, information related to payments and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held by physicians\u00a0\u00a0and their immediate family members; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">Federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</font></p></td></tr></table></div>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">44</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU43\"></a><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"></font><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"></font><font style=\"font-family:Times New Roman;\">analogous state laws and regulations, including: st</font><font style=\"font-family:Times New Roman;\">ate anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor</font><font style=\"font-family:Times New Roman;\">, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry\u2019s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restri</font><font style=\"font-family:Times New Roman;\">ct payments that may be made to healthcare providers and other potential referral sources; and state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other</font><font style=\"font-family:Times New Roman;\"> remuneration and items of value provided to healthcare professionals and entities, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not</font><font style=\"font-family:Times New Roman;\"> preempted by HIPAA, thus complicating compliance efforts; and </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">European and other foreign law equivalents of each of the laws, including reporting requirements detailing interactions with and payments to healthcare providers. </font></p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment. If any of the above occur, it could adversely affect our ability to operate our business and our results of operations. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Our competitors may develop drugs that are less expensive, safer, or more effective, which may diminish or eliminate the commercial success of any drugs that we may commercialize. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Our competitors may: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">develop drug candidates and market drugs that are less expensive or more effective than our future drugs; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">commercialize competing drugs before we or our partners can launch any drugs developed from our drug candidates; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">initiate or withstand substantial price competition more successfully than we can; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">have greater success in recruiting skilled scientific workers from the limited pool of available talent; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">more effectively negotiate third-party licenses and strategic collaborations; and </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">take advantage of acquisition or other opportunities more readily than we can. </font></p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We will compete for market share against large pharmaceutical and biotechnology companies and smaller companies that are collaborating with larger pharmaceutical companies, new companies, academic institutions, government agencies and other public and private research organizations. Many of these competitors, either alone or together with their partners, may develop new drug candidates that will compete with ours, as these competitors may, and in certain cases do, operate larger research and development programs or have substantially greater financial resources than we do. Our competitors may also have significantly greater experience in: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">developing product candidates; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">undertaking preclinical testing and clinical trials; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">building relationships with key customers and opinion-leading physicians; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">obtaining and maintaining FDA and other regulatory approvals of product candidates; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">formulating and manufacturing drugs; and </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">launching, marketing and selling drugs. </font></p></td></tr></table></div>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">45</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU44\"></a><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">If our competitors market drugs that are less expensive, safer or more effective than our potential drugs, or that reach the market sooner than our potential drugs, we may not achiev</font><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">e commercial success. In addition, the life sciences industry is characterized by rapid technological change. Because our research approach integrates many technologies, it may be difficult for us to stay abreast of the rapid changes in each technology. If</font><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"> we fail to stay at the forefront of technological change, we may be unable to compete effectively. Our competitors may render our technologies obsolete by advances in existing technological approaches or the development of new or different approaches, pot</font><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">entially eliminating the advantages in our drug discovery process that we believe we derive from our research approach and proprietary technologies. </font></p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">Public opinion and heightened regulatory scrutiny of precision medicine for the treatment of cardiovascular disease may impact public perception of our product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Precision medicine remains a novel technology, particularly in the field of cardiovascular disease, with no products approved to date in the United\u00a0States that are specifically targeted at correcting the underlying biomechanical defects in cardiac contractility associated with HCM and DCM. Public perception may be influenced by claims that these therapies are unproven or unsafe, and our product candidates may not gain the acceptance of the public or the medical community. In particular, our success will depend upon physicians, who specialize in the treatment of those diseases that our product candidates target, prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments they are already familiar with and for which greater clinical data may be available. More restrictive government regulations or negative public opinion could have an adverse effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. Adverse events in our clinical trials, even if not ultimately attributable to our product candidates, and the resulting publicity, could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In the United States, the EU, and other foreign jurisdictions, there have been a number of legislative and regulatory changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the United States federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, ACA changes the way healthcare is financed by both governmental and private insurers and significantly impacts the U.S. pharmaceutical and biotechnology industries. ACA, among other things, subjects biologic products to potential competition by lower-cost biosimilars, addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations, establishes annual fees and taxes on manufacturers of certain branded prescription drugs and biologic products, and a new Medicare Part\u00a0D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer\u2019s outpatient drugs to be covered under Medicare Part\u00a0D. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The new presidential administration has indicated that enacting change to the ACA is a legislative priority, and has alternatively discussed repealing and replacing the ACA. In January 2017, Congress voted to adopt a budget resolution for fiscal year 2017, that while not a law, is widely viewed as the first step toward the passage of legislation that would repeal certain aspects of the ACA.\u00a0\u00a0The 2017 Tax Reform Act includes a provision repealing the individual mandate, effective January 1, 2019.\u00a0\u00a0Further, on January 20, 2017, U.S. President Donald Trump signed an Executive Order directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. On October 13, 2017, President Trump signed an Executive Order terminating the cost-sharing subsidies that reimburse the insurers under the ACA.\u00a0\u00a0Several state Attorneys General filed suit to stop the administration from terminating the subsidies, but their request for a restraining order was denied by a federal judge in California on October 25, 2017.\u00a0\u00a0In addition, CMS has recently proposed regulations that would give states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through these marketplaces.\u00a0\u00a0Thus, there may be further action to repeal, replace, or modify the ACA. While any further legislative and regulatory changes will likely take time to develop, and may or may not have an impact on the regulatory regime to which we are subject, we cannot predict the ultimate content, timing or effect of any healthcare reform legislation or the impact of potential legislation on us.</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">46</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU45\"></a><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In addition, other </font><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">legislative changes have been proposed and adopted in the United States since ACA was enacted. On August\u00a02, 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit </font><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation\u2019s automatic reduction to several government programs. This in</font><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">cludes aggregate reductions of Medicare payments to providers of 2%\u00a0per fiscal year. These reductions went into effect on April\u00a01, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2025 unless additional Congr</font><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">essional action is taken. On January\u00a02, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatmen</font><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">t centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other health care funding, which could have a ma</font><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">terial adverse effect on our customers and accordingly, our financial operations. </font></p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. The U.S. federal government has set a goal of moving 50% of Medicare payments into these \u201cAlternative Payment Models\u201d by the end of 2018. <font style=\"Background-color:#FFFFFF;color:#000000;\">In addition, recently there has been heightened governmental scrutiny over the manner in which drug manufacturers set prices for their commercial products.</font><font style=\"Background-color:#FFFFFF;color:#000000;font-size:12pt;\">\u00a0</font>We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">Our future success depends on our ability to retain key employees and consultants, including our scientific advisors and founders, and to attract, retain and motivate qualified personnel. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We are highly dependent on our scientific advisors and founders and the principal members of our executive team, the loss of whose services may adversely impact the achievement of our objectives. While we have entered into employment agreements with each of our executive officers, any of them could leave our employment at any time, as all of our employees are \u201cat will\u201d employees. Recruiting and retaining other qualified employees, consultants and advisors for our business, including scientific and technical personnel, will also be critical to our success. There is currently a shortage of skilled executives and scientific experts in our industry, which is likely to continue. As a result, competition for skilled personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies, as well as from academic and research institutions, for individuals with similar skill sets. In addition, any failure of our programs to succeed in preclinical studies or clinical trials may make it more challenging to recruit and retain qualified personnel. The inability to recruit or the loss of the services of any executive, key employee, consultant or advisor may impede the progress of our research, development and commercialization objectives. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">We will need to expand our organization and we may experience difficulties in managing this growth, which could disrupt our operations. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">As of March 31, 2018, we had 120 full-time employees. As we mature, we expect to expand our full-time employee base and to hire more consultants and contractors. Our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial medicines or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable medicines. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">47</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU46\"></a><font style=\"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">Our anticipated international operations may expose us to business, re</font><font style=\"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">gulatory, political, operational, financial, pricing and reimbursement and economic risks associated with doing business outside of the United States. </font></p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We have a wholly-owned Australian subsidiary through which we conduct clinical trials in Australia. Our business strategy also contemplates potential additional international operations as we seek to continue the development of <font style=\"color:#000000;\">mavacamten</font>, MYK-491 and other product candidates that we have or may identify, seek regulatory approval for our product candidates, and commercialize any product candidates that are approved outside the United States. If any product candidates for which we have retained worldwide commercial rights are approved, we may hire sales representatives and conduct physician and patient group outreach activities outside of the United States. Doing business internationally involves a number of risks, including but not limited to: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">multiple, conflicting, and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements, and other governmental approvals, permits, and licenses; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">failure by us to obtain and maintain regulatory approvals for the use of our products in various countries; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">complexities and difficulties in obtaining protection for and enforcing our intellectual property rights; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">difficulties in staffing and managing foreign operations; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">complexities associated with managing multiple payor reimbursement regimes, government payors, or patient self-pay systems; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">limits in our ability to penetrate international markets; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">financial risks, such as exposure to foreign currency exchange rate fluctuations and their impact on payments required in local currency; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">natural disasters, political and economic instability, including wars, terrorism, and political unrest, outbreak of disease, boycotts, curtailment of trade, and other business restrictions; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">certain expenses including, among others, expenses for travel, translation, and insurance; and </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its books and records provisions, or its anti-bribery provisions. </font></p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Any of these factors could significantly harm our future international expansion and operations and, consequently, our results of operations. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Although we maintain workers\u2019 compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">48</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU47\"></a><font style=\"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">Our employees, independent contractors, principal investigators, CROs, consultants, vendors and collaboration partners may engage in misconduct or other improper activities, includ</font><font style=\"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">ing noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business. </font></p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants, vendors and collaboration partners may engage in fraudulent conduct or other illegal activities. Misconduct by these parties could include intentional, reckless and/or negligent conduct or unauthorized activities that violate: (i)\u00a0the regulations of the FDA, EMA and other regulatory authorities, including those laws that require the reporting of true, complete and accurate information to such authorities; (ii)\u00a0manufacturing standards; (iii)\u00a0federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and abroad; or (iv)\u00a0laws that require the reporting of true, complete and accurate financial information and data. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use of information obtained in the course of clinical trials or creating fraudulent data in our preclinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent misconduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other U.S. federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">Unfavorable global economic and political conditions could adversely affect our business, financial condition or results of operations. </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Our ability to invest in and expand our business and meet our financial obligations, to attract and retain third-party contractors and collaboration partners and to raise additional capital depends on our operating and financial performance, which, in turn, is subject to numerous factors, including the prevailing economic and political conditions and financial, business and other factors beyond our control, such as the rate of unemployment, the number of uninsured persons in the United States, political influences and inflationary pressures. For example, an overall decrease in or loss of insurance coverage among individuals in the United States as a result of unemployment, underemployment or the potential repeal of certain provisions of the ACA, may decrease the demand for healthcare services and pharmaceuticals. If fewer patients are seeking medical care because they do not have insurance coverage, we may experience difficulties in any eventual commercialization of our product candidates and our business, results of operations, financial condition and cash flows could be adversely affected. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In addition, our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets upon which biopharmaceutical companies such as us are dependent for sources of capital. In the past, global financial crises have caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including a reduced ability to raise additional capital when needed on acceptable terms, if at all, and weakened demand for our product candidates. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Earthquakes or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business. </p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">49</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU48\"></a><font style=\"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any medicines that we may develop. </font></p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any medicines that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or medicines caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">decreased demand for any product candidates or medicines that we may develop; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">injury to our reputation and significant negative media attention; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">withdrawal of clinical trial participants; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">significant costs to defend the related litigation; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">substantial monetary awards to trial participants or patients; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">loss of revenue; and </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the inability to commercialize </font><font style=\"color:#000000;font-family:Times New Roman;\">mavacamten</font><font style=\"font-family:Times New Roman;\">, MYK-491 or any other product candidates that we may develop. </font></p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Although we maintain product liability insurance, including coverage for clinical trials that we sponsor, it may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage as we commence additional clinical trials and if we successfully commercialize any product candidates. The market for insurance coverage is increasingly expensive, and the costs of insurance coverage will increase as our clinical programs increase in size. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">Our internal computer systems, or those of our third-party CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our operations. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Despite the implementation of security measures, our internal computer systems and those of our third-party CROs and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs. For example, the loss of clinical trial data for our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications or other data or applications relating to our technology or product candidates, or inappropriate disclosure of confidential or proprietary information, we could incur liabilities and experience delays or disruptions to various aspects of our operations, including our financial reporting and the development of our product candidates. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_cp_text_1_228\"></a><a name=\"_cp_text_1_229\"></a><a name=\"_cp_text_1_230\"></a><a name=\"_cp_text_1_232\"></a><a name=\"_cp_text_1_234\"></a>We have incurred substantial losses during our history and do not expect to become profitable in the near future. To the e<a name=\"_cp_text_1_228\"></a>xtent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (<a name=\"_cp_text_1_229\"></a>the \u201c<a name=\"_cp_text_1_230\"></a>Code\u201d) if a corp<a name=\"_cp_text_1_232\"></a>oration undergoes an \u201cownership change,\u201d generally defined as a greater than 50 percentage point change (by value) in its equity ownership over a rolling three-year period, the corporation\u2019s ability to use its pre-change net operating loss carryforwards (\u201c<a name=\"_cp_text_1_234\"></a>NOLs\u201d) and other pre-change tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. While we have determined that an ownership change occurred in April 2015 in connection with our Series\u00a0B redeemable convertible preferred stock financing and in August 14, 2017 due to a subsequent stock offering, we do not believe that these ownership changes will result in the expiration of any of our existing NOLs prior to utilization. We may experience subsequent shifts in our stock ownership, some of which are outside our control. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In addition, under the Tax Cuts and Jobs Act (the \u201cTax Act\u201d), the amount of post 2017 NOLs that we are permitted to deduct in any taxable year is limited to 80% of our taxable income in such year, where taxable income is determined without regard to the NOL deduction itself.\u00a0 The Tax Act generally eliminates the ability to carry back any NOL to prior taxable years, while allowing post 2017 unused NOLs to be carried forward indefinitely.\u00a0 There is a risk that due to changes under the Tax Act, regulatory changes or other unforeseen reasons, our existing NOLs could expire or otherwise be unavailable to offset future income tax liabilities.</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">50</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU49\"></a><font style=\"font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Risks Related to Our Common Stock </font></p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">The market price of our common stock has been and may continue to be highly volatile. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The market price of our common stock has experienced volatility since our IPO in October 2015 and is likely to continue to be volatile. Our stock price could be subject to wide fluctuations in response to a variety of factors, including the following: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">adverse results or delays in preclinical studies or clinical trials; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">reports of adverse events in clinical trials of our product candidates or in other products for the treatment of cardiovascular diseases or clinical trials of such products; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">inability to obtain additional funding; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">any delay in filing an IND or NDA for any of our product candidates and any adverse development or perceived adverse development with respect to the FDA\u2019s review of that IND or NDA; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">failure to develop successfully and commercialize our product candidates; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">any adverse developments relating to our Collaboration Agreement with Sanofi, or any failure to maintain our existing strategic collaborations or enter into new collaborations; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">failure by us or our licensors and strategic collaborators to prosecute, maintain or enforce our intellectual property rights; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">changes in laws or regulations applicable to future products; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">inability to obtain adequate product supply for our product candidates or the inability to do so at acceptable prices; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">adverse regulatory decisions affecting our product candidates or development programs; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">introduction of new products, services or technologies by our competitors; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">failure to meet or exceed financial projections we may provide to the public or to the investment community; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us, our strategic collaboration partner or our competitors; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">additions or departures of key scientific or management personnel; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">significant lawsuits, including patent or stockholder litigation; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">changes in the market valuations of similar companies; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">sales of our common stock by us or our stockholders in the future; and </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">trading volume of our common stock. </font></p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_cp_text_1_237\"></a><a name=\"_cp_text_1_239\"></a>In addition<a name=\"_cp_text_1_237\"></a>, companies trading in the stock market in general, and The NASDAQ Global Select Market (\u201c<a name=\"_cp_text_1_239\"></a>NASDAQ\u201d) in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance.\u00a0\u00a0In the past, following periods of volatility in the market, securities class-action litigation has often been instituted against companies. Such litigation, if instituted against us, could result in substantial costs and diversion of management\u2019s attention and resources, which could materially and adversely affect our business, financial condition, results of operations and growth prospects.</p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">51</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU50\"></a><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In addition,</font><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"> sales of a substantial number of shares of our outstanding common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could re</font><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">duce the market price of our common stock. Persons who were our stockholders prior to our IPO continue to hold a substantial number of shares of our common stock that many of them are now able to sell in the public market.\u00a0\u00a0Significant portions of these sh</font><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">ares are held by a relatively small number of stockholders.\u00a0\u00a0Sales by our stockholders of a substantial number of shares, or the expectation that such sales may occur, could significantly reduce the market price of our common stock.\u00a0\u00a0 </font></p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We have also registered all shares of our common stock subject to options or other equity awards issued or reserved for future issuance under our equity incentive plans. As a result, these shares will be eligible for sale in the public market to the extent permitted by any applicable vesting requirements and the exercise of options, and restrictions under applicable securities laws. In addition, our directors, executive officers and certain affiliates have established or may in the future establish programmed selling plans under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, for the purpose of effecting sales of our common stock.\u00a0\u00a0If any of these events cause a large number of our shares to be sold in the public market, the sales could reduce the trading price of our common stock and impede our ability to raise future capital.\u00a0\u00a0Moreover, certain holders of our common stock have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders.\u00a0\u00a0In particular, we have filed a registration statement on Form S-3 registering for resale 9,184,352 shares of common stock held by entities affiliated with our major shareholder, Third Rock Ventures, which was declared effective by the SEC on July 21, 2017. These shares, together with any additional shares that we may register for resale, can be freely sold in the public market. If these additional shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_cp_text_1_241\"></a><a name=\"_cp_text_1_242\"></a><a name=\"_cp_text_1_243\"></a><a name=\"_cp_text_1_245\"></a><a name=\"_cp_text_1_246\"></a><a name=\"_cp_text_1_248\"></a><a name=\"_cp_text_1_241\"></a>Pursuant to our 2015 Stock Option and Incentive Plan (<a name=\"_cp_text_1_242\"></a>the \u201c<a name=\"_cp_text_1_243\"></a>2015 Plan\u201d), we are authorized to grant stock options and other equity-based awards to our employees, directors and consultants. Beginning on January 1, 2017, the number of shares available for future grant under the 2015 Plan will automatically increase each year by up to 4% of all shares of our capital stock outstanding as of December\u00a031 of <a name=\"_cp_text_1_245\"></a>the prior calendar year, subject to the ability of our board of directors to take action to reduce the size of the increase in any given year. In addition, pursuant to our 2015 Employee Stock Purchase Plan (<a name=\"_cp_text_1_246\"></a>the \u201c<a name=\"_cp_text_1_248\"></a>2015 ESPP\u201d), we have initially reserved 255,000 shares for purchase by eligible employees. Beginning on January 1, 2017 and ending on January 1, 2025, the number of shares available for future issuance under the 2015 ESPP will automatically increase each year by up to the lesser of 3,000,000 shares of common stock or 1% of all shares of our capital stock outstanding as of December 31 of the prior calendar year, subject to the ability of our board of directors to take action to reduce the size of the increase in any given year. Currently, we plan to register the increased number of shares available for issuance under the 2015 Plan and the 2015 ESPP each year. If our board of directors elects to increase the number of shares available for future grant under these plans by the maximum amount each year, our stockholders may experience additional dilution, which could cause our stock price to fall. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_Hlk508059787\"></a>As of March 31, 2018, our executive officers, directors, five percent or greater stockholders and their affiliates beneficially own approximately 41.6% of our outstanding voting stock. These stockholders will have the ability to influence us through their ownership positions. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders, acting together, may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">We have broad discretion in the use of our cash and cash equivalents and may not use them effectively. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Our management has broad discretion in the application of our existing cash and cash equivalents, and you will not have the opportunity to assess whether our existing cash and cash equivalents are being used appropriately. Because of the number and variability of factors that will determine our use of our existing cash and cash equivalents, their ultimate use may vary substantially from their currently intended use. The failure by our management to apply these funds effectively could harm our business. Pending their use, we may invest our cash and cash equivalents in short-term, investment-grade, interest-bearing securities. These investments may not yield a favorable return to our stockholders. </p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">52</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU51\"></a><font style=\"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, our stock price and trading volume could decline. </font></p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The trading market for our common stock will depend, in part, on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts may not publish an adequate amount of research on our company, which may negatively impact the trading price for our stock. In addition, if one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. Further, if our operating results fail to meet the forecasts of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">We are an \u201cemerging growth company,\u201d and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors.</p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_cp_text_1_250\"></a><a name=\"_cp_text_1_251\"></a><a name=\"_cp_text_1_252\"></a><a name=\"_cp_text_1_253\"></a><a name=\"_cp_text_1_255\"></a><a name=\"_cp_text_1_257\"></a><a name=\"_cp_text_1_258\"></a>We are an \u201cemerging growth company,\u201d as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, includ<a name=\"_cp_text_1_250\"></a>ing not being required to comply with the auditor attestation requirements of Section\u00a0404 of the Sarbanes-Oxley Act of 2002 (<a name=\"_cp_text_1_251\"></a>the \u201c<a name=\"_cp_text_1_252\"></a>Sarbanes-Oxley Act\u201d), reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We will remain an emerging growth company until the earliest of (i)<a name=\"_cp_text_1_253\"></a>\u00a0December 31, 2020, (ii)\u00a0the last day of the fiscal year in which we have total annual gross revenue of $1.07 billion or more, (iii)\u00a0the last day of the fiscal year in which we are deemed to be a large accelerated filer, which means the market value of our<a name=\"_cp_text_1_255\"></a> common stock that is held by non-affiliates exceeds $700.0 million as of the prior June 30<sup style=\"font-size:85%; vertical-align:top\">th</sup> and (iv)\u00a0the date on which we have issued more than $1.0\u00a0billion in non-convertible debt during any three-year period before that time. Even after we no longer qualify as an emerging growth company, we may still qualify as a \u201csmaller reporting company\u201d which would allow us to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestati<a name=\"_cp_text_1_257\"></a>on requirements of Section\u00a0404 of the Sarbanes-Oxley Act (\u201c<a name=\"_cp_text_1_258\"></a>Section\u00a0404\u201d), and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, are subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">We will continue to incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">As a public company, and particularly after we are no longer an emerging growth company, we incur and will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act and rules subsequently implemented by the SEC and NASDAQ have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Pursuant to Section\u00a0404, we are required to furnish a report by our management on our internal control over financial reporting starting with our Annual Report on Form 10-K for the fiscal year ending December 31, 2017. However, while we remain an emerging growth company, we will not be required to obtain an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section\u00a0404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. </p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">53</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU52\"></a><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section\u00a0404. </font><font style=\"font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">This could impair our ability to produce timely and accurate consolidated financial statements and result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our consolidated financial statements. </font></p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">Our operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Our quarterly and annual operating results may fluctuate significantly in the future, which makes it difficult to predict our future operating results. Our net loss and other operating results will be affected by numerous factors, many of which are outside of our control and may be difficult to predict, including: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">variations in the level of expenses related to our clinical development programs, our precision medicine platform or our preclinical research and development programs; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">the timing and success or failure of preclinical studies and clinical trials for our product candidates or competing product candidates;</font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">our ability to obtain regulatory approval for our product candidates, and the timing and scope of any such approvals we may receive;</font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">if any of our product candidates receives regulatory approval, the level of underlying demand for these product candidates and our ability to successfully commercialize any approved product; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">addition or termination of clinical trials or funding support; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">our execution of any new collaborative, licensing or similar arrangements, and the timing of payments we may make or receive under these arrangements. </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">any intellectual property infringement or other lawsuits in which we may become involved; and </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">regulatory developments affecting our product candidates or those of our competitors. </font></p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">If our operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. Additionally, due to the unpredictability of our quarterly and annual operating results, we believe that period-to-period comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. </p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">We could be subject to securities class action litigation. </p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management\u2019s attention and resources, which could harm our business. </p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">54</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU53\"></a><font style=\"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws, as well as provisions of Delaware law, could make it mo</font><font style=\"font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">re difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders or remove our current management. </font></p>\n<p style=\"margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law contain provisions that may have the effect of delaying or preventing a change in control of us or changes in our management. Our amended and restated certificate of incorporation and amended and restated bylaws include provisions that: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">authorize \u201cblank check\u201d preferred stock, which could be issued by our board of directors without stockholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">create a classified board of directors whose members serve staggered three-year terms; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">specify that special meetings of our stockholders can be called only by our board of directors, the chairperson of our board of directors, our chief executive officer or our president; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">prohibit stockholder action by written consent; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">provide that our directors may be removed only for cause and with the vote of the holders of 75% or more of our outstanding capital stock then entitled to vote at an election of directors; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even if less than a quorum; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">specify that no stockholder is permitted to cumulate votes at any election of directors; </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">expressly authorize our board of directors to modify, alter or repeal our amended and restated bylaws; and </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;\"><font style=\"font-family:Times New Roman;\">require supermajority votes of the holders of our common stock to amend specified provisions of our amended and restated certificate of incorporation and amended and restated bylaws. </font></p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management. </p>\n<p style=\"margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section\u00a0203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Any provision of our amended and restated certificate of incorporation or amended and restated bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:10.27%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Item\u00a02.</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\"><a name=\"ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT\"></a><a name=\"ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT\"></a>Unregistered Sales of Equity Securities and Use of Proceeds</p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:2.27%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-style:italic;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\"><font style=\"font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">(a)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-style:italic;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">Recent Sales of Unregistered Equity Securities</p></td></tr></table></div>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">None.</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:2.27%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:18pt;margin-bottom:0pt;font-style:italic;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:18pt;margin-bottom:0pt;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\"><font style=\"font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">(b)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:18pt;margin-bottom:0pt;font-style:italic;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">Use of Proceeds</p></td></tr></table></div>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Not applicable.</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">55</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:2.27%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:18pt;margin-bottom:0pt;font-style:italic;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:18pt;margin-bottom:0pt;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\"><font style=\"font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">(c)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:18pt;margin-bottom:0pt;font-style:italic;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU54\"></a><font style=\"font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\"></font><font style=\"font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">Issuer Repurchases of Company Equity Securities.</font></p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.26%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">(a)\u00a0Total\u00a0Number\u00a0of</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Shares<font style=\"font-family:Calibri;\">\u00a0</font>Purchased\u00a0(1)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">(b)\u00a0Average\u00a0Price</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Paid per\u00a0Share</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">(c)\u00a0Total\u00a0Number\u00a0of</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Shares\u00a0Purchased</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">as\u00a0Part\u00a0of Publicly\u00a0Announced</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Plans\u00a0or\u00a0Programs</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">(d)\u00a0Maximum\u00a0Number</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">(or\u00a0Approximate\u00a0Dollar</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Value)\u00a0of\u00a0Shares</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">that\u00a0May\u00a0Yet\u00a0Be</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Purchased\u00a0Under\u00a0the</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Plans\u00a0or\u00a0Programs</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.26%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;\">Period</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"14\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">(in thousands, except per share amounts)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.26%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">January 1, 2018 through January 31, 2018</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">770</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1.51</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.26%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">February 1, 2018 through February 28, 2018</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.26%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">March 1, 2018 through March 31, 2018</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.26%; border-bottom:double 2.5pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Total</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">770</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1.51</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(1)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">Under certain stock purchase agreements with employees, we have the right to repurchase common stock at the lower of fair value and the stockholders' original purchase price, which right lapses according to individual vesting schedules. </p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:10.27%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Item\u00a03.</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\"><a name=\"ITEM_3_DEFAULTS_UPON_SENIOR_SECURITIES\"></a><a name=\"ITEM_3_DEFAULTS_UPON_SENIOR_SECURITIES\"></a>Defaults Upon Senior Securities</p></td></tr></table></div>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">None.</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:10.27%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Item\u00a04.</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\"><a name=\"ITEM_4_MINE_SAFETY_DISCLOSURES\"></a><a name=\"ITEM_4_MINE_SAFETY_DISCLOSURES\"></a>Mine Safety Disclosures</p></td></tr></table></div>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Not applicable.</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:10.27%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Item\u00a05.</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\"><a name=\"ITEM_5_OR_INFORMATION\"></a><a name=\"ITEM_5_OR_INFORMATION\"></a>Other Information</p></td></tr></table></div>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">None.</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:10.27%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Item\u00a06.</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\"><a name=\"ITEM_6_EXHIBITS\"></a><a name=\"ITEM_6_EXHIBITS\"></a>Exhibits</p></td></tr></table></div>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The following exhibits are filed or furnished as part of this Quarterly Report on Form 10-Q: </p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">56</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU55\"></a><a name=\"EXHIBIT_INDEX\"></a><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"EXHIBIT_INDEX\"></a>EXHIBIT</font><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"> INDEX</font></p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Exhibit</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Number</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.72%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Exhibit Description</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:12.92%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Incorporated\u00a0by</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Reference\u00a0From</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:9.14%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Date</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Number</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Filed</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Herewith</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%; border-top:solid 0.75pt #000000;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.72%; border-top:solid 0.75pt #000000;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:12.92%; border-top:solid 0.75pt #000000;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:9.14%; border-top:solid 0.75pt #000000;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%; border-top:solid 0.75pt #000000;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0\u00a03.1</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.72%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:underline;\">Restated Certificate of Incorporation.</font></a> </p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:12.92%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_cp_text_1_265\"></a>10-Q</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:9.14%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_cp_text_1_266\"></a>11/18/2015</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;\" valign=\"middle\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_cp_text_1_267\"></a> 3.1</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.72%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:12.92%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:9.14%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;\" valign=\"middle\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.72%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:12.92%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:9.14%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;\" valign=\"middle\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_cp_text_1_754\"></a>\u00a0\u00a0 3.2</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.72%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"></p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:12.92%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_cp_table_18_757\"></a>S-1/A</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:9.14%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_cp_table_18_759\"></a>10/13/2015</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;\" valign=\"middle\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_cp_text_1_760\"></a>3.4</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.72%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:12.92%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:9.14%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0\u00a04.1</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.72%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:underline;\">Specimen Common Stock Certificate.</font></a> </p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:12.92%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">S-1/A</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:9.14%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">10/19/2015</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">4.1</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.72%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:12.92%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:9.14%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a010.1#</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.72%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:underline;\">Employment Offer Letter Agreement by and between MyoKardia, Inc. and Taylor Harris, dated March 26, 2018.</font></a></p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:12.92%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">8-K</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:9.14%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">4/4/2018</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">10.1</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.72%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:12.92%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:9.14%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a010.2</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.72%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:underline;\">Amendment No. 1 to Sublease Agreement by and between REG Life Sciences, LLC (\u201cSublandlord\u201d) and MyoKardia, Inc. (\u201cSubtenant\u201d), dated January 1, 2018.</font></a></p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:12.92%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:9.14%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">X</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.72%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:12.92%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:9.14%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a031.1</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.72%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:underline;\">Certification of Principal Executive Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.</font></a></p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:12.92%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:9.14%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">X</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.72%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:12.92%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:9.14%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a031.2</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.72%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:underline;\">Certification of Principal Financial Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.</font></a></p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:12.92%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:9.14%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">X</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.72%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:12.92%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:9.14%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a032.1*</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.72%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:underline;\">Certification of Principal Executive Officer and Principal Financial Officer Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. \u00a71350.</font></a></p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:12.92%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:9.14%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">X</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.72%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:12.92%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:9.14%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">101.INS</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.72%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">XBRL Instance Document.</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:12.92%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:9.14%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">X</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.72%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:12.92%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:9.14%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">101.SCH</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.72%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">XBRL Taxonomy Extension Schema Document.</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:12.92%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:9.14%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">X</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.72%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:12.92%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:9.14%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">101.CAL</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.72%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">XBRL Taxonomy Extension Calculation Linkbase Document.</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:12.92%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:9.14%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">X</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.72%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:12.92%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:9.14%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">101.DEF</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.72%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">XBRL Taxonomy Extension Definition Linkbase Document.</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:12.92%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:9.14%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">X</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.72%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:12.92%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:9.14%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">101.LAB</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.72%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">XBRL Taxonomy Extension Label Linkbase Document.</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:12.92%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:9.14%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">X</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.72%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:12.92%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:9.14%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">101.PRE</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.72%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">XBRL Taxonomy Extension Presentation Linkbase Document.</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:12.92%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:9.14%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"width:1.06%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.16%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">X</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">#</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">Represents management compensation plan, contract or arrangement.</p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">*</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">The certification attached as Exhibit\u00a032.1 that accompanies this Quarterly Report on Form\u00a010-Q is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of MyoKardia, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form\u00a010-Q, irrespective of any general incorporation language contained in such filing.</p></td></tr></table></div>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">57</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU56\"></a><a name=\"SIGNATURES\"></a><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"SIGNATURES\"></a>SIGNA</font><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">TURES</font></p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:48%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Date: May 8, 2018</p></td>\n<td style=\"width:2%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td colspan=\"2\" style=\"width:50%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">MYOKARDIA, INC.</p></td>\n</tr>\n<tr>\n<td style=\"width:48%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;\">\u00a0</p></td>\n<td style=\"width:2%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;\">\u00a0</p></td>\n<td style=\"width:2%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;\">\u00a0</p></td>\n<td style=\"width:48%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;\">\u00a0</p></td>\n</tr>\n<tr>\n<td style=\"width:48%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td colspan=\"2\" style=\"width:4%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">By:</p></td>\n<td style=\"width:48%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">/s/ Tassos Gianakakos</p></td>\n</tr>\n<tr>\n<td style=\"width:48%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:2%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:2%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:48%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Tassos Gianakakos</p></td>\n</tr>\n<tr>\n<td style=\"width:48%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:2%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:2%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:48%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">President, Chief Executive Officer</p></td>\n</tr>\n<tr>\n<td style=\"width:48%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:2%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:2%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:48%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">(Principal Executive Officer)</p></td>\n</tr>\n<tr>\n<td style=\"width:48%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td style=\"width:2%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td style=\"width:2%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td style=\"width:48%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n</tr>\n<tr>\n<td style=\"width:48%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td style=\"width:2%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td style=\"width:2%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td style=\"width:48%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n</tr>\n<tr>\n<td style=\"width:48%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Date: May 8, 2018</p></td>\n<td colspan=\"2\" style=\"width:4%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">By:</p></td>\n<td style=\"width:48%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">/s/ Taylor Harris</p></td>\n</tr>\n<tr>\n<td style=\"width:48%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:2%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:2%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:48%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Taylor Harris</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">Chief Financial Officer </p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">(Principal Financial and Accounting Officer)</p></td>\n</tr>\n<tr>\n<td style=\"width:48%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:2%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:2%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:48%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"></p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">58</p></body>\n</html>\n</text>\n</description></filename></sequence></type></document>\n"}, "reportNo10": {"reportType": "8-K", "url": "https://www.sec.gov/Archives/edgar/data/1552451/000156459018011834/myok-8k_20180331.htm", "dateOfReport": "2018-05-08", "content": "", "htmlOfReport": " <document>\n<type>8-K\n<sequence>1\n<filename>myok-8k_20180331.htm\n<description>8-K\n<text>\n<!DOCTYPE HTML PUBLIC \"-//W3C//DTD HTML 4.01 Transitional//EN\" \"http://www.w3.org/TR/html4/loose.dtd\">\n\n<html>\n<head>\n<title>\nmyok-8k_20180331.htm\n</title>\n</head>\n<!-- NG Converter v4.0.8.21 -->\n<body>\n<p style=\"border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;\">\u00a0</p>\n<p style=\"text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">UNITED STATES</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">SECURITIES AND EXCHANGE COMMISSION</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Washington, D.C. 20549</p>\n<p style=\"text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:12pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:12pt;font-family:Times New Roman;\">\u00a0</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">FORM 8-K</p>\n<p style=\"text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:12pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:12pt;font-family:Times New Roman;\">\u00a0</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">CURRENT REPORT</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Pursuant to Section\u00a013 or 15(d)</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">of the Securities Exchange Act of 1934</p>\n<p style=\"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Date of Report (Date of earliest event reported): May 8, 2018</p>\n<p style=\"text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:12pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:12pt;font-family:Times New Roman;\">\u00a0</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">MYOKARDIA,\u00a0INC.</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">(Exact name of registrant as specified in its charter)</p>\n<p style=\"margin-bottom:0pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:12pt;font-family:Times New Roman;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33.34%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Delaware</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33.34%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">001-37609</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33.32%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">44-5500552</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33.34%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">(State or other jurisdiction</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">of incorporation)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33.34%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">(Commission</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">File Number)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33.32%;\" valign=\"top\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">(I.R.S. Employer</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Identification No.)</p></td>\n</tr>\n</table></div>\n<p style=\"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">333 Allerton Ave.</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">South San Francisco, CA 94080</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">(Address of principal executive offices, including zip code)</p>\n<p style=\"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">(650) 741-0900</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">(Registrant\u2019s telephone number, including area code)</p>\n<p style=\"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Not Applicable</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">(Former Name or Former Address, if Changed Since Last Report)</p>\n<p style=\"text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:12pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:12pt;font-family:Times New Roman;\">\u00a0</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Check the appropriate box below if the Form\u00a08-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2610</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">Written communications pursuant to Rule\u00a0425 under the Securities Act (17 CFR 230.425)</p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2610</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">Soliciting material pursuant to Rule\u00a014a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2610</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">Pre-commencement communications pursuant to Rule\u00a014d-2(b)\u00a0under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:4.54%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2610</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">Pre-commencement communications pursuant to Rule\u00a013e-4(c)\u00a0under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table></div>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (\u00a7\u2009230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (\u00a7\u2009240.12b-2 of this chapter).</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Emerging growth company\u00a0<font style=\"color:#000000;font-size:9pt;font-family:'Times New Roman';\"><font style=\"font-size:9pt;font-family:'Times New Roman'\">\u2612</font></font></p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_gjdgxs\"></a>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.\u00a0<font style=\"color:#000000;font-size:9pt;font-family:'Times New Roman';\"><font style=\"font-size:9pt;font-family:'Times New Roman'\">\u2612</font></font></p>\n<p style=\"border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;\">\u00a0</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU2\"></a><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Ite</font><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">m\u00a02.02\u00a0Results of Operations and Financial Condition.</font></p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">On May 8, 2018, MyoKardia, Inc. announced its financial results for the first quarter ended March 31, 2018. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The information in Item\u00a02.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed \u201cfiled\u201d for purposes of Section\u00a018 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.</p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Item\u00a09.01\u00a0Financial Statements and Exhibits</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(d)\u00a0Exhibits.</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Exhibit\u00a0No.</p></td>\n<td style=\"width:1%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td style=\"width:90%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Description</p></td>\n</tr>\n<tr>\n<td style=\"width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td style=\"width:1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td style=\"width:90%; border-top:solid 0.75pt #000000;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n</tr>\n<tr>\n<td style=\"width:9%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">99.1</p></td>\n<td style=\"width:1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:90%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Press Release issued by MyoKardia, Inc. on May 8, 2018, furnished herewith</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU3\"></a><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">EXHIBIT\u00a0INDEX</font></p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Exhibit\u00a0No.</p></td>\n<td style=\"width:1%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;\">\u00a0</p></td>\n<td style=\"width:90%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Description</p></td>\n</tr>\n<tr>\n<td style=\"width:9%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td style=\"width:1%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td style=\"width:90%; border-top:solid 0.75pt #000000;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n</tr>\n<tr>\n<td style=\"width:9%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">99.1</p></td>\n<td style=\"width:1%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0</p></td>\n<td style=\"width:90%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:none;\">Press Release issued by MyoKardia, Inc. on May 8, 2018, furnished herewith</font></a></p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;\">\u00a0</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU4\"></a><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">SIGNATURES</font></p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:48%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Date: May 8, 2018</p></td>\n<td style=\"width:1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:1%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td colspan=\"3\" style=\"width:2%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">MyoKardia, Inc.</p></td>\n</tr>\n<tr>\n<td style=\"width:48%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;\">\u00a0</p></td>\n<td style=\"width:1%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;\">\u00a0</p></td>\n<td colspan=\"4\" style=\"width:1%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;\">\u00a0</p></td>\n</tr>\n<tr>\n<td style=\"width:48%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:1%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:1%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:2%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">By:</p></td>\n<td style=\"width:1%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:47%; border-bottom:solid 0.75pt #000000;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">/s/ Taylor Harris</p></td>\n</tr>\n<tr>\n<td style=\"width:48%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:1%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:2%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:47%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Taylor Harris</p></td>\n</tr>\n<tr>\n<td style=\"width:48%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:1%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:1%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:2%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:47%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Chief Financial Officer <font style=\"font-weight:bold;\">(principal\u00a0financial\u00a0officer)</font></p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></body>\n</html>\n</text>\n</description></filename></sequence></type></document>\n"}, "companyProfile": "MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which has completed Phase II clinical trial that is designed to reduce left ventricular contractility to potentially alleviate the functional consequences and symptoms of hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression. The company also develops MYK-491, an orally-administered small molecule, which is in Phase I b clinical trial that is designed to restore normal contractility in the diseased dilated cardiomyopathy (DCM) heart. Its three preclinical programs include HCM-2 that is used to reduce cardiac muscle contractility to normal levels in HCM patients; DCM-2, which is used to enhance cardiac muscle contractility to normal levels in genetic DCM patients; and LUS-1 that is used to counteract a muscle disruption that results in impaired relaxation of the heart, a biomechanical defect found in specific HCM and genetic DCM patient subgroups, as well as in other less common heritable cardiomyopathies. The company has a strategic collaboration with Aventis Inc. for the research, development, and commercialization of pharmaceutical products to treat, prevent, and diagnose HCM and DCM, as well as additional indications. MyoKardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.", "stockSymbol": "MYOK", "float": "33.6M", "instOwn": "89.66%", "shortFloat": "9.61%", "sharesOutstanding": "40115401", "going concern": false, "companyAddress": "SOUTH SAN FRANCISCO 650-741-0900 CA 333 ALLERTON AVENUE 94080"}